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Abstract	  	  Gene	  expression	  is	  a	  process	  that	  is	  tightly	  regulated	  by	  many	  factors.	  Different	  genes	  are	  transcribed	  not	  only	  in	  a	  cell	  specific	  manner	  but	  are	  also	  differentially	  expressed	   at	   different	   stages	   of	   the	   cell	   cycle.	   Cnot3	   is	   part	   of	   the	   CCR4-­‐NOT	  deadenylation	   complex,	   which	   is	   involved	   in	   the	   turnover	   of	   mRNAs	   in	   the	  cytoplasm	  and	  has	  also	  been	  shown	  to	  have	  roles	  in	  regulating	  transcription	  and	  cell	   proliferation	   and	   in	   maintaining	   ES	   cell	   pluripotency.	   Previous	   work	  demonstrated	   that	   Cnot3	   interacts	   directly	   with	   Aurora	   B	   kinase	   and	   is	  phosphorylated	  by	  Aurora	  B	  in	  an	  in	  vitro	  assay.	  Aurora	  B	  and	  Cnot3	  co-­‐localise	  at	  active	  gene	  promoters	  in	  resting	  B	  cells.	  Since	  Aurora	  B	  is	  a	  cell	  cycle	  kinase,	  I	  have	  developed	  a	  cell	   synchronization	  system	  to	  analyse	   the	  role	  of	   the	  Cnot3-­‐Aurora	  B	  interaction	  at	  different	  stages	  of	  the	  cell	  cycle	  in	  primary	  B	  cells.	  Using	  this	  system,	  I	  have	  demonstrated	  that	  the	  interaction	  between	  Cnot3	  and	  Aurora	  B	   varies	   during	   cell	   cycle	   progression.	   In	   vitro	   analysis	   showed	   that	   the	  interaction	   occurs	   through	   the	   NOT	   box	   domain	   of	   Cnot3.	   Mass	   spectrometry	  analysis	  of	  Cnot3	  interactors,	  performed	  on	  nuclear	  extracts	  from	  B	  cells	   in	  the	  early	  G1	  and	  G2	  phases	  of	  the	  cell	  cycle,	  identified	  interactions	  with	  many	  factors	  that	   are	   known	   to	   have	   roles	   in	   transcription	   regulation	   and	   RNA	   processing.	  Interaction	   of	   Cnot3	   with	   Histone	   H1	   was	   confirmed	   using	   a	   peptide	   binding	  assay,	   suggesting	   a	   potential	   role	   in	   chromatin	   organization.	   Cnot3	   was	   also	  shown	   to	   interact	   with	   Xrn2,	   a	   5’-­‐3’	   exoribonuclease	   that	   is	   involved	   in	   RNA	  turnover	  and	  termination	  of	  transcription.	  ChIP	  analysis	  demonstrated	  promoter	  binding	   of	   Cnot3	   at	   a	   number	   of	   cell	   cycle	   stages.	   Cnot3	   shows	   cell	   cycle	  dependent	   binding	   to	   promoters	   of	   a	   wide	   range	   of	   active	   genes,	   including	  promoters	   that	   are	  not	   directly	   involved	   in	   cell	   cycle	   regulation.	  Genome	  wide	  analysis	  using	  ChIP	  sequencing	  revealed	  changes	  in	  the	  binding	  profiles	  of	  Cnot3	  at	  promoters	  and	  enhancers	  during	   cell	   cycle	  progression.	  A	  Cnot3	   conditional	  knock	  out	  mouse	  has	  been	  generated,	  which	  will	  be	  used	   to	   test	   the	   functional	  importance	  of	  these	  observations.	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Chapter	  1 -­	  Introduction	  
	  
1.1 Overview	  	  Cnot3	   is	   a	   member	   of	   the	   CCR4-­‐NOT	   deadenylase	   complex,	   which	   controls	  mRNA	   turnover	   and	   has	   also	   been	   implicated	   in	   transcriptional	   and	   cell	   cycle	  control.	   Co-­‐immunoprecipitation	   and	   mass	   spectrometry	   analysis	   identified	  Cnot3	   as	   a	   major	   interactor	   with	   the	   chromosomal	   passenger	   complex	   (CPC),	  which	   has	   major	   roles	   in	   orchestrating	   mitosis	   and	   cytokinesis	   through	   the	  activity	  of	  its	  catalytic	  component,	  the	  Aurora	  B	  kinase.	  The	  interaction	  suggests	  that	   Cnot3	   could	   be	   involved	   in	   some	   of	   the	   many	   functions	   that	   have	   been	  identified	  for	  the	  CPC.	  The	  aim	  of	  this	  project	  was	  to	  investigate	  the	  role	  of	  Cnot3	  in	  gene	  regulation	  and	  cell	  cycle	  progression	  in	  B	  cells.	  	  	  
1.2 Cell	  cycle	  The	  concept	  of	  a	  ‘cell	  cycle’	  was	  first	  explored	  around	  50	  years	  ago	  when	  the	  mitotic	   cycle	   was	   described	   as	   having	   4	   phases.	   Cell	   cycle	   was	   therefore	   sub-­‐divided	   into	  Gap	  phase	  1	   (G1),	  DNA	  synthesis	   (S	  phase),	  Gap	  phase	  2	   (G2)	  and	  Mitosis	  (M)	  (Figure	  1.1).	  This	  study	  was	  the	  first	  one	  that	  gave	  a	  description	  of	  the	  length	  of	  the	  cell	  cycle	  (Sisken	  and	  Morasca,	  1965).	  	  
Figure	  1.1:	  Representation	  of	  the	  cell	  cycle	  phases.	  	  The	   chart	   shows	   the	  phases	  of	   the	   cell	   cycle.	  Each	  phase	   is	   charachterized	  by	   the	  presence	  of	  different	  active	  cyclin/CDK	  complexes.	  G1	  is	  divided	  into	  two	  parts	  by	  the	  restriction	  point	  (Adapted	  from	  (Dehay	  and	  Kennedy,	  2007)).	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During	   the	   G	   phases,	   cells	   are	   actively	   transcribing	   the	   genome	   in	   order	   to	  prepare	  for	  correct	  DNA	  replication	  and	  cellular	  division.	  The	  process	  of	  cellular	  division	  occurs	  after	  G2,	   and	   represents	  a	   crucial	  moment	   for	   the	   formation	  of	  two	  daughter	   cells	   carrying	   identical	   genetic	  material.	   The	   duration	   of	   the	   cell	  cycle	  phases	  is	  different	  among	  species	  and	  cell	  types.	  There	  are	  a	  few	  examples	  where	   gap	   phases	   are	   very	   short	   and	   cells	   spend	  most	   of	   the	   time	   in	   S	   phase.	  Murine	   and	   human	   embryonic	   stem	   cells	   (Stead	   et	   al.,	   2002)	   and	   embryonal	  germ	  cells	  (Resnick	  et	  al.,	  1992)	  have	  a	  fast	  cell	  cycle	  composed	  mainly	  of	  S	  phase	  and	  a	  very	  short	  G1	  and	  G2.	  In	  these	  cells	  the	  cell	  cycle	  structure	  resembles	  the	  one	  present	  in	  lower	  vertebrates,	  where	  the	  cell	  cycle	  is	  essentially	  composed	  by	  rounds	   of	   S	   phase	   and	   mitosis	   (Murray	   and	   Kirschner,	   1989).	   Mammalian	  somatic	  cells	  usually	  complete	  a	  cell	  cycle	  in	  about	  24	  hours	  and	  cells	  spend	  most	  of	  the	  time	  in	  G1.	  During	  G1	  and	  G2,	  cells	  grow	  in	  size	  and	  production	  of	  RNAs	  and	  proteins	  increases.	  	  The	  progression	   through	  each	  phase	  of	   the	  cell	   cycle	   is	  governed	  by	  cellular	  checkpoints,	  which	  are	  regulated	  by	  different	  complexes.	  The	  proteins	  in	  charge	  of	   controlling	   phase	   transitions	   are	   complexes	   formed	   by	   Cyclin-­‐Dependent	  Kinases	  (CDKs)	  and	  cyclins	  (Pavletich,	  1999).	  During	  the	  cell	  cycle,	  the	  activity	  of	  CDK-­‐cyclin	   complexes	   is	   regulated	   by	   the	   cell	   cycle	   dependent	   expression	   of	  cyclins.	  Several	  cyclins	  are	  expressed	  in	  mammals	  and	  once	  they	  have	  completed	  their	   functions	   in	   a	   specific	   cell	   cycle	   phase,	   they	   are	   degraded	   (Evans	   et	   al.,	  1983).	   The	   presence	   of	   complexes	   controlling	   different	   cellular	   checkpoints	   is	  necessary	  to	  achieve	  a	  fine	  regulation	  of	  the	  cell	  cycle.	  	  	  
1.2.1 Cell	  cycle	  checkpoints	  Cell	   checkpoints	   are	   control	   mechanisms	   that	   the	   cell	   uses	   to	   ensure	   that	  processes	  such	  as	  DNA	  replication	  or	  mitosis	  are	  carried	  out	  properly.	  Cell	  cycle	  checkpoints	  are	  controlled	  by	  different	  CDK-­‐cyclin	  complexes	   that	  are	  active	  at	  different	   times	   during	   cell	   cycle	   (Arellano	   and	  Moreno,	   1997).	   CDK	   activity	   is	  controlled	   by	   binding	   to	   cyclins	   and	   by	   the	   action	   of	   two	   classes	   of	   inhibitors.	  These	   inhibitors	   are	   grouped	   into	   two	   families:	   the	   INK4	   and	   the	   Cip/Kip	  families.	  The	   INK4	   inhibitors	  are	  specific	   for	  CDK4	  and	  CDK6,	  and	  regulate	   the	  G1/S	   transition.	   They	   impede	   the	   catalytic	   site	   of	   CDKs,	   blocking	   their	   activity	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and	   inducing	   cell	   cycle	   arrest	   (Serrano	   et	   al.,	   1993).	   The	   other	   family	   of	   CDK	  inhibitors	   is	   represented	   by	   the	   Cip/Kip	   family	   and	   exert	   their	   functions	   in	   a	  broader	  manner	  throughout	  the	  cell	  cycle	  through	  inhibition	  of	  cyclins	  D,	  A,	  B,	  E.	  The	  CDKIs,	  p21	  and	  p27	  (Harper	  et	  al.,	  1993;	  Toyoshima	  and	  Hunter,	  1994)	  are	  included	  in	  this	  group.	  	  Cyclins	  represent	  the	  regulatory	  part	  of	   the	  cyclin-­‐CDK	  complexes.	  They	  are	  expressed	  in	  a	  cell	  cycle	  dependent	  manner	  and	  mediate	  temporal	  regulation	  of	  the	  activity	  of	  CDKs.	  Their	  stability	  is	  controlled	  by	  proteasomal	  degradation	  via	  two	  different	   families	   of	  E3	  ubiquitin	   ligases:	   the	   SCF	   complex,	  which	   is	   active	  from	  late	  G1	  to	  mitosis,	  and	  the	  APC/C	  complex,	  which	  operates	  from	  anaphase	  to	  late	  G1	  (Nakayama	  and	  Nakayama,	  2006).	  	  CDKs	   phosphorylate	   the	   Retinoblastoma	   (Rb)	   protein	   whose	   activity	   is	  regulated	   by	   its	   phosphorylation	   state.	   Rb	   regulates	   the	   G1/S	   transition	   by	  inhibiting	  S	  phase	  genes,	  including	  cyclin	  E	  (Weinberg,	  1995).	  In	  early	  G1,	  cyclin	  D	  is	  expressed	  and	  forms	  a	  complex	  with	  CDK4	  or	  CDK6.	  Rb	  is	  phosphorylated	  by	  CDK4/6	   and	   it	   switches	   from	   a	   non-­‐phosphorylated	   to	   a	   hypophosphorylated	  form	   (Connell-­‐Crowley	   et	   al.,	   1997).	   In	   this	   state	   the	   transcriptional	   inhibition	  caused	  by	  Rb	  is	  only	  partial	  and	  consequently	  cyclin	  E	  can	  be	  transcribed.	  Cyclin	  E	  is	  expressed	  in	  late	  G1,	  due	  to	  the	  release	  of	  HDAC1	  from	  its	  interaction	  with	  Rb	   and	   consequent	   activation	   of	   the	   cyclin	   E	   promoter	   (Harbour	   et	   al.,	   1999).	  However,	   the	   inhibitory	   power	   of	   Rb	   is	   not	   totally	   blocked	   because	   it	   can	   still	  bind	  to	  and	  repress	  E2F,	  which	  is	  responsible	  for	  transcription	  of	  S	  phase	  specific	  genes	  (Bagchi	  et	  al.,	  1991).	  Transcription	  of	  cyclin	  E	  leads	  to	  the	  activation	  of	  its	  binding	  partner	  CDK2,	  which	  generates	  a	  hyperphosphorylated	  form	  of	  Rb.	  This	  conformation	  of	  Rb	  cannot	  interact	  with	  E2F	  and	  consequently	  S	  phase-­‐specific	  genes	  are	  transcribed	  due	  to	  E2F	  release	  (Morris	  et	  al.,	  2000).	  	  One	   of	   the	   consequences	   of	   E2F	   transcriptional	   activity	   is	   also	   that	   it	  promotes	  the	  expression	  of	  cyclin	  A	  (Soucek	  et	  al.,	  1997).	  Cyclin	  A	  keeps	  CDK2	  in	  an	  active	  state,	  which	  keeps	  Rb	  in	  a	  phosphorylated	  and	  inactive	  state	  (Akiyama	  et	  al.,	  1992).	  Moreover,	  cyclin	  A-­‐CDK2	  is	  present	  during	  S	  phase,	  while	  cyclin	  B–CDK1	  is	  active	  in	  G2	  and	  during	  mitosis.	  The	  hyperphosphorylated	  form	  of	  Rb	  is	  retained	   until	   the	   mitotic	   process	   is	   completed.	   	   Cyclin	   A-­‐CDK2	   and	   cyclin	   B-­‐CDK1	   phosphorylate	   the	   transcription	   factor	   FoxM1	   during	   G2	   promoting	   its	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Figure	  1.2:	  Transcriptional	  regulation	  of	  Rb	  and	  FoxM1.	  Rb	  phosphorylation	  by	  the	  Cdk4/cycD	  and	  Cdk2/cycE	  complexes	  releases	  E2F	  from	  Rb	  inhibition.	  E2F	  is	  required	  for	  transcription	  of	  S	  phase	  genes.	  Phosphorylation	  of	  FoxM1	   promotes	   its	   activity.	   During	   G2	   it	   is	   phosphorylated	   by	   Cdk2/cycA	   and	  Cdk1/cycB.	  This	  leads	  to	  self-­‐activation	  and	  promotes	  binding	  to	  CBP,	  which	  is	  a	  co-­‐activator.	   Activation	   of	   FoxM1	   leads	   to	   transcription	   of	   genes	   required	   during	  mitosis.	   The	   phosphorylation	   state	   of	   FoxM1	   is	   counteracted	   by	   the	   action	   of	   the	  phosphotase	  PP2A/B55α.	  (Adapted	  from	  (Lim	  and	  Kaldis,	  2013)).	  
	  	  
1.2.2 The	  restriction	  point	  	  The	   existence	   of	   the	   restriction	   point	  was	   first	   hypothesized	   in	   1974	  when	  Pardee	  et	  al.	  showed	  that	  during	  G1,	  cells	  decide	  whether	  to	  proceed	  through	  the	  cell	   cycle	   or	   become	   quiescent	   (Pardee,	   1974).	   A	   better	   characterization	   was	  provided	  by	  Zetterberg	  et	  al.	  who	  analysed	  the	  restriction	  point	  in	  serum	  starved	  Swiss	   3T3	   cells.	   They	   demonstrated	   that	   the	   restriction	   point	   was	   located	   3.5	  hours	  after	  cell	  cycle	  re-­‐entry	   in	  response	  to	  mitogenic	  stimuli.	  Therefore,	   they	  divided	  G1	   into	   two	  parts:	  G1	  post-­‐mitotic	  before	   the	  restriction	  point	  and	  G1-­‐
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pre-­‐S	  after	  the	  restriction	  point.	  The	  presence	  of	  mitogenic	  stimuli	  during	  G1	  was	  the	  determining	  factor	  for	  a	  cell	  to	  decide	  whether	  to	  go	  through	  S	  phase	  or	  not	  (Zetterberg	   and	   Larsson,	   1985).	   However,	   a	   recent	   study	   has	   revealed	   new	  details	   about	   the	   decision	   to	   undergo	   cell	   cycle	   progression.	   Spencer	   et	   al.	  confirmed	  the	  data	  published	  by	  Zetterberg	  et	  al.	  by	  showing	  that	  serum	  starved	  cells,	   once	   back	   in	   the	   cell	   cycle,	   are	   susceptible	   to	   the	   presence	   of	  mitogenic	  stimuli	  before	  reaching	  the	  restriction	  point.	  	  This	  is	  mainly	  due	  to	  the	  low	  levels	  of	  CDK2	  and	  the	  hypophosphorylated	  state	  of	  Rb	  (Spencer	  et	  al.,	  2013).	  They	  also	  showed	   that	   cycling	   MCF10A	   cells	   behave	   differently	   to	   serum-­‐starved	   Swiss	  3T3	   cells.	   In	   cycling	   MCF10A	   cells	   the	   decision	   to	   proceed	   to	   S	   phase	   is	  dependent	  on	   levels	  of	  CDK2	   in	   the	  previous	  cycle.	  Levels	  of	  CDK2	  accumulate	  after	   formation	  of	   the	  nuclear	  envelope	  and	  are	   inversely	  proportional	   to	  CDKI	  p21.	   Withdrawal	   of	   mitogenic	   stimuli	   from	   these	   cells	   does	   not	   cause	   an	  immediate	   exit	   from	   the	   cell	   cycle.	   The	   deprivation	   of	   mitogenic	   stimuli	   will	  determine	   low	   levels	   of	   CDK2	   in	   the	   next	   cell	   cycle	   due	   to	   high	   levels	   of	   p21.	  During	   the	   following	   G1,	   the	   presence	   or	   absence	   of	   mitogenic	   stimuli	   will	  determine	  whether	  cells	  will	  cycle	  or	  become	  quiescent	  (Spencer	  et	  al.,	  2013).	  	  
1.2.3 	  Regulation	  of	  quiescence	  Quiescence	   is	   a	   reversible	   state	   of	   the	   cell,	   which	   is	   called	   G0,	   and	   can	   be	  activated	  due	   to	  different	   reasons,	   such	  as	   serum	  starvation,	   contact	   inhibition	  and	  loss	  of	  adhesion.	  The	  quiescent	  state	  is	  thought	  to	  preserve	  the	  genome	  from	  damage	  and	  to	  allow	  cells	  to	  respond	  to	  particular	  external	  stimuli.	  Cells	  in	  a	  G0	  state	   present	   some	   distinctive	   features,	   such	   as	   low	   rate	   of	   transcription	   and	  translation,	   hypophoshorylated	   Rb,	   low	   levels	   of	   CDK2	   and	   high	   levels	   of	   p21	  (Spencer	  et	  al.,	  2013).	  Indeed,	  quiescent	  cells	  can	  re-­‐enter	  the	  cell	  cycle	  following	  a	  mitogenic	   stimulus.	   They	   have	   unique	   characteristics	   and	   in	   the	   last	   decade	  increasing	  evidence	  has	  been	  obtained	  for	  the	  existence	  of	  a	  quiescence	  program.	  Quiescence	  does	  not	  correspond	  to	  dormancy,	  because	  cells	  are	  active.	  However,	  processes	  such	  as	  DNA	  replication	  and	  cell	  division	  that	  require	  a	  large	  amount	  of	   energy	   and	   the	   activation	   of	   biosynthetic	   pathways,	   are	   inhibited.	   The	  transcription	  and	  translation	  rates	  are	  also	  much	  lower	  than	  in	  cycling	  cells.	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As	   described	   above,	   there	   are	   known	   molecular	   mechanisms	   and	  transcription	   programmes	   that	   drive	   cells	   towards	   quiescence.	   The	   restriction	  point	  was	  first	  described	  using	  mitogenic	  stimulation	  of	  quiescent	  serum	  starved	  fibroblasts	   (Zetterberg	   and	   Larsson,	   1985).	   One	   of	   the	   first	   experiments	   to	  characterize	  quiescence	  in	  a	  more	  detailed	  way	  was	  carried	  out	  by	  Coller	  et	  al..	  They	  studied	  the	  activation	  of	  quiescence	  transcription	  program	  in	  fetal	  human	  lung	   diploid	   fibroblasts	   following	   three	   different	   pathways.	   The	   G0	   state	   was	  generated	  either	  by	   loss	  of	  adhesion,	  contact	   inhibition,	  serum	  starvation	  or	  by	  combining	  all	  three	  states.	  They	  revealed	  that	  each	  of	  these	  conditions	  activated	  a	  different	  pathway	  to	  achieve	  quiescence,	  and	  showed	  that	  synergy	  between	  the	  pathways	  resulted	   in	  a	  robust	  activation	  of	  a	  quiescence	  program	  (Coller	  et	  al.,	  2006).	  According	   to	   their	  work	  many	  genes	  were	  upregulated,	   including	  genes	  involved	   in	   suppressing	   apoptosis	   or	   differentiation,	   and	   many	   others	   were	  downregulated,	   for	   example	   genes	   required	   for	   cell	   cycle	   progression,	   DNA	  replication	  or	  mitosis.	  Moreover,	  they	  also	  showed	  that	  a	  cell	  cycle	  arrest	  due	  to	  CDK	   inhibitors	   activated	   a	   different	   set	   of	   genes,	   not	   resembling	   the	   quiescent	  program.	  They	  concluded	  that	  cell	  cycle	  arrest	  and	  quiescence	  are	  two	  separate	  events	  (Coller	  et	  al.,	  2006).	  	  Quiescent	   cells	   are	   active	   cells	   that	   direct	   their	   metabolic	   processes	   in	   a	  different	   direction	   than	   the	   cell	   cycle.	   To	   reinforce	   the	   theory	   of	   a	   specific	  transcription	   program,	   Chen	   et	   al.	   generated	   serum	   starved	   human	   foreskin	  fibroblasts.	   They	   showed	   fibroblasts	   that	   undergo	   quiescence	   are	   more	  responsive	  to	  inflammatory	  responses,	  activating	  genes	  such	  as	  COX-­‐2	  and	  IL-­‐2,	  which	  are	  downregulated	  in	  cycling	  fibroblasts	  (Chen	  et	  al.,	  2012).	  A	  very	  recent	  study	  comparing	  G0	  and	  G1	  mouse	  embryonic	  fibroblasts	  supports	  the	  idea	  of	  a	  specific	   quiescence	   program.	   The	   analysis	   showed	   that	   G1	   cells	   transcribed	  genes	   involved	   in	   mitosis,	   cell	   cycle,	   proliferation	   whereas	   G0	   cells	   expressed	  genes	   coding	   for	   epigenetic	   regulators,	   inflammatory	   responses	   and	   tumor	  suppressors	  (Oki	  et	  al.,	  2014).	  Studies	  in	  lymphocytes	  have	  shown	  a	  requirement	  of	  activating	  genes	  such	  as	  Gadd45	  and	  repressing	  others	  such	  as	  Myc	  (Glynne	  et	  al.,	  2000).	  Two	  major	  groups	  of	  transcription	  factors	  that	  play	  an	  important	  role	  in	   lymphocyte	   quiescence	   are	   the	   KLF	   family	   proteins	   and	   the	   FOXO	   proteins.	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These	  two	  class	  of	  proteins	  cause	  a	  reversible	  exit	  of	  the	  cell	  cycle	  by	  acting	  on	  cell	  cycle	  checkpoints	  and	  proliferative	  factors	  (Yusuf	  and	  Fruman,	  2003).	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Figure:	  1.3:	  Chromosomal	  Passenger	  Complex	  (CPC).	  The	  CPC	  is	  composed	  by	  four	  subunits:	  Aurora	  B	  kinase,	  INCENP,	  Borealin,	  Survivin.	  INCENP	   is	   the	   scaffold	   protein	   that	   interacts	   with	   the	   other	   three	   subunits.	  Activation	   of	   the	   complex	   is	   triggered	   by	   binding	   of	   INCENP	   to	   Aurora	   B.	   This	  promotes	   autophosphorylation	   and	   phosphorylation	   of	   other	   components	   to	  achieve	  full	  activation.	  (Adapted	  from	  (Ruchaud	  et	  al.,	  2007)).	  	   In	  mitosis	   the	   CPC	   complex	   is	   first	   present	   on	   chromosome	   arms	   and	   then	  progressively	   migrates	   towards	   centromeric	   chromatin.	   Phosphorylation	   of	  histone	  H3S10	  by	  Aurora	  B	  on	  the	  centromeric	  heterochromatin	  and	  binding	  of	  INCENP	  promote	  the	  displacement	  of	  the	  Heterochromatin	  Protein	  1	  (HP1)	  from	  histone	   H3K9me3	   (Hirota	   et	   al.,	   2005).	   The	   migration	   of	   the	   CPC	   from	   the	  chromosomal	  arms	  towards	  the	  pericentromeric	  chromatin	  regulates	  the	  correct	  orientation	  of	  sister	  kinetochores	  attachment	  to	  opposite	  spindle	  poles	  (Tanaka	  et	   al.,	   2002).	   Furthermore,	   after	   the	  migration	  of	  CPC	   towards	   the	   centromere,	  Aurora	   B	   interacts	   with	   and	   phosphorylates	   the	   centromeric	   histone	   variant	  CENP-­‐A	  (Zeitlin	  et	  al.,	  2001).	  The	  presence	  of	  minor	  satellite	  RNA	  also	  seems	  to	  have	  a	   role	   in	   recruiting	   the	  CPC	   to	   the	  centromeric	   region	   (Ferri	  et	  al.,	  2009).	  The	   RNA	   not	   only	   influences	   the	   Aurora	   B	   CENP-­‐A	   interaction	   but	   also	   the	  binding	  of	  the	  kinase	  to	  Survivin.	  It	  has	  been	  reported	  that	  the	  kinase	  activity	  of	  Aurora	   B	   is	   considerably	   reduced	   in	   the	   absence	   of	   RNA	   (Ferri	   et	   al.,	   2009).	  These	  results	  have	  been	  confirmed	  very	  recently	  by	  Jambhekar	  et	  al.	  showing	  the	  presence	   of	   RNA	   in	   a	   complex	  with	   the	   CPC,	   and	   presenting	   evidence	   that	   the	  presence	  of	  RNA	  in	  the	  complex	  affects	  CPC	  localization	  (Jambhekar	  et	  al.,	  2014).	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The	  presence	  of	  the	  CPC	  at	  the	  kinetochore	  is	  important	  to	  ensure	  formation	  of	  a	  correct	  SAC	  and	  to	  avoid	  problems	  with	  microtubule	  attachment.	  The	  CPC	  is	  localized	  at	   the	   inner	  kinetochore	  and	   is	  able	   to	  recognize	   incorrect	  or	  missing	  binding	   between	   kinetochores	   and	   microtubules	   (Kelly	   and	   Funabiki,	   2009).	  Syntelic	  or	  merotelic	  binding	  of	   chromosomes	   to	   spindle	  poles	  would	   result	   in	  generation	  of	  aneuploid	  cells.	  When	  incorrect	  binding	  occurs,	  the	  CPC	  can	  sense	  the	   loss	  of	   tension	   in	   the	  attachment	  of	  microtubules.	  Consequently,	   the	  SAC	   is	  triggered	   to	   allow	   the	   cell	   to	   remedy	   the	   incorrect	   binding.	   This	   mechanism	  promotes	  phosphorylation	  of	  kinetochore	  proteins	  by	  Aurora	  B,	  causing	  release	  of	   the	   microtubules	   (Lampson	   et	   al.,	   2004).	   Once	   all	   of	   the	   chromosomes	   are	  bound	   to	   the	   spindle	   in	   a	   correct	   orientation,	   the	   SAC	   is	   repressed	   and	  chromosomes	  can	  migrate	  towards	  the	  spindle	  poles	  during	  anaphase	  (Sampath	  et	  al.,	  2004).	  	  The	   CPC	   remains	   in	   the	   midbody	   during	   anaphase,	   where	   it	   promotes	   the	  formation	   of	   the	   cleavage	   furrow.	   During	   telophase	   a	   contractile	   ring	   in	   the	  midzone	   initiates	   cellular	   division,	   which	   will	   be	   completed	   in	   cytokinesis	  (Miller,	   2011).	   The	   CPC	   is	   localized	   in	   the	   midzone	   during	   telophase	   and	   its	  components	  are	  important	  for	  completion	  of	  cytokinesis.	  INCENP	  localizes	  at	  the	  inner	   plasma	  membrane	   in	   the	   cleavage	   furrow	   (Earnshaw	   and	   Cooke,	   1991).	  Aurora	  B	  has	  been	  shown	  to	  be	  required	  for	  normal	  cytokinesis.	  Expression	  of	  a	  kinase-­‐dead	   Aurora	   B	   can	   cause	   abortive	   cytokinesis,	   leading	   to	   formation	   of	  diploid	   cells	   (Terada	   et	   al.,	   1998).	   One	   of	   the	   functions	   of	   Aurora	   B	   during	  cytokinesis	   is	   to	   phosphorylate	   components	   of	   the	   cytoskeleton.	   Vimentin	   is	   a	  target	  of	  Aurora	  B	  and	  is	  required	  for	  correct	  division	  (Goto	  et	  al.,	  2003).	  It	  has	  also	  been	  shown	  that	  another	  target	  of	  Aurora	  B	  is	  the	  GTPase	  activating	  protein	  (GAP)	  MgcRacGAP,	  which	  is	  essential	  for	  cytokinesis.	  Loss	  of	  phosphorylation	  of	  MgcRacGAP	  by	  Aurora	  B	  leads	  to	  polyploidy	  (Minoshima	  et	  al.,	  2003).	  	  	  
1.2.5 The	  role	  of	  Aurora	  B	  in	  cell	  cycle	  progression	  The	  end	  of	  mitosis	  marks	   the	  beginning	  of	  a	  new	  cell	   cycle	   for	   the	   two	  new	  daughter	   cells.	   After	   peaking	   in	   mitosis,	   levels	   of	   Aurora	   B	   drop	   dramatically	  after	   mitotic	   exit.	   The	   kinase	   is	   a	   target	   for	   the	   anaphase	   promoting	   complex	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(APC/C),	   which	   poly-­‐ubiquitinates	   Aurora	   B	   and	   promotes	   its	   degradation	   via	  the	  proteasome	  (Stewart	  and	  Fang,	  2005).	  	  The	   role	   of	   Aurora	   B	   in	   the	   regulation	   of	   mitosis	   has	   been	   extensively	  described.	  Protein	   levels	  of	  Aurora	  B	   in	  G1	  are	  much	   lower	  than	   in	  mitosis	  but	  are	   still	   detectable	   (Kimura	   et	   al.,	   2004).	   A	   study	   carried	   out	   by	   Song	   et	   al.	  provided	   evidence	   that	   Aurora	   B	   is	   in	   a	   complex	   together	   with	   mTOR	   and	  Survivin	  that	  controls	  G1/S	  progression	  in	  T	  lymphocytes.	  	  Inhibition	  of	  Aurora	  B	  or	  mTOR	  suppresses	  activation	  of	  cyclin	  A	  and	  therefore	  activation	  of	  CDK	  1	  and	  CDK2.	  Aurora	  B	  phosphorylates	   Survivin	   and	  mTOR	  and	   this	   complex	   controls	  cell	   cycle	   progress	   by	   regulation	   of	   Rb,	   activation	   of	   CDK1	   and	   CDK2	   and	  repression	   of	   cyclin	   A	   (Song	   et	   al.,	   2007).	   Furthermore,	   Aurora	   B	   activity	   is	  dependent	   on	   mTOR.	   When	   cells	   were	   treated	   with	   rapamicin,	   the	   mTOR	  inhibitor,	   Aurora	   B	   was	   expressed	   normally,	   however	   phosphorylation	   of	  Survivin,	   Rb,	   CDK1	   and	   CDK2	   were	   affected	   by	   the	   presence	   of	   rapamicin,	  showing	  that	  mTOR	  affects	  the	  activity	  of	  Aurora	  B	  (Song	  et	  al.,	  2007).	  It	   has	   also	   been	   shown	   that	   Aurora	   B	   is	   involved	   in	   regulating	   the	   G1/S	  transition	  in	  many	  cancer	  cell	  lines.	  Aurora	  B	  interacts	  with	  and	  phosphorylates	  Rb	   in	   HCT-­‐116	   cells	   (Nair	   et	   al.,	   2009).	   This	   post-­‐translational	  modification	   is	  necessary	   to	   avoid	   endoreduplication	   after	   aberrant	   mitosis.	  Hyperphosphoryated	  Rb	  normally	  releases	  E2F,	  which	  promotes	  transcription	  of	  S	  phase	  genes,	  as	  described	  in	  section	  1.2.1.	  However,	  Aurora	  B	  phosphorylation	  of	  Rb	  has	  the	  opposite	  effect	  because	  it	  stabilizes	  the	  Rb-­‐E2F1	  interaction	  instead	  of	   promoting	   the	   release	   of	   E2F1.	   Thus,	   the	   cell	   cycle	   is	   arrested	   and	  endoreduplication	  is	  inhibited	  (Nair	  et	  al.,	  2009).	  	  Recently	  it	  has	  been	  shown	  that	  Aurora	  B	  controls	  the	  transcriptional	  activity	  of	   p53.	   Aurora	   B	   is	   able	   to	   phosphorylate	   p53	   targeting	   it	   for	   proteasome	  degradation	  in	  a	  breast	  cancer	  cell	  line	  (MCF-­‐7).	  Inhibition	  of	  Aurora	  B	  promotes	  the	  upregulation	  of	  p53	  target	  genes,	  such	  as	  p21	  and	  MDM2	  (Gully	  et	  al.,	  2012).	  Another	  study	  in	  mouse	  embryonic	  fibroblasts	  (MEFs)	  has	  revealed	  that	  Aurora	  B	  knock	  down	  generates	  a	  delay	  in	  entry	  into	  S	  phase	  rather	  then	  a	  G1/S	  arrest.	  The	  delay	  is	  due	  to	  high	  levels	  of	  p21,	  which	  is	  upregulated	  by	  p53.	  Furthermore,	  the	   high	   levels	   of	   p21	   in	   Aurora	   B	   ablated	   cells	   do	   not	   affect	   entry	   in	  mitosis.	  However,	  due	  to	  the	   inhibition	  of	  CDK1	  by	  p21,	  cells	  undergo	  a	  premature	  exit	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from	  mitosis	   (Trakala	   et	   al.,	   2013).	   Additional	   Aurora	   B	   studies	   on	   cancer	   cell	  lines	  have	  confirmed	  that	  Aurora	  B	  controls	  p53	  and	  p21	  activity.	  Genes	   in	   the	  p53	  pathway	  are	  upregulated	  in	  cells	  where	  Aurora	  B	  has	  been	  inhibited,	  while	  E2F-­‐regulated	  genes	  have	  a	  decreased	  expression.	  Cell	  cycle	  arrest	  is	  generated	  by	  the	  presence	  of	  p21,	  hyperphosphorylation	  of	  Rb	  and	  consequent	  repression	  of	  E2F	  (Kumari	  et	  al.,	  2014).	  	  	  	  
1.3 Transcriptional	  regulation	  
	  
1.3.1 Transcription	  is	  regulated	  by	  post-­translational	  modifications	  and	  
histone	  variants	  Gene	  transcription	  is	  a	  highly	  regulated	  process	  that	  involves	  many	  different	  proteins,	   regulatory	   RNAs	   and	   the	   input	   of	   signalling	   pathways.	   The	   state	   of	  transcription	   is	  also	  affected	  by	  the	  composition	  of	  chromatin.	  A	  tightly	  packed	  chromatin	   conformation	   generally	   corresponds	   to	   a	   repressive	   transcriptional	  state,	  while	  in	  the	  case	  of	  active	  transcription	  the	  chromatin	  is	  more	  accessible.	  Chromatin	  is	  formed	  by	  strings	  of	  nucleosomes,	  which	  are	  composed	  of	  DNA	  and	  histones.	  Nucleosomes	  consist	  of	  an	  octamer	  formed	  from	  two	  molecules	  of	  each	  of	  histone	  H2A,	  H2B,	  H3	  and	  H4.	  146	  base	  pairs	  (bp)	  of	  DNA	  is	  wrapped	  around	  the	   octamer	   (Luger	   et	   al.,	   1997).	   The	   linker	   histone	   H1	   sits	   outside	   of	   the	  nucleosomal	  core	  on	  the	  linker	  DNA	  between	  the	  nucleosomes.	  The	  N-­‐tails	  of	  the	  histones	   are	   exposed	   to	   the	   action	  of	   enzymes	   that	   generate	  post-­‐translational	  modifications.	  	  The	   function	   of	   histone	   modifications	   is	   to	   control	   the	   compaction	   of	  chromatin	   and	   therefore	   the	   accessibility	   to	   transcription	   factors.	   A	   large	  number	   of	   post-­‐translational	   modifications	   have	   been	   studied,	   including	  methylation,	   acetylation,	   phosphorylation,	   ubiquitination,	   sumoylation,	   ADP	  ribosylation,	   deimination,	   proline	   isomerization	   (Kouzarides,	   2007).	   The	  multiple	  combinations	  of	  different	  modifications	  that	  are	  found	  on	  histone	  tails	  have	   important	   roles	   in	   the	   regulation	   of	   gene	   transcription.	   A	   particular	  modification	  does	  not	   in	   itself	   imply	  a	   repressive	  or	  active	   state	  as	   it	   can	  have	  different	   effects	   depending	   on	   which	   residue	   is	   modified.	   For	   example,	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methylation	   on	   histone	   H3K4me3	   is	   considered	   to	   be	   an	   active	   marker	   for	  transcription	  (Santos-­‐Rosa	  et	  al.,	  2002),	  whereas	  histone	  H3K9me3	  has	  generally	  been	   thought	   to	   be	   repressive	   feature	   as	   it	   is	   a	   target	   for	   binding	   of	  heterochromatin	  protein-­‐1	   (HP1)	   (Bannister	  et	  al.,	  2001).	  Acetylation	  seems	   to	  be	   mostly	   associated	   with	   transcriptional	   activation	   but	   acetylation	   of	   H4K12	  has	  been	  shown	  to	  be	  associated	  with	  heterochromatin	  formation	  in	  Drosophila	  (Turner	  et	  al.,	  1992).	  Post-­‐translational	   modifications	   can	   act	   in	   combinations	   to	   regulate	  transcription.	   For	   instance,	  when	   the	  H3K9me3	  modification	   is	   combined	  with	  phosphorylation	  on	  H3S10	  in	  the	  G2	  stage	  of	  the	  cell	  cycle,	  there	  is	  a	  switch	  that	  leads	  to	  displacement	  of	  HP1	  binding	  to	  H3K9me3	  (Hirota	  et	  al.,	  2005).	  Another	  combination	   of	   modifications	   is	   represented	   by	   bivalent	   domains	   in	   ES	   cells,	  which	   are	   marked	   by	   H3K4me3	   and	   H3K27me3.	   The	   presence	   of	   two	  modifications	   that	   are	   respectively	   active	   and	   repressive	  markers	   in	   the	   same	  chromatin	   domains	   has	   been	   hypothesised	   to	   keep	   developmentally	   regulated	  genes	   in	   a	   poised	   state,	   ready	   for	   activation	   when	   ES	   cells	   differentiate.	  (Bernstein	  et	  al.,	  2006).	  	  Post-­‐translational	  modifications	  on	  histone	  tails	  are	  not	   the	  only	  mechanism	  by	  which	  histones	  can	  affect	  gene	  transcription.	  Canonical	  histone	  proteins	  can	  be	   replaced	   by	   histone	   variants	   that	   have	   different	   functions	   in	   cellular	  processes.	   The	   histone	   H3	   variant	   H3.3	   is	   particularly	   enriched	   at	  transcriptionally	   active	   loci	   (Ahmad	   and	   Henikoff,	   2002b).	   Nucleosome	  containing	   H3.3	   are	   unstable	   and	   therefore	   chromatin	   is	   more	   accessible	   to	  transcription	  factors	  (Chow	  et	  al.,	  2005).	  CENP-­‐A	  is	  another	  variant	  of	  histone	  H3	  that	   is	   found	   at	   centromeres	   and	   is	   required	   for	   kinetochore	   assembly	   (Van	  Hooser	  et	  al.,	  2001)	  (Figure	  1.4).	  Histone	  H2A,	  has	  19	  variants,	  among	  which	  are	  H2A.Z,	  H2AX,	  macroH2A	  and	  H2ABBD	  (Figure	  1.4).	  H2A.Z	  has	  recently	  been	  the	  focus	   of	  much	   research,	   as	   it	  was	   shown	   to	   be	   present	   in	   promoters	   of	   active	  genes	  in	  mice	  (Bargaje	  et	  al.,	  2012).	  Promoter	  nucleosomes	  become	  unstable	  due	  to	   the	   presence	   of	   H2A.Z	   and	   H3.3,	   indicating	   that	   H2A.Z/H3.3	   containing	  nucleosomes	  promote	   the	   access	   of	   transcription	   factors	   (Jin	   et	   al.,	   2009).	   The	  histone	   variant	   H2AX	   is	   recruited	   to	   the	   regions	   surrounding	   double	   strand	  breaks	  where	  it	  promote	  DNA	  repair	  (Paull	  et	  al.,	  2000).	  MacroH2A	  is	  found	  on	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the	   inactive	  X	  chromosome	  and	   is	   involved	   in	   silencing	   (Costanzi	  and	  Pehrson,	  1998).	  H2ABBD	  is	  the	  most	  recently	  discovered	  of	  the	  H2	  variants	  and	  has	  been	  connected	   to	   transcriptional	   activation.	   A	   recent	   study	   has	   shown	   that	   its	  presence	   in	   the	   gene	   body	   is	   crucial	   for	   a	   correct	   splicing	   (Tolstorukov	   et	   al.,	  2012)	  
Figure	  1.4:	  Schematic	  representation	  of	  nucleosomal	  core	  histone	  variants	  
and	  post-­tranlsational	  modifications.	  The	  most	   studied	   histone	   variants	   are	   shown.	   Known	   functions	   are	   listed	   on	   the	  right.	   Each	   variant	   has	   a	   common	  Histone	   Fold	  Domain	   (HFD).	   Residues	   that	   are	  targets	  for	  modification	  are	  marked	  with	  green	  circles	  for	  phosphorylation	  and	  red	  flags	  for	  methylation.	  	  (Adapted	  from	  (Sarma	  and	  Reinberg,	  2005)).	  	  Histone	  H1	   is	  positioned	  outside	  of	   the	  nucleosomal	  core	  on	   the	   linker	  DNA	  between	   nucleosomes	   and	   is	   involved	   in	   controlling	   the	   compaction	   of	  chromatin.	  In	  mammals	  there	  are	  11	  known	  histone	  H1	  variants,	  5	  of	  which	  are	  somatic.	   The	  other	   variants	   are	   either	   tissue-­‐specific	   or	   expressed	   in	   the	   germ	  line.	   	  H1.1,	  H1.2,	  H1.3,	  H1.4	   and	  H1.5	   are	   expressed	   in	   somatic	   cells,	  while	   the	  variant	   H1.0	   is	   expressed	   in	   terminally	   differentiated	   or	   growth	   arrested	   cells	  (Happel	   and	   Doenecke,	   2009).	   There	   is	   only	   limited	   information	   about	   the	  variant	  H1.x.	   It	   has	   been	   reported	   to	   be	   an	  ubiquitous	  protein	  with	   repressive	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proterties	  and	  is	  enriched	  in	  less	  accessible	  areas	  of	  genome	  (Shahhoseini	  et	  al.,	  2010).	   The	   remaining	   H1	   variants,	   H1.oo,	   H1.t,	   Hils1,	   H1T2,	   are	   expressed	   in	  testis	  and	  oocytes	  or	  in	  the	  zygote	  (Happel	  and	  Doenecke,	  2009).	  	  The	   role	  of	  histone	  H1	   in	   regulating	   transcription	  has	  been	   long	  debated.	   In	  general,	   histone	   H1	   has	   been	   considered	   to	   be	   a	   repressor	   of	   transcription	  (Buttinelli	  et	  al.,	  1999).	  Studies	  have	  shown	  that	  H1	  promotes	  the	  compaction	  of	  chromatin	  and	  its	  presence	  around	  genes	  does	  not	  allow	  transcription	  factors	  to	  bind	   (Robinson	   and	  Rhodes,	   2006).	   Furthermore,	   the	   linker	   histones	   are	   often	  associated	  with	  areas	  of	   the	  genome	  that	  are	   in	  a	  repressive	  state.	  A	  study	  has	  reported	   that	   the	   interaction	  between	  histone	  H1	   and	  Nucleolin	   is	   responsible	  for	   decondensing	   the	   chromatin	   as	   it	   displaces	   the	   linker	  histone	   (Erard	   et	   al.,	  1988).	  However,	  recent	  studies	  have	  shown	  that	  acetylation	  of	  histone	  H1.4	  on	  the	   lysine	   34	   is	   connected	  with	   active	   transcription	   (Kamieniarz	   et	   al.,	   2012).	  Histone	  H1.4K34	  is	  acetylated	  by	  GNC5	  and	  it	   is	  present	  at	  promoters	  of	  active	  genes.	   Therefore,	   the	   chromatin	   is	   more	   open	   and	   accessible	   to	   transcription	  factors	  (Kamieniarz	  et	  al.,	  2012).	  	  	  
1.3.2 Chromatin	  remodelers	  affect	  chromatin	  conformational	  state	  	  Chromatin	   conformation	   and	   accessibility	   at	   promoters	   and	   enhancers	   is	  affected	   by	   positioning	   of	   nucleosomes	   with	   respect	   to	   these	   elements.	  Nucleosomes	  can	  be	  positioned	  by	   local	  displacement	  by	  a	  bound	  transcription	  factor	  or	  by	  specific	  DNA	  sequences	  that	  favour	  or	  disfavour	  the	  formation	  of	  a	  nucleosome	  (Jiang	  and	  Pugh,	  2009).	  DNA	  sequences	  of	  this	  type	  can	  create	  local	  nucleosome-­‐free	   areas	   in	   important	   regulatory	   regions,	   such	   as	   promoters.	  Alternatively,	   they	  can	  promote	   the	   formation	  of	  nucleosome	  condensed	  areas,	  such	  as	  heterochromatic	  regions	  (Ahmad	  and	  Henikoff,	  2002a).	  	  Protein	   complexes	   called	   chromatin	   remodellers	   have	   been	   shown	   to	   be	  responsible	  of	  modifying	  the	  composition	  of	  chromatin.	  Remodelling	  complexes	  are	   ATP-­‐dependent	   DNA	   translocases	   that	   affect	   the	  DNA-­‐histone	   interactions.	  Chromatin	   remodellers	   can	  mediate	   either	   repositioning,	   sliding	   or	   removal	   of	  nucleosomes	  along	  the	  chromosome	  (Clapier	  and	  Cairns,	  2009).	  There	  are	   four	  families	  of	   chromatin	   remodellers,	   characterized	  by	  an	  ATPase	  domain	   flanked	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by	   different	   domains,	   which	   are	   specific	   for	   each	   family.	   The	   chromatin	  remodeller	   families	   are	   SWI/SNF,	   INO80,	   CHD	   and	   ISWI.	   The	   mechanism	   of	  action	   is	   common	   among	   these	   families	   as	   they	   all	   use	   ATP	   hydrolysis	   to	  mobilize	  DNA	  from	  the	  nucleosome	  octamer	  (Vignali	  et	  al.,	  2000).	  	  	  The	   SWI/SNF	   complex	   has	   been	   shown	   to	   mediate	   nucleosome	   sliding	   or	  eviction	   of	   histones	   from	   nucleosomes.	   However,	   this	   remodeller	   cannot	  participate	   in	   the	   assembly	   of	   the	   nucleosome.	   Members	   of	   the	   SWI/SNF	  complex	   family	   can	   recognize	   acetylated	   histones	   and	   promote	   transcription	  activation.	  In	  humans,	  the	  complexes	  that	  belong	  to	  this	  family	  are	  BAF	  and	  PBAF	  (Sudarsanam	  and	  Winston,	  2000).	  ISWI	  remodelers,	  such	  as	  ACF	  and	  CHRAC,	  are	  involved	   in	   promoting	   nucleosome	   spacing	   in	   order	   to	   facilitate	   chromatin	  assembly	  and	  repression	  (Langst	  and	  Becker,	  2001).	  The	  NURF	  complex	  is	  part	  of	  the	  ISWI	  family	  however	  it	  promotes	  transcription	  activation	  (Mizuguchi	  et	  al.,	  1997).	   Another	   family	   called	   CHD	   is	   composed	   of	   complexes	   that	   can	   act	   as	  activators	  or	  repressors.	  CHD1	  is	  known	  to	  be	  an	  activator	  because	  it	  promotes	  ejection	   or	   sliding	   of	   nucleosomes	   and	   it	   has	   been	   shown	   to	   participate	   in	  transcriptional	   elongation.	   A	   CHD	   family	   remodeler	   called	  Mi2-­‐NuRD	  has	   been	  connected	  with	  repression	  and	  is	  formed	  by	  deacetylases	  and	  proteins	  that	  bind	  methyl	   CpG	   nucleotides	   (Hall	   and	   Georgel,	   2007).	   The	   chromatin	   remodellers	  that	   belong	   to	   the	   INO80	   family	   are	   mainly	   associated	   with	   transcriptional	  activation,	  but	  there	   is	  evidence	  that	  they	  can	  also	  be	   involved	   in	  repression	   in	  association	  with	  the	  polycomb	  proteins	  (Bhatia	  et	  al.,	  2010).	  The	  INO80	  complex	  members	   can	   mediate	   the	   exchange	   of	   the	   H2A.Z/H2A	   dimer	   with	   H2B/H2A	  (Papamichos-­‐Chronakis	  et	  al.,	  2011).	  	  	  
1.3.3 Transcription	  performed	  by	  RNA	  polymerase	  II:	  initiation,	  
elongation	  and	  termination	  RNA	  polymerases	  are	  the	  enzymes	  that	  are	  responsible	   for	  the	  transcription	  of	   RNA.	   In	  most	   eukaryotes,	   there	   are	   three	   RNA	   polymerases	   that	   transcribe	  different	  types	  of	  genes.	  RNA	  polymerase	  II	  (Pol	  II)	  is	  the	  most	  studied	  because	  it	  is	   involved	   in	   the	   transcription	   of	   all	  mRNAs	   and	  most	   snRNA	   and	  microRNA.	  RNA	  polymerase	  I	  transcribes	  ribosomal	  genes	  with	  the	  exception	  of	  the	  5S	  rRNA	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(Grummt,	  2003),	  which	  is	  produced	  by	  RNA	  polymerase	  III.	  This	  enzyme	  exerts	  its	   functions	   by	   trancribing	   tRNAs,	   5S	   rRNA	   and	   other	   non	   coding	   RNAs,	  including	  the	  SK7RNA	  that	  controls	  RNA	  Polymerase	  II	  activity	  (White,	  2011).	  	  	  Pol	   II	   is	   composed	   of	   12	   subunits	   called	   Rpb.	   The	   largest	   subunit,	   Rpb1,	   is	  important	   for	   regulation	   of	   Pol	   II	   enzyme	   activity	   (Kimura	   et	   al.,	   1997).	   In	  mammals	  the	  carboxy	  terminal	  domain	  (CTD)	  of	  this	  subunit	  is	  composed	  by	  52	  hepta-­‐repetitions	  of	  YSPTSPS.	  Serine	  residues	  are	  located	  within	  each	  repetition	  in	   position	   2,	   5,	   7	   (Corden,	   2007).	   	   These	   serine	   residues	   are	   phosphorylated	  during	   the	   process	   of	   transcription	   and	   are	   involved	   in	   regulating	   initiation,	  elongation	  and	  termination	  (Figure	  1.5).	  	  
Figure	  1.5:	  RNA	  polymerase	  II	  cycle	  of	  transcription.	  The	   process	   of	   transcription	   can	   be	   divided	   into	   initiation,	   elongation	   and	  termination.	  These	  stages	  are	  regulated	  by	  phosphorylation	  of	  serines	  on	  the	  CTD	  of	  the	   Pol	   II.	   Upon	   binding	   to	   the	   promoter,	   the	   CTD	   is	   unphosphorylated.	   During	  initiation,	   it	   is	   phosphorylated	   at	   serine-­‐5	   and	   during	   elongation	   it	   becomes	  phoshorylated	  at	  serine-­‐2.	  	  	  (Adapted	  from	  (Kuehner	  et	  al.,	  2011)).	  	  
1.3.3.1 Initiation	  The	   unphosphorylated	   form	   of	   Pol	   II	   binds	   to	   the	   promoter	   upstream	   the	  transcriptional	  start	  site.	  It	  is	  recruited	  in	  this	  regulatory	  part	  of	  the	  gene	  to	  form	  a	   complex	   called	   Pre-­‐Initiation	   Complex	   (PIC)	   (Nikolov	   and	  Burley,	   1997).	   PIC	  formation	   is	   important	   for	   transcription	   and	   is	   related	   to	   recognition	   of	   DNA	  sequences	   at	   the	   promoter	   by	   the	   PIC	   components	   (Orphanides	   et	   al.,	   1996).	  Promoters	  can	  have	  different	   features	  according	   to	  sequence	  elements	   that	  are	  included	   in	   them	   and	   can	   be	   broadly	   divided	   into	   AT-­‐rich	   and	   CpG	   island	  promoters.	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AT-­‐rich	   promoters	   are	   characterized	   by	   the	   presence	   of	   specific	   sequences	  that	   are	   required	   for	   their	   recognition	   by	   general	   transcription	   factors.	   These	  types	   of	   promoters	   can	   have	   a	   TATA	   box	   located	   30	   bp	   upstream	   of	   the	  Transcription	   Start	   Site	   (TSS).	   The	   TATA	   box	   is	   bound	   by	   the	   general	  transcription	   factor	   TBP,	  which	   promotes	   the	   formation	   of	   the	   PIC	   (Wong	   and	  Bateman,	  1994).	  TBP	   is	  part	  of	   the	  TFIID	  complex,	  which	   is	   also	   important	   for	  the	   recognition	   of	   other	   promoter	   elements	   (Inr	   and	   DPE)	   that	   are	   situated	  downstream	  from	  the	  TSS	  (Emami	  et	  al.,	  1997).	  Binding	  of	  TFIID	  to	  the	  promoter	  elements	   is	   important	   to	   promote	   the	   binding	   of	   TFIIA	   and	   TFIIB,	   thereby	  stabilizing	   the	   binding	   of	   TBP	   to	   the	   DNA.	   TFIIB	   binds	   to	   another	   promoter	  element	  called	  BRE,	  which	  is	  located	  upstream	  of	  the	  TATA	  box	  (Lagrange	  et	  al.,	  1998).	  An	   important	   function	  of	  TFIIB	   is	   to	  ensure	   the	  correct	  directionality	  of	  Pol	   II	   and	   to	   stimulate	   the	   activity	   of	   the	   enzyme	   by	   preventing	   short	   newly	  formed	  DNA-­‐RNA	  hybrids	  from	  impeding	  RNA	  synthesis	  (Sainsbury	  et	  al.,	  2013).	  TFIIB	   is	   then	   stabilized	   by	   the	   presence	   of	   TFIIF,	   which	   is	   also	   required	   for	  transcription	   initiation	   (Cabart	   et	   al.,	   2011).	   Furthermore,	   TFIIF	   interacts	  with	  another	  factor,	  TFIIE,	  which	  in	  turn	  interacts	  with	  the	  unphosphorylated	  Pol	  II.	  Assembly	  of	   the	  PIC	   is	   completed	  after	   recruitment	  of	  TFIIH,	  which	   is	   the	  only	  GTF	   with	   enzymatic	   activity	   (Maxon	   et	   al.,	   1994).	   TFIIH	   is	   composed	   of	   the	  helicases	  XBP	  and	  XDP	  and	  the	  kinase	  Cdk7.	  The	  activity	  of	  TFIIH	  is	  required	  for	  the	  unwinding	  of	  DNA	  to	  create	  the	  transcription	  bubble	  that	   is	  needed	  for	   the	  polymerase	  to	  start	   transcribing	  (Bradsher	  et	  al.,	  2000).	  Cdk7	  also	   is	  necessary	  for	   transcription	   initiation	   because	   it	   phosphorylates	   Serine	   5	   on	   the	   CTD	  (Tirode	  et	  al.,	  1999).	  The	  Mediator	  complex	  also	  plays	  important	  roles	  in	  the	  formation	  of	  the	  PIC.	  Mediator	  can	  recruit	  TFIIH	  and	  this	  interaction	  facilitates	  phosphorylation	  of	  Pol	  II.	  Furthermore,	  Mediator	   interacts	  with	  co-­‐activators	  to	  stimulate	  formation	  of	  the	  PIC	  (Esnault	  et	  al.,	  2008).	  Transcription	  factors	  are	  needed	  for	  the	  formation	  of	   the	   PIC	   because	   they	   recognize	   promoter	   elements.	   The	   TATA	   box	   is	  recognised	   by	   general	   transcription	   factors	   but	   genes	   lacking	   the	   presence	   of	  TATA	   box	   are	   bound	   by	   the	   general	   transcription	   factors	   (GTFs)	   via	   other	  promoter	  elements.	  TFIID	  is	  crucial	  for	  the	  formation	  of	  the	  PIC	  and	  is	  recruited	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to	  TATA-­‐less	  promoters	  via	   transcription	   factors,	   such	  as	  Sp1	   (Pugh	  and	  Tjian,	  1991).	  	  CpG	  islands	  are	  regions	  that	  have	  a	  high	  frequency	  of	  CpG	  dinucleotides	  that	  are	  often	  found	  at	  gene	  promoters.	  The	  CpG	  dinucleotide	  is	  underrepresented	  in	  the	  genome	  because	  methylation	  of	  the	  cytosine	  results	   in	  deamination	  leading	  to	   conversion	   to	   thymidine.	  However,	   a	   high	  proportion	  of	   genes	   in	  mammals,	  including	  most	  housekeeping	  genes,	  have	  CpG	  islands	  at	  their	  promoters.	  These	  regions	  are	  characterized	  by	  the	  presence	  of	  multiple	  TSS	  and	  are	  nucleosome-­‐deficient	   (Ramirez-­‐Carrozzi	   et	   al.,	   2009).	   CpG	   island	   promoters	   often	   lack	  classical	   promoter	   elements	   such	   as	   TATA	   boxes	   and	   are	   regulated	   by	   the	  binding	  of	  ubiquitous	  transcription	  factors,	  such	  as	  Sp1	  (Deaton	  and	  Bird,	  2011).	  	  
1.3.3.2 Transcriptional	  elongation	  Once	  assembly	  of	  the	  PIC	  is	  completed,	  escape	  from	  the	  promoter	  is	  triggered	  by	  phosphorylation	  of	  the	  CTD	  at	  Serine	  5.	  This	  modification	  is	  mediated	  by	  Cdk7	  and	  allows	  the	  polymerase	  to	  transcribe	  around	  30	  bp	  (Ramanathan	  et	  al.,	  2001).	  At	   this	   point	   transcription	   is	   paused	   due	   to	   the	   presence	   of	   DRB	   Sensitivity	  Inducing	   Factor	   (DSIF)	   and	   Negative	   elongation	   factor	   (NELF),	   which	   are	  inhibitors	   of	   transcription	   (Yamaguchi	   et	   al.,	   1999).	   This	   might	   also	   be	   a	  checkpoint	  to	  promote	  the	  addition	  of	  a	  methylguanosine	  cap.	  The	  cap	  is	  needed	  to	   protect	   the	   newly	   produced	   RNA	   from	   degradation	   as	   well	   as	   promoting	  mRNA	   export	   and	   enhance	   translation	   (Lewis	   and	   Izaurralde,	   1997).	   The	  RNA	  capping	   is	   a	   three	   step	   reaction	   that	   starts	   with	   the	   digestion	   of	   the	   5’	  triphosphate,	  followed	  by	  the	  addition	  of	  a	  guanine	  and	  it	  is	  terminated	  with	  by	  methylation	  of	  the	  added	  guanine.	  The	  reaction	  is	  exerted	  catalysed	  by	  a	  single	  capping	   enzyme,	  which	   is	   recruited	   by	   the	   phosphorylation	   on	   serine-­‐5	   of	   the	  CTD	  and	   also	  by	  DSIF,	   and	   a	   cap	   guanine-­‐N7	  methyltransferase	   (Mandal	   et	   al.,	  2004).	   In	   the	  case	  of	  production	  of	  aberrant	  pre-­‐mRNA	  due	   to	  splicing	  defects,	  the	  cap	  of	  the	  RNA	  is	  removed	  by	  decapping	  enzymes	  and	  the	  RNA	  is	  degraded	  by	   Xrn2.	   This	   leads	   to	   premature	   transcription	   termination	   and	   represents	   a	  mechanism	  of	  transcription	  regulation	  (Davidson	  et	  al.,	  2012).	  	  Release	  from	  the	  paused	  state	  is	  mediated	  by	  the	  protein	  P-­‐TEFb.	  This	  protein	  is	   usually	   sequestrated	   by	   the	   complex	   7sk	   RNP	   (Nguyen	   et	   al.,	   2001).	   After	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transcription	  initiation,	  P-­‐TEFb	  is	  released	  either	  by	  Mediator	  or	  Brda4,	  allowing	  it	   to	   phosphorylate	   target	   proteins	   (Jang	   et	   al.,	   2005).	   P-­‐TEFb	   phosphorylates	  serine-­‐2	  on	  the	  CTD	  of	  Pol	  II.	  CTD	  phosphorylation	  at	  serine-­‐2	  is	  the	  hallmark	  of	  promoter	  escape	  and	  promotes	  elongation	  (Ramanathan	  et	  al.,	  2001).	  Following	  release	   of	   the	   polymerase	   from	   the	   promoter,	   the	   level	   of	   serine-­‐5	  phosphorylation	  decreases	  to	  reach	  low	  levels	  at	  the	  3’	  end	  of	  the	  gene.	  P-­‐TEFb	  is	  also	  responsible	  for	  phosphorylation	  of	  the	  pausing	  factors	  DSIF	  and	  NELF.	  This	  causes	   release	  of	  NELF,	  while	  DSFI	   is	   kept	   in	   the	   elongation	   complex	   (Peterlin	  and	  Price,	  2006)	  (Figure	  1.6).	  
	  	  
Figure	  1.6:	  Promoter	  proximal	  pausing	  of	  Pol	  II.	  Pol	  II	  is	  hold	  in	  pausing	  state	  around	  30	  bp	  by	  the	  factors	  DSIF	  and	  NELF.	  Upon	  the	  P-­‐TEFb	  activation,	  the	  two	  factors	  are	  phosphorylated	  as	  well	  as	  Serine	  2	  on	  the	  Pol	  II	   CTD.	   These	   phosphorylations	   cause	   the	   release	   of	   NELF	   and	   generate	   the	  elongating	  Pol	  II.	  	  (Adapted	  from	  (Levine,	  2011)).	  	  	  In	   order	   to	   escape	   from	   the	   paused	   state,	   Pol	   II	   needs	   to	   recruit	   factors	   to	  overcome	   the	   barrier	   of	   nucleosomes.	  One	   of	   these	   is	   the	   PAF	   complex,	  which	  does	  not	  have	  any	  enzymatic	  activity.	  However,	  this	  complex	  acts	  as	  a	  platform	  for	  recruiting	  proteins	   that	  are	  needed	  to	  generate	  a	   loose	  conformation	  of	   the	  nucleosome	  that	  can	  be	  transcribed	  by	  Pol	  II	  (Kim	  et	  al.,	  2010).	  In	  particular,	  the	  FACT	  complex	  has	  an	  important	  role	  as	  it	  removes	  the	  H2A-­‐H2B	  dimer	  from	  the	  nucleosome.	  The	  ejection	  of	  H2A-­‐H2B	  creates	  a	  nucleosomal	  conformation	  that	  allows	  the	  polymerase	  to	  transcribe	  along	  nucleosomal	  DNA.	  After	  the	  passage	  of	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the	   enzyme,	   FACT	   re-­‐deposites	   the	   H2A-­‐H2B	   dimer	   back	   into	   the	   nucleosome	  (Belotserkovskaya	  et	  al.,	  2003).	  	  	  
1.3.3.3 Termination	  Factors	   involved	   in	   3’end	   RNA	   formation	   constitute	   a	   complex	   that	   is	  composed	   of	   more	   than	   14	   proteins	   (Mandel	   et	   al.,	   2008).	   Serine-­‐2	  phosphorylation	   at	   the	   Pol	   II	   CTD	   is	   important	   to	   recruit	   proteins	   that	   are	  required	   for	   3’end	   cleavage	   of	   the	   nascent	   RNA	   (Gu	   et	   al.,	   2013).	   Once	   Pol	   II	  reaches	   the	   3’	   end	   of	   the	   gene,	   recognition	   of	   a	   poly-­‐A	   site	   sequence	  mediates	  pausing	   of	   the	   enzyme.	   The	   Cleavage	   and	   Polyadenylation	   Specificity	   Factor	  (CPSF),	  which	  is	  composed	  of	  five	  subunits	  and	  interacts	  with	  the	  body	  of	  Pol	  II,	  is	   present	   in	   the	   elongating	   complex	   and	   recognizes	   the	   poly-­‐A	   sequence	  (Dantonel	   et	   al.,	   1997).	   This	   is	   constituted	   by	   the	   sequence	   AAUAAA,	  which	   is	  located	   around	   10-­‐30	   nucleotides	   upstream	   of	   the	   cleavage	   site.	   A	   G-­‐U	   rich	  sequence	   downstream	   of	   the	   cleavage	   site	   is	   important	   for	   3’	   end	   processing	  (Chou	  et	  al.,	  1994)	  (Figure	  1.7-­‐1).	  The	  binding	  of	  CPSF	  to	  the	  AAUAAA	  sequence	  causes	  pausing	  of	  the	  polymerase	  and	  promotes	   interaction	  between	  Pol	  II	  and	  the	  cleavage	  stimulation	  factor	  (Cstf)	  (Nag	  et	  al.,	  2007).	  Moreover,	  binding	  of	  Cstf	  to	  the	  G-­‐U	  rich	  sequence	  is	  facilitated	  by	  the	  interaction	  with	  Pol	  II	  (Figure	  1.7-­‐2)	  (Nag	   et	   al.,	   2007).	   The	   binding	   of	   CPSF	   and	   Cstf,	   respectively	   upstream	   and	  downstream	  of	   the	   cleavage	   site,	   promotes	   formation	  of	   the	  pre-­‐mRNA	  3’	   end.	  For	  correct	  completion	  of	  the	  process	  two	  other	  factors,	  called	  CFI	  and	  CFII,	  are	  needed	   (Takagaki	   et	   al.,	   1989).	   CFI	   promotes	   recognition	   of	   the	   poly-­‐A	   site	  (Brown	  and	  Gilmartin,	  2003),	  while	  CFII	  mediates	   the	   interaction	  between	  CFI	  and	  CPSF	  (de	  Vries	  et	  al.,	  2000).	  A	  protein	  called	  symplekin	  acts	  as	  a	  scaffold	  for	  the	  interaction	  of	  these	  factors	  (Takagaki	  and	  Manley,	  2000).	  Once	  all	  of	  the	  proteins	  that	  are	  involved	  in	  3’end	  formation	  are	  recruited,	  the	  CPSF-­‐73	   subunit	   carries	   out	   the	   cleavage	  of	   the	  pre-­‐mRNA	   (Ryan	   et	   al.,	   2004).	  However,	   the	   cut	   generates	   a	   free	  a	  3’end	   that	  needs	   to	  be	  protected	   from	   the	  action	   of	   ribonucleases.	   The	   CPSF	   subunit	   Fip1	   stimulates	   the	   activity	   of	   the	  poly-­‐A	   polymerase	   (Pap)	   (Kaufmann	   et	   al.,	   2004).	   Pap	   is	   present	   in	   the	  termination	   complex	   machinery	   and	   has	   the	   function	   of	   adding	   a	   poly-­‐A	   tail	  composed	   of	   around	   200	   Adenines	   to	   the	   3’	   end	   of	   the	   RNA	   (Bardwell	   et	   al.,	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Figure	  1.7:	  mRNA	  transcription	  termination.	  1)	   The	   elongating	   complex	   recognizes	   the	   AAUAAA	   sequence	   through	   the	   CPSF	  complex.	  2)	  Pol	   II	  pauses	  after	   the	   stop	   signal	   and	   the	  Cstf	   complex	  binds	   the	  GU	  rich	  sequence	  downstream	  of	  the	  cleavage	  site.	  3)	  After	  cleavage	  and	  release	  of	  the	  mRNA,	   Xrn2	   degrades	   the	   new	   uncapped	   RNA	   that	   Pol	   II	   transcribes	   after	   the	  cleavage	  site.	  The	  action	  of	  Xrn2	  causes	  the	  release	  of	  Pol	  II	  from	  DNA.	  (Adapted	  from	  (Kuehner	  et	  al.,	  2011)).	  
	  
	  	  
1.4 	  Splicing	  is	  a	  two-­step	  reaction	  	   Splicing	   is	   an	   essential	   process	   that	   is	   required	   for	   removal	   of	   introns	   from	  primary	  transcripts	  to	  generate	  a	  mature	  RNA.	  The	  mRNA	  is	  then	  exported	  to	  the	  cytoplasm	  where	  it	   is	  translated	  into	  proteins.	  Splicing	  is	  carried	  out	  by	  a	  large	  group	  of	  proteins	  that	  contribute	  to	  the	  formation	  of	  the	  spliceosome	  (Will	  and	  Luhrmann,	  2011).	  This	  is	  a	  heterogeneous	  complex	  formed	  by	  ribonucleoprotein	  (RNP)	  complexes.	  The	  composition	  of	  RNP	  complexes	  is	  based	  on	  the	  interaction	  of	  small	  nuclear	  RNA	  (snRNA)	  with	  Sm	  proteins.	  The	  snRNAs	  are	  characterized	  by	  the	  presence	  of	  secondary	  structures	  that	  are	  crucial	  for	  the	  interaction	  with	  proteins	   and	  DNA.	  The	   snRNAs	  are	  U1,	  U2,	  U5,	  U4/U6	  and	  each	  RNA	   interacts	  with	  a	  ring	  shaped	  complex	  formed	  by	  seven	  Sm	  proteins	  (Wahl	  et	  al.,	  2009).	  An	  exception	  is	  represented	  by	  the	  snRNAs	  U4	  and	  U6	  that	  are	  base-­‐paired	  forming	  a	   single	   RNA	  molecule.	   The	   unwinding	   of	   U4/U6	   by	   the	   RNA	   helicase	   Prp8	   is	  necessary	  for	  the	  formation	  of	  an	  active	  U6	  molecule	  during	  splicing	  (Kuhn	  et	  al.,	  1999).	  	  Splicing	  is	  a	  two-­‐step	  process	  that	  consists	  of	  two	  transesterification	  reactions	  for	   the	   excision	   of	   the	   intron.	   Excision	   is	   achieved	   by	   an	   intermediate	   lariat	  conformation	   of	   the	   intron	   (Moore	   and	   Sharp,	   1993).	   Removal	   of	   the	   intron	   is	  mediated	  by	  the	  snRNP	  complexes,	  which	  are	  able	  to	  recognize	  sequences	  within	  the	  intron.	  These	  consist	  of	  the	  5’	  splice	  site	  (5’SS),	  the	  Adenine	  of	  the	  branch	  site	  (BS)	  and	  the	  3’	  splice	  site	  (3’SS)	  (Figure	  1.8).	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Figure	  1.8:	  Schematic	  representation	  of	  sequence	  elements	  within	  introns.	  The	   intron	   is	   characterized	   by	   a	   5’	   splice	   site	   (5’SS),	   a	   branch	   site	   (BS),	   a	  polypyrimidine	   tract	   and	   the	   3’	   splice	   site	   (3’SS).	   The	   first	   transesterification	  reaction	   is	   between	   the	   adenine	   in	   the	   BS	   and	   the	   5’SS	   to	   achieve	   the	   lariat	  formation.	  The	  3’	  hydroxyl	  of	   the	  cleaved	  5’	  exon	  then	  attacks	  the	  phosphodiester	  bond	   at	   the	   3’	   splice	   site.	   This	   results	   in	   ligation	   of	   the	   5’	   and	   3’	   splice	   sites	   and	  excision	  of	  the	  lariat	  (Adapted	  from	  (Semlow	  and	  Staley,	  2012)).	  	  	  	  	   The	   splicing	   reactions	   are	   characterized	   by	   the	   presence	   of	   different	  spliceosome	   complexes	   formed	   by	   different	   combinations	   of	   snRNPs.	   The	  snRNAs	  and	  pre-­‐mRNA	  interact	  weakly	  and	  therefore	  the	  presence	  of	  accessory	  proteins	  is	  required	  to	  stabilize	  the	  interactions.	  First,	  the	  5’SS	  downstream	  of	  an	  exon	  is	  recognized	  by	  the	  U1	  70K	  snRNP.	  This	  binding	  is	  stabilized	  by	  interaction	  of	  the	  U1	  sRNP	  with	  the	  Serine-­‐Arginine	  (SR)-­‐rich	  splicing	  factor	  1	  (SRSF1).	  The	  Sm	  and	  SR	  proteins	  are	  required	  to	  stabilize	  the	  binding	  of	  U1	  snRNA	  to	  the	  5’SS	  (Cho	  et	  al.,	  2011).	  Furthermore,	  the	  binding	  of	  U2AF65	  and	  U2AF35,	  respectively	  to	   the	  polypyrimidine	   tract	  and	  the	  dinucleotide	  AG	  at	   the	  3’SS,	  are	  needed	   for	  the	   formation	   of	   the	   first	   spliceosome	   complex,	   called	   E	   (Zamore	   and	   Green,	  1989).	   Complex	  E	   also	   contains	   the	  protein	   SF1/BBP,	  which	   interacts	  with	   the	  Branch	   Site	   (Figure	   1.9).	   The	   formation	   of	   complex	   E	   is	   important	   for	   the	  recognition	  of	  the	  5’SS	  and	  3’SS	  within	  the	  intron	  (Michaud	  and	  Reed,	  1993).	  	  From	   this	   point,	   the	   presence	   of	   eight	   RNA	   helicases	   in	   different	   steps	   is	  required	   to	   deliver	   energy	   to	   the	   spliceosome	   in	   an	   ATP-­‐dependent	   manner.	  These	  helicases	  belong	  to	  DEAD-­‐box,	  DEAH-­‐box	  and	  Ski-­‐2	   like	   families	  and	  can	  perform	  ATP	  binding	  and	  hydrolysis	  as	  well	  as	  nucleic	  acid	  interactions	  (Cordin	  and	   Beggs,	   2013).	   The	   DEAD-­‐box	   RNA	   helicase	   Sub2/UAP56	   displaces	   the	  SF1/BBP	  complex,	  which	  is	  bound	  to	  the	  BS.	  On	  the	  other	  hand,	  the	  helicase	  Prp5	  is	   important	   for	   the	  binding	  and	   remodelling	  of	  U2	   snRNA.	  Prp5	  promotes	   the	  interaction	  between	  U2	  snRNP	  and	  the	  polypyrimidine	  tract	  (Xu	  et	  al.,	  2004).	  U2	  snRNP	   then	   interacts	  with	   U2AF65	   and	   consequently	   promotes	   the	   binding	   of	  
	   40	  







	   41	  
	  
Figure	  1.9:	  Spliceosome	  complexes	  and	  splicing	  process.	  The	   splicing	   processes	   is	   carried	   out	   by	   the	   snRNP	   complexes	   that	   mediate	  recognition	  of	  the	  intron	  sequences	  and	  the	  two	  transesterification	  reactions.	  RNA	  helicases	  play	  a	  crucial	  role	  during	  the	  splicing	  process.	  (Adapted	  from	  (Wahl	  et	  al.,	  2009)).	  	  
1.4.1 Alternative	  splicing	  as	  a	  source	  of	  variation	  The	  processing	  of	  pre-­‐mRNA	  results	   in	  the	  formation	  of	  a	  mature	  transcript.	  However,	   alternative	   splicing	   has	   been	   shown	   to	   be	   a	   means	   for	   generating	  different	  isoforms	  of	  the	  same	  protein.	  This	  process	  has	  been	  estimated	  to	  affect	  around	  95%	  of	  human	  genes	  (Pan	  et	  al.,	  2008).	  The	  difference	  in	  composition	  of	  the	  mRNA	   is	  driven	  by	   the	  presence	  or	  absence	  of	  exons	   through	  regulation	  of	  exon	   inclusion	   or	   exclusion	   by	   proteins	   connected	   to	   splicing.	   Two	   models,	  which	  are	  not	  mutually	  exclusive,	  have	  been	  proposed	  to	  explain	  the	  presence	  of	  different	   isoforms	  generated	  by	   alternative	   splicing.	  The	   first	   of	   these	   is	   called	  the	  recruitment	  model,	  according	  to	  which	  Pol	  II	  recruits	  splicing	  factors	  during	  transcription	  that	  determine	  the	  fate	  of	  the	  primary	  transcript.	  Interaction	  with	  SR	  proteins	  promotes	  exon	  inclusion	  whereas	  hnRNP	  proteins	  have	  an	  inhibitory	  effect	   that	   results	   in	   exon	   skipping.	   For	   example,	   it	   has	   been	   reported	   that	  interaction	   of	   the	   CTD	   of	   Pol	   II	   with	   SRp20	   promotes	   alternative	   splicing	   by	  including	   alternative	   exons	   (de	   la	   Mata	   and	   Kornblihtt,	   2006).	   The	   binding	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partners	   of	   Pol	   II	   during	   transcription	   are	   responsible	   for	   the	   choice	   of	   exon	  inclusion/skipping.	  A	  second	  model	  to	  explain	  alternative	  splicing	  is	  the	  kinetic	  model.	  According	  to	  this	  model,	  Pol	  II	  regulates	  the	  inclusion/exclusion	  of	  exons.	  Alternative	  splicing	  in	  the	  kinetic	  model	  is	  dependent	  on	  the	  rate	  of	  transcription	  of	  Pol	  II	  and	  the	  strength	  of	  the	  splice	  sites	  in	  the	  pre-­‐mRNA.	  Usually,	  strong	  and	  upstream	  splice	  sites	  are	   included	  while	  weak	  and	  downstream	  splice	  sites	  are	  skipped	  (Ip	  et	  al.,	  2011).	  Sequence	  elements	  residing	  within	  the	  exon	  are	  targets	  for	  binding	  of	  proteins	  involved	  in	  splicing	  regulation.	  These	  elements	  are	  Exonic	  Splicing	  Enhancers	  (ESE)	  and	  Exonic	  Splicing	  Silencers	  (ESS).	  The	  same	  elements	  can	   control	   splicing	   processing	   by	   their	   presence	   within	   introns	   (Wang	   and	  Burge,	  2008)(Figure	  1.10).	  	  Splicing	   is	   regulated	   by	   accessory	   proteins	   that	   affect	   the	   binding	   of	   snRNP	  complexes.	   The	   SR	   proteins	   are	   known	   to	   promote	   the	   formation	   of	   the	  spliceosome	  after	  recognition	  of	  an	  exon.	  These	  proteins	  bind	  to	  the	  ESE	  and	  are	  known	  to	  bind	  with	  UAF35	  and	  UAF65	  to	  stabilize	  their	  binding	  to	  the	  3’SS	  of	  the	  intron	  and	  also	  with	  U1	  snRNP	  at	  the	  5’SS	  (Long	  and	  Caceres,	  2009).	  However,	  competition	   between	   SR	   proteins	   proteins	   and	   heterogeneous	   nuclear	  ribonucleoproteins	  (hnRNPs)	  has	  a	  role	  in	  alternative	  splicing	  regulation	  (Zhu	  et	  al.,	   2001).	   hnRNPs	   are	   a	   large	   family	   of	   20	   proteins	   that	   are	   involved	   in	   RNA	  processing	  as	  well	  as	  mRNA	  export	  to	  the	  cytoplasm.	  HnRNPs	  contain	  a	  Nuclear	  Localization	   Signal	   (NLS)	   that	   allows	   them	   to	   shuttle	   between	   nucleus	   and	  cytoplasm	  (Pinol-­‐Roma	  and	  Dreyfuss,	  1992).	  These	  proteins	  can	  bind	  RNA	  either	  through	  an	  RRM	  or	  KH	  domain.	  Many	  of	  the	  hnRNP	  proteins	  have	  been	  involved	  in	  repression	  of	  splicing	  by	  binding	  of	  ESS	  elements	  in	  exons	  or	  introns	  (Han	  et	  al.,	   2010).	   Furthermore,	   hnRNP	   proteins	   promote	   exon	   skipping	   either	   by	  inhibiting	  binding	  of	  snRNP	  factors	  or	  by	  promoting	  the	  looping	  out	  of	  the	  exon.	  An	   example	   of	   exon	   looping	   out	   is	   represented	   by	   the	  mechanism	  of	   action	   of	  hnRNP	  A1,	  which	  promotes	  extrusion	  of	  the	  exon	  (Blanchette	  and	  Chabot,	  1999).	  hnRNP	   proteins	   can	   also	   promote	   splicing.	   An	   example	   of	   this	   is	   the	   role	   of	  hnRNP	  H	  in	  the	  alternative	  splicing	  of	  c-­‐src	  in	  neuronal	  cells	  (Chou	  et	  al.,	  1999).	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1.5 RNA	  decay	  
	   The	   formation	   of	   mature	   RNA	   requires	   a	   correct	   splicing	   process.	  Furthermore,	   export	   of	   mRNA	   to	   the	   cytoplasm	   and	   translation	   to	   generate	   a	  functional	  protein	  are	  dependent	  on	  the	  production	  of	  a	  functional	  mRNA,	  which	  is	  formed	  by	  a	  5’	  7-­‐methylguanosine	  cap	  and	  poly-­‐A	  tail	  bound	  by	  several	  PABPs.	  These	   structures	   at	   the	   ends	   of	   the	   RNA	   are	   required	   for	   correct	   initiation	   of	  translation	  and	  to	  protect	  the	  molecule	  from	  nuclease	  degradation.	  The	   steps	   from	   transcription	   to	   the	   formation	   of	   a	   polypetpide	   require	  accurate	   RNA	   processing.	   However,	   RNAs	   can	   be	  misprocessed,	   leading	   to	   the	  production	  of	  aberrant	  proteins.	  In	  order	  to	  avoid	  production	  of	  these	  proteins,	  several	  mechanisms	  of	  RNA	  decay	  have	  been	  developed	   in	   the	  cell	   (Garneau	  et	  al.,	  2007).	  The	  major	  mechanisms	  of	  RNA	  degradation	  relate	  to	  the	  exposure	  of	  either	   the	  5’	  or	   the	  3’	   end	  of	   the	  mRNA.	  Decapping	  enzymes	  and	  deadenylases	  are	   required	   respectively	   for	   the	   removal	   of	   the	   5’	   cap	   and	   the	   poly-­‐A	   tail.	  Alternatively,	  RNA	  decay	  can	  be	  carried	  out	  by	  endonucleases	  able	  to	  cut	  inside	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the	  RNA	  molecule.	  This	   cut	   generates	   two	   free	   ends	   that	   can	  be	   recognized	  by	  exonucleases	  to	  perform	  the	  degradation	  (Figure	  1.11)	  	  
Figure	  1.11:	  RNA	  decay	  pathways.	  	  In	   the	   decapping	   mediated	   degradation,	   decapping	   enzymes	   are	   responsible	   for	  removing	  the	  cap	  at	  the	  5’end	  of	  the	  RNA.	  Xrn1	  can	  then	  degrade	  the	  RNA	  from	  the	  exposed	  5’end.	  The	  endonucleolitic	  cleavage	  of	  the	  RNA	  triggers	  the	  degradation	  by	  the	  exosome	  and	  Xrn1.	  In	  the	  3’end	  mediated	  degradation,	  the	  deadenylases	  CCR4-­‐NOT,	  PARN	  or	  Pan2/3	  start	  degrading	   the	  poly-­‐A	   tail.	  Trimming	  of	   the	   tail	   allows	  the	  3’-­‐5’	  decay	  mediate	  by	  the	  exosome	  (Adapted	  from	  (Jones	  and	  Newbury,	  2010)).	  	  	  	   RNA	  stability	  at	  the	  5’	  end	  is	  provided	  by	  the	  cap.	  During	  post-­‐transcriptional	  maturation,	   the	  RNA	  cap	   is	  protected	  by	   the	   cap-­‐binding	   complex	   (CBC)	   in	   the	  nucleus,	  while	  in	  the	  cytoplasm	  it	  is	  bound	  by	  the	  translation	  initiation	  factor	  4F	  (eIF4F).	  The	  CBC	  has	  been	  shown	  to	  be	  important	  for	  pre-­‐mRNA	  splicing	  and	  3’	  end	   formation	   (Izaurralde	   et	   al.,	   1994).	   It	   also	   mediates	   mRNA	   export	   to	   the	  cytoplasm.	  In	  the	  cytoplasmic	  compartment,	  it	  is	  replaced	  by	  eIF4F,	  which	  binds	  the	  cap	  and	  promotes	   translation	   (Lewis	  and	   Izaurralde,	  1997).	  The	  decapping	  complex	  is	  responsible	  for	  removing	  the	  cap,	  leaving	  an	  unprotected	  5’	  end.	  This	  complex	   is	  composed	  by	  Dcp1,	  Dcp2,	  Ecd4	  and	  Xrn1	  (Chang	  et	  al.,	  2014).	  Ecd4	  acts	  as	  platform	  and	  is	  crucial	  because	  it	  is	  needed	  for	  recruitment	  of	  the	  other	  factors	  and	  to	  mediate	  their	  interactions.	  The	  contact	  between	  Dcp1	  and	  Dcp2	  is	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facilitated	  by	  Ecd4.	  Dcp1	  then	  generates	  a	  conformational	  change	  in	  Dcp2,	  which	  carries	  out	   the	   cap	   removal.	  Once	   the	   cap	  has	  been	   removed,	   the	  5’	   end	  of	   the	  RNA	  is	  recognized	  by	  Xrn1	  and	  degraded	  (Chang	  et	  al.,	  2014).	  	  RNA	  decay	  can	  be	   triggered	  by	  a	  deadenylation	  process,	  which	   removes	   the	  poly-­‐A	   tail,	   exposing	   the	  3’end	  of	   the	  RNA	  molecule.	   In	  mammals	   there	   are	  26	  enzymes	   responsible	   for	   deadenylation.	   The	   large	   number	   of	   enzymes	   was	  possibly	  generated	  by	  gene	  duplication	  events	  (Goldstrohm	  and	  Wickens,	  2008).	  Three	  major	  mediators	  of	  deadenylation	  are	  Poly-­‐A-­‐specific	  ribonuclease	  (Parn),	  the	  Pan2/3	  complex	  and	  the	  CCR4-­‐NOT	  complex.	  The	  mechanisms	  used	  by	  these	  enzymes	   to	   carry	   out	   shortening	   of	   the	   poly-­‐A	   tail	   are	   different	   and	   mRNA	  specific.	  Parn	  is	  a	  deadenylase	  that	  is	  cap	  dependent	  and	  it	  has	  been	  shown	  that	  its	   activity	   is	   inhibited	   by	   the	   presence	   of	   the	   CBC	   and	   Pabp	   (Balatsos	   et	   al.,	  2006).	  A	  different	  induction	  is	  required	  for	  the	  Pan	  enzymes	  that	  are	  stimulated	  by	   the	   presence	   of	   the	   Pabps.	   Pan2	   is	   the	   deadenylase	   subunit	   of	   the	   Pan	  complex	  and	  is	  responsible	  for	  trimming	  of	  the	  poly-­‐A	  tail,	  reducing	  the	  length	  of	  the	  tail	   from	  around	  200	  nucleotides	  to	  around	  80	  (Wolf	  and	  Passmore,	  2014).	  Decapping	  enzymes	  are	  inhibited	  by	  the	  Pabps	  and	  therefore	  in	  the	  presence	  of	  an	   intact	   poly-­‐A	   tail,	   the	   decapping	   process	   does	   not	   happen	   (Khanna	   and	  Kiledjian,	   2004).	   Poly-­‐A	   shortening	   facilitates	   binding	   at	   the	   3’end	   of	   Lsm	  proteins	   that	   interact	   with	   Dcp2	   promoting	   decapping	   (van	   Dijk	   et	   al.,	   2002).	  When	  the	  poly-­‐A	  tail	   is	  shorter	  the	  CCR4-­‐NOT	  complex	  degrades	  the	  remaining	  part	   leaving	  a	   free	  3’	  RNA	  end.	  The	  RNA	   is	   then	  degraded	  by	   the	  action	  of	   the	  exosome,	  which	  is	  3’-­‐5’	  exoribonuclease.	  Therefore,	  this	  type	  of	  deadenylation	  is	  a	  biphasic	  process	  (Yamashita	  et	  al.,	  2005).	  Following	  deadenylation	  and	  the	  3’-­‐5’	   degradation	   by	   the	   exosome,	   another	   enzyme	   called	   scavenger	   decapping	  (Dcps)	   is	   recruited	   to	   degrade	   the	   cap	   at	   the	   5’end	   of	   the	   RNA.	   The	   Dcps	   is	  required	  because	  Dcp2	  cannot	  act	  on	  RNA	  shorter	  than	  9	  nucleotides	  (van	  Dijk	  et	  al.,	  2003).	  	  RNA	  decay	  in	  the	  cytoplasm	  is	  mediated	  by	  the	  mechanisms	  described	  above.	  However,	   this	  process	  of	  RNA	   control	   has	  been	   confined	   to	   granules	   that	  have	  been	   found	   in	   the	   cytoplasm.	   These	   structures	   are	   called	   P	   bodies	   and	   are	  formed	   by	   RNAs	   and	   proteins	   involved	   in	   RNA	   decay	   and	   translation.	   Within	  these	   granules	   are	   proteins	   involved	   in	   5’-­‐3’	   RNA	   degradation	   (Anderson	   and	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Kedersha,	  2006).	  The	  decapping	  enzymes,	  Xrn1,	  and	  Lsm	  proteins	  were	  found	  in	  P	  bodies,	  as	  well	  as	   the	  deadenylases	  Pan2/3	  and	  CCR4-­‐NOT.	   Interestingly,	   the	  exosome	  proteins	  are	  not	  in	  the	  P	  bodies,	  meaning	  that	  two	  mechanisms	  of	  RNA	  decay	  are	  present	  in	  separated	  factories	  in	  the	  cytoplasm	  (Kulkarni	  et	  al.,	  2010).	  RNA	   surveillance	   is	   needed	   as	   a	   quality	   control	   for	   the	   newly	   processed	   RNA.	  There	   are	   three	   pathways	   in	   the	   cytoplasm	   that	   trigger	  RNA	  decay:	   non-­‐sense	  mediated	  decay	  (NMD),	  non-­‐stop	  decay	  (NSD)	  and	  no-­‐go	  decay	  (NGD).	  The	  NMD	  is	   able	   to	   detect	   transcripts	   with	   a	   premature	   termination	   codon	   (PTD).	   The	  NMD	   is	   triggered	   by	   the	   presence	   of	   an	   exon	   junction	   complex	   (EJC)	   after	   a	  termination	  codon.	  The	  EJC	   is	  usually	  deposited	  20-­‐24	  nucleotides	  upstream	  of	  the	  junction	  between	  two	  exons.	  	  In	  the	  case	  of	  premature	  termination,	  the	  EJC	  is	  retained	  on	  junctions	  downstream	  from	  the	  PTD	  (Le	  Hir	  et	  al.,	  2000).	  Moreover,	  the	  PTD	  causes	  stalling	  of	   the	  ribosome,	  which	   is	  recognized	  by	  proteins	  of	   the	  Surf	  complex.	  The	  Surf	  complex	  subunit	  Upf1	  is	  able	  to	  interact	  with	  the	  protein	  Upf2	  present	  in	  the	  EJC	  downstream.	  Therefore,	  the	  interaction	  between	  the	  Surf	  complex	  and	  the	  EJC	  triggers	  RNA	  decay	  (Kashima	  et	  al.,	  2006).	  Another	   mechanism	   of	   RNA	   surveillance	   is	   non-­‐stop	   decay.	   Unlike	   the	  previous	   pathway,	   this	   leads	   to	   RNA	   decay	   due	   to	   lack	   of	   a	   stop	   codon.	   The	  ribosome	  translates	  the	  RNA,	  but	  the	  lack	  of	  a	  stop	  codon	  causes	  stalling	  of	  the	  ribosome	  at	   the	  3’	  end.	  The	  stalled	  ribosome	   is	   recognized	  by	   the	  Ski	  complex,	  which	   displaces	   the	   ribosome	   and	   recruits	   the	   exosome	   to	   degrade	   the	   RNA	  (Frischmeyer	  et	  al.,	  2002).	  Finally,	   the	   last	  mechanism	   of	   RNA	   surveillance	   is	   represented	   by	   the	  NGD.	  This	  has	  been	   studied	   in	   yeast	   and	  has	  been	   shown	   to	  be	   responsible	   for	  RNA	  decay	   triggered	   by	   ribosome	   stalling.	   The	   presence	   of	   the	   stalled	   ribosome	  signals	   recruitment	   of	   the	   Dom34-­‐Hbs1	   proteins,	   which	   generate	   an	  endonucleolytic	   cleavage	   in	   the	  RNA	  molecule.	   The	   new	   formed	   fragments	   are	  then	  degraded	  by	  the	  exosome	  and	  Xrn1	  (Doma	  and	  Parker,	  2006).	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1.6 The	   CCR4-­NOT	   complex	   is	   involved	   in	   many	   cellular	  
processes	  The	   CCR4-­‐NOT	   complex	   is	   a	   large	   complex	   of	   proteins	   that	   has	   been	  implicated	   in	   many	   cellular	   processes	   in	   both	   nuclear	   and	   cytoplasmic	  compartments.	  The	  complex	  was	  first	  isolated	  and	  characterized	  in	  yeast.	  There	  are	  a	  large	  number	  of	  proteins	  associated	  with	  CCR4-­‐NOT,	  but	  the	  proteins	  that	  are	  considered	  to	  be	  the	  core	  subunits	  are	  Not1,	  Not2,	  Not3,	  Not4,	  Not5,	  Caf40,	  Caf130	  and	  the	  deadenylase	  subunits	  Ccr4	  and	  Pop2/Caf1	  (Liu	  et	  al.,	  1998).	  The	  first	  description	  of	  a	  human	  complex	  was	  reported	  by	  Albert	  et	  al.,	  who	  looked	  for	   yeast	   homologues	   in	   the	   human	   genome.	   They	   were	   able	   to	   identify	   the	  proteins	   hNOT2,	   hNOT3,	   hNOT4	   and	   the	   deadenylases	   hCAF1	   (CNOT7)	   and	  hCALIF/hPOP2	  (CNOT8)	  as	  subunits	  of	  the	  human	  CCR4-­‐NOT	  complex	  (Albert	  et	  al.,	   2000).	   It	  was	   then	   shown	   that	   the	  protein	  CNOT4	   is	   an	  E3	  ubiquitin	   ligase	  that	   interacts	   with	   CNOT1	   (Albert	   et	   al.,	   2002).	   The	   study	   of	   the	   CCR4-­‐NOT	  complex	   in	  mammals	   revealed	   the	   presence	   of	  multiple	   deadenylase	   subunits,	  indicating	  the	  existence	  of	  different	  sub-­‐complexes.	  The	  deadenylase	  hCAF1	  was	  also	  shown	  to	  be	  in	  different	  locations	  at	  different	  the	  cell	  cycle	  stages.	  In	  G0	  and	  G1	  the	  protein	  was	  mainly	  detected	  in	  the	  nucleus,	  whereas	  during	  S	  phase	  there	  was	  a	  switch	  to	  the	  cytoplasm	  (Morel	  et	  al.,	  2003).	  The	  yeast	  CCR4	  subunit	  has	  been	  shown	  to	  have	  two	  homologs	   in	  mammals	   initially	  called	  CCR4a	  (CNOT6)	  and	  CCR4b	  (CNOT6L)	  (Yamashita	  et	  al.,	  2005).	  	  Lau	   et	   al.	   provided	   more	   detailed	   characterization	   of	   different	   CCR4-­‐NOT	  complexes	   in	   HeLa	   and	   293T	   cells	   (Lau	   et	   al.,	   2009).	   They	   reported	   that	   in	  human	   cells,	   different	   CCR4-­‐NOT	   complexes	   have	   different	   deadenylase	  components.	   CNOT10	   and	   CNOT9,	   which	   is	   homologous	   to	   yeast	   Caf40,	   were	  shown	   to	   be	   part	   of	   the	   complex.	   CNOT7	   and	   CNOT8	   compete	   for	   the	   same	  binding	  site	  on	  CNOT1,	  which	  is	  the	  scaffold	  subunit	  of	  the	  complex.	  Therefore,	  the	  presence	  of	  CNOT7	  and	  CNOT8	  was	  reported	  to	  be	  mutually	  exclusive	  (Lau	  et	  al.,	  2009).	  The	  same	  result	  was	  obtained	  for	  CNOT6	  and	  CNOT6L,	  as	  they	  were	  not	  found	  in	  the	  same	  complex.	  However,	  a	  more	  stable	  complex	  was	  isolated	  in	  the	   presence	   of	   CNOT8	   than	  with	  CNOT7.	  Moreover,	   it	  was	   demonstrated	   that	  CNOT4	  is	  not	  a	  stable	  part	  of	  the	  complex.	  In	  the	  same	  study,	  two	  new	  proteins	  were	   identified	   as	   new	   components	   of	   the	   CCR4-­‐NOT	   complex,	   TAB182	   and	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C2ORF29	  (Figure	  1.12)	  (Lau	  et	  al.,	  2009).	  Another	  study	  in	  293T	  cells	  confirmed	  the	  presence	  of	  C2ORF29,	  which	  was	  called	  CNOT11,	  and	  revealed	  a	  new	  module	  within	  the	  complex	  formed	  by	  interaction	  of	  CNOT11	  with	  CNOT10	  (Mauxion	  et	  al.,	  2013).	  Recently,	  a	  crystal	  structure	  for	  a	  module	  composed	  by	  CNOT1,	  CNOT2	  and	   CNOT3	   has	   been	   published.	   CNOT2	   and	   CNOT3	   form	   an	   heterodimer	  through	   their	   C-­‐terminal	   NOT-­‐box	   and	   interact	   with	   CNOT1	   via	   their	   NOT1	  anchor	  regions	  (Boland	  et	  al.,	  2013).	  	  	  
	  
Figure	   1.12:	   Human	   CCR4-­NOT	   complexes	   showing	   different	   compositions	  
with	  respect	  to	  their	  deadenylases	  subunits.	  The	  deadenylases	  subunit	  CNOT7	  and	  CNOT8	  are	  considered	  mutually	  exclusive	  as	  well	   as	   CNOT6	   and	   CNOT6L.	   The	   ubiquitin	   ligase	   CNOT4	   is	   considered	   to	   be	   a	  transient	  interactor	  with	  the	  complex.	  (Adapted	  from	  (Lau	  et	  al.,	  2009)).	  	  	   As	  described	  above,	  CCR4-­‐NOT	   is	   a	  deadenylase	   complex	   that	   is	   involved	   in	  RNA	  decay.	  However,	  many	  studies	  have	  reported	  functions	  for	  the	  complex	  in	  a	  number	   of	   different	   cellular	   processes.	   Most	   of	   the	   papers	   that	   have	   been	  published	  regarding	  CCR4-­‐NOT	  functions	  were	  generated	  in	  yeast	  and	  revealed	  a	  role	   for	   the	   complex	   in	   controlling	   gene	   expression	   and	   RNA	   processing	   and	  stability.	   For	   example,	   it	   has	   been	   reported	   that	   CCR4-­‐NOT	   is	   important	   in	  transcriptional	   initiation	   and	   can	   promote	   elongation	   of	   stalled	   Pol	   II	   by	  interacting	  with	  the	  body	  of	  Pol	  II	  (Kruk	  et	  al.,	  2011).	  CCR4-­‐NOT	  interacts	  with	  the	  TRAMP	  polyadenylation	  complex	  and	  the	  nuclear	  exosome	  and	  is	  likely	  to	  be	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a	  platform	  for	  the	  recruitment	  of	  the	  two	  complexes.	  This	  might	  be	  connected	  to	  a	  role	  in	  controlling	  RNA	  quality	  in	  the	  nucleus	  (Azzouz	  et	  al.,	  2009).	  Moreover,	  the	   involvement	  of	  CCR4-­‐NOT	   in	   the	   export	   of	  RNA	  has	  been	   shown,	   as	   it	  was	  unveiled	   a	   physical	   interaction	  with	   the	   hnRNP	   proteins	   and	   the	   nuclear	   pore	  complex	  (Kerr	  et	  al.,	  2011).	  It	  was	  also	  shown	  that	  deletion	  of	  the	  gene	  encoding	  the	  Cnot4	  E3	  ligase	  in	  Saccharomyces	  cerevisiae	  results	  in	  a	  decrease	  in	  the	  active	  H3K4me3	  mark	  (Laribee	  et	  al.,	  2007).	  Studies	  carried	  out	  in	  mammals	  have	  confirmed	  the	  importance	  of	  CCR4-­‐NOT	  in	  transcription	  regulation	  and	  cell	  cycle	  progression.	  A	  number	  of	  studies	  have	  identified	   roles	   for	   CCR4-­‐NOT	   subunits	   in	   controlling	   the	   activation	   of	   nuclear	  hormone	  receptors.	  Cnot7	  binds	  the	  retinoid	  X	  receptor	  beta	  (Rxrb)	  and	  acts	  as	  co-­‐activator	   to	   promote	   normal	   spermatogenesis	   in	   mice	   (Nakamura	   et	   al.,	  2004).	  CNOT6	  and	  CNOT9	  were	  reported	  to	  enhance	  the	  transcriptional	  activity	  of	   several	  nuclear	  hormone	  receptors,	   such	  as	  TRα,	  RARα	   and	  RXRα,	   acting	  as	  co-­‐activators	   in	  conjunction	  with	  NIF-­‐1	   (Garapaty	  et	  al.,	  2008).	  However,	   these	  studies	  have	  been	  performed	  by	  transient	  transfections	  or	  protein	  knock	  down	  of	  single	  subunits.	  Therefore,	  the	  results	  obtained	  for	  single	  subunits	  cannot	  be	  extended	  to	  the	  whole	  complex.	  For	  example,	  CNOT1	  was	  shown	  to	  repress	  the	  activity	  of	  ERα	   resulting	   in	  downregulation	  of	   the	   transcription	   levels	  of	  genes	  controlled	   by	   ERα	   in	   MCF-­‐7	   cells.	   In	   the	   presence	   of	   the	   HDAC	   inhibitor	  Trichostatin	  A	  (TSA),	  the	  inhibition	  caused	  by	  CNOT1	  was	  diminished	  suggesting	  that	   the	   inhibitory	   effects	   of	   CNOT1	   could	   be	   due	   to	   recruitment	   of	   histone	  deacetylases	   (HDACs).	   In	   the	   same	   study	   CNOT3	   was	   also	   shown	   to	   have	   an	  inhibitory	  influence	  on	  genes	  controlled	  by	  ERα	  (Winkler	  et	  al.,	  2006).	  A	  similar	  behaviour	  was	  also	  reported	  for	  CNOT2,	  which	  had	  a	  repressive	  effect	  in	  a	  gene	  reporter	   assay	   performed	   in	   human	   osteosarcoma	   cell	   line	   (U2OS).	   The	  inhibition	  was	   sensitive	   to	   TSA	   and	  mediated	   by	   the	  NOT-­‐box	   (Zwartjes	   et	   al.,	  2004).	  The	  HDAC	  dependent	  mechanism	  of	  CNOT2	  was	  further	  supported	  by	  the	  observation	   that	   CNOT2	   interacts	   with	   the	   SMRT/NCoR–HDAC3	   complex.	  	  Overexpression	   of	   CNOT2	   and	   the	   HDAC3	   complex	   augmented	   the	   repression	  activity	   mediated	   by	   CNOT2	   (Jayne	   et	   al.,	   2006).	   CNOT2	   is	   important	   for	   the	  integrity	   of	   the	   CCR4-­‐NOT	   complex	   and	   it	   mediates	   the	   interaction	   of	   CNOT3	  with	  the	  rest	  of	  the	  complex.	  Depletion	  of	  CNOT2	  leads	  to	  an	  over-­‐production	  of	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misfolded	  proteins	  that	  induces	  apoptosis	  triggered	  by	  endoplasmatic	  reticulum	  (ER)	  stress	  (Ito	  et	  al.,	  2011).	  	  The	  CCR4-­‐NOT	  complex	  has	  also	  been	  implicated	  in	  miRNA	  repression.	  CCR4-­‐NOT	   interacts	   with	   GW182	   proteins	   at	   the	   3’	   end	   of	   mRNAs	   promoting	  deadenylation.	   Interestingly,	   the	   interaction	  between	  GW182	  and	  CCR4-­‐NOT	   is	  needed	  to	  repress	  not	  only	  poly-­‐A+	  but	  also	  poly-­‐A-­‐	  mRNA.	  In	  the	  case	  of	  poly-­‐A-­‐	  RNA,	  repression	  of	  translation	  is	  not	  mediated	  by	  RNA	  decay	  as	  the	  mRNA	  levels	  do	  not	  change	  (Chekulaeva	  et	  al.,	  2011).	  A	   small	   number	   of	   studies	   have	   reported	   that	   CCR4-­‐NOT	   subunits	   are	  important	   for	   controlling	   cell	   proliferation.	   CNOT6L	   ablation	   provides	   insights	  that	   could	   play	   a	   role	   in	   cell	   growth	   in	  NIH	   3T3	  mouse	   fibroblast	   through	   the	  stabilization	  of	  a	  crucial	  cell	  cycle	  gene	  such	  as	  p27	  (Morita	  et	  al.,	  2007).	   It	  has	  been	  reported	  that	  in	  MCF-­‐7	  cells,	  depletion	  of	  both	  CNOT6	  and	  CNOT6L	  leads	  to	  decreased	   cell	   proliferation	   as	   well	   as	   decreased	   cell	   survival.	   Knockdown	   of	  CNOT6	   and	   CNOT6L	   showed	   that	   the	   two	   deadenylases	   are	   involved	   in	  controlling	  not	  only	  cell	  cycle	  progression	  but	  also	  have	  roles	  in	  the	  prevention	  of	   cell	   death	   and	   senescence.	   Moreover,	   it	   was	   found	   that	   depletion	   of	  CNOT6/CNOT6L	  or	   CNOT7/CNOT8	   affects	   different	   sets	   of	   genes	   (Mittal	   et	   al.,	  2011).	   A	   similar	   mechanism	   has	   been	   described	   for	   the	   action	   of	   CNOT7	   and	  CNOT8	   in	   MCF-­‐7	   cells.	   The	   knockdown	   of	   these	   deadenylases	   causes	   cells	   to	  accumulate	   in	   G1	   due	   to	   up-­‐regulation	   of	   genes	   that	   are	   involved	   in	   cell	   cycle	  control	   (Aslam	   et	   al.,	   2009).	   The	   role	   in	   cell	   proliferation	   reported	   in	   many	  studies	  of	  CCR4-­‐NOT	  components	  seems	  to	  be	  cell	  specific.	  The	  different	  roles	  of	  complexes	   that	  have	  different	  deadenylase	   subunits	  might	  be	   explained	  by	   the	  specificity	  of	  each	  enzyme	  for	  different	  mRNA	  targets.	  	  	  
1.7 The	  role	  of	  CNOT3	  in	  gene	  expression	  and	  cell	  cycle	  control	  	   CNOT3	  is	  part	  of	  the	  CCR4-­‐NOT	  complex	  and	  has	  recently	  been	  shown	  to	  form	  a	  module	  with	  CNOT1	  and	  CNOT2	   through	   the	  NOT	  box	  domain	  (Boland	  et	  al.,	  2013).	   However,	   the	   presence	   of	   CNOT3	   within	   the	   CCR4-­‐NOT	   complex	   is	  mediated	  by	  CNOT2	  because	  depletion	  of	  CNOT2	  causes	  loss	  of	  CNOT3	  from	  the	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complex	  (Ito	  et	  al.,	  2011).	  CNOT3	  has	  been	  implicated	  in	  many	  cellular	  processes	  mainly	   through	   post-­‐transcriptional	   effects	   on	   the	   stability	   of	   target	   mRNA.	  However,	   several	   studies	   have	   reported	   an	   involvement	   in	   controlling	   gene	  transcription.	  Expression	  studies	  carried	  out	  in	  293T	  and	  U2OS	  cells	  have	  shown	  that	   full	   length	  CNOT3	  does	  not	  affect	   transcription	  while	   the	  NOT	  box	  domain	  acts	   as	   a	   repressor	   of	   reporter	   gene	   activity	   (Zwartjes	   et	   al.,	   2004).	   Another	  study	  in	  MCF-­‐7	  cells	  showed	  that	  CNOT3	  represses	  transcription	  dependent	  on	  ERα.	   Transcripts	   of	   ERα	   target	   genes	   were	   upregulated	   following	   CNOT3	  knockdown	  (Winkler	  et	  al.,	  2006).	  An	  RNAi	  screen	  performed	  in	  mouse	  ES	  cells	  has	  provided	  evidence	  of	  a	  role	  for	  Cnot3	  in	  the	  self-­‐renewal	  program	  of	  pluripotent	  cells.	  Cnot3	  acts	  in	  concert	  with	   Trim28,	   Zfx	   and	   c-­‐myc	   by	   binding	   promoters	   of	   a	   cohort	   of	   genes	   that	   is	  distinct	  from	  the	  genes	  that	  are	  controlled	  by	  the	  canonical	  transcription	  factors	  Nanog,	   Sox2	   and	   Oct4	   (Hu	   et	   al.,	   2009).	   The	   genes	   that	   are	   controlled	   by	   this	  newly	   identified	   module	   are	   mainly	   involved	   in	   cell	   cycle	   control	   and	   cell	  survival.	  Knockdown	  of	  Cnot3	  in	  mouse	  ES	  cells	  leads	  to	  the	  loss	  of	  pluripotency	  and	   the	   acquisition	   of	   a	   phenotype	   that	   resembles	   cells	   of	   trophoectoderm	  lineage	   (Hu	   et	   al.,	   2009).	   Furthermore,	   Cnot3	   keeps	   the	   self-­‐renewal	   program	  active	  together	  with	  Cnot1	  and	  Cnot2	  (Zheng	  et	  al.,	  2012).	  They	  form	  a	  module	  that	   is	   required	   for	   the	   repression	   of	   the	   trophoectoderm	   factors.	   Silencing	   of	  Cnot1-­‐3	  leads	  to	  upregulation	  of	  transcription	  factors	  such	  as	  Cdx2	  or	  Gata3	  that	  are	  important	  for	  trophoectoderm	  lineage	  specification	  (Zheng	  et	  al.,	  2012).	  This	  module	   of	   Cnot	   proteins	   was	   also	   shown	   to	   be	   responsible	   of	   the	   conversion	  from	   partial	   iPS	   state	   to	   a	   genuine	   iPS.	   The	   mechanism	   by	   which	   the	   Cnot	  proteins	  mediate	  the	  conversion	  involves	  repression	  of	  factors	  that	  are	  involved	  in	  developmental	  process	  (Kamon	  et	  al.,	  2014).	  CNOT3	  has	  also	  been	  reported	  to	  be	  important	  for	  cell	  cycle	  progression	  and	  has	  been	  shown	  to	  be,	  necessary	  for	  proliferation	  of	  MCF-­‐7	  cells.	  Knockdown	  of	  Cnot3	   leads	   to	   accumulation	   of	   the	   cells	   in	   G1,	   indicating	   that	   is	   required	   for	  entry	  into	  S	  phase.	  However,	  CNOT3	  is	  not	  necessary	  for	  cell	  survival	  (Mittal	  et	  al.,	   2011).	   Another	   study	   has	   highlighted	   the	   importance	   of	   CNOT3	   during	  mitotic	  progression	  (Takahashi	  et	  al.,	  2012).	  Knockdown	  of	  CNOT3	  in	  HeLa	  cells	  resulted	   in	  mitotic	   arrest.	   Evidence	  was	  presented	   that	  CNOT3	   controls	  mRNA	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levels	  of	  MAD1,	  which	  is	  a	  protein	  involved	  in	  mitotic	  spindle	  assembly.	  CNOT3	  might	   therefore	   represent	   a	   player	   in	   controlling	   the	   spindle	   assembly	  checkpoint	  (Takahashi	  et	  al.,	  2012).	  
	  
1.7.1 Involvement	  of	  CNOT3	  in	  human	  disease	  	  An	   important	   study	   published	   recently	   reported	   that	   CNOT3	   is	   a	   tumor	  suppressor	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  (T-­‐ALL)	  (De	  Keersmaecker	  et	  al.,	  2013).	  The	  study	  was	  performed	  by	  exome	  sequencing	  of	  T-­‐ALL	  samples.	  The	  analysis	   of	   patients	   affected	   by	   T-­‐ALL	   reported	   that	   around	   8%	   of	   the	   cases	  carried	  mutations	  on	  CNOT3	  gene.	  Arg57	  in	  the	  N	  terminal	  region	  was	  identified	  as	   a	   mutation	   hot-­‐spot	   for	   missense	   mutations	   that	   also	   seemed	   to	   result	   in	  splicing	   defects,	   leading	   to	   low	   expression	   of	   Cnot3	   mRNA.	   The	   study	   was	  extended	   to	   a	   Drosophila	   eye	   cancer	   model	   and	   it	   was	   reported	   that	   loss	   of	  CNOT3	  greatly	   increased	  the	   incidence	  of	  tumor	  onset	  (De	  Keersmaecker	  et	  al.,	  2013).	  	  Potential	  roles	  for	  CNOT3	  have	  been	  identified	  in	  a	  number	  of	  other	  diseases.	  CNOT3	   has	   been	   shown	   to	   affect	   penetrance	   of	   the	   autosomal	   dominant	   eye	  disease	  Retinitis	  Pigmentosa	   (RP).	  Heterozygous	  mutations	  on	   the	  PRPF31	  are	  responsible	   for	   the	   disease.	   However,	   the	   penetrance	   of	   the	   disease	   changes	  according	   to	   the	   expression	   levels	   of	   PRPF31	   and	   asymptomatic	   carriers	   have	  been	   shown	   to	   compensate	   for	   the	   mutation	   in	   one	   allele	   by	   expressing	   high	  levels	   of	   PRPF31	   from	   the	   other	   allele	   (Venturini	   et	   al.,	   2012).	   It	   has	   been	  reported	   that	   CNOT3	   negatively	   affects	   the	   expression	   of	   the	   gene	   PRPF31.	  Therefore,	   high	   levels	   of	   CNOT3	   promote	   onset	   of	   the	   disease,	   whereas	  asymptomatic	  carriers	  express	  low	  levels	  of	  CNOT3,	  allowing	  high	  expression	  of	  PRPF31	  (Venturini	  et	  al.,	  2012).	  Studies	   on	   osteoporosis	   in	   mice	   have	   revealed	   a	   role	   for	   Cnot3	   in	   causing	  osteopenia.	  Deficiency	  of	  Cnot3	  was	  reported	  to	  diminish	  bone	  mass	  volume	  and	  promoted	   bone	   resorption	   by	   increasing	   osteoclast	   number	   (Watanabe	   et	   al.,	  2014).	  However,	  depletion	  of	  Cnot3	  did	  not	  affect	  bone	  formation.	  Cnot3	  absence	  augmented	   stability	   of	   the	   3’UTR	   of	   the	   receptor	   activator	   of	   NF-­‐κB	   (RANK)	  mRNA,	  which	  is	  responsible	  for	  differentiation	  of	  osteoclasts.	  Cnot3	  controls	  the	  onset	  of	  osteoporosis,	  as	   it	  has	  been	  shown	  that	  absence	  of	  Cnot3	  worsens	   the	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disease	  in	  aged	  osteoporotic	  mice	  by	  promoting	  osteoclast	  formation.	  Therefore,	  Cnot3	  has	  a	  protective	  effect	  in	  maintaining	  the	  bone	  mass	  in	  mice	  (Watanabe	  et	  al.,	  2014).	  Cnot3	  has	  also	  been	  shown	  to	  be	   involved	   in	  regulating	  metabolism.	  Studies	  carried	   out	   in	   Cnot3+/-­‐	   mice	   have	   reported	   a	   new	   function	   for	   protein	   in	  controlling	   metabolism-­‐related	   genes.	   The	   mice	   have	   an	   increased	   glucose	  tolerance	  and	  are	  resistant	  to	  a	  high	  fat	  diet.	  The	  body	  size	  and	  weight	  of	  body	  and	  tissues	  are	  also	  lower	  than	  in	  wild	  type	  mice.	  The	  reduction	  in	  Cnot3	  levels	  corresponds	  to	  an	  increase	  in	  the	  expression	  of	  genes	  that	  are	  involved	  in	  lipid	  catabolism,	  while	  genes	  that	  are	  responsible	  for	  lipogenesis	  are	  downregulated.	  Cnot3	   has	   been	   shown	   to	   control	   the	   stability	   of	   specific	   mRNAs	   that	   are	  involved	  in	  lipid	  and	  glucose	  catabolism	  (Morita	  et	  al.,	  2011).	  	  Lastly,	   a	   role	   in	   heart	   function	   was	   unveiled	   in	   Cnot3+/-­‐mice.	   The	   analysis	  showed	   that	   heart	   functionality	   was	   impaired	   with	   development	   of	   cardiac	  contractile	   abnormalities.	   It	   was	   also	   shown	   that	   Cnot3+/-­‐	   mice	   that	   were	  subjected	   to	   cardiac	   stress	   underwent	   heart	   failure.	   Analysis	   of	   histone	  modifications	   in	   heart	   extracts	   revealed	   a	   decreased	   presence	   of	   histone	  H3K4me3	  and	  H3K9ac.	  Treatment	  with	  the	  HDAC	  inhibitor	  VPA	  restored	  normal	  heart	  function,	  even	  in	  the	  presence	  of	  cardiac	  stress,	  avoiding	  heart	  failure.	  This	  study	  also	  showed	  that	  a	  Single	  Nucleotide	  Polymorphism	  (SNP)	  in	  the	  promoter	  of	  human	  CNOT3	  is	  associated	  with	  cardiac	  malfunctions	  (Neely	  et	  al.,	  2010).	  	  	  
1.8 Development	  of	  B	  lymphocytes	  and	  regulation	  of	  the	  B	  cell	  
cycle	  	  Development	  of	  B	  cells	  is	  defined	  by	  a	  number	  of	  stages	  that	  occur	  initially	  in	  the	  bone	  marrow	  and	  are	  then	  completed	  in	  the	  secondary	   lymphoid	  organs.	  B	  cells	   arise	   from	   the	   hematopoietic	   stem	   cells	   (HSCs),	  which	   reside	   in	   the	   bone	  marrow	  and	  have	  two	  major	  features:	  the	  ability	  to	  generate	  all	  of	  the	  blood	  cell	  lineages	  and	  the	  capacity	  for	  self-­‐renewal.	  HSCs	  are	  multipotent	  cells	  that	  can	  be	  identified	  by	  the	  absence	  of	   lineage	  specific	  markers	  (Lin-­‐)	  and	  the	  presence	  of	  the	  stem	  cell	  factor	  receptor,	  c-­‐kit	  (CD117)	  (Bryder	  et	  al.,	  2006).	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Figure	  1.13:	  Hematopietic	  stem	  cell	  differentiation.	  Hematopoietic	   stem	   cells	   (HSC)	   differentiate	   to	   become	   multipotent-­‐progenitor	  cells	  (MPP).	  The	  next	  step	  towards	   lymphocyte	  differentiation	  is	  the	  repression	  of	  genes	  defining	  the	  Common	  Myeloid	  Progenitor	  (CMP)	  cells	  and	  the	  upregulation	  of	  Common	   Lymphoid	   Progenitor	   (CLP)	   specific	   genes.	   The	   expression	   of	   B	   cell	  specific	  genes	  in	  CLPs	  drives	  commitment	  and	  differentiation	  into	  pro-­‐B,	  pre-­‐B	  and	  B	  cells.	  	  	  At	  this	  stage	  of	  development,	  after	  expression	  of	  CD19,	  cells	  are	  called	  pro-­‐B.	  They	   next	   undergo	   V(D)J	   recombination	   of	   the	   immunoglobulin	   heavy-­‐chain	  genes	  in	  order	  to	  generate	  the	  antibody	  repertoire.	  This	  involves	  recombination	  of	   the	   (variable),	   D	   (diversity),	   J	   (joining)	   regions	   in	   the	   Ig	   heavy-­‐chain	   locus	  (Bassing	  et	  al.,	  2002).	  The	  transition	  from	  pro-­‐B	  to	  pre-­‐B	  cells	  is	  accompanied	  by	  formation	   of	   the	   pre	   B	   Cell	   Receptor	   (BCR)	   complex.	   The	   pre-­‐BCR	   complex	   is	  formed	   by	   two	   surrogate	   light	   chains	   (Martensson	   et	   al.,	   2007).	   Large	   cycling	  pre-­‐B	   cells	   exit	   the	   cell	   cycle	   to	   become	   small	   non-­‐cycling	   pre-­‐B	   cells.	   At	   this	  point	  recombination	  of	   the	   Igκ	  or	   Igλ	   light	  chain	   loci,	   formation	  of	  a	   functional	  IgM	  and	  downregulation	  of	  the	  pre-­‐BCR	  marks	  the	  transition	  to	  the	  immature	  B	  cell	  stage.	  	  The	  expression	  of	  the	  BCR	  on	  the	  cell	  membrane	  is	   important	   for	  control	  of	  migration	   from	   the	   bone	   marrow	   to	   the	   peripheral	   lymphoid	   organs.	   Before	  migrating	  to	  secondary	  lymphoid	  organs,	  the	  BCR	  of	  immature	  B	  cells	  is	  tested	  to	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verify	   the	   affinity	   for	   self-­‐elements.	   If	   there	   is	   high	   reactivity	   the	   cells	   trigger	  induction	  of	  apoptosis	  by	  the	  BCR	  (Chen	  et	  al.,	  1995).	   In	  the	  case	  of	  absence	  of	  response	   after	   BCR	   stimulation,	   B	   cells	   undergo	   a	   state	   of	   unresponsiveness	  called	   anergy	   (Cambier	   et	   al.,	   2007).	   B	   cells	   that	   are	   highly	   reactive	   to	   self-­‐elements	  can	  also	  edit	  the	  BCR	  (Hertz	  and	  Nemazee,	  1997).	  If	  the	  affinity	  for	  self-­‐elements	   is	   low,	   the	   cells	   migrate	   out	   of	   the	   bone	   marrow	   to	   the	   secondary	  lymphoid	  organs,	  such	  as	  the	  spleen	  and	  lymph	  nodes	  (Niiro	  and	  Clark,	  2002).	  	  The	   spleen	   is	   composed	   of	   the	   red	   pulp	   and	   the	   white	   pulp.	   The	   red	   pulp	  contains	  splenic	  sinuses	  enriched	  in	  macrophages.	  The	  red	  pulp	  filters	  blood	  and	  cleanses	   it	   of	   bacteria,	   pathogens	   and	   old	   erythrocytes.	   	   The	   white	   pulp	   is	  composed	  by	  the	  periarteriolar	  lymphoid	  sheath	  (PALS),	  which	  is	  enriched	  in	  T	  lymphocytes,	   follicles	  containing	  B	  cells	  and	  the	  marginal	  zone	  (Cesta,	  2006).	  B	  cells	  that	  arrive	  in	  the	  spleen	  are	  called	  T1	  (transitional-­‐1)	  and	  are	  characterized	  by	   IgMhighCD21-­‐CD23-­‐	   expression	   on	   their	   membrane.	   Immature	   T1	   B	   cells	  migrate	  from	  the	  red	  pulp	  to	  the	  follicles	  in	  the	  white	  pulp.	  Before	  reaching	  the	  mature	   B	   cell	   stage,	   they	   go	   through	   two	   transitional	   states	   that	   are	  characterized	   by	   expression	   of	   different	   cellular	   markers:	  	  IgMhighCD21+CD23+(T2)	  and	  IgMlow	  CD21+CD23+(T3)	  (Allman	  et	  al.,	  2001).	  B	  cell	  activation	  factor	  (BAFF),	  which	  is	  a	  member	  of	  the	  TNF	  family,	   is	   important	  for	  the	   transition	   to	   mature	   B	   cells	   in	   synergy	   with	   BCR	   signalling	   (Batten	   et	   al.,	  2000).	  	  In	   the	   spleen,	  B	   cells	   can	   reside	   in	   the	   follicles	  or	   in	   the	  marginal	   zone.	  The	  decision	   to	   reside	   in	   either	   of	   these	   locations	   is	   driven	   by	   differences	   in	   the	  strength	   of	   BCR	   signalling.	   High	   BCR	   stimulation	   determines	   the	   follicular	  localization	  of	  B	  cells,	  whereas	  weak	  BCR	  stimulation	  promotes	  the	  formation	  of	  marginal	  zone	  B	  cells	  (Allman	  and	  Pillai,	  2008).	  B	  cells	  in	  the	  marginal	  zone	  are	  mainly	   involved	   in	   the	  T-­‐cell	   independent	   response,	   acting	  against	  non-­‐protein	  antigens,	  such	  as	  lipids	  from	  bacterial	  cell	  wall	  components	  (Cerutti	  et	  al.,	  2013).	  The	   B	   cells	   in	   the	   spleen	   follicles	   are	   involved	   in	   the	   T-­‐dependent	   immune	  response.	   Activation	   of	   B	   cell	   in	   the	   follicles	   leads	   to	   formation	   of	   either	   long-­‐lived	   plasma	   cells	   or	   a	   pool	   of	  memory	  B	   cells	   (Goodnow	  et	   al.,	   2010).	   	   In	   the	  spleen,	  B	  cells	   can	  be	   in	  a	  quiescent	  state	   for	  months	  and	  are	  characterized	  by	  low	  levels	  of	  transcription	  and	  low	  metabolic	  rate.	  Resting	  B	  cells	  need	  low-­‐level	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BCR	  stimulation	  to	  enhance	  survival	  (Kraus	  et	  al.,	  2004).	  This	  does	  not	  represent	  a	   mitogenic	   stimulus	   and	   cells	   do	   not	   proliferate	   in	   response	   to	   it.	   However,	  resting	  B	  cells	  can	  become	  active	  when	  they	  encounter	  antigens	  (Figure	  1.14).	  	  
	  
Figure1.14:	  Anatomy	  of	  the	  spleen.	  Two	   different	   areas	   form	   the	   spleen:	  white	   pulp	   and	   red	   pulp.	   The	  white	   pulp	   is	  involved	  in	  the	  immune	  response	  while	  the	  main	  function	  of	  the	  red	  pulp	  instead	  is	  the	  filtration	  of	  red	  blood	  cells.	  In	  the	  white	  pulp	  there	  are	  two	  types	  of	  B	  cells:	  the	  follicular	  ones	  in	  the	  inner	  part	  and	  the	  marginal	  zone	  B	  cells	  in	  the	  part	  in	  contact	  with	   the	   red	   pulp.	   The	   white	   pulp	   is	   in	   contact	   with	   the	   periarteriolar	   sheath	  enriched	  in	  T	  cells.	  	  (Adapted	  from	  (Pillai	  and	  Cariappa,	  2009).	  	  
1.8.1 T-­dependent	  and	  T-­independent	  B	  cell	  activation	  B	  cells	  are	  one	  of	  the	  most	  important	  effectors	  of	  the	  immune	  response.	  They	  are	  involved	  in	  the	  identification	  of	  antigen	  and,	  respond	  to	  it	  in	  a	  manner	  that	  is	  either	  T	  cell-­‐dependent	  or	  T-­‐cell	  independent.	  In	  T	  cell-­‐dependent	  activation,	  the	  antigen	   binds	   to	   and	   activates	   the	   BCR.	   However,	   to	   achieve	   full	   activation,	   B	  cells	   need	  other	   signals	   from	  T	  helper	   cells	   (Noelle	   and	  Snow,	  1991).	  T	  helper	  cells	   are	   activated	   by	   antigen	   presenting	   cells	   (APC)	   and	   are	   able	   to	   bind	   the	  major	   histocompatibility	   complex	   (MHC)	   and	   CD40	   on	   B	   cells	   (Kupfer	   et	   al.,	  1994).	   APC	   can	   be	   dendritic	   cells,	  macrophages	   or	  B	   cells.	   Therefore,	   T	   helper	  cells	   are	   able	   to	   release	   cytokines	   to	   promote	   the	   development	   of	   B	   cells	   into	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antibody-­‐secreting	   long	   lived	   plasma	   cells	   or	   memory	   B	   cells.	   T	   dependent	  activation	   targets	   B	   cells	   that	   are	   present	   in	   the	   spleen	   follicles	   (Berek	   et	   al.,	  1991).	   This	   activation	   leads	   to	   production	   of	   germinal	   centres	   where	   B	   cells	  divide	   in	  order	  to	  then	  differentiate	   into	   long-­‐lived	  plasma	  cells	  (Vernino	  et	  al.,	  1992).	  However,	   in	  an	  alternative	  pathway,	  a	  pool	  of	   follicular	  activated	  B	  cells	  enters	   into	   a	   quiescent	   state	   to	   form	   memory	   B	   cells,	   which	   will	   be	   able	   to	  recognize	   the	   same	   antigen	   in	   case	   of	   a	   second	   exposure	   (McHeyzer-­‐Williams	  and	  Ahmed,	  1999).	  	  	  In	  the	  T-­‐dependent	  response,	  binding	  of	  antigen	  to	  the	  BCR	  has	  a	  central	  role	  in	  the	  activation	  of	  B	  cells.	  The	  BCR	  is	  composed	  of	  two	  immunoglobulin	  heavy	  and	  light	  chains	  and	  two	  signalling	  components	  Igα	  and	  Igβ	  (Schamel	  and	  Reth,	  2000).	  The	  antigen	  binding	  causes	  translocation	  of	  the	  BCR	  complex	  into	  specific	  areas	   of	   the	   cellular	   membrane	   called	   lipid	   rafts,	   which	   have	   a	   peculiar	  composition	   of	   sphingolipids	   and	   phospholipids	   (Gupta	   and	   DeFranco,	   2007).	  Furthermore,	   lipid	  rafts	  are	  enriched	   for	   the	  presence	  of	   the	  kinase	  Lyn,	  which	  phosphorylates	   the	   immunoreceptor	   tyrosine-­‐based	   activation	   motifs	   (ITAMs)	  on	  the	  Igα	  and	  Igβ	  (Pierce,	  2002).	  The	  phosphorylated	  ITAM	  is	  recognized	  by	  the	  protein	   tyrosine	   kinase	   (PTK)	   SYK,	   which	   triggers	   the	   signalling	   pathway	   and	  activates	  transcription	  factors	  such	  as	  NFkb	  and	  NFAT	  (Niiro	  and	  Clark,	  2002).	  	  In	   the	   T	   cell-­‐independent	   response	   bacterial	   wall	   lipids	   or	   non	   proteic	  bacterial	  components	  bind	  to	  the	  Toll	  Like	  Receptors	  (TLR)	  on	  marginal	  zone	  B	  cells.	  The	  marginal	  zone	  B	  cells	  are	  in	  close	  contact	  with	  antigens	  present	  in	  the	  blood	  of	  the	  spleen	  marginal	  sinus	  (Martin	  and	  Kearney,	  2000).	  These	  cells	  can	  respond	   to	   the	  presence	  of	   antigens	   in	   two	  ways:	   they	   can	  develop	   short	   lived	  plasma	  cells	  or	  they	  can	  shuttle	  to	  the	  follicles	  to	  present	  the	  antigen	  either	  to	  T	  or	  B	  cells	  to	  trigger	  a	  more	  specific	  immune	  response	  (Cinamon	  et	  al.,	  2008).	  	  TLRs	  are	  membrane	  glycoproteins	  that	  can	  bind	  different	  ligands	  to	  initiate	  an	  immune	  response.	  One	  of	  the	  most	  studied	  TLRs	  is	  TLR4,	  which	  can	  mediate	  the	  response	  to	  LipoPolySaccharide	  (LPS)	  (Poltorak	  et	  al.,	  1998).	  Stimulation	  of	  TLR	  leads	   to	   activation	   of	   the	   transduction	   signal	   that	   is	   driven	   by	   the	   myeloid	  differentiation	   primary-­‐response	   protein	   88	   (MyD88)	   and	   IL-­‐1R-­‐associated	  kinase	   4	   (IRAK4).	   The	   pathway	   that	   is	   triggered	   by	   the	   binding	   of	   antigens	   to	  TLR	  drives	  the	  transcription	  of	  NF-­‐kb	  regulated	  genes	  (Takeda	  and	  Akira,	  2004).	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1.9 Aim	  of	  the	  study	  	  The	  aim	  of	  this	  project	  was	  to	  study	  the	  role	  of	  Cnot3	  in	  gene	  regulation	  and	  cell	   cycle	   progression.	   Preliminary	   data	   collected	   in	   our	   lab	   revealed	   a	   strong	  interaction	   of	   Cnot3	   with	   the	   Aurora	   B	   kinase,	   which	   has	   been	   shown	   to	   be	  involved	   in	   controlling	   transcription	   in	   resting	  B	   cells.	   Cnot3	  was	   found	   to	   co-­‐localise	  with	  Aurora	  B	  at	  many	  active	  gene	  promoters	   in	   these	  cells.	  Moreover,	  recent	  published	  studies	  have	  demonstrated	  a	   role	   for	  Cnot3	   in	   transcriptional	  regulation	  in	  ES	  cells	  and	  in	  several	  human	  pathologies.	  These	  results	  formed	  the	  basis	  for	  a	  detailed	  investigation	  of	  the	  role	  of	  Cnot3	  in	  gene	  regulation	  and	  the	  cell	  cycle,	  using	  quiescent	  and	  activated	  mouse	  splenic	  B	  cells	  as	  a	  model	  system.	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Chapter	  2 	  Material	  and	  methods	  	  	  
2.1 	  Resting	  B	  cell	  isolation	  	   Resting	  B	  cells	  were	   isolated	   from	  6	   to	  8	  week	  old	  C57BL/6	  mouse	  spleens.	  Cells	  were	  isolated	  using	  EasySep	  B	  cell	  enrichment	  kit	  (STEMCELL	  Technology)	  according	   to	   manufacturer’s	   instructions.	   Spleens	   were	   homogenized	   and	  centrifuged	   for	   10	  minutes	   at	   2,000	   rpm	  without	   break	   in	   a	   Ficoll-­‐Paque	   (GE	  Healthcare)	   gradient	   to	   separate	   lymphocytes	   from	   erythroid	   cells.	   Cells	   were	  incubated	   15	   minutes	   at	   4°C	   with	   a	   cocktail	   that	   included	   monoclonal	  biotinylated	   antibodies	   that	   recognize	   surface	   markers	   of	   mouse	   cells	   of	  hemapoietic	  origin	   (CD4,	  CD8,	  CD11b,	  CD43,	  CD49b,	  Ly-­‐6G	   (Gr-­‐1),	  TER119).	   In	  the	   cocktail	   is	   also	   present	   an	   FcR	   blocker	   that	   recognizes	  mouse	   CD16/CD32	  (Fcγ	  III/II	  Receptor),	  which	  is	  present	  on	  B	  cells	  and	  other	  FcR+	  cells.	  Cells	  were	  then	  incubated	  15	  minutes	  at	  4°C	  with	  a	  cocktail	  containing	  Tetrameric	  Antibody	  Complexes	   (TAC)	   that	   recognizes	   the	  biotin	  of	   the	  antibodies	  bound	   to	   the	  cell	  surface.	  A	  suspension	  of	  magnetic	  dextran	  iron	  beads	  was	  used	  for	  5	  minutes	  at	  4°C	   to	  bind	   the	  TAC	  on	   cells	   carrying	  biotinylated	  antibodies	  on	   the	   surface.	  A	  magnet	  was	  then	  used	  to	  deplete	  the	  suspension	  of	  unwanted	  cells	  leaving	  a	  pure	  resting	  B	  cell	  population	  in	  suspension.	  	  
2.2 B	  cell	  culture	  and	  synchronization	  	   Resting	   B	   cells	   were	   cultured	   in	   RPMI-­‐1640	   supplemented	   with	   15%	   Fetal	  Calf	   Serum	   (FCS)	   (Sigma),	   0.1	  U/ml	  penicillin	   (Lonza),	   0.1	  µg/ml	   streptomycin	  (Lonza),	  2	  mM	  L-­‐Glutamine	  (Lonza),	  50µM	  beta-­‐mercapthoethanol	  (Gibco).	  The	  resting	  B	  cells	  were	   treated	  with	  25	  µg/ml	  of	  anti-­‐IgM	  antibody	  (Millipore)	   for	  20	  hours	  to	  obtain	  cells	  in	  early	  G1.	  LPS	  (Sigma)	  was	  added	  at	  a	  concentration	  of	  25	  µg/ml	  and	  cells	  were	  left	   in	  culture	  for	  6	  hours	  to	  reach	  late	  G1.	  In	  order	  to	  synchronize	   cells,	   Aphidicolin	   (Sigma)	   was	   added	   to	   the	   culture	   at	   1	   µg/ml	  followed	   by	   incubation	   for	   16	   hours.	   After	   the	   treatment,	   aphidicolin	   blocked	  cells	   were	   washed	   once	   in	   medium	   at	   1,800	   rpm	   for	   5	   minutes	   at	   room	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temperature	   to	   remove	   the	   inhibitor.	   The	   cells	   were	   then	   cultured	   in	   fresh	  medium.	   They	   were	   collected	   30	   minutes	   and	   1,	   2,	   4	   and	   6	   hours	   after	   the	  release.	  	  
2.3 ES	  cell	  culture,	  electroporation	  and	  crystal	  violet	  staining	  Mouse	   A7	   ES	   cells	   expressing	   Cre	   recombinase	   (kindly	   provided	   by	   Prof.	  Merkenschlager,	  MRC	  CSC	  London)	  were	  cultured	  on	  lamin	  coated	  plates	  in	  the	  following	   medium:	   Neurobasal	   (Gibco)	   and	   DMEM:F12	   1:1	   (Lonza)	   medium	  supplemented	   with	   N2	   (Gibco),	   B27	   (Gibco),	   2	   mM	   L-­‐glutamine	   (Gibco),	   100	  uds/ml	   Penicillin-­‐Streptomycin	   	   (Gibco),	   0.1	  mM	  β-­‐mercaptoethanol	   (Gibco),	   1	  μM	  PDO3	  (Stemgent),	  3	  μM	  CHIRON	  (Stemgent),	  200	  uds/ml	  LIF	  (Millipore).	  3x106	  cells	  were	  used	  for	  the	  electroporation	  of	  the	  TALEN	  plasmids	  and	  the	  linearized	  donor	  vector.	  The	   final	   amount	  of	  DNA	   that	  was	  electroporated	  was	  10	   μg,	  which	   included	   3	   μg	   of	   each	   TALEN	  plasmid	   and	   4	   μg	   of	   the	   linearized	  donor	  vector	   containing	  a	  neomycin	   resistance.	  Cells	  were	  washed	   three	   times	  with	  cold	  Phosphate-­‐Buffered	  Saline	  (PBS)	  by	  centrifugation	  at	  80g	  for	  5	  minutes	  at	  4°C.	  They	  were	  then	  resuspended	  in	  90μl	  of	  nucleofector	  solution	  and	  mixed	  with	  10μl	  of	  the	  DNA	  mix.	  The	  cells	  and	  DNA	  mix	  were	  transferred	  to	  a	  cuvette	  and	  electroporated	  using	  the	  program	  A24	  in	  the	  Nucleofector™	  Device	  (Lonza).	  0.5	  ml	  of	  warm	  medium	  was	  then	  added	  to	  cells	  to	  plate	  them.	  Cells	  were	  growth	  in	  medium	  containing	  neomycin	  in	  order	  to	  select	  cells	  that	  integrated	  the	  donor	  vector.	  	  Crystal	   violet	  was	  performed	   to	   stain	   the	  presence	  of	   colonies	   in	   the	  plates.	  After	   one	   week	   of	   selection,	   plates	   were	   washed	   and	   fixed	   in	   4%	  paraformaldheyde	  (PFA)	  for	  10	  minutes.	  They	  were	  washed	  three	  times	  in	  PBS	  for	   5	   minutes.	   Cells	   were	   then	   stained	   with	   0.5%	   Crystal	   violet/water	   for	   15	  minutes.	  Plates	  were	  washed	  with	  water	  and	  let	  air-­‐dry.	  	  
	  
2.4 Aurora	  B	  conditional	  knockout	  mice	  Aurora	   B	   conditional	   knockout	   (cKO)	   mice	   were	   generated	   by	   Dr.	   Mónica	  Román	  Trufero	   by	   crossing	   homozygous	  Rosa26-­‐CreERT2	  mice	  with	   a	   strain	   of	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mice	  in	  which	  exons	  2	  and	  6	  of	  the	  Aurora	  B	  gene	  flanked	  by	  loxP	  sites	  (Aurkbfl/fl,	  kindly	  provided	  by	  Dr.	  Marcos	  Malumbres,	  CNIO,	  Madrid).	  The	  mice	  generated	  from	  this	  cross	  express	  the	  cre-­‐estrogen	  receptor	  fusion	  protein,	  CreERT2,	  under	  the	   control	   of	   the	   ubiquitous	   Rosa26	   promoter.	   After	   treatment	   with	   4-­‐hydroxytamoxifen	   (4-­‐OHT),	   CreERT2	   migrates	   into	   the	   nucleus	   and	   the	   Cre	  recombinase	  excises	  the	  floxed	  region	  and	  shuts	  down	  expression	  the	  Aurora	  B	  gene.	  	  	  
2.5 FACS	  analysis	  
2.5.1 PI	  staining	  For	   Propidium	   Iodide	   (PI)	   staining,	   1x106	   cells	   were	   collected	   by	  centrifugation	  at	  2,500	  rpm	  for	  5	  minutes	  at	  4°C.	  Cells	  were	  washed	  in	  1ml	  of	  2%	  FCS/PBS.	   Fixation	   was	   performed	   by	   resuspending	   cells	   in	   70%	   ethanol	   and	  leaving	  them	  for	  10	  minutes	  at	  -­‐20°C.	  Two	  further	  washes	  in	  2%	  FCS/PBS	  were	  carried	  out	  before	   incubating	  cells	   for	  30	  minutes	  at	   room	  temperature	   in	  PBS	  containing	  0.05	  mg/ml	  PI	   (Sigma),	  0.05%	   Igepal	  CA-­‐630	  and	  1	  µg/ml	  RNase	  A	  (Sigma).	  Cells	  were	  analyzed	  on	  a	  FACSCalibur	  machine	  (BD	  Pharmigen).	  	  
2.5.2 Staining	  of	  cell	  surface	  markers	  	  To	  determine	  the	  expression	  of	  cell	  surface	  markers,	  1x106	  cells	  were	  washed	  in	   2%	   FCS/PBS.	   Cells	   were	   then	   blocked	   using	   5%	   goat	   serum	   and	   anti-­‐CD16	  antibody	   for	   5	   minutes	   at	   4°C.	   A	   1:100	   dilution	   of	   anti-­‐CD69	   and	   anti-­‐B220	  antibodies	   were	   used.	   After	   two	   washes	   with	   2%	   FCS/PBS,	   cells	   were	  resuspended	  in	  PBS	  and	  analyzed	  on	  a	  LSRII	  FACS	  machine.	  	  	  
2.5.3 EdU	  incorporation	  assay	  EdU	  incorporation	  experiments	  were	  carried	  out	  using	  the	  kit	  Click-­‐iT	  EdU	  Flow	   Cytometry	   Assay	   Kits	   (Invitrogen)	   according	   to	   manufacturer’s	  instructions.	  The	  experiments	  were	  performed	  using	  1x106	  cells.	  EdU	  was	  added	  at	  a	  concentration	  of	  10	  µM	  for	  30	  minutes	  at	  37°C	  before	  harvesting.	  	  Cells	  were	  collected	  and	  washed	  in	  3	  ml	  of	  1%	  Bovine	  Serum	  Albumin	  (BSA)	  in	  PBS.	  After	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centrifugation	   at	   room	   temperature	   for	   5	   minutes	   at	   1,800rpm,	   they	   were	  resuspended	  in	  100	  μl	  of	  Click-­‐iT	  fixative	  and	  incubated	  for	  15	  minutes	  at	  room	  temperature,	  protected	  from	  light.	  Cells	  were	  then	  washed	  once	  with	  3	  ml	  of	  1%	  BSA/PBS	  and	  spun	  for	  5	  minutes	  at	  1,800rpm.	  They	  were	  resuspended	  in	  100	  μl	  of	   Click-­‐iT	   saponin-­‐based	  permeabilization	   and	  wash	   reagent	   and	   incubated	   at	  room	  temperature	  for	  15	  minutes.	  0.5	  ml	  of	  Click-­‐iT	  reaction	  cocktail	  were	  added	  and	   cells	   were	   incubated	   30	   minutes	   at	   room	   temperature.	   Cells	   were	   then	  washed	   once	   in	   3	   ml	   of	   Click-­‐iT	   saponin	   based	   permeabilization	   buffer	   and	  resuspended	  in	  0.5	  ml	  of	  the	  same	  buffer	  for	  analysis	  on	  a	  LSR	  II	  FACS	  machine.	  	  
2.6 DAPI	  staining	  Coverslips	  were	  coated	  with	  400	  μl	  of	  poly-­‐Lysine	  at	  room	  temperature	  for	  15	  minutes.	  They	  were	  then	  washed	  once	  with	  PBS	  and	  once	  with	  RPMI	  medium	  for	  3	  minutes	  at	  room	  temperature.	  5x105	  cells	  were	  spread	  over	  the	  coverslip.	  Cells	  were	   left	  5	  minutes	   to	   attach	   to	   the	   coverslip	   and	   incubated	   for	  15	  minutes	   at	  room	  temperature	  with	  3	  ml	  of	  4%	  PFA.	  The	  coverslip	  was	  washed	  three	  times	  for	  3	  minutes	  with	  3ml	  of	  PBS	  at	   room	  temperature.	   In	  order	   to	   stain	   for	  DNA	  content,	   cells	  were	   incubated	  1	  minute	  with	  1	  μg/ml	  of	  DAPI	   solution	  at	   room	  temperature.	  To	  mount	  the	  coverslip	  on	  a	  slide	  20	  μl	  of	  Mowiol	  were	  used.	  The	  slides	  were	  analysed	  using	  the	  Leica	  SP5	  confocal	  microscope.	  	  
2.7 Proteomics	  
2.7.1 Nuclear	  protein	  extraction	  for	  IP	  In	   order	   to	   extract	   proteins	   from	   the	   nuclear	   soluble	   and	   chromatin	   bound	  fraction,	  15	  million	  cells/IP	  were	  collected	  and	  washed	  2	  times	  in	  1	  ml	  of	  ice	  cold	  PBS.	  Cells	  were	  then	  resuspended	  in	  1	  ml	  of	  Sucrose	  buffer	  (10	  mM	  Tris	  pH	  8.0,	  320	  mM	   sucrose,	   3	  mM	   CaCl2,	   2	  mM,	  Magnesium	   acetate,	   1	  mM	  DTT,	   0.1	  mM	  EDTA,	   0.5%	   Igepal	   CA-­‐630,	   supplemented	   with	   Complete	   MINI,	   EDTA-­‐free	  protease	  inhibitors	  (Roche	  Diagnostics))	  and	  incubated	  for	  5	  minutes	  on	  ice.	  The	  tube	  was	  spun	  at	  500	  g	  for	  5	  minutes	  at	  4°C.	  In	  order	  to	  get	  rid	  of	  the	  cytoplasmic	  fraction,	  the	  supernatant	  was	  discarded	  and	  the	  nuclei	  resuspended	  in	  200	  μl	  of	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high	  salt	  buffer	  (50	  mM	  Tris	  pH	  7.5,	  400	  mM	  NaCl,	  1mM	  MgCl2,	  10%	  glycerol,	  0.5	  mM	   EDTA,	   Igepal	   CA-­‐630	   (Sigma),	   supplemented	   with	   Complete	   MINI,	   EDTA-­‐free	  protease	  inhibitors).	  The	  samples	  were	  placed	  on	  a	  shaker	  at	  1,400rpm	  for	  30	  minutes	  at	  4°C.	  They	  were	  then	  centrifuged	  at	  14,000	  rpm	  for	  15	  minutes	  at	  4°C.	  The	  supernatant	  representing	  the	  nuclear	  soluble	  fraction	  was	  kept	  on	  ice.	  	  The	   pellet	   of	   chromatin	   was	   digested	   following	   two	   different	   protocols.	  Samples	  from	  resting	  B,	  20	  hours	  anti-­‐IgM	  and	  20	  hours	  anti-­‐IgM	  +	  6	  hours	  LPS	  cells	  were	  incubated	  with	  6	  units	  of	  micrococcal	  nuclease	  (MNase)	  (Sigma)	  and	  15	  units	  of	  benzonase	  (Novagen)	  at	  4°C	  for	  1	  hour	  on	  a	  rotating	  wheel	  at	  20	  rpm.	  The	   salt	   concentration	   was	   then	   increased	   to	   340	   mM	   and	   the	   tubes	   were	  incubated	   for	   1	   hour	   at	   20	   rpm	  on	   a	   rotating	  wheel	   at	   4°C.	   The	   samples	  were	  then	   centrifuged	   at	   8,000	   g	   for	   10	  minutes	   at	   4°C	   to	   remove	   all	   the	   insoluble	  material.	  The	  supernatant	  was	  recovered	  and	  combined	  with	  the	  nuclear	  soluble	  fraction.	  The	  salt	  concentration	  was	  adjusted	  to	  150	  mM	  NaCl.	  	  Aphidicolin	  blocked	  and	  30	  minutes,	  1	  hour,	  4	  hours	  and	  6	  hours	  aphidicolin	  released	  cells	  were	  treated	  with	  1,000	  gel	  units	  of	  MNase	  (NEB)	  at	  1,400	  rpm	  for	  15	  minutes	  at	  37°C	  on	  a	  thermoshaker.	  The	  tubes	  were	  then	  spun	  at	  8,000	  g	  for	  10	   minutes	   at	   4°C	   to	   remove	   the	   insoluble	   material.	   The	   supernatant	   was	  recovered	   and	   combined	   with	   the	   nuclear	   soluble	   fraction.	   The	   salt	  concentration	  was	  adjusted	  to	  150	  mM	  NaCl.	  	  	  
2.7.2 Co-­immunoprecipitation	  and	  western	  blotting	  	   	  All	   IPs	   for	   Co-­‐immunoprecipitation	   (Co-­‐IP)	   experiments	   were	   performed	  using	  nuclear	  soluble	  and	  chromatin	  bound	  fraction	  proteins	  extracted	  from	  15	  million	   cells.	   The	   protein	   extract	   was	   incubated	   for	   16	   hours	   with	   50	   μl	   of	  Dynabeads	   protein	   G	   (Invitrogen),	   pre-­‐coupled	   with	   2.5	   µg	   of	   antibody.	   The	  beads	  were	  then	  washed	  three	  times	  with	  500	  μl	  of	  0.1%	  Tween	  20	  at	  4°C	  for	  5	  minutes	  at	  12	  rpm.	  The	   immunocomplexes	  were	  eluted	  by	  boiling	  the	  beads	  at	  70°C	  for	  15	  minutes	  at	  1,400	  rpm	  in	  60	  μl	  of	  2X	  loading	  buffer	  (125	  mM	  Tris-­‐HCl	  pH	  6.8,	  5%	  SDS,	  0.004	  %	  Bromophenol	  Blue,	  0.2	  M	  DTT,	  10%	  glycerol).	  To	  carry	  out	  the	  western	  blot,	  half	  of	  the	  eluted	  material	  was	  diluted	  1:2	  in	  water	  and	  then	  loaded	   on	   acrylamide/bis-­‐acrylamide	   gel.	   Proteins	   were	   transferred	   onto	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nitrocellulose	  membranes	   (GE)	   using	   transfer	   buffer	   (25	  mM	  Tris	   pH	   8.3,	   192	  mM	  glycine,	  0,1%	  SDS,	  20	  %	  methanol	  (VWR)).	  The	  membrane	  was	  blocked	  for	  2	  hours	   at	   room	   temperature	   in	   5%	   milk/0.05%	   Igepal	   CA-­‐630	   in	   TBS.	   The	  primary	   and	   secondary	   antibodies	   were	   both	   diluted	   in	   blocking	   solution,	   in	  which	  the	  milk	  was	  replaced	  by	  0.5	  %	  BSA.	  The	  membrane	  was	  incubated	  over	  night	  with	   the	   primary	   antibody	   at	   4°C	   and	   45	  minutes	  with	   the	   secondary	   at	  room	   temperature.	   The	   secondary	   antibodies	   were	   horseradish	   peroxidase	  (HRP)-­‐conjugated	  and	   the	  Western	  Lightning	  Chemiluminescence	  Reagent	  Plus	  (Perkin	   Elmer)	   was	   used	   as	   chemiluminescent	   substrate	   for	   visualization	   of	  bands.	  	  	  
2.7.3 GST	  Aurora	  B	  protein	  expression,	  extraction	  and	  purification	  Full-­‐length	   mouse	   Aurora	   B	   cDNA	   (Addgene)	   was	   cloned	   in	   pGEX-­‐4T-­‐1,	  containing	   an	   ampicillin	   resistance	   gene,	   and	   then	   transformed	   in	   BL21	  competent	   E.Coli	   cells.	   Bacteria	   were	   then	   grown	   in	   LB	   ampicillin	   agar	   plates	  over	  night	  at	  37°C.	  A	  colony	  of	  bacteria	  was	  inoculated	  over	  night	  at	  37°C	  in	  2	  ml	  of	  LB	  broth	  containing	  Ampicillin.	  The	  pre-­‐inoculum	  was	  added	   to	  98	  ml	  of	  LB	  broth	   containing	   ampicillin	   and	   grown	   at	   37°C	   to	   reach	   OD600	   density	   of	   0.6.	  Isopropyl	   β-­‐D-­‐1-­‐thiogalactopyranoside	   (IPTG)	   (Sigma)	   was	   added	   at	   a	  concentration	   of	   0.4	  mM	   to	   induce	   protein	   expression.	   Cells	  were	   grown	   for	   3	  hours	  at	  37°C	  and	  centrifuged	  at	  6,000	  rpm	  for	  10	  minutes	  at	  4°C.	  	  The	  pellet	  was	   resuspended	   in	  6	  ml	  of	   lysis	  buffer	   (50	  mM	  Tris-­‐HCl	  pH	  8.0,	  0.15	   M	   NaCl,	   1	   mM	   EDTA,	   supplemented	   with	   Complete	   MINI,	   EDTA-­‐free	  protease	  inhibitors).	  Lysozome	  was	  added	  to	  a	  final	  concentration	  of	  100	  µg/ml	  and	   cells	   were	   incubated	   20	   minutes	   on	   ice.	   DTT	   was	   then	   added	   at	   a	  concentration	  of	  1	  mM	  together	  with	  1.5%	  sarcosyl	   and	   the	   tube	  was	   inverted	  several	  times.	  The	  lysate	  was	  then	  sonicated	  at	  intervals	  of	  15	  seconds	  on	  and	  45	  seconds	  off	  for	  5	  minutes.	  The	  lysate	  was	  then	  centrifuged	  at	  10,000	  rpm	  for	  10	  minutes	  at	  4°C.	  The	  supernatant	  was	  collected	  and	  TritonX-­‐100	  was	  added	  to	  a	  final	  concentration	  of	  1%	  and	  the	  lysate	  was	  filtered	  through	  a	  45	  µm	  filter.	  100	  μl	   of	   Glutathione	   Sepharose	   High	   performance	   (GSH)	   beads	   (GE	   Healthcare)	  were	  pre-­‐washed	   in	   lysis	   buffer	   and	   incubated	  overnight	   at	   4°C	  at	   8	   rpm	  on	   a	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rotating	  wheel	  with	  the	  bacterial	   lysate.	  Beads	  were	  washed	  three	  times	  at	  4°C	  for	  10	  minutes	   at	   12	   rpm	  with	  500	  μl	   of	  washing	  buffer	   (0.5%	  TritonX-­‐100	   in	  lysis	   buffer).	   The	  GST	   fused	  proteins	  were	   eluted	   twice	   in	   1	   volume	  of	   elution	  buffer	   (10	  mM	   glutathione	   reduced,	   5%	   glycerol	   in	   lysis	   buffer	   supplemented	  with	   Complete	   MINI,	   EDTA-­‐free	   protease	   inhibitors)	   for	   30	   minutes	   at	   room	  temperature	  on	  a	  rotating	  wheel	  at	  8	  rpm.	  	  	  
2.7.4 In	  vitro	  transcription/translation	  	  Cnot3	   full	   length	   cDNA	   (Addgene)	   was	   cloned	   in	   pCDNA	   3.2/V5/GW/D-­‐TOPO	   by	   PCR	   addition	   of	   restriction	   sites	   SmaI/NotI	   following	   the	  manufacturer’s	   instructions.	  The	  cloning	  was	  carried	  out	  using	  pCDNA	  plasmid	  to	   take	  advantage	  of	   the	  T7	  promoter	   for	   the	   in	  vitro	   transcription/translation.	  For	  the	  cloning	  of	  the	  full	  length	  Cnot3	  the	  following	  primers	  were	  used:	  Fw	  5’-­‐CACCATGGCGGACAAGCGCAAACT-­‐3’,	  Rv	  5’-­‐	  CTGGAGGTCCCGGTCCTCCAGGTA-­‐3’.	  In	   order	   to	   generate	   Cnot3	  mutants,	  mutant	   cDNAs	  were	   produced	   by	   PCR	  and	   then	  cloned	   in	  pCDNA	  3.2/V5/GW/D-­‐TOPO.	  For	   the	  cloning	  of	   the	  Cnot3	  mutant	   Δ1-­‐200	   the	   following	   primers	   were	   used:	   Fw	   5’-­‐CACCATGGAGATTAAGAAGCTACA-­‐3’,	   Rv	   5’-­‐CTGGAGGTCCCGGTCCTCCAGGTA-­‐3’.	  For	  the	  cloning	  of	  the	  Cnot3	  mutant	  Δ701-­‐751	  the	  following	  primers	  were	  used:	  Fw	   5’-­‐CACCATGGCGGACAAGCGCAAACT	   -­‐3’,	   Rv	   5’-­‐CATCATATACTTGGTGTGGAATCG	  -­‐3’.	  For	  the	  cloning	  of	  the	  Cnot3	  mutant	  Δ651-­‐751	  the	   following	  primers	  were	  used:	  Fw	  5’-­‐	  CACCATGGCGGACAAGCGCAAACT-­‐3’,	  Rv	  5’-­‐GGGTGGCATCTGGTGGTGGTAGGG-­‐3’.	  	  	  In	   order	   to	   perform	   a	   GST	   pull	   down	   assay	   with	   GST	   Aurora	   B,	   Cnot3	   full	  length	  and	  the	  mutants	  were	  in	  vitro	  transcribed/translated	  using	  a	  TNT®	  Quick	  Coupled	   Transcription/Translation	   kit	   (Promega)	   according	   to	   manufacturer’s	  instructions.	  0.5	  µg	  of	  plasmid	  were	  incubated	  with	  20	  μl	  of	  TNT	  T7	  quick	  Master	  Mix,	  1	  μl	  of	  35S	  Methionine	  10µCi	  and	  H2O	  to	  reach	  a	  final	  volume	  of	  25	  μl.	  The	  reaction	  of	  transcription/translation	  was	  performed	  for	  90	  minutes	  at	  30°C.	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2.7.5 GST	  pull	  down	  assay	  50	  μl	  of	  GSH	  beads	  were	  washed	  three	  times	  at	  4°C	  for	  5	  minutes	  at	  12	  rpm	  with	   the	   200	   μl	   of	   binding	   buffer	   (50	   mM	   Tris	   HCl	   pH	   8.0,	   150	   mM	  monopotassium	  glutamate,	  1mM	  EDTA,	  0.1	  %	  Igepal	  CA-­‐630,	  5%	  glycerol,	  0,2%	  BSA	   and	   supplemented	  with	   Complete	  MINI,	   EDTA-­‐free	   protease	   inhibitors).	   1	  
µg	  of	  GST	  or	  GST	  Aurora	  B	  was	  added	   to	   the	  beads	  and	   incubated	  at	  4°C	   for	  2	  hours	   at	   8	   rpm	   rotation.	   The	   beads	  were	   then	  washed	   two	   times	   at	   4°C	   for	   5	  minutes	   at	   12	   rpm	   rotation	  with	   500	   μl	   of	   binding	   buffer.	   5	   μl	   of	   the	   in	   vitro	  transcribed/translated	   Cnot3,	   generated	   as	   described	   in	   section	   2.7.4,	   was	  incubated	  with	   the	  beads	   at	  4°C	  over	  night	   at	  8	   rpm	  rotation.	  The	  beads	  were	  then	  washed	  three	  times	  at	  4°C	  for	  5	  minutes	  at	  12	  rpm	  rotation	  with	  500	  μl	  of	  binding	   buffer	   without	   BSA.	   The	   beads	   were	   resuspended	   in	   40	   μl	   of	   loading	  buffer	  and	  incubated	  for	  5	  minutes	  at	  95°C.	  The	  eluted	  proteins	  were	  loaded	  on	  acrylamide/bis-­‐acrylamide	  gel.	  The	  gel	  was	  stained	  for	  15	  minutes	  in	  a	  staining	  solution	  (0.1%	  coomassie	  blue,	  50%	  methanol,	  10%	  acetic	  acid,	  40%	  H2O)	  and	  destained	   for	   2	   hours	   in	   destaining	   solution	   (50%	  methanol,	   10%	   acetic	   acid,	  40%	  H2O).	  The	  gel	  was	  dried	  for	  1	  hour	  at	  80°C	  and	  consequently	  exposed	  to	  X-­‐ray	  film	  over	  night	  at	  room	  temperature.	  	  	  
2.7.6 Mass	  Spectrometry	  (MS)	  analysis	  Co-­‐IP	  experiments	  of	  Cnot3	  IP	  in	  nuclear	  extracts	  were	  performed	  using	  early	  G1	  and	  G2	  cells	  as	  described	  in	  sections	  2.7.1	  and	  2.7.2.	  To	  perform	  the	  IP	  a	  mix	  of	  two	  Cnot3	  antibodies	  was	  used	  to	  a	  final	  amount	  of	  2.5	  μg.	  An	  anti-­‐IgG	  control	  was	  used	  to	  carry	  out	  an	  IP	  in	  both	  samples	  and	  used	  as	  a	  negative	  control.	  	  Eluted	   samples	   from	   the	   co-­‐IP	   experiments	   were	   run	   on	   acrylamide/bis-­‐acrylamide	   gel.	   The	   gel	   was	   then	   incubated	   with	   a	   staining	   solution	   (0.1%	  coomassie	  blue,	  50%	  methanol,	  10%	  acetic	  acid,	  40%	  H2O)	   for	  1	  hour	  at	   room	  temperature.	  The	  stained	  gel	  was	  processed	   for	  MS	  analysis	  by	   the	  Proteomics	  facility	  at	  the	  MRC	  CSC.	  	  The	   samples	   were	   injected	   in	   a	   Thermo	   Scientific	   (Dionex)	   Ultimate	   3000	  nano	   liquid	   chromatography	   system	   to	   separate	   peptides	   prior	   to	   mass	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spectrometric	  analysis.	  Peptides	  were	  then	  eluted	  on-­‐line	  to	  an	  analytical	  column	  (Thermo	  Scientific	  Acclaim	  Pepmap	  RSLC).	  Eluted	  peptides	  were	  analysed	  using	  a	   Thermo	   LTQ-­‐Orbitrap	   Velos	   operating	   in	   positive	   polarity,	   top	   10	   MSA	   CID	  (multistage	   activation	   collision	   induced	   dissociation	   mode)	   method.	   Ions	   for	  dissociation	  were	  determined	  from	  an	   initial	  15,000	  resolution	  MS	  survey	  scan	  (event	  1)	  followed	  by	  MSA	  on	  the	  top	  10	  most	  abundant	  ions.	  	  The	   analysis	   generated	   raw	   files	   that	   were	   searched	   against	  UniprotKB/Swiss-­‐Prot	   database	   (version	   March	   2012)	   restricted	   to	   mouse	  entries	  using	  Mascot	   v2.3.1	   and	  Mascot	  Distiller	   v2.4.1.	  A	   fixed	  modification	  of	  carbamidomethylation	   (cysteine)	   was	   used,	   with	   variable	   modifications	   of	  oxidation	   (methionine),	   acetylation	   (protein	   N-­‐terminal)	   and	   phosphorylation	  (serine,	   threonine,	   tyrosine).	  Precursor	  mass	   tolerance	  of	  10ppm	  and	   fragment	  tolerance	  (MS/MS)	  of	  600	  mmu	  were	  used.	  	  In	  the	  Co-­‐IP	  MS	  analysis	  all	  the	  proteins	  with	  Normalised	  MS	  intensities	  (fold	  over	   max)	   above	   0.1	   in	   the	   control	   lane	   were	   discarded.	   The	   gene	   ontology	  analysis	  was	  performed	  using	  the	  free	  on-­‐line	  software	  GOrilla.	  	   	  	   	   	   	   	   	   	   	  	  
2.7.7 In	  vitro	  peptide	  binding	  assay	  Two	  peptides	  were	  synthesized	  by	  GL	  Biochem	  Shangai	  with	  the	  sequence	  of	  the	  mouse	  histone	  H1.3.	  They	  included	  amino	  acids	  25	  to	  41	  of	  H1.3.	  One	  peptide	  carried	   an	   acetylation	   on	   the	   lysine	   corresponding	   to	   the	   H1.3K35,	   while	   the	  other	  peptide	  had	  the	  same	  sequence	  without	  modification.	  Both	  peptides	  were	  synthesized	  with	  an	  N	   terminal	  acetylation	  and	  C	   terminal	  biotinylation.	  The	  N	  terminal	   was	   acetylated	   to	   enhance	   the	   solubility	   and	   stability	   of	   the	   peptide.	  The	   sequences	   are	   as	   it	   follows:	   Ac-­‐KKTGAAAGKRK(Acetyl)ASGPPVSELIGK-­‐(Biotin)	   and	   Ac-­‐KKTGAAAGKRKASGPPVSELIGK-­‐	   (Biotin).	   25	   μl	   of	   NeutrAvidin	  Agarose	  Resin	  were	  washed	  three	  times	  at	  12	  rpm	  rotation	  for	  5	  minutes	  at	  4°C	  in	  0.2%	  Triton-­‐X/PBS.	  2.5	  µg	  of	  peptide	  were	  added	  to	  the	  beads	  and	  incubated	  at	  4°C	  overnight	  at	  8	  rpm	  rotation.	  	  Cnot3	   full	   length	   and	   mutants	   were	   transcribed/translated	   as	   reported	   in	  section	  2.7.4.	  A	  5	  μl	  aliquot	  of	  the	  reaction	  was	  incubated	  with	  25	  μl	  of	  the	  resin	  in	  a	   final	  volume	  of	  500	  μl	  of	  binding	  buffer	   (50	  mM	  Tris	  HCl	  pH	  8.0,	  150	  mM	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monopotassium	  glutamate,	  1mM	  EDTA,	  0.1	  %	  Igepal	  CA-­‐630,	  5%	  glycerol,	  0,2%	  BSA	  and	  supplemented	  with	  Complete	  MINI,	  EDTA-­‐free	  protease	  inhibitors)	  and	  incubated	  at	  8	  rpm	  rotation	  for	  4	  hours	  at	  4°C.	  The	  resin	  was	  washed	  three	  times	  in	  binding	  buffer	  without	  BSA	  at	  4°C	  for	  10	  minutes	  at	  12	  rpm	  rotation.	  Proteins	  were	  eluted	  by	  adding	  30	  μl	  of	  loading	  buffer	  and	  boiling	  at	  95°C	  for	  5	  minutes.	  The	   eluted	  material	  was	   loaded	   onto	   a	   acrylamide/bis-­‐acrylamide	   gel.	   The	   gel	  was	   stained	   for	   15	  minutes	   in	   a	   staining	   solution	   (0.1%	   coomassie	   blue,	   50%	  methanol,	   10%	   acetic	   acid,	   40%	  H2O)	   and	   destained	   for	   2	   hours	   in	   destaining	  solution	   (50%	  methanol,	   10%	   acetic	   acid,	   40%	  H2O).	   The	   gel	   was	   dried	   for	   1	  hour	  at	  80°C	  and	  exposed	  to	  X-­‐ray	  film	  overnight	  at	  room	  temperature.	  	  	  
2.8 Chromatin	  Immunoprecipitation	  
2.8.1 Chromatin	  preparation	  B	  cells	  were	  treated	  with	  formaldehyde	  (Sigma)	  to	  a	  final	  concentration	  of	  1%	  to	  crosslink	  proteins	   to	  DNA.	  Cells	  were	   incubated	  at	  room	  temperature	   for	  10	  minutes	  with	  gentle	  tumbling.	  The	  reaction	  was	  then	  stopped	  by	  adding	  glycine	  (Sigma)	  to	  the	  medium	  to	  a	   final	  concentration	  of	  0.125	  M	  and	  incubating	  cells	  for	  10	  minutes	  at	  room	  temperature	  with	  gentle	  tumbling.	  The	   crosslinked	   cells	  were	   spun	   for	  7	  minutes	   at	   780	   g	   and	  4°C.	   Cells	  were	  washed	   twice	  with	  10	  ml	  of	   ice	   cold	  PBS.	  They	  were	   resuspended	   in	  1.5	  ml	  of	  swelling	  buffer/25x106	  cells	  	  (25	  mM	  Hepes	  pH	  7.9	  (Sigma),	  10	  mM	  KCl	  (Sigma),	  1.5	  mM	  MgCl2,	  0.1	  %	  Igepal	  CA-­‐630	  (Sigma))	  supplemented	  with	  Complete	  MINI,	  EDTA-­‐free	  protease	  inhibitors	  (Roche	  Diagnostics).	  The	  cells	  were	  incubated	  for	  10	  minutes	  on	  ice	  and	  then	  homogenized	  using	  a	  tight	  dounce	  homogeniser	  with	  50	  strokes.	  	  The	  nuclei	  were	  centrifuged	  at	  3,000	  g	  for	  5	  minutes	  at	  4°C	  and	  resuspended	  to	  a	  final	  concentration	  of	  2.5x107cells/ml	  in	  sonication	  buffer	  (50	  mM	  Hepes	  pH	  7.5,	   140	   mM	   NaCl	   (Sigma),	   0,1	   %	   sodium	   deoxycholate	   (Sigma),	   0.1	   %	   SDS	  (Sigma),	   1%	   Triton-­‐X	   100	   (Sigma),	   1	   mM	   EDTA	   (VWR))	   supplemented	   with	  Complete	  MINI-­‐EDTA	   free	   protease	   inhibitors	   (Roche	  Diagnostics).	   Aphidicolin	  treated	   cells	   and	   anti-­‐IgM+	   14	   hours	   LPS	   were	   resuspended	   to	   a	   final	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concentration	   of	   2x107cells/ml	   in	   sonication	   buffer.	   1	   ml	   of	   suspension	   was	  transferred	   to	  15	  ml	   falcon	   tubes	  containing	  a	  probe	   for	   sonication.	  The	   falcon	  tubes	  were	  placed	  in	  a	  carousel	  of	  a	  Bioruptor	  sonicator	  (Diagenode)	  connected	  to	  a	  water	  bath	  (Thermo	  Scientifics),	  which	  kept	  the	  temperature	  of	  the	  water	  in	  the	   sonicator	   basin	   constantly	   at	   4°C.	   The	   nuclei	  were	   sonicated	   at	   30-­‐second	  on/off	   intervals	   for	   1.5	   hours	   at	   high	   intensity	   to	   obtain	   a	   fragment	   size	   of	  approximately	  500-­‐3,000	  bp.	  	  The	  sonicated	  material	  was	  centrifuged	  at	  10,000	  g	   for	  10	  minutes	  at	  4°C	  to	  remove	  the	   insoluble	  material.	  The	  purified	  chromatin	  was	  quantified	  after	  a	  5	  minute	   alkaline	   lysis	   (1:10	   dilution	   of	   chromatin	   in	   0.1	   M	   NaOH	   (Sigma))	   by	  measuring	   the	   DNA	   concentration	   using	   a	   ND-­‐1000	   spectrophotometer	  (Nanodrop).	  A	  5	  µg	  aliquot	  of	  chromatin	  was	  saved	  as	  input	  material.	  	  
2.8.2 Immunoprecipitation	  Antibodies	   were	   pre-­‐bound	   to	   paramagnetic	   Protein	   G	   Dynabeads	  (Invitrogen).	  For	  the	  immunoprecipitation	  (IP),	  5	  µg	  of	  antibody	  was	  incubated	  with	   15	   μl	   of	  magnetic	   beads	   at	   4°C	   for	   4	   hours	   at	   8	   rpm	   rotation.	   The	   beads	  were	   then	  washed	  with	   200	   μl	   of	   sonication	   buffer	   by	   incubating	   at	   4°C	   for	   7	  minutes	  at	  8	  rpm	  rotation.	  For	  each	  ChIP	  assay,	  100	  µg	  of	  chromatin	  were	  added	  to	  the	  antibody-­‐bound	  beads.	   The	   samples	  were	   incubated	  overnight	   at	   4°C	  with	  8	   rpm	   rotation.	   The	  beads	   were	   sequentially	   washed	  with	   200	   μl	   of	   each	   of	   the	   following	   buffers:	  sonication	   buffer,	   high	   salt	   buffer	   (50	  mM	  Hepes	   pH	   7.5,	   500	  mM	  NaCl,	   0.1%	  sodium	  deoxycholate,	  0.1%	  SDS,	  1%	  Triton-­‐X	  100,	  1	  mM	  EDTA),	  LiCl	  buffer	  (20	  mM	  Tris	   pH	   8	   (Sigma),	   250	  mM	  LiCl	   (VWR),	   0.5%	   sodium	  deoxycholate,	   0.5%	  Igepal	   CA-­‐630	   (Sigma),	   1	   mM	   EDTA)	   and	   TE	   buffer	   (10	   mM	   Tris	   pH	   8,	   1mM	  EDTA).	  To	   elute	   the	   chromatin	   from	   the	   beads	   and	   reverse	   the	   formaldehyde	  crosslinking,	  the	  beads	  and	  the	  input	  DNA	  were	  resuspended	  in	  150	  μl	  of	  elution	  buffer	  (50	  mM	  Tris	  pH	  8,	  50	  mM	  NaCl,	  1%	  SDS,	  1	  mM	  EDTA,	  20	  µg/ml	  DNase-­‐free	  RNase	  (Roche	  Diagnostics))	  and	  incubated	  at	  68°C	  for	  6	  hours	  at	  1,400	  rpm	  on	  a	  thermoshaker.	  	  	  The	  supernatant	  was	  collected	  and	  the	  beads	  were	  further	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eluted	   for	  1	  hour	  with	  150	  μl	  of	  elution	  buffer	  at	  68°C	  at	  1,400	  rpm.	  For	   input	  samples,	   a	   final	   volume	   of	   200	   μl	   of	   elution	   was	   added	   to	   5	   µg	   of	   input	   and	  crosslink	  reversal	  was	  carried	  out	  for	  a	  total	  of	  7	  hours.	  The	  resulting	  mixture	  of	  DNA	  and	  proteins	  was	  incubated	  at	  42°C	  overnight	  at	  300	  rpm	  in	  the	  presence	  of	  200	  µg/ml	  proteinase	  K	  (Sigma)	  to	  cleave	  proteins.	  The	   DNA	   was	   further	   purified	   using	   QIAQuick	   PCR	   purification	   kit	   (Qiagen),	  according	   to	   manufacturer’s	   instructions.	   The	   DNA	   from	   IP	   experiments	   and	  input	  was	  eluted	  in	  100	  μl	  of	  AnalaR	  grade	  water	  (VWR).	  	  
2.8.3 Quantitative	  real-­time	  PCR	  	  Quantitative	   real-­‐time	   PCR	   (qRT-­‐PCR)	   were	   performed	   to	   determine	   the	  binding	   levels	   of	   each	   factor	   using	   the	   same	   volume	   (2	   μl)	   for	   the	  immunoprecipitated	   and	   input	   samples	   per	   reaction.	   The	   enrichment	   of	   the	  amplified	  sequence	  was	  reported	  as	  the	  percentage	  of	  the	  input	  that	  was	  pulled	  down	  by	  the	  specific	  antibody	  and	  calculated	  by	  the	  equation:	  	  	  %	  of	  INPUT=	  ((2	  –average	  CT	  IP	  /	  2	  –	  average	  CT	  input	  )X100)/input	  dilution	  factor	  	  The	  input	  dilution	  factor	  is	  the	  ratio	  between	  the	  amount	  of	  chromatin	  used	  for	  the	   IP	   and	   the	   volume	   input	   chromatin.	   qRT-­‐PCR	   was	   performed	   either	   on	  Chromo	  4	  (Biorad)	  or	  DNA	  Engine	  Opticon	  system	  (MJ	  research)	  following	  these	  conditions:	   initial	  denaturation	  at	  95°C	  for	  10	  minutes	  followed	  by	  37	  cycles	  at	  95°C	  for	  15	  seconds,	  annealing	  at	  60°C	  for	  15	  seconds,	  extension	  at	  72°C	  for	  15	  seconds	   and	   final	   extension	   at	   72°C	   for	   5	   minutes.	   The	   threshold	   for	   every	  experiment	  was	  set	  to	  meet	  a	  point	  at	  which	  the	  amplification	  was	  linear.	  For	   every	   primer	   pair,	   the	   Ct	   values	   for	   the	   IP	   DNA	   and	   the	   input	   were	  generated	   in	   duplicate	   PCRs	   (technical	   duplicates).	   For	   each	   primer	   pair,	   each	  well	  on	  qRT-­‐PCR	  plates	  (Biorad)	  was	  loaded	  with	  2	  μl	  of	  DNA	  and	  23	  μl	  of	  primer	  mix	  (10.3	  μl	  of	  water,	  0.1	  μl	  of	  100	  µM	  forward	  primer,	  0.1	  μl	  f	  100	  µM	  reverse	  primer,	  12.5	  μl	  of	  SYBR	  Green	  JumpStart	  Taq	  Ready	  Mix	  (Sigma)).	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2.9 ChIP-­sequencing	  (ChIP-­seq)	  
2.9.1 Preparation	  of	  libraries	  ChIP-­‐seq	   libraries	   were	   prepared	   from	   10	   ng	   of	   DNA	   that	   was	  immunoprecipitated	  using	  the	  ChIP	  protocol	  described	  in	  section	  2.8.2.	  The	  DNA	  was	  first	  tested	  by	  qRT-­‐PCR	  and	  then	  used	  to	  prepare	  libraries	  using	  the	  Library	  Prep	   Master	   Mix	   Set	   for	   Illumina	   (NEB)	   with	   minor	   variations	   on	   the	  manufacturer’s	  protocol.	  The	  quantity	  of	  DNA	  adaptors	  was	  a	  1:60	  dilution	  of	  the	  recommended	  amount,	   to	   reduce	   the	  amount	  of	  unligated	  adaptors	   that	  would	  compete	   with	   and	   reduce	   the	   sequenced	   specific	   DNA	   fragments.	   Short	  fragments	   (such	   as	   those	   generated	   by	   unligated	   fragments)	   tend	   to	   be	  sequenced	  more	  than	  long	  ones.	  To	  sequence	  more	  than	  one	  library	  per	  lane	  in	  the	  Illumina	  HiSeq2000	  (Illumina),	  DNA	  Illumina	  adapters	  and	  indexes	  from	  the	  Multiplexing	   Sample	   Preparation	   Oligonucleotide	   Kit	   (Illumina)	   were	   used	   to	  allow	  sample	  multiplexing.	  Following	   PCR	   enrichment	   of	   adaptor	   ligated	   DNA	   fragments,	   the	   libraries	  were	  resolved	  on	  a	  2%	  agarose	  gel	  to	  get	  rid	  of	  primer	  dimers	  and	  gel	  purified	  with	  Qiaquick	  Gel	  extraction	  kit	  (Qiagen)	  according	  to	  manufacturer’s	  guidelines.	  The	   purified	   libraries	  were	   analysed	   on	   the	   Bioanalyser	   (Agilent)	  with	   a	   High	  Sensitivity	  DNA	  kit	  (Agilent)	  for	  the	  determination	  of	  the	  average	  fragment	  size	  and	   to	   assess	   the	   integrity	   of	   the	   library.	   ChIP-­‐seq	   libraries	  were	   given	   to	   the	  analyzed	   on	   an	   Illumina	  HiSeq2000	   sequencer	   by	   the	   Genomics	   Laboratory	   at	  the	  MRC	  CSC.	   Libraries	  were	   always	   subjected	   to	   single	   ended	   sequencing	   and	  the	  output	  size	  was	  50	  bp.	  Dr.	  Gopuraja	  Dharmalingam	  and	  Dr.	  Thomas	  Carroll	  from	  the	  CSC	  Core	  Bioinformatic	  Facility	  provided	  post-­‐sequencing	  bioinformatic	  analysis	  of	  all	  the	  output	  files.	  	  
2.9.2 Data	  analysis	  and	  peak	  calling	  The	   data	   analysis	   was	   carried	   out	   in	   collaboration	   with	   Dr.	   Gopuraja	  Dharmalingam	   and	   Dr.	   Thomas	   Carroll.	   The	   overall	   quality	   of	   the	   sequencing	  reads	   including	   per	   base	   quality	   distribution,	   duplicate	   level,	   GC	   content	   and	  adapter	  contamination	  were	  assessed	  by	   fastqc	  version	  0.10.0.	  The	  reads	  were	  aligned	  to	  Mouse	  genome	  mm9	  using	  Bowtie	  version	  0.12.8	  using	  “-­‐S	  –n	  2	  –I	  25	  –
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m	  1’	  parameters.	  Only	  reads	  aligned	  uniquely	  to	  the	  genome	  were	  considered	  for	  further	  analysis.	  The	  SAM	  files	  generated	  by	  Bowtie	  were	  converted	  to	  BAM	  files	  using	   Samtools	   version	   0.1.18,	   sorted	   according	   to	   chromosomal	   co-­‐ordinates	  and	  orientation	  (duplicates)	  were	  filtered	  using	  Picard	  version	  1.65.	  To	  visualize	  the	   genomic	   coverage	   of	   samples	   in	   UCSC	   genome	   browser,	   the	   reads	   were	  extended	   to	   estimate	   fragment	   size	   and	   converted	   to	   BigWig	   format.	   The	  fragment	   size	   was	   computationally	   estimated	   using	   SISSR	   method	   for	   each	  sample	  (Jothi	  et	  al.,	  2008)	  and	  the	  reads	  were	  extended	  using	  R	  script.	  Coverage	  for	  each	  base	  was	  computed	  using	  the	  extended	  the	  reads	  visualised	  using	  UCSC	  server.	   ChIP-­‐seq	   experiments	   from	   resting	   B,	   20	   hours	   anti-­‐IgM	   and	   20	   hours	  anti-­‐IgM	  +	  6	  hours	  LPS	  were	  done	  in	  biological	  duplicate.	  The	  tracks	  generated	  from	   the	   duplicates	   were	   pooled	   together.	   	   ChIP-­‐seq	   experiments	   from	   30	  minutes,	  4	  hours	  and	  6	  hours	  aphidicolin	  released	  cell	  were	  performed	  once.	  Peaks	  were	   identified	  using	  MACS2	  (https://github.com/taoliu/MACS/)	  with	  parameters	  "callpeak	  -­‐-­‐broad	  -­‐-­‐qvalue	  0.05"	  and	  peaks	  with	  fold	  enrichment	  less	  than	  20	  were	  excluded	  from	  the	  analysis	  (Zhang	  et	  al.,	  2008).	  Peaks	  were	  filtered	  for	  mm9	  blacklists	  and	  annotated	  to	  genic	  regions	  and	  distance	  to	  nearest	  TSSs	  using	  Chipseeker	  Bioconductor	  package.	  	  
2.9.3 Density	  plot	  generation	  	  To	   visualize	   the	   ChIP-­‐seq	   enrichment	   for	   each	   factor/modification	   around	  TSS,	  we	  divided	  TSS	  +/-­‐	  1kb	  region	   in	  to	  50	  base	  bins	  (total	  40	  bins).	  Gene	  co-­‐ordinates	  were	  retrieved	  from	  Ensembl	  version67	  using	  ‘biomRT’	  bioconductor	  package.	   The	   genes	   were	   ordered	   by	   Cnot3	   binding	   strength.	   The	   number	   of	  reads	   overlapping	   with	   each	   bin	   was	   counted	   and	   Reads	   per	   Million	   per	   bin	  (RPM)	  was	  calculated.	  	  For	   the	  heatmaps	  generation,	   the	  area	  of	   the	  TSS	  +/-­‐	  3kb	  was	  divided	   in	  50	  base	  bins	  (120	  bins).	  Me	  V	  version	  4.8	  was	  used	  to	  generate	  the	  heatmap	  images	  and	  visualize	  the	  enrichment.	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2.9.4 Gene	  ontology	  analysis	  Gene	   ontology	   analysis	  was	   carried	   using	   peaks	   coordinates	   called	   in	   every	  cell	  cycle	  phase.	  The	  analysis	  was	  performed	  using	  a	  free	  software	  available	  on-­‐line	  and	  developed	  by	  the	  Bejerano	  lab	  (McLean	  et	  al.,	  2010).	  	  
2.10 Transcriptional	  Analysis	  	  
2.10.1 Spike-­in	  preparation	  The	   necessity	   of	   studying	   RNA	   levels	   during	   cells	   cycle	   requires	   having	   an	  accurate	  control	  to	  study	  gene	  expression	  variation.	  Due	  to	  the	  difficulty	  to	  find	  a	  housekeeping	   gene	   that	   does	   not	   change	   during	   the	   cell	   cycle,	  we	   generated	   a	  random	   DNA	   sequence	   that	   is	   not	   present	   in	   any	   genome.	   The	   sequence	   was	  created	   by	   using	   a	   free	   online	   software	  (http://www.bioinformatics.org/sms2/random_dna.html).	  	  The	  sequence	  is	  the	  following:	  5’-­‐CACCATGGTACTCTGGGGTGATATCTTTCCGGCATTTTGGGCAATGACCGGAACAGATAGGCATTGTGGGACCGGACGCGAGGGCCATACATGGTGGTGCCGACATACCACCCGAGGCGCACCACGAGAATCATTTATTCTGTGTGTGGCATGTACGCTGACCATAAGGCGCCAGTGGTTAGAGCTTTCCTTTCGGCATT-­‐3’.	  	  The	   DNA	   was	   cloned	   into	   pCDNA	   3.2/V5/GW/D-­‐TOPO	   by	   PCR	   addition	   of	  restriction	  sites	  SmaI/NotI.	  	  The	  part	  of	   the	  plasmid	  containing	   the	  spike	  sequence	  and	   the	  T7	  promoter	  was	   then	   amplified	   by	   PCR.	   The	   PCR	   was	   performed	   using	   a	   Forward	  biotinylated	   primer	   in	   order	   to	   get	   a	   biotinylated	   linear	   DNA.	   The	   primer	  sequences	  used	  were	  the	  following:	  	  Fw	  5’-­‐BtnATGCGGTTTTGGCAGTACAT-­‐3’,	  Rv	  5’-­‐	   AAGGGCGAAAAACCGTCTAT-­‐3’.	   The	   DNA	  was	   biotinylated	   to	   allow	   it	   to	   be	  immobilized	   on	   streptavidin	   beads	   during	   the	   process	   of	   transcription	   of	   the	  spike	  RNA.	  This	  procedure	  was	  carried	  out	  to	  allow	  high	  purity	  recovery	  of	  the	  RNA	  after	  the	  in	  vitro	  transcription.	  	  DNA	   was	   purified	   using	   a	   PCR	   purification	   kit	   to	   remove	   the	   biotinylated	  primers.	  10	  µg	  of	  biotinilated	  DNA	  were	  incubated	  over	  night	  at	  25°C	  with	  40	  µl	  of	  Dynabeads®	  MyOne™	  Streptavidin	  T1	  (Invitrogen)	  in	  wash	  and	  binding	  buffer	  (10	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  EDTA,	  2	  M	  NaCl).	  The	  beads	  were	  then	  washed	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with	  the	  same	  buffer	  three	  times	  at	  25°C	  for	  10	  minutes	  at	  300	  rpm	  to	  remove	  the	  unbound	  DNA.	  The	  transcription	  reaction	  was	  carried	  out	  while	  the	  DNA	  was	  bound	   to	   the	   beads.	   The	   experiment	   was	   carried	   out	   using	   T7	   Polymerase	  (Promega)	   according	   to	   manufacturer’s	   instructions.	   100	   µl	   of	   transcription	  reaction	   mix	   Transcription	   optimized	   buffer,	   10	   mM	   DTT,	   0.5	   µM	   rNTP	   mix,	  Phage	  RNA	  Polymerase	  40	  units)	  were	  added	  to	  the	  DNA-­‐beads	  and	  incubated	  at	  300	  rpm	  for	  2	  hours	  at	  37°C.	  	  The	  supernatant	  containing	  the	  RNA	  was	  separated	  from	  the	  beads	  using	  a	  magnet.	  To	  ensure	  that	  there	  was	  no	  contaminating	  DNA	  in	   the	   supernatant,	   a	   DNase	   digestion	   was	   carried	   out	   using	   the	   RNeasy	   kit	  (Qiagen).	  The	  RNA	  was	  quantified	  on	  an	  ND-­‐1000	  spectrophotometer.	  	  	  
2.10.2 Isolation	  of	  nuclear	  RNA	  and	  preparation	  of	  cDNA	  	  Cells	  from	  different	  phases	  of	  the	  cell	  cycle	  were	  collected	  and	  counted.	  5x106	  cells	  were	  resuspended	  in	  500	  µl	  of	  buffer	  A	  (10	  mM	  Hepes	  pH	  7.9,	  10	  mM	  KCl,	  1.5	   mM	   MgCl2,	   0.5	   mM	   DTT,	   10%	   glycerol,	   0.2%	   Triton-­‐X	   100).	   Cells	   were	  incubated	  on	  ice	  for	  10	  minutes.	  Nuclei	  were	  centrifuged	  at	  4°C	  for	  15	  seconds	  at	  14,000	   rpm	   and	   the	   supernatant	  was	   discarded.	   The	   same	   volume	   of	   buffer	   A	  was	  added	  to	  the	  nuclei	  and	  they	  were	  spun	  at	  4°C	  for	  15	  seconds	  at	  14,000	  rpm.	  Nuclei	   were	   resuspended	   in	   1	   ml	   of	   Trizol	   and	   spike	   RNA	   was	   added	   to	   a	  concentration	   of	   0.1	   ng/million	   cells.	   The	   lysate	   was	   incubated	   at	   room	  temperature	  for	  5	  minutes.	  200	  µl	  of	  Chloroform	  were	  added	  to	  the	  samples	  and	  vortexed	   for	  10	  seconds.	  Samples	  were	   left	   for	  3	  minutes	  at	  room	  temperature	  and	   centrifuged	   at	   4°C	   for	   15	   minutes	   at	   15,000	   g.	   The	   aqueous	   phase	   was	  transferred	   to	  a	  new	   tube	  and	  500	  µl	  of	   isopropanol	  were	  added.	  The	  samples	  were	  incubated	  10	  minutes	  at	  room	  temperature	  and	  then	  centrifuged	  at	  4°C	  for	  10	  minutes	   at	  15,000	  g.	  The	  pellet	  was	  washed	  once	   in	  75%	  ethanol	   and	   then	  resuspended	  in	  30	  µl	  of	  DEPC-­‐treated	  water.	  	  The	   RNA	  was	   subjected	   to	   DNase	   digestion	   and	   RNA	   clean	   up	   by	   using	   the	  RNeasy	   kit	   according	   to	   manufacturer’s	   instructions.	   The	   RNA	   was	   then	  quantified	   with	   a	   ND-­‐1000	   spectrophotometer	   and	   used	   for	   reverse	  transcription	  with	   random	  Hexamers	   (Applied	   Biosystems)	   and	   SuperScript	   II	  (Invitrogen).	  The	  protocol	  was	  performed	  as	  follows:	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  The	   reverse	   transcription	   reaction	   was	   carried	   out	   as	   follows:	   10	   minutes	   at	  25°C,	  50	  minutes	  at	  42°C,	  10	  minutes	  at	  94°C.	  0.5	  µl	  of	  RNase	  H	  was	  added	  to	  the	  sample	  to	  digest	  the	  RNA	  in	  RNA-­‐DNA	  hybrids.	  Samples	  were	  then	  diluted	  1:20	  and	  1	  µl	  was	  used	  for	  each	  qRT-­‐PCR	  reaction.	  For	  each	  primer	  pair	  the	  Ct	  values	  were	  generated	  in	  duplicate,	  while	  in	  the	  No	  RT	  the	  Ct	  values	  were	  produced	  in	  single.	   The	   qRT-­‐PCR	  was	   carried	   out	   as	   described	   in	   Section	   2.8.3	  with	   except	  that	  the	  PCR	  was	  carried	  out	  for	  40	  cycles	  instead	  of	  37.	  	  
2.10.3 RNA	  quantification	  Specific	  primers	  were	  designed	   for	   the	   spike-­‐in	  RNA	  and	   they	  were	  used	   to	  detect	  the	  level	  of	  the	  spike-­‐in	  in	  every	  sample.	  To	  calculate	  the	  expression	  level	  of	  each	  gene	  relative	  to	  the	  spike-­‐in	  RNA,	  the	  following	  formula	  was	  used:	  	  RNA	  expression	  Gene	  X	  =	  2Ct(Spike-­‐in)-­‐Ct(X).	  	  
2.11 Cnot3	  conditional	  knockout	  mice	  
	  
2.11.1 TALEN	  design	  and	  construction	  TALEN	   genomic	   binding	   sites	   were	   chosen	   using	   the	   online	   software	  published	   by	   Cermak	   et	   al,	   2011.	   Input	   sequences	  were	   both	   introns	   1	   and	   7.	  From	  all	  possibilities,	  we	  chose	  TALEN	  pairs	  that	  cut	  200	  bp	  or	  further	  from	  the	  exon	   to	  avoid	   interference	  with	   transcription	  and	  splicing	  as	  much	  as	  possible.	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The	   protein	   sequences	   of	   the	   final	   TALENs	   used	   are	   as	   follows:	   (the	   repeat	  variable	  di-­‐residues	  (RVDs)	  are	  shown	  underlined).	  Intron	  1	  5’	  TALEN	  MASSPPKKKRKVSWKDASGWSRMHADPIRPRRPSPARELLPGPQPDRVQPTADRGVSAPAGSPLDGLPARRTVSRTRLPSPPAPSPAFSAGSFSDLLRPFDPSLLDTSLLDSMPAVGTPHTAAAPAEWDEAQSALRAADDPPPTVRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTGAPLNLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVADYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSRNGLVQLFRRVGVTELEARGGTLPPASQRWDRILQASGMKRAKPSPTSAQTPDQASLHAFADSLERDLDAPSPMHEGDQTRASSRKRSRSDRAVTGPSAQQAVEVRVPEQRDALHLPLSWRVKRPRTRIWGGLPDPISRSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF	  	  3’	  TALEN	  MASSPPKKKRKVSWKDASGWSRMHADPIRPRRPSPARELLPGPQPDRVQPTADRGVSAPAGSPLDGLPARRTVSRTRLPSPPAPSPAFSAGSFSDLLRPFDPSLLDTSLLDSMPAVGTPHTAAAPAEWDEAQSALRAADDPPPTVRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTGAPLNLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVADYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSRNGLVQLFRRVGVTELEARGGTLPPASQRWDRILQASGMKRAKPSPTSAQTPDQASLHAFADSLERDLDAPSPMHEGDQTRASSRKRSRSDRAVTGPSAQQAVEVRVPEQRDALHLPLSWRVKRPRTRIWGGLPDP
	   78	  
ISRSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF	  	  Intron	  7	  5’	  TALEN	  MASSPPKKKRKVSWKDASGWSRMHADPIRPRRPSPARELLPGPQPDRVQPTADRGVSAPAGSPLDGLPARRTVSRTRLPSPPAPSPAFSAGSFSDLLRPFDPSLLDTSLLDSMPAVGTPHTAAAPAEWDEAQSALRAADDPPPTVRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTGAPLNLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVADYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSRNGLVQLFRRVGVTELEARGGTLPPASQRWDRILQASGMKRAKPSPTSAQTPDQASLHAFADSLERDLDAPSPMHEGDQTRASSRKRSRSDRAVTGPSAQQAVEVRVPEQRDALHLPLSWRVKRPRTRIWGGLPDPISRSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF	  	  3’	  TALEN	  MASSPPKKKRKVSWKDASGWSRMHADPIRPRRPSPARELLPGPQPDRVQPTADRGVSAPAGSPLDGLPARRTVSRTRLPSPPAPSPAFSAGSFSDLLRPFDPSLLDTSLLDSMPAVGTPHTAAAPAEWDEAQSALRAADDPPPTVRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTGAPLNLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVADYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSRNGLVQLFRRVGVTELEARGGTLPPASQRWDRILQASGMKRAKPSPTSAQTPD
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QASLHAFADSLERDLDAPSPMHEGDQTRASSRKRSRSDRAVTGPSAQQAVEVRVPEQRDALHLPLSWRVKRPRTRIWGGLPDPISRSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF	  	   All	   TALEN	   plasmids	   were	   synthesized	   using	   the	   Golden	   Gate	   method	  developed	  by	  Cermak	  et	  al.	  2011	  (Addgene)	  following	  the	  protocol	  indicated	  by	  the	  authors.	  The	  final	  cloning	  step	  was	  done	  using	  the	  pTAL4	  vector	  that	  allows	  subclone	  of	  TALEN	  sequences	  into	  mammalian	  expression	  vectors.	  The	   targeting	   vectors	   comprised	   two	   homology	   regions	   of	   300	   bp	   flanking	  each	  LoxP	  sequence.	  GenScript	  synthesized	  both	  vectors.	  The	  sequences	  are	  the	  following:	  Intron	  1:	  5’-­‐	  ACTCATAAACCCTCTTAGGGTCTTCCTCTCCAGGATGCCCTGTTTCGGGGTCAACTTTTGTAGTGTGGATTTCCCTGCCAACCGACCTCCTCTCCTCAGTCCTTTGTCCTCAGGCCCTTCTGAATTAAACTCTGCTTCCTTCAGAATAAAAATAGGTGTCTTTGACCTCCCTGATGGGTTCATGTTTCTGAGTCTAAATTGCCAGTCTATCTGATGTGGAACTCCTCCATGTGTGCAGATCTGTTCACTCATAGCTAAGGTTCTTCTCTTTATCTTTTTGAGATTTCTATCTTCTCATCGATAACTTCGTATAGCATACATTATACGAAGTTATATTCTA	  CCCTCCTTGAGTGCTGCTTCCTGCTTCCAAGTTTCTATAGCCATTTTTAGTGTCGGGCTTCTGCTGTGGAATAAATTTCTCGAAAGTGTAAGACCCTCTTGTTTGATATCCTGCCTTGTCCTGTATGAATGGGCCTTGATCTTCATATCTCTCTTCCCCTTCAGCTCACACCTCTTAGCCTTTCCAGGAGCTGCCAGCCTCATGTATTCTGTGACTTACCTAGAGTGGCCTCTCTCAGTCACCTCTGCTCTCAGCCCCTCAGTTTAGAAAGTACCAT-­‐3’.	  	  Intron	  7:	  	  5’-­‐	  TGGGGGCACCATCACCCACAGGGTAAGGGTGGAGGTGGCCTGTGAACAGAGGGCATCTGGAGGCTCATAGGAGTCTGGTCCTGGATACACCTGGGGCAGAGATTGAAAAGGCAGAACAAGGCAGCTTAGCTGGCTGAGTTGTGGTATAGGGAGGAAGTGAGAGAGGATATTGGGATATTTGGGTAGACAGTGTAGCCATTGTTAGGGGCAGTTTGGGTGAAGATGGACTTAGGTTCAGCTGGCACCACATAGTGAGACCTGAAGAAAGGACCAAATTATAACTTCGTATAGCATACATTATACGAAGTTATGGGAAGATACACAGCACTCCAAAAATTCCCAGGATCTCAGGAGGGGGTTGGTATGTCTCTAAGAACCAGTTGCTGTTGGAAACCTGGAAATGGTTTGGGCCAAAGTCATATGATAGGGTCCCGAATCTTACACCTTTAGGATTGTAAGGGTGTGAGTTCAAAGGGATGTCGACTCTGTCTCGTTAATGGTGTCACCAGGGAAGGAAGTTCTGATGGGATGGAAAGAAAGAAAGATGTCACTGGGAGGGAAAAGAGTAGATCCTTGATAAAAGGAGGAATTTGGAGCTGGCACTAAGGCAT-­‐3’.	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2.11.2 TALEN	  mRNA	  and	  targeting	  vector	  preparation	  TALENs	  were	   subcloned	   into	   pCDNA3.1.	   The	   new	   plasmids	  were	   linearised	  and	   transcribed	   in	   vitro	   using	   the	   mMessage	   mMachine	   T7	   Ultra	   kit	   and	   the	  Megaclear	  kit	   (Life	  Technologies)	  according	   to	   the	  manufacturer’s	   instructions.	  The	  targeting	  vectors	  were	  linearised,	  precipitated	  and	  resuspended	  in	  injection	  buffer	  (10	  mM	  TrisHCl,	  0.1	  mM	  EDTA).	  The	  final	  injection	  mix	  consisted	  of	  the	  four	  TALEN	  mRNAs	  each	  one	  at	  a	  final	  concentration	  of	   5	  ng/μl	   and	  both	   targeting	   vectors	   at	   final	   concentration	  of	   2	  ng/μl	  each	  in	  injection	  buffer.	  	  
2.11.3 Microinjection	  into	  mouse	  oocytes	  All	  procedures	  for	  injection	  of	  the	  TALEN	  construcs	  into	  mouse	  oocytes	  were	  carried	   out	   by	   the	   MRC	   CSC	   Transgenic	   Facility.	   C57BL/6	   females	   were	  superovulated	   and	   mated	   with	   Rosa26-­‐ERT2Cre	   homozygous	   males.	   TALEN	  mRNA-­‐targeting	  vector	  mix	  described	  above	  was	  injected	  into	  pronuclei	  of	  0.5d-­‐post-­‐coitum	  oocytes.	  	  
2.11.4 Genotyping	  of	  mice	  Genomic	   DNA	  was	   obtained	   from	   ear	   notches.	   The	   tissue	   was	   incubated	   at	  95°C	   for	   10	   minutes	   in	   50	   μl	   of	   NaOH	   and	   spun	   for	   5	   min	   at	   16,000	   g.	  Supernatant	  was	  then	  mixed	  with	  50	  μl	  of	  0.5	  M	  TrisHCl	  pH	  8.0.	  1	  μl	  of	  the	  DNA	  solution	  was	   subjected	   to	   PCR	  with	   primers	   amplifying	   around	   both	   targeting	  sites	  in	  introns.	  	  Intron	  1	  (FW	  5’-­‐ATCTGTTCACTCATAGCTAAG-­‐3’,	  RV	  5’-­‐GAAGAGAGATATGAAGATCAAG-­‐3’).	  	  Intron	  7	  (FW	  5’-­‐GAGATTGAAAAGGCAGAACAAG-­‐3’	  and	  RV	  5’-­‐CAGAACTTCCTTCCCTGGTG-­‐3’).	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Table	  2.1:	  Antibodies	  
	  
Table	  2.2:	  Primers	  for	  ChIP	  (promoter	  region)	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Table	  2.4:	  Primers	  for	  mRNA	  analysis	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Chapter	  3 	  -­Interaction	  of	  Cnot3	  with	  the	  AuroraB	  kinase	  
during	  the	  B	  cell	  cycle	  	  
3.1 Introduction	  	  Our	   lab	   is	   interested	   in	   studying	   roles	   for	   the	   Aurora	   B	   kinase	   outside	   of	  mitosis.	  Aurora	  B	  is	  widely	  described	  as	  having	  its	  main	  function	  during	  mitosis	  and	  cytokinesis	  (Adams	  et	  al.,	  2001).	  However,	  emerging	  evidence	  has	  suggested	  involvement	   in	  other	   cellular	  processes	   such	  as	   cell	   cycle	  progression	   (Song	  et	  al.,	  2007)	  and	  gene	  regulation	  (Tardaguila	  et	  al.,	  2011).	  Recent	  results	  from	  the	  group	  showed	  that	  Aurora	  B	  is	  part	  of	  the	  transcriptional	  machinery	  controlling	  the	   program	   of	   quiescence	   in	   resting	   B	   cells	   (Frangini	   et	   al.,	   2013).	   Previous	  work	   in	   the	   lab	   identified	   interactors	  of	   the	  kinase	   in	  resting	  and	  elutriated	  G1	  LPS-­‐activated	   B	   cells	   by	   mass	   spectrometry.	   Among	   many	   proteins	   that	   were	  identified	  as	  potential	   interactors	   in	   the	  analysis,	  one	  of	   the	  strongest	  hits	  was	  subunit	  3	  of	  the	  CCR4-­‐NOT	  deadenylase	  complex	  	  (Cnot3).	  	  CNOT3	  was	  recently	  shown	  to	  be	  a	  tumor	  suppressor,	  which	  is	  mutated	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  (T-­‐ALL)	  (De	  Keersmaecker	  et	  al.,	  2013).	  It	  has	  also	   been	   shown	   to	   play	   a	   role	   in	  maintaining	   the	   self-­‐renewal	   program	   in	   ES	  cells	   by	   transcriptional	   activation	   of	   pluripotent	   genes	   (Hu	   et	   al.,	   2009).	  Preliminary	   data	   generated	   by	   Dr.	   Alberto	   Frangini	   revealed	   the	   presence	   of	  Cnot3	   on	   promoters	   of	   active	   genes	   in	   resting	   B	   cells,	   showing	   co-­‐localization	  with	  Aurora	  B	  at	  many	  genes.	  	  The	  aim	  of	  this	  PhD	  project	  was	  to	  investigate	  the	  interaction	  between	  Cnot3	  and	  Aurora	  B	  and	  the	  role	  of	  Cnot3	  in	  gene	  regulation	  and	  cell	  cycle	  progression.	  In	  order	  to	  achieve	  this	  goal,	   I	  have	  developed	  a	  B	  cell	  system	  that	  has	  made	  it	  possible	  to	  study	  population	  of	  cells	  enriched	  in	  different	  cell	  cycle	  phases.	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3.2 	  Characterization	  of	  a	  B	  cell	  system	  to	  study	  different	  phases	  
of	  the	  cell	  cycle	  	   To	   study	   the	   behaviour	   of	   Cnot3	   during	   the	   cell	   cycle,	   a	   B	   cell	   system	  was	  developed	   based	   on	   activation	   of	   resting	   B	   cells	   isolated	   from	   adult	   mouse	  spleen.	  Resting	  B	  cells	  are	  mature	  cells	  in	  a	  quiescent	  state	  that	  can	  re-­‐enter	  the	  cell	  cycle	  by	  stimulation	  of	  the	  B	  cell	  receptor	  on	  the	  cellular	  membrane.	   	  More	  than	   three	   decades	   ago,	   De	   Franco	   et	   al.	   showed	   that	   resting	   B	   cells	   can	   be	  partially	   activated	   and	   induced	   to	   enter	   the	   blast	   stage	   by	   incubation	   anti-­‐IgM	  antibody,	   which	   binds	   to	   the	   BCR.	   The	   cells	   become	   larger	   and	   production	   of	  RNA	   and	   proteins	   increases,	   although	   even	   24	   hours	   after	   activation,	   no	   cells	  entered	  S	  phase.	  Cells	  did,	  however,	  respond	  rapidly	  to	  mitogenic	  stimuli,	  such	  as	  LPS,	  to	  proceed	  through	  S	  phase	  (Defranco	  et	  al.,	  1982).	  	  	  We	  decided	  to	  use	  this	  method	  as	  a	  starting	  point	  for	  obtaining	  synchronised	  populations	  of	   cells	   in	  different	   cell	   cycle	  phases.	  Resting	  B	   cells	  were	   isolated	  from	   adult	   mouse	   spleen	   using	   a	   negative	   selection	   procedure.	   A	   cocktail	   of	  biotinylated	   antibodies	   (EasySep	   kit	   from	   STEMCELL	   technology),	   that	   bind	  receptors	   on	   different	   types	   of	   hematopoietic	   cells,	   was	   used	   to	   deplete	  unwanted	   cells	   from	   the	   splenocyte	   suspension	   leaving	  a	  high	  purity	   resting	  B	  cell	  population	  (see	  Material	  and	  Methods	  Section	  2.1	  for	  details).	  Staining	  with	  antibodies	  against	  a	  marker	  of	  mature	  B	  cells	  (B220)	  and	  a	  marker	  for	  activation	  (CD69)	  showed	  that	  the	  isolated	  cells	  were	  more	  then	  98%	  B220+	  and	  less	  than	  0.2%	  CD69+	  (Figure	  3.1).	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Purified	  resting	  B	  cells	  were	  incubated	  with	  anti-­‐IgM	  antibody,	  which	  binds	  to	  the	   BCR,	   activating	   it	   and	   causing	   cell	   size	   to	   increase.	   In	   corroboration	   of	   De	  Franco’s	   work	   I	   did	   not	   observe	   a	   significant	   number	   of	   cells	   in	   S	   phase,	  confirming	  that	  the	  antibody	  binding	  to	  the	  BCR	  for	  20	  hours	  causes	  entry	  into	  the	  blast	  stage,	  but	  not	  full	  activation	  (Figure.	  3.2).	  When	  the	  anti-­‐IgM	  activated	  cells	  were	  left	  in	  culture	  for	  48	  hours,	  a	  small	  percentage	  (around	  30%	  of	  cells),	  were	   present	   in	   S	   or	   G2/M	   (data	   not	   shown).	   Therefore,	   all	   incubations	   with	  anti-­‐IgM	  were	  carried	  out	  for	  20	  hours.	  
Figure	  3.2:	  Activation	  of	  resting	  B	  cells	  by	  treatment	  with	  anti-­IgM	  antibody.	  	  FACS	  analysis	  of	  propidium	  iodide	  stained	  resting	  and	  anti-­‐IgM	  treated	  B	  cells.	  The	  left	   panels	   show	   the	  DNA	   content,	  with	   percentages	   relative	   to	   the	   proportion	   of	  cells	  in	  each	  cell	  cycle	  phase.	  The	  right	  panels	  show	  the	  distribution	  of	  cell	  size	  for	  resting	  and	  anti-­‐IgM	  treated	  B	  cells.	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However,	   this	   approach	   did	   not	   yield	   a	   population	   of	   cells	   that	   were	   fully	  synchronised	  in	  S	  phase	  (data	  not	  shown).	  To	  further	  enhance	  the	  synchronization	  of	  the	  cells,	  we	  adopted	  a	  strategy	  of	  blocking	   the	   cells	   at	   the	   beginning	   of	   S-­‐phase	   using	   the	   reversible	   DNA	  polymerase-­‐α	   and	   -­‐δ	   inhibitor	  aphidicolin.	  This	   compound	  acts	   as	   a	  nucleotide	  competitor	  for	  the	  active	  site	  of	  DNA	  polymerase	  and	  can	  be	  used	  to	  block	  cells	  at	   the	   onset	   of	   DNA	   replication	   (Krokan	   et	   al.,	   1981).	   To	   establish	   the	   most	  appropriate	   time	   point	   for	   applying	   aphidicolin,	   the	   timing	   of	   DNA	   replication	  after	  LPS	  addition	  to	  anti-­‐IgM	  treated	  cells	  was	  determined.	  To	  achieve	  this,	  an	  EdU	   incorporation	   time	   course	   was	   performed	   to	   precisely	   detect	   when	   cells	  begin	   to	   incorporate	   the	   nucleotide	   analogue	   following	   activation	   with	   LPS.	  Samples	  were	  analysed	  4,	  6	  or	  8	  hours	  after	  addition	  of	  LPS	  to	  anti-­‐IgM	  treated	  cells.	  FACs	  analysis	  showed	  that	  around	  5%	  of	  the	  cells	  were	  in	  S-­‐phase	  at	  the	  6	  hours	   time	   point,	   suggesting	   that	   cells	   were	   starting	   to	   enter	   S	   phase	   (Figure	  3.3).	   Hence,	   the	   decision	   was	   taken	   that	   aphidicolin	   should	   be	   added	   after	   6	  hours	  incubation	  with	  LPS.	  	  
	  
Figure	  3.3:	  LPS	  response	  of	  anti-­IgM	  treated	  cells.	  FACS	  profile	  of	  EdU	  incorporation	  assay	  performed	  in	  resting	  and	  anti-­‐IgM	  treated	  B	  cells	  at	  different	  time	  points	  after	  LPS	  addition.	  The	  green	  profile	  represents	  cells	  that	   were	   incubated	   for	   30	   minutes	   with	   EdU	   before	   harvesting,	   while	   the	   red	  profile	  shows	  the	  cells	  that	  have	  not	  been	  incubated	  with	  EdU.	  The	  value	  in	  the	  top	  right	  quadrangle	  of	  each	  FACS	  plot	  represents	  the	  percentage	  of	  EdU	  that	  has	  been	  incorporated.	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The	  cells	  were	  incubated	  with	  aphidicolin	  for	  16	  hours	  and	  the	  inhibitor	  was	  washed	  out	  and	  the	  cells	  were	  cultured	   in	   fresh	  medium.	  The	  cell	  viability	  was	  measured	  after	  the	  treatment	  with	  the	  aphidicolin	  by	  trypan	  blue	  exclusion.	  The	  treatment	  with	  the	  DNA	  polymerase	  inhibitor	  caused	  around	  40%	  of	  cell	  death.	  The	   cells	   were	   analysed	   by	   PI	   staining	   and	   FACS	   analysis	   immediately	   after	  release	  from	  the	  aphidicolin	  block	  and	  at	  different	  time	  points	  following	  release.	  Entry	   into	   S	   phase	  was	   observed	   to	   occur	   in	   a	   synchronous	  manner.	   After	   30	  minutes	  a	  shift	  was	  detected	  from	  G1	  to	  a	  DNA	  content	  that	  is	  characteristic	  of	  S-­‐phase,	   indicating	   that	   these	   cells	   were	   at	   the	   early	   stage	   of	   the	   replication	  process.	   The	   population	   of	   cells	   was	   enriched	   in	   S	   phase	   two	   hours	   from	   the	  wash-­‐out	   of	   the	   aphidicolin.	   At	   this	   point	   around	   80%	   of	   cells	   were	   in	   the	  replication	  phase	  of	  the	  cell	  cycle	  (Figure.	  3.4A).	  This	  observation	  was	  confirmed	  by	  EdU	  incorporation,	  which	  gave	  very	  similar	  results	  for	  the	  percentage	  of	  cells	  in	  S	  phase	  (Figure	  3.4B).	  
Figure	  3.4:	  Synchronization	  of	  B	  cells	  in	  S	  phase.	  
	  A)	   FACS	   profile	   of	   propidium	   iodide	   staining	   of	   aphidicolin-­‐blocked	   cells	   30	  minutes,	   1	   hour	   and	   2	   hours	   after	   wash-­‐out	   of	   out	   the	   inhibitor.	   The	   numbers	  indicate	  the	  percentage	  of	  cells	  present	  in	  each	  cell	  cycle	  phase.	  B)	  FACS	  profile	  of	  EdU	   incorporation	   2	   hours	   after	   the	   aphidicolin	  wash-­‐out.	   The	   gate	   has	   been	   set	  using	  the	  resting	  B	  cell	  profile.	  	   In	  order	   to	  obtain	  a	  population	  of	   cells	  enriched	   in	  G2	  and	  mitosis,	   the	  cells	  were	   released	   for	   4	   hours	   after	   the	   aphidicolin	   blocking.	   Visualisation	   by	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confocal	  microscopy	  revealed	  an	  absence	  of	  mitotic	  cells,	  indicating	  that	  the	  cells	  were	   still	   in	   G2.	   After	   6	   hours,	   the	   cells	   were	   starting	   to	   divide,	   as	   shown	   in	  Figure	   3.5	   where	   characteristic	   metaphase	   plates	   can	   be	   clearly	   identified	  (Figure	  3.5).	  	  
	  
Figure	  3.5:	  Populations	  of	  cells	  enriched	  in	  G2	  and	  M	  phases.	  A)	   FACS	   profile	   of	   propidium	   iodide	   staining	   showing	   the	   DNA	   content	   of	   cells	  collected	   4	   hours	   after	   aphidicolin	   release	   (G2)	   and	   after	   6	   hours	   (G2/M).	   The	  percentage	  of	  cells	  present	  in	  each	  cell	  cycle	  phase	  is	  shown.	  B)	  DAPI	  staining	  of	  the	  same	  population	  of	  cells	  to	  show	  the	  difference	  between	  G2	  and	  G2/M	  populations.	  	  	  
3.3 	  Characterisation	   of	   the	   interaction	   between	   Cnot3	   and	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antibodies	   were	   used	   to	   immunoprecipitate	   the	   two	   proteins	   from	   the	   nuclear	  soluble	   and	   chromatin	   bound	   fractions	   of	   resting	   B	   nuclear	   protein	   extract.	  Western	  blot	   analysis	  was	   then	  used	   to	  probe	   for	   the	  presence	  of	  Aurora	  B	  and	  Cnot3	  in	  the	  immunoprecipitated	  material.	  IP	  using	  an	  anti-­‐IgG	  antibody	  was	  used	  as	   a	   negative	   control	   to	   guard	   against	   spurious	   IPs	   resulting	   from	   general	  stickiness	  or	  non-­‐specific	  binding.	  A	  strong	  band	  for	  Cnot3	  was	  observed	  for	  the	  Aurora	   B	   IP,	   confirming	   the	   interaction	   between	   the	   proteins	   (Figure	   3.6).	   The	  Cnot3	  IP	  gave	  a	  relatively	  weak	  IP	  of	  Aurora	  B,	  this	  may	  be	  due	  to	  the	  difference	  in	  abundance	   of	   the	   two	   proteins	   or	   to	   differences	   between	   the	   efficiency	   of	  pulldown	  by	  different	  antibodies.	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Figure	   3.7:	   Interaction	   between	   Aurora	   B	   and	   Cnot3	   during	   cell	   cycle	  
progression	  in	  primary	  B	  cells	  Anti-­‐Aurora	   B	   and	   anti-­‐IgG	   antibodies	   were	   pre-­‐bound	   to	   magnetic	   beads	   and	  incubated	  with	  nuclear	  protein	  extracts	  from	  different	  cell	  cycle	  phases:	  anti-­‐IgM	  20	  hours	  (A),	  anti-­‐IgM+LPS	  6	  hours	  (B),	  aphidicolin	  blocked	  cells,	  30	  minutes	  and	  one	  hour	  after	  release	  (C),	  4	  and	  6	  hours	  after	  release	  (D).	  5%	  of	  the	  extract	  used	  for	  the	  IP	  was	  analysed	  as	  INPUT.	  	  
	  
3.4 In	   vitro	   analysis	   of	   the	   interaction	   between	   Cnot3	   and	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structure	   of	   Cnot3	   was	   not	   available,	   so	   the	   production	   of	   Cnot3	   truncated	  proteins	   was	   based	   on	   structure	   prediction.	   At	   the	   end	   of	   2013	   a	   crystal	  structure	  for	  human	  CNOT3	  was	  published	  (Boland	  et	  al.,	  2013).	  	  Human	  CNOT3	  and	   mouse	   Cnot3	   proteins	   share	   95%	   of	   the	   sequence	   identity,	   with	   some	  differences	   present	   in	   the	   middle	   linker	   region.	   The	   N-­‐terminus	   and	   the	   C-­‐terminus	   are	   conserved,	   so	   we	   were	   able	   to	   use	   the	   crystal	   structure	   of	   the	  human	   CNOT3	   protein	   to	   validate	   our	   mapping.	   The	   N	   terminus	   of	   Cnot3	  consists	  of	  a	  coiled	  coil	  domain,	  while	  the	  C-­‐terminus	  of	  the	  protein	  is	  called	  the	  NOT	   box	   domain	   and	   also	   includes	   the	   NOT1	   anchor	   region	   (NAR)	   and	   the	  connector	  sequence	  (CS)	  (Figure	  3.8).	  
	  
Figure	   3.8:	   Schematic	   representation	   of	   the	   domain	   structure	   of	   wild-­type	  
human	  CNOT3	  and	   the	  deletions	  of	  mouse	  Cnot3	  used	   in	   the	  GST	  pull	  down	  
assays.	  
A)	   Domains	   of	   human	   CNOT3,	  which	   is	   characterized	   by	   a	   coiled	   coil	   N-­‐terminal	  domain,	  a	  central	   linker	  region	  and	  a	  C-­‐terminal	  region	  that	   includes	  the	  NOT	  box	  domain,	  a	  Not1	  anchor	  region	  (NAR)	  and	  a	  connector	  sequence	  (CS)	  	  (Adapted	  from	  (Boland	  et	  al.,	  2013)).	  	  
B)	  Deletions	  of	  mouse	  Cnot3	  that	  were	  used	  for	  the	  GST	  pulldowns.	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The	  results	  of	  the	  analysis	  (Figure	  3.9)	  show	  that	  in	  vitro	  translated	  full	  length	  Cnot3	   interacts	   directly	   with	   Aurora	   B.	   Of	   the	   three	   truncated	   Cnot3	   proteins	  that	  were	   analysed,	   neither	   the	  N-­‐terminal	   deletion	   of	   200	   amino	   acids	   or	   the	  
Δ701-­‐751	  C-­‐terminal	  deletion	  seem	  to	  have	  a	  significant	  effect	  on	  the	  binding	  of	  Cnot3	  to	  Aurora	  B.	  Notably,	  the	  interaction	  was	  completely	  abolished	  when	  the	  NOT	  box	  was	  absent,	  indicating	  that	  the	  NOT	  box	  region	  of	  Cnot3	  extending	  from	  651	  to	  701	  is	  required	  for	  the	  interaction	  with	  Aurora	  B.	  	  
	  	  
Figure	  3.9:	  Mapping	  of	  Cnot3-­Aurora	  B	  interaction.	  GST	   pull-­‐down	   using	   a	   purified	   bacterial	   expressed	   GST	   tagged	   Aurora	   B	   and	   in	  
vitro	  translated	  Cnot3	  proteins.	  GST	  Aurora	  B	  was	  pre-­‐bound	  to	  GST	  agarose	  beads	  and	   then	   incubated	  with	   in	   vitro	   translated	   Cnot3,	   which	  was	   previously	   labeled	  with	   S35	   methionine.	   A)	   Autoradiography	   of	   gel	   samples.	   GST	   Aurora	   B	   was	  incubated	   with	   in	   vitro	   translated	   proteins:	   Cnot3	   full	   length,	   Cnot3Δ	   701-­‐751,	  Cnot3Δ	  651-­‐751,	  Cnot3	  Δ	  1-­‐200.	  B)	  Coomassie	  staining	  of	  the	  gel	  in	  the	  experiment	  in	  A	  to	  show	  the	  loading	  of	  the	  GST	  Aurora	  B.	  	  
3.5 Summary	  	   In	  this	  chapter	  I	  have	  described	  a	  B	  cell	  system	  that	  makes	  it	  possible	  to	  study	  populations	  of	  primary	  B	  cells	  that	  are	  enriched	  in	  different	  cell	  cycle	  phases.	   	  I	  have	  used	  this	  system	  first	  to	  confirm	  the	  interaction	  previously	  revealed	  in	  our	  lab	   between	   Aurora	   B	   and	   Cnot3	   in	   resting	   B	   cells,	   and	   then	   to	   extend	   the	  analysis	   to	  different	  phases	  of	   the	  cell	  cycle.	  The	   interaction	  between	  Aurora	  B	  and	   Cnot3	   is	   dynamic	   and	   varies	   during	   cell	   cycle	   progression.	   Furthermore,	   I	  have	  demonstrated	  that	  the	  two	  proteins	  interact	  directly	  and	  I	  have	  mapped	  the	  region	   responsible	   for	   this	   to	   residues	   651-­‐701	   of	   the	   NOT	   box	   of	   the	   Cnot3	  protein.
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Chapter	  4 -­	  Analysis	  of	  Cnot3	  interactors	  in	  early	  G1	  and	  
G2	  
	  
4.1 Introduction	  In	   order	   to	   analyse	   the	   role	   of	   Cnot3	   during	   cell	   cycle	   in	   B	   cells,	   a	   co-­‐immunoprecipitation	   analysis	   was	   carried	   out	   using	   anti-­‐Cnot3	   antibodies	   to	  identify	  Cnot3	  interactors.	  The	  Cnot3	  IP	  was	  followed	  by	  mass	  spectometry	  (MS)	  analysis.	   The	   analysis	   was	   performed	   on	   early	   G1	   and	   G2	   cells	   to	   identify	  proteins	  that	  interact	  with	  Cnot3	  in	  these	  phases	  of	  the	  cell	  cycle.	  Data	  that	  was	  described	  in	  Chapter	  3	  indicated	  a	  difference	  in	  the	  interaction	  of	   Cnot3	   with	   Aurora	   B	   between	   early	   G1	   and	   G2.	   These	   results	   raised	   the	  possibility	  that	  Cnot3	  interacting	  proteins	  might	  be	  different	  between	  these	  two	  phases	  and	  suggest	  that	  Cnot3	  could	  be	  part	  of	  different	  complexes	  at	  different	  cell	  cycle	  stages.	  	  	  	  
4.2 Mass	  spectrometry	  analysis	  of	  Cnot3	  interactors	  The	  Cnot3	   IP	  was	  performed	  on	  a	  nuclear	  protein	  extract,	   including	  nuclear	  soluble	  and	  insoluble	  fractions.	  To	  maximise	  pulldown,	  a	  mix	  of	  two	  antibodies	  that	   recognise	  different	  part	   of	   the	  protein	  was	  used.	   IP	  done	  with	   an	  anti-­‐IgG	  antibody	   was	   used	   as	   a	   negative	   control.	   The	   recovered	   proteins	   were	   then	  separated	   on	   a	   polyacrylamide	   gel	   and	   analysed	   by	   MS.	   The	   total	   number	   of	  proteins	   that	  were	   co-­‐IPd	   in	   either	   or	   both	   samples	  was	   approximately	   1,500.	  After	  quality	  control	  analysis,	  a	  total	  of	  591	  proteins	  was	  obtained	  that	  gave	  high	  confidence	  of	  recognition	  and	  were	  not	  present	  in	  the	  anti-­‐IgG	  sample	  (see	  2.7.6	  for	  details	  of	  quality	  control).	  An	  initial	  gene	  ontology	  analysis	  was	  carried	  out	  all	  of	  the	  proteins	  that	  were	  co-­‐IPd	  in	  early	  G1	  and	  G2.	  Figure	  4.1	  shows	  a	  chart	  of	  the	  classes	  of	  proteins	   that	   interact	  with	  Cnot3	   in	   the	   two	  stages.	   	  The	  class	  of	  proteins	  with	  the	  highest	  significance	  is	  RNA	  processing,	  but	  proteins	  involved	  in	  RNA	  metabolism	  and	  maturation	  also	  show	  low	  p-­‐values.	  A	  good	  p-­‐value	  score	  was	   also	   obtained	   for	   mRNA	   processing	   and	   splicing	   proteins.	   The	   analysis	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shows	  that	  Cnot3	  interacts	  with	  many	  splicing	  factors	  and	  RNA	  helicases	  that	  are	  involved	   in	   the	   mRNA	   production	   process.	   Proteins	   with	   functions	   related	   to	  RNA	   termination,	   turnover	   and	   export	   were	   also	   detected.	   From	   the	   global	  analysis	   of	   Cnot3	   interactors	   in	   early	   G1	   and	   G2,	   it	   appears	   that	   the	   largest	  category	   of	   Cnot3	   interactions	   are	  with	   proteins	   that	   are	   involved	   in	  multiple	  aspects	  of	  RNA	  metabolism.	  
	  
Figure	   4.1:	   Gene	   ontology	   analysis	   of	   Cnot3	   interactors	   in	   early	   G1	   and	   G2	  
cells.	  The	   GO	   analysis	   was	   carried	   out	   on	   591	   proteins	   identified	   by	   the	   MS	   analysis.	  Proteins	   that	   were	   included	   in	   the	   analysis	   were	   co-­‐IPd	   by	   the	   anti-­‐Cnot3	  antibodies	  either	  in	  early	  G1	  or	  in	  G2	  or	  in	  both	  stages.	  The	  list	  of	  proteins	  obtained	  from	   the	   MS	   data	   was	   run	   on	   GOrilla	   software.	   A	   color	   scale	   from	   white	   to	   red	  represents	  the	  p-­‐values	  for	  each	  category	  with	  red	  representing	  the	  most	  significant	  and	  white	  the	  least.	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4.3 Cnot3	   interacts	   with	   chromatin	   organization	   factors	   and	  
splicing	  factors	  in	  early	  G1	  cells	  The	  aim	  of	  the	  analysis	  was	  to	  identify	  differences	  between	  Cnot3	  interactions	  in	   early	   G1	   and	   G2.	   Therefore,	   proteins	   have	   been	   divided	   to	   create	   two	   sub-­‐groups	  relative	  to	  proteins	  present	   in	  one	  phase.	  Overlapping	  proteins	  that	  are	  present	  in	  both	  G1	  and	  G2	  were	  included	  in	  both	  lists.	  One	  major	  difference	  was	  the	   number	   of	   interacting	   proteins	   detected	   in	   each	   stage.	   In	   early	   G1,	   239	  proteins	  were	  detected	  by	  MS	  with	  high	  confidence	  whereas	  425	  proteins	  were	  detected	  in	  G2.	  This	  difference	  in	  the	  number	  of	  protein	  interactors	  in	  early	  G1	  and	   G2	   might	   reflect	   a	   different	   activation	   state	   of	   the	   cell	   and	   suggests	   that	  Cnot3	  might	  be	  involved	  in	  more	  cellular	  processes	  in	  G2.	  	  Among	   the	   most	   enriched	   classes	   of	   proteins	   in	   the	   G1	   pulldown	   are	  chromatin	  organization	  proteins.	  They	  represent	  13.1%	  of	  the	  proteins	  that	  are	  co-­‐IPd	  with	   Cnot3	   in	   early	   G1.	   Included	   in	   the	   chromatin	   organization	   protein	  group	  are	  histones,	  nucleolar	  proteins	  and	  transcription	  factors.	  Histone	  H1	  was	  particularly	  enriched	  among	  the	  top	  hits	  in	  the	  list	  (Table	  4.2).	  Five	  isoforms	  of	  histone	  H1	  were	  co-­‐IP’d	  (H1.1,	  H1.2,	  H1.3,	  H1.4,	  H1.5	  and	  H1.t).	  Other	  histones	  are	  detected	  as	  well	  as	  histone	  H1,	  for	  instance	  histone	  H3.3	  and	  many	  isoforms	  of	  the	  histone	  H2A.	  One	  of	  these	  is	  H2.AZ,	  which	  has	  recently	  been	  shown	  to	  be	  involved	  in	  recruitment	  of	  RNA	  polymerase	  II	  to	  active	  gene	  promoters	  (Bargaje	  et	  al.,	  2012).	  Another	  Cnot3	  interactor	  that	  was	  identified	  in	  early	  G1	  was	  Nucleolin	  (Table	  4.2).	  This	  protein	   acts	   together	  with	  histone	  H1	   to	   regulate	   the	   accessibility	  of	  chromatin	   (Erard	   et	   al.,	   1988).	   Nucleolin	   is	   an	   ATPase	   and	   is	   one	   of	   the	  most	  abundant	   proteins	   in	   the	   nucleus.	  Nucleolin	   is	   involved	   in	   rRNA	   synthesis	   and	  ribosome	  biogenesis	  (Cong	  et	  al.,	  2012).	  Furthermore,	  it	  has	  been	  shown	  to	  have	  a	  role	  in	  regulating	  transcription	  in	  activated	  B	  cells	  (Hanakahi	  et	  al.,	  1997).	  	  The	  role	  of	  Cnot3	  in	  RNA	  regulation	  has	  been	  widely	  studied.	  The	  MS	  analysis	  has	  reported	  the	  interaction	  with	  proteins	  involved	  in	  splicing.	  In	  early	  G1	  Cnot3	  interacts	   with	   different	   classes	   of	   proteins	   involved	   in	   RNA	   maturation.	   They	  represent	  around	  12.3%	  of	  the	  G1	  proteins.	  Examples	  of	  these	  proteins	  are	  RNA	  helicases,	   small	   nuclear	   riboproteins	   and	   heterogeneous	   nuclear	  ribonucleoproteins	  (hnRNP	  proteins).	  The	  hnRNP	  proteins	  are	  involved	  in	  RNA	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splicing,	   3’end	  processing	  and	   regulation	  of	   transcription,	   as	  well	   as	  mediating	  the	  transfer	  of	  the	  mRNAs	  from	  the	  nucleus	  to	  the	  cytoplasm	  (Chaudhury	  et	  al.,	  2010).	  	  
	  
	  Table	  4.2:	  Early	  G1	  interactors	  of	  Cnot3.	  The	   table	  shows	   the	   first	  40	  out	  of	  239	  hits	  present	   in	  early	  G1	  with	  a	  high	  protein	  score.	  The	  protein	  score	   is	  relative	  to	  the	  abundance	  and	  the	  quality	  of	   the	  peptide.	  The	   function	   for	  each	  protein	  is	  also	  shown.	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4.4 In	  vitro	  interaction	  Cnot3-­histone	  H1	  Among	  of	  the	  most	  abundant	  proteins	  found	  in	  the	  analysis	  were	  isoforms	  of	  histone	  H1.	  Cnot3	  appeared	  to	  interact	  with	  many	  of	  histone	  H1	  isoforms	  mainly	  in	  early	  G1.	  Histone	  H1	  has	  eleven	   isoforms	   in	  mammals	  and	   is	  known	  to	  bind	  linker	   DNA,	   thus	   residing	   outside	   of	   the	   nucleosome.	   The	   main	   role	   for	   this	  protein	  is	  to	  regulate	  the	  condensation	  of	  chromatin	  by	  changing	  the	  structure	  of	  the	  chromatin	  fibres	  (Robinson	  and	  Rhodes,	  2006).	  Moreover,	  the	  main	  function	  attributed	  to	  this	  histone	  variant	  was	  to	  control	  the	  accessibility	  of	  chromatin	  to	  transcription	   factors.	   However,	   there	   has	   been	   some	   controversy	   in	   the	   last	  decade	  about	  the	  role	  of	  H1	  in	  regulating	  gene	  transcription.	  The	  first	  evidence	  obtained	  from	  studies	  on	  H1	  suggested	  that	  it	  has	  a	  repressive	  role,	  promoting	  a	  closed	   state	   of	   the	   chromatin	   (Buttinelli	   et	   al.,	   1999).	   Nonetheless,	   there	   are	  some	  examples	  where	  H1	  is	  involved	  in	  activation	  of	  transcription.	  This	  is	  mainly	  dependent	   on	   post-­‐translational	   modifications.	   It	   has	   been	   reported	   that	  acetylation	   on	   lysine	   34	   of	   histone	   H1.4	   can	   promote	   transcription,	   as	   it	   is	  enriched	  at	  promoters	  of	  active	  genes	  (Kamieniarz	  et	  al.,	  2012).	  	  	  From	  the	  list	  of	  Cnot3	  interactors,	  six	  isoforms	  of	  histone	  H1	  were	  identified:	  H.1,	   H1.2,	   H1.3,	   H.4,	   H1.5	   and	   H1.t.	   Furthermore,	   a	   post-­‐translational	  modification	   analysis	   on	   the	   histone	   H1	   isoforms	   has	   been	   done	   to	   check	  whether	  Cnot3	  was	  preferentially	  binding	  any	  modifications	  on	   these	  proteins.	  The	   result	   revealed	  an	   interaction	  between	  Cnot3	  and	   the	   isoform	  H1.3	   that	   is	  acetylated	  at	  K35	  (data	  not	  shown).	  Moreover,	  the	  N	  terminal	  part	  of	  the	  isoform	  H1.3,	   in	   which	   K35	   resides,	   has	   80%	   of	   homology	   with	   the	   isoform	   H1.4.	  Acetylation	   of	  H1.4K34	  has	   been	   linked	   to	   transcriptional	   activation.	   From	   the	  alignment	  of	  the	  two	  proteins,	  H1.4K34	  corresponds	  to	  H1.3K35.	  	  To	   validate	   this	   interaction,	   an	   in	   vitro	   assay	   was	   performed	   using	   in	   vitro	  translated	  Cnot3	  and	  a	  histone	  H1.3	  peptide	  modified	  at	  the	  lysine	  35.	  The	  assay	  was	   carried	   out	   by	   incubating	   in	   vitro	   translated	   Cnot3	   either	   with	   an	   un-­‐modified	   histone	   H1.3	   peptide	   or	   the	   K35Ac	   peptide.	   The	   experiment	   used	   in	  
vitro	  translated	  Cnot3	  full	  length	  and	  Cnot3	  mutants	  that	  were	  	  used	  previously	  to	  map	  the	  Cnot3-­‐Aurora	  B	  interaction.	  As	  a	  negative	  control	  streptavidin	  beads	  were	  incubated	  with	  in	  vitro	  translated	  Cnot3	  proteins	  to	  verify	  the	  presence	  of	  non-­‐specific	   binding.	   	   The	   Cnot3-­‐H1	   interaction	  was	   confirmed	   but	   it	   was	   not	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possible	   to	  detect	  a	   strong	  difference	   in	  binding	  between	   the	  modified	  and	   the	  unmodified	   peptide.	   A	   difference	   was	   observed	   in	   the	   interaction	   of	   the	   two	  peptides	   with	   the	   Cnot3	   mutant	   lacking	   the	   701-­‐751	   region	   of	   the	   NOT	   box	  domain.	  This	  truncated	  protein	  had	  a	  higher	  affinity	  for	  the	  un-­‐modified	  peptide.	  The	  peptide	  did	  not	  interact	  with	  the	  mutants	  that	  lacked	  either	  the	  NOT	  box	  at	  the	  C	  terminal	  or	  a	  200	  amino	  acid	  region	  at	  the	  N	  terminal	  (Figure	  4.3).	  	  	  	  
Figure	  4.3:	  Cnot3	  in	  vitro	  interaction	  with	  histone	  H1	  peptides.	  Histone	   H1.3	   biotinylated	   peptides	   were	   synthesised	   by	   GenScript.	   The	   peptides	  contained	   the	   amino	   acids	   from	   the	   residue	   25	   to	   the	   residue	   41	   of	   the	   mouse	  histone	  H1.3.	  In	  the	  assay	  has	  been	  used	  a	  peptide	  carrying	  an	  acetylated	  lysine	  35	  and	  an	  unmodified	  peptide.	  The	  peptides	  were	   immobilized	  on	  streptavidin	  beads	  and	  then	  incubated	  either	  with	   in	  vitro	  translated	  Cnot3	  full	   length,	  Cnot3	  Δ1-­‐200,	  Cnot3	   Δ701-­‐751	   or	   Cnot3	   Δ651-­‐751.	   The	   in	   vitro	   translated	   proteins	   were	  previously	   labelled	   with	   S35	   methionine.	   In	   the	   figure	   it	   is	   shown	   an	  autoradiography	  of	  the	  experiment.	  	  
4.5 In	  G2	  Cnot3	  interacts	  with	  components	  of	  the	  CPC	  complex	  
and	  proteins	  involved	  in	  RNA	  maturation	  
	   The	  co-­‐IP	  and	  MS	  revealed	  a	  large	  group	  of	  proteins	  that	  were	  pulled	  down	  by	  Cnot3	  in	  G2.	  As	  described	  in	  Section	  4.3,	  425	  interacting	  proteins	  were	  detected	  in	   this	   cell	   cycle	   phase.	   The	   results	   of	   co-­‐IP	   and	  western	   blotting	   presented	   in	  Chapter	   3	   showed	   a	   strong	   interaction	   between	   Cnot3	   and	   Aurora	   B	   in	   G2,	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whereas	  in	  early	  G1	  the	  interaction	  was	  much	  weaker.	  In	  accord	  with	  this	  result,	  the	  MS	  analysis	  of	  the	  Cnot3	  pulldown	  detected	  Aurora	  B	  in	  G2,	  but	  not	  in	  early	  G1.	   The	  MS	   analysis	   also	   revealed	   the	   presence	   of	   the	   CPC	   complex	  members	  Incenp	   and	   Borealin	   among	   the	   Cnot3	   interactors	   (Table	   A,	   Appendix).	   This	  suggests	  that	  Cnot3	  interacts	  with	  the	  intact	  CPC.	  Gene	  ontology	  was	  performed	  on	  the	  proteins	  that	  interact	  with	  Cnot3	  in	  G2.	  The	   chart	   in	   Figure	   4.4	   shows	   the	   results	   of	   the	   analysis.	   The	   categories	   of	  proteins	   that	   were	   more	   enriched	   and	   with	   high	   significance	   represented	  processes	   such	   as	   splicing,	   RNA	   processing,	   mRNA	   metabolism.	   Many	   hnRNP	  proteins	  were	   detected	   as	  well	   as	   RNA	   helicases,	  which	   are	   known	   to	   play	   an	  important	  role	  in	  promoting	  splicing.	  Ddx1,	  Ddx18	  and	  Ddx20	  are	  RNA	  helicases	  that	   have	   been	   reported	   to	   be	   involved	   in	   RNA	   maturation,	   export	   and	  degradation	   (Rocak	   and	   Linder,	   2004).	   Cnot3	   interactors	   that	   have	   roles	   in	  transcription	  termination	  were	  also	  detected,	  including	  Cpsf1	  and	  Fip1l1.	  Cpsf1	  participates	   in	   transcription	   termination	   by	   recognizing	   a	   specific	   sequence	   at	  the	   3’	   end	   of	   the	   pre-­‐mRNA.	   Cpsf1	   not	   only	   promotes	   termination,	   but	   also	  interacts	  with	  Fip1l1,	  which	  recruits	  the	  Poly-­‐A	  polymerase	  for	  the	  addition	  of	  a	  poly-­‐A	   tail	   to	   pre-­‐mRNAs	   (Keller	   et	   al.,	   1991)	   (Kaufmann	   et	   al.,	   2004).	   Cnot3	  interacts	  with	  both	  proteins	  in	  G2	  as	  well	  as	  with	  Pabp1	  (Table	  4.5).	  Pabp1	  binds	  the	   nascent	   pre-­‐mRNA	   poly-­‐A	   tail	   in	   order	   to	   stabilize	   the	   RNA	   and	   avoid	  degradation	  (Kuhn	  et	  al.,	  2009).	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Figure	  4.4:	  Gene	  ontology	  analysis	  of	  Cnot3	  interactors	  in	  G2.	  The	  chart	  was	  generated	  by	  using	  the	  software	  GOrilla.	  425	  proteins	  were	  included	  to	  perform	  the	  gene	  ontology	  analysis.	  A	  color	  scale	  indicates	  p-­‐values.	  	   Cnot3	  is	  part	  of	  the	  CCR4-­‐NOT	  complex,	  so	  it	  is	  not	  surprising	  that	  the	  protein	  that	  was	  most	  abundant	  among	  the	  Cnot3	  interactors	  in	  G2	  was	  Cnot1,	  which	  has	  already	   been	   shown	   to	   be	   part	   of	   a	   ternary	   complex	   with	   Cnot2	   and	   Cnot3	  (Boland	   et	   al.,	   2013).	   Cnot2	   was	   also	   identified	   among	   the	   Cnot3	   interactors	  identified	  in	  G2.	  The	  MS	  data	  also	  showed	  interaction	  with	  other	  components	  of	  the	  CCR4-­‐NOT	  complex,	   including	  Cnot6,	  Cnot6L,	  Cnot7,	  Cnot8,	  Cnot10,	  Cnot11	  (Table	  4.5	  and	  Table	  A,	  Appendix).	  However,	  not	  all	  of	  the	  subunits	  of	  the	  CCR4-­‐NOT	   complex	  were	   found	   among	   the	  Cnot3	   interacting	  proteins.	   This	   could	  be	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due	  to	  the	  presence	  of	  sub-­‐complexes	  of	  the	  CCR4-­‐NOT,	  as	  described	  by	  (Lau	  et	  al.,	  2009).	  The	  CCR4-­‐NOT	  complex	  is	  the	  major	  eukaryotic	  deadenylase.	  In	  the	  process	  of	  RNA	   turnover,	   it	   interacts	   with	   other	   cellular	   complexes	   such	   as	   the	   exosome	  and	   the	  TRAMP	   complex	   (Azzouz	   et	   al.,	   2009).	   In	   accordance	   to	   this,	   the	  mass	  spectrometry	  analysis	  showed	  that	  Cnot3	  interacts	  with	  Rrp46	  that	  is	  a	  subunit	  of	   the	   exosome,	   which	   is	   known	   to	   be	   part	   of	   the	   apparatus	   for	   the	   RNA	  degradation	  (Mitchell	  et	  al.,	  1997).	  	  
Table	  4.5:	  Cnot3	  interactors	  in	  G2.	  In	  the	  table	  are	  reported	  the	  first	  40	  out	  of	  425	  hits	  present	  in	  G2	  with	  a	  high	  protein	  score.	  The	  protein	   score	   is	   relative	   to	   the	   abundance	   and	   the	   quality	   of	   the	   peptide.	   It	   is	   reported	   the	  function	  for	  each	  protein.	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4.6 Cnot3	  interacts	  with	  the	  Xrn2	  5’-­3’exoribonuclease	  	  
	   The	  5’-­‐3’exoribonuclease,	  Xrn2,	  is	  involved	  in	  transcriptional	  termination	  and	  RNA	  degradation	   in	   the	   nucleus.	   Xrn2	  degrades	  RNA	   at	   the	   3’	   end	   of	   the	   gene	  after	  cleavage	  of	   the	  RNA	  at	   the	  poly-­‐A	  site.	  According	  to	   the	  torpedo	  model	  of	  transcriptional	  termination,	  5’-­‐3’	  degradation	  of	  RNA	  downstream	  from	  the	  poly-­‐A	   site	   displaces	   RNA	   polymerase	   II	   from	   DNA	   and	   promotes	   termination	  (Proudfoot,	   2011).	   Xrn2	   has	   been	   shown	   to	   be	   involved	   in	   degrading	  prematurely	  terminated	  transcripts	  around	  the	  transcription	  start	  site	  and	  may	  be	   involved	   in	  controlling	   transcription	   levels	  by	  displacing	  RNA	  polymerase	   II	  from	  DNA	  (Brannan	  et	  al.,	  2012).	  Xrn2	  also	  promotes	  the	  maturation	  of	  rRNAs	  by	  degrading	  aberrant	  mRNAs	  together	  with	  the	  nuclear	  exosome	  (Davidson	  et	  al.,	  2012)	   as	   well	   as	   regulating	   the	   length	   of	   telomeres	   by	   degrading	   the	   RNA	  transcribed	  at	  termini	  of	  the	  chromosomes	  (Luke	  et	  al.,	  2008).	  Because	  of	  the	  important	  roles	  played	  by	  Xrn2	  in	  transcriptional	  termination	  and	  RNA	  processing,	  I	   focused	  on	  the	  interaction	  between	  Cnot3	  and	  Xrn2.	  The	  interaction	   was	   initially	   detected	   in	   G2	   cells	   by	   MS	   and	   was	   subsequently	  validated	  by	  co-­‐IP	  and	  western	  blotting.	  Co-­‐IP	  was	  also	  used	   to	  verify	  whether	  Xrn2	  and	  Aurora	  B	  interact.	  The	  co-­‐IP	  experiments	  were	  performed	  with	  nuclear	  extracts	   from	  mid-­‐late	  S	  phase	  and	  G2	   cells.	  The	  experiment	   revealed	  a	   strong	  interaction	  between	  these	  two	  proteins	  in	  both	  phases	  (Figure	  4.6).	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  A	   co-­‐IP	   experiment	   was	   performed	   using	   mid/late	   S	   and	   G2	   cells	   to	   test	  whether	  Aurora	  B	  interacts	  with	  Xrn2.	  The	  results	  show	  a	  clear	  pulldown	  of	  Xrn2	  by	   anti-­‐Aurora	   B.	   	   A	   difference	   in	   the	   amount	   of	   IPd	   Xrn2	  was	   detected,	   with	  stronger	   pulldown	   observed	   in	   G2	   than	   in	  mid/late	   S	   phase	   (Figure	   4.7).	   This	  variation	  in	  the	  amount	  of	  interaction	  was	  similar	  to	  the	  difference	  observed	  for	  Aurora	  B-­‐Cnot3	  during	  the	  same	  phases	  of	  the	  cell	  cycle.	  	  
	  
































	   105	  
	  
	  
Figure	  4.8:	  Xrn2	  interaction	  with	  Aurora	  B	  and	  Cnot3	  in	  resting	  B	  cells.	  Anti-­‐Aurora	   B	   and	   anti-­‐IgG	   antibodies	   were	   pre-­‐bound	   to	   magnetic	   beads	   and	  incubated	  with	   nuclear	   protein	   extracts	   from	  mid/late	   S	   phase	   and	   G2	   cells.	   The	  proteins	  obtained	  after	  the	  IP	  were	  analyzed	  by	  western	  blot	  with	  antibodies	  that	  recognise	   Cnot3,	   Xrn2	   and	  Aurora	  B.	   	   5%	  of	   the	   extract	   used	   for	   the	   IP	   has	   been	  used	  as	  INPUT.	  
	  
4.7 Summary	  Analysis	   of	   the	  profile	   of	  Cnot3	   interactors	   in	   early	  G1	  and	  G2	   cells	   showed	  that	  Cnot3	  interacts	  during	  early	  G1	  with	  chromatin	  organization	  factors,	  such	  as	  histones	  and	  transcription	  factors.	  Five	  isoforms	  of	  histone	  H1	  were	  detected	  by	  the	  MS	  analysis	  in	  early	  G1	  and	  the	  interaction	  with	  H1	  was	  validated	  using	  an	  in	  
vitro	   peptide	   binding	   assay.	   The	   second	   most	   enriched	   group	   of	   interacting	  proteins	   contained	  proteins	   that	   are	   involved	   in	  RNA	  processing,	   transcription	  regulation,	   splicing,	   RNA	   export	   and	   degradation.	   Among	   these	   classes	   of	  proteins,	   Cnot3	   also	   interacts	   with	   many	   hnRNPs	   that	   are	   components	   of	   the	  spliceosome.	  A	  higher	  number	  of	  interactors	  was	  observed	  in	  G2	  compared	  with	  early	  G1.	  Components	  of	  the	  CPC,	  (Aurora	  B,	  Incenp	  and	  Borealin),	  were	  shown	  to	  interact	  with	  Cnot3.	  Factors	  involved	  in	  splicing	  and	  RNA	  maturation	  interact	  with	  Cnot3	  in	  G2,	  as	  well	  as	  proteins	  with	  a	  role	   in	   transcription	   termination.	  Fipl1l,	  Spsf1	  and	  Papb	  are	  Cnot3	   interactors	  and	   function	  respectively	   to	  recognize	   the	  stop	  signal,	  recruit	  cleavage	  factors	  and	  bind	  the	  poly-­‐A	  tail.	  The	  5’-­‐3’	  exoribonuclease	  Xrn2	  was	  also	  detected	  as	  a	  Cnot3	  interactor	  in	  the	  MS	  analysis.	  The	  interaction	  with	   Xrn2	   with	   Cnot3	   and	   Aurora	   B	   was	   confirmed	   by	   co-­‐IP	   experiments	   in	  resting,	  mid/late	  S	  phase	  and	  G2.	  The	  Xrn2	   interaction	  with	  both	  proteins	  was	  highest	   in	   G2,	   somewhat	   reduced	   in	  mid/late	   S	   phase	   and	   lowest	   in	   resting	   b	  cells.
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Chapter	  5 -­	  Cell	  cycle	  regulated	  binding	  of	  Cnot3	  to	  gene	  
promoters	  	  	  
5.1 Introduction	  A	  number	  of	  lines	  of	  evidence	  obtained	  in	  the	  lab	  point	  to	  a	  role	  for	  Cnot3	  in	  gene	   regulation.	   Cnot3	   interacts	   with	   Aurora	   B	   in	   resting	   B	   cells	   and	   the	   two	  proteins	  are	  present	  on	  the	  same	  active	  gene	  promoters	  in	  these	  cells.	  Cnot3	  also	  interacts	   in	   resting	   B	   cells	   with	   Ring1B,	   which	   is	   another	   protein	   involved	   in	  transcriptional	   regulation	   in	   resting	   B	   cells	   (Frangini	   et	   al.,	   2013).	   Cnot3	   was	  found	  to	  be	  phosphorylated	  by	  Aurora	  B	  in	  an	  in	  vitro	  kinase	  assay.	  A	  published	  study	   reported	   that	   Cnot3	   binds	   to	   promoters	   of	   active	   genes	   in	   ES	   cells,	  suggesting	   a	   role	   for	  Cnot3	   in	   controlling	   self-­‐renewal	   in	   these	   cells	   (Hu	   et	   al.,	  2009).	  	  In	  this	  chapter	  the	  results	  of	  a	  ChIP	  analysis	  of	  Cnot3	  binding	  to	  promoters	  of	  active	   genes	   at	   different	   phases	   of	   the	   cell	   cycle	   will	   be	   described.	   The	  description	  of	  Cnot3	  occupancy	  on	  promoters	  will	  be	  studied	  in	  conjunction	  with	  the	  presence	  of	   the	  5’-­‐3’	   exoribonuclease	  Xrn2.	  Binding	  of	   Cnot3	   to	  promoters	  will	  be	  then	  related	  to	  the	  transcriptional	  state	  of	  the	  cell.	  	  	  	  
5.2 Aurora	  B	  and	  Cnot3	  co-­occupy	  promoters	  of	  active	  genes	  in	  
resting	  B	  cells	  	  The	   interaction	   between	   Cnot3	   and	   the	   Aurora	   B	   kinase	   during	   cell	   cycle	  progression	  was	  described	  in	  Chapter	  3.	  Data	  generated	  in	  the	  lab	  showed	  that	  Aurora	  B	  binds	  to	  promoters	  of	  active	  genes	  in	  resting	  B	  cells.	  After	  activation	  by	  LPS,	   Aurora	   B	   does	   not	   bind	   to	   promoters	   and	   is	   replaced	   by	   the	  MSK	   1	   and	  MSK2	  kinases	  (Frangini	  et	  al.,	  2013).	  	  Cnot3	  binds	  to	  the	  same	  active	  gene	  promoters	  where	  Aurora	  B	  was	  detected,	  while	   very	   little	  binding	  was	  observed	  at	   inactive	   genes	   (Figure	  5.1).	   Levels	   of	  enrichment	   of	   Cnot3	   and	   Aurora	   B	   were	   not	   the	   same	   for	   the	   two	   proteins.	  Although	  it	   is	  not	  possible	  to	  directly	  compare	  ChIP	  enrichments	  obtained	  with	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different	   antibodies,	   enrichments	   obtained	   for	   Cnot3	   at	   active	   genes	   were	  substantially	  higher	  than	  Aurora	  B.	  This	  could	  be	  due	  to	  the	  fact	  to	  differences	  in	  the	   levels	  of	   the	   two	  proteins	   in	   the	  nucleus	  and/or	   the	   fact	   that	  Aurora	  B	   is	  a	  kinase	  and	  therefore	  binds	  more	  dynamically	  than	  Cnot3.	  	  
	  
Figure	  5.1:	  Aurora	  B	  and	  Cnot3	  bind	  the	  same	  active	  gene	  promoters.	  Anti-­‐Aurora	  B	  and	  anti	  Cnot3	  antibodies	  were	  bound	  to	  magnetic	  beads.	  Chromatin	  extracted	  from	  resting	  B	  cells	  was	  then	  incubated	  with	  the	  antibody-­‐beads	  complex.	  The	  binding	  of	   Cnot3	   and	  Aurora	  B	   to	   gene	  promoters	  was	   assessed	  by	  qRT-­‐PCR	  using	  pair	  of	  primers	  that	  amplify	  promoter	  regions.	  Error	  bars	  represent	  standard	  deviation	   of	   the	   mean	   (n=4	   biological	   replicates).	   The	   Aurora	   B	   ChIP	   data	   was	  generated	  by	  A.	  Frangini.	  	  	   To	  follow	  up	  the	  results	  that	  were	  obtained	  for	  Aurora	  B	  and	  Cnot3,	  the	  B	  cell	  system	   described	   in	   Chapter	   3	   was	   used	   to	   analyse	   the	   binding	   of	   Cnot3	  throughout	   the	   cell	   cycle.	   ChIP	   experiments	   for	   Aurora	   B	   did	   not	   show	  enrichment	  on	  gene	  promoters	  (data	  not	  shown).	  It	  is	  known	  that	  protein	  levels	  of	   Aurora	   B	   rise	   dramatically	   in	   S	   phase	   to	   reach	   a	   peak	   in	   G2/M.	   In	   G2	  especially,	   Aurora	  B	   is	   spread	   all	   over	   the	   chromosomes	   (Terada	   et	   al.,	   1998).	  The	  effect	  of	  this	  generalized	  spreading	  would	  be	  to	  prevent	  detection	  of	  specific	  enrichment	  on	  gene	  promoters,	  since	  the	  IP	  of	  Aurora	  B	  would	  pull	  down	  DNA	  sequences	   that	  are	   localized	  not	  only	  on	  promoters	  but	  everywhere	  else	   in	   the	  chromosome.	  Therefore,	  there	  would	  not	  be	  any	  sequence	  enriched	  in	  respect	  to	  the	   ones	   present	   in	   the	   INPUT.	   Because	   of	   these	   issues,	   it	  was	   not	   possible	   to	  analyse	  binding	  of	  Aurora	  B	  to	  gene	  promoters	  in	  G2	  by	  ChIP.	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5.3 Binding	   of	   Cnot3	   to	   promoters	   in	   resting	   B	   cells	   is	   not	  
affected	  by	  Aurora	  B	  depletion	  
	   Attempts	   to	   knock	   down	   Cnot3	   to	   obtain	   functional	   data	   about	   the	   role	   of	  Cnot3	  did	  not	  achieve	  positive	  results.	  Our	  efforts	  to	  infect	  resting	  B	  cells	  using	  lentiviral	   vectors	   (Scott,	   2011)	   (Su	   et	   al.,	   2011),	   were	   unsuccessful	   (data	   not	  shown).	   Furthermore,	   there	   are	   no	  molecules	   available	   that	   can	   inhibit	   Cnot3	  activity	   and	   there	   have	   not	   been	   any	   reports	   of	   a	   Cnot3	   conditional	   knockout	  mouse	   that	   would	   allow	   depletion	   of	   Cnot3	   in	   B	   cells.	   The	   germline	   of	   Cnot3	  knockout	   has	   been	   shown	   to	   be	   pre-­‐implantation	   embryonic	   lethal,	   with	   the	  zygote	  unable	  to	  develop	  beyond	  the	  blastocyst	  (Neely	  et	  al.,	  2010).	  	  To	  study	  the	  functions	   of	   Cnot3	   using	   the	   systems	   that	   I	   have	   set	   up,	   a	   strategy	   has	   been	  developed	   for	   the	  generation	  of	  a	  Cnot3	  conditional	  knockout	  mouse.	  This	  will	  allow	  characterization	  of	  the	  functional	  role	  of	  Cnot3	  in	  B	  cells.	  The	  strategy	  and	  progress	   of	   the	   generation	   of	   the	   Cnot3	   conditional	   knockout	   mouse	   will	   be	  discussed	  in	  the	  Chapter	  7.	  	  Because	  Aurora	  B	  was	  shown	  to	  interact	  with	  Cnot3	  and	  to	  phosphorylate	  it	  in	  
vitro,	   I	   set	  out	   to	  verify	  whether	   the	  absence	  of	   the	  kinase	  could	   interfere	  with	  the	  binding	  of	  Cnot3	  to	  chromatin.	  The	  analysis	  was	  carried	  out	  using	  mice	  that	  are	  homozygous	  for	  a	  floxed	  Aurora	  B	  allele	  (Aurkbfl)	  and	  a	  tamoxifen	  inducible	  Cre-­‐ERT2	   gene	   under	   the	   control	   of	   constitutive	   Rosa	   26	   promoter.	   ChIP	  experiments	  were	  carried	  out	  in	  Aurora	  B	  knockout	  resting	  B	  cells.	  The	  resting	  B	  cells	  were	  isolated	  from	  Aurkbfl/fl/Cre-­‐ERT2/Cre-­‐ERT2	  mice	  and	  incubated	  for	  48	  hours	  with	  tamoxifen,	  to	  promote	  entry	  of	  the	  Cre	  recombinase	  into	  the	  nucleus.	  The	   cre	   enzyme	   in	   the	  nucleus	  deletes	   genomic	   sequence	  present	  between	   the	  two	   LoxP	   sites.	   As	   control	   cells,	   resting	   B	   cells	   were	   also	   isolated	   from	   mice	  homozygous	  for	  Cre-­‐ERT2	  only	  and	  treated	  for	  48	  hours	  with	  tamoxifen.	  The	  level	  of	  Aurora	  B	  protein	  was	  analysed	  by	  western	  blot	  to	  confirm	  knockdown	  of	  the	  protein	  (Figure	  5.2	  A).	  	  ChIP	   experiments	   were	   performed	   with	   an	   anti-­‐Cnot3	   antibody	   using	  chromatin	   isolated	   from	   Aurora	   B	   knockout	   and	   Cre-­‐ERT2	   only	   cells.	   No	  indicative	   change	  was	   found	   in	  Cnot3	  binding	  at	  any	  of	   the	  active	  genes	   in	   the	  Aurora	  B	  knockout	   cells	   (Figure	  5.2	  B).	   This	   led	   to	   the	   conclusion	   that	   neither	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interaction	  with	  nor	  phosphorylation	  by	  Aurora	  B	  are	  needed	  for	  Cnot3	  to	  bind	  to	  chromatin	  in	  resting	  B	  cells.	  
	  
	  
Figure	  5.2:	  Cnot3	  binds	  gene	  promoters	  in	  Aurora	  B	  knock	  out	  cells.	  A)	   Confirmation	   of	   Aurora	   B	   knockout.	   Resting	   B	   cells	   were	   isolated	   from	   mice	  homozygous	   for	  Aurkbfl	   and	  Cre-­‐ERT2	   (AurkB-­‐KO)	  and	   from	  mice	  homozygous	   for	  Cre-­‐ERT2	  only	  (Cre-­‐ERT2).	  The	  cells	  were	  incubated	  for	  48	  hours	  with	  tamoxifen	  and	  chromatin	  was	  extracted	  and	  used	  for	  the	  ChIP	  shown	  in	  (B).	  Protein	  extracted	  from	  106	   AurkB-­‐KO	   and	   Cre-­‐ERT2	   cells	  was	   loaded	   onto	   a	   10%	   polyacrilamide	   gel	   and	  analysed	  by	  western	  blot.	  β-­‐tubulin,	  was	  used	  as	  a	  loading	  control.	  	  B)	   qRT-­‐PCR	   ChIP	   analysis	   of	   Cnot3	   binding	   using	   chromatin	   from	   resting	   B	   cells	  isolated	   from	   Cre-­‐ERT2	   and	   AurkB-­‐KO	   mice	   and	   incubated	   with	   tamoxifen.	  Immunoprecipitated	  DNA	  was	  analysed	  using	  primers	  specific	  for	  the	  promoters	  of	  the	  indicated	  genes.	  Error	  bars	  represent	  the	  standard	  deviation	  of	  the	  mean	  (n=2	  biological	  replicates).	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5.4 Binding	   of	   Cnot3	   to	   gene	   promoters	   during	   cell	   cycle	  
progression	  
	   Cnot3	   binding	   to	   gene	   promoters	   was	   analysed	   by	   ChIP	   to	   assess	   possible	  changes	   during	   cell	   cycle	   progression.	   The	   analysis	   focused	   on	   genes	   that	   are	  known	  to	  be	  active	  in	  B	  cells.	  They	  included	  the	  B	  cell-­‐specific	  Fc	  receptor-­‐like	  1	  (Fcrl1)	   gene	   as	  well	   as	  more	  widely	   expressed	   genes	   that	  mediate	   a	   variety	   of	  cellular	  processes	  including	  cell	  cycle	  progression	  and	  cell	  growth	  (Arhgef2,	  Prcc,	  
Pmf1)	   protein	   chaperones	   (Cct3)	   and	  mitochondrial	   transport	   proteins	   (Mtx1).	  	  Binding	  of	  Cnot3	  was	  also	  analysed	  on	  gene	  promoters	  that	  are	  not	  expressed	  in	  B	  cells	  such	  as	  Insrr	  and	  Nestin.	  These	  genes	  are	  located	  in	  a	  gene-­‐dense	  region	  of	  mouse	  chromosome	  3	  that	  the	  lab	  has	  studied	  for	  a	  number	  of	  years.	  The	   result	   of	   the	   ChIP	   confirmed	   that	   Cnot3	   binds	   to	   active	   promoters	   in	  resting	  B	  cells.	  The	  highest	  binding	  was	  detected	  on	  the	  promoter	  of	  Fcrl1,	  which	  is	   a	   B	   cell	   gene	   involved	   in	   activation	   and	   cell	   growth.	   Substantial	   binding	   of	  Cnot3	  was	  also	   found	  at	   other	   active	  promoters.	   Conversely,	   Cnot3	  was	  barely	  detected	   on	   the	   promoters	   of	   inactive	   genes.	   Following	   activation	   of	   the	   cells	  with	   LPS,	   the	   binding	   of	   Cnot3	   did	   not	   change	   significantly	   on	   active	   genes	  during	  early	  and	  late	  G1	  (Figure	  5.3).	  	  When	  ChIP	  was	  carried	  out	  on	  cells	  that	  were	  blocked	  at	  the	  G1/S	  boundary	  by	   incubation	  with	  aphidicolin	  a	  change	  in	  binding	  was	  evident.	  The	  binding	  of	  Cnot3	   at	   active	   genes	   decreased	   sharply	   compared	  with	   late	   G1	   cells.	   An	   even	  larger	  drop	  in	  binding	  was	  observed	  2	  hours	  after	  washout	  of	  aphidicolin	  when	  the	  cells	  were	  in	  mid	  to	  late	  S	  phase.	  The	  level	  of	  Cnot3	  binding	  on	  promoters	  of	  active	  genes	  increased	  again	  in	  G2/M.	  However,	  the	  levels	  of	  binding	  detected	  in	  this	   phase	  were	   lower	   than	   the	   levels	   observed	   in	   resting	   B	   cells.	   	   A	   possible	  reason	  for	  this	  might	  be	  a	  shift	  in	  the	  binding	  profile	  of	  Cnot3	  at	  gene	  promoters.	  As	  will	  be	  described	  in	  Section	  6.3,	  the	  Cnot3	  binding	  peak	  is	  displaced	  towards	  the	  body	  of	  the	  gene	  in	  G2	  cells.	  Therefore,	  the	  analysis	  by	  qRT-­‐PCR	  of	  the	  same	  area	   of	   the	   promoter	  might	   be	   expected	   to	   deliver	   a	  weaker	   signal.	   A	  modest	  decrease	   in	   Cnot3	   binding	   was	   observed	   in	   the	   G2/M	   population	   of	   cells	  compared	  to	  the	  G2	  cells	  (Figure	  5.3).	  This	  could	  be	  due	  to	  displacement	  of	  Cnot3	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from	  the	  chromatin	  in	  the	  proportion	  of	  the	  cells	  in	  this	  population	  that	  were	  in	  metaphase.	  	  	  
Figure	  5.3:	  Binding	  of	  Cnot3	  to	  gene	  promoters	  during	  cell	  cycle	  progression.	  qRT-­‐PCR	   ChIP	   was	   carried	   out	   with	   anti-­‐Cnot3	   antibodies	   on	   chromatin	   from	  resting,	  anti-­‐IgM	  treated	  (early	  G1),	  anti-­‐IgM+LPS6h	  (late	  G1),	  aphidicolin	  blocked,	  2	  hours	  (mid-­‐late	  S-­‐phase),	  4	  hours	  (G2)	  and	  6	  hours	  (G2/M)	  aphidicolin	  released	  B	  cells.	   PCR	   primers	   detected	   immunoprecipitated	   DNA	   from	   the	   promoters	   of	   the	  indicated	   genes.	   Error	   bars	   represent	   the	   standard	   deviation	   of	   the	   mean	   (n=3	  biological	  replicates).	  	  	  
5.5 Analysis	  of	  Cnot3	  binding	  to	  gene	  promoters	  during	  S	  phase	  	  	   The	  result	  shown	  in	  Figure	  5.3	  provide	  evidence	  that	  binding	  of	  Cnot3	  to	  gene	  promoters	   changes	   during	   the	   cell	   cycle.	   The	   largest	   change	   in	   binding	   was	  observed	  in	  mid	  to	  late	  S	  phase,	  where	  Cnot3	  binding	  was	  very	  low	  compared	  to	  resting	  cells.	   In	  order	   to	  exclude	   the	  possibility	  of	  artefacts	  caused	  by	   the	  DNA	  polymerase	   inhibitor,	   a	   ChIP	   experiment	  was	   performed	   in	   an	   aphidicolin-­‐free	  system.	   Because	   it	   is	   not	   possible	   to	   obtain	   a	   B	   cell	   population	   that	   is	   fully	  synchronised	  in	  S-­‐phase	  without	  using	  a	  DNA	  polymerase	  inhibitor,	  we	  decided	  to	   perform	  a	  ChIP	   experiment	   on	   a	   cell	   population	  prepared	  using	   a	   drug-­‐free	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method,	  that	  is	  enriched	  for	  cells	  in	  S	  phase.	  If	  the	  results	  shown	  in	  Figure	  5.3	  are	  correct,	   the	   binding	   of	   Cnot3	   to	   active	   promoters	   should	   decrease	   in	   this	  population.	  	  The	  strategy	  used	  involved	  incubation	  of	  resting	  B	  cells	  with	  anti-­‐IgM	  for	  20	  hours,	  followed	  by	  incubation	  with	  LPS	  (see	  Section	  3.2).	  In	  order	  to	  determine	  the	  optimal	   time	  of	  LPS	   incubation	  for	  obtaining	  a	  high	  percentage	  of	  cells	   in	  S	  phase,	  anti-­‐IgM	  treated	  cells	  were	  incubated	  with	  LPS	  for	  6,	  8,	  10,	  12	  or	  14	  hours	  and	   cells	   were	   incubated	   with	   EdU	   for	   30	   minutes	   before	   harvesting	   to	  determine	  the	  number	  of	  cells	  in	  S-­‐phase.	  As	  previously	  shown	  in	  Section	  3.2,	  the	  percentage	  of	   cells	   incorporating	  EdU	  after	  6	  hours	  was	  around	  5%.	  A	  gradual	  increase	   in	   number	   of	   cells	   entering	   S	   phase	  was	  detected	   from	  8	  hours	   to	   10	  hours,	  with	  the	  percentage	  rising	  from	  5.8%	  to	  9.7%.	  At	  the	  12	  hour	  time	  point,	  around	   18.3%	   of	   cells	   incorporated	   the	   nucleotide	   analogue.	   Cells	   that	   were	  treated	  for	  14	  hours	  with	  LPS	  were	  used	  for	  the	  ChIP	  experiment,	  as	  around	  30%	  of	  them	  incorporated	  EdU	  (Figure	  5.4).	  	  	  
	  
	  
Figure	  5.4:	  EdU	  incorporation	  in	  resting	  and	  anti-­IgM+LPS	  treated	  B	  cells.	  FACS	  profile	  of	  EdU	  incorporation	  assay	  performed	  in	  resting	  and	  anti-­‐IgM	  treated	  B	  cells	  at	  different	  time	  points	  after	  the	  LPS	  addition.	  The	  green	  profile	  represents	  cells	  that	  were	  incubated	  for	  30	  minutes	  with	  EdU	  before	  harvesting,	  while	  the	  red	  profile	  shows	  the	  cells	  that	  have	  not	  been	  incubated	  with	  EdU.	  The	  numbers	  in	  each	  histogram	  represent	  the	  percentage	  of	  EdU	  that	  was	  incorporated	  by	  the	  cells.	  	  	  ChIP	  was	  carried	  out	  to	  compare	  Cnot3	  binding	  in	  anti-­‐IgM+14h	  LPS	  cells	  and	  the	   mid	   to	   late	   S-­‐phase	   cells	   obtained	   2	   hours	   after	   washout	   of	   aphidicolin.	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Resting	  B	  cells	  were	  also	   included	   in	   the	  analysis.	  The	  binding	  of	  Cnot3	   in	  anti-­‐IgM+14h	  LPS	  cells	  was	  very	  low	  on	  gene	  promoters	  and	  was	  similar	  to	  the	  levels	  detected	  in	  the	  mid	  to	  late	  S	  phase	  cells	  obtained	  with	  aphidicolin.	  Moreover,	   in	  both	   samples	   Cnot3	   binding	   was	   very	   low	   relative	   to	   the	   binding	   observed	   in	  resting	   B	   cells	   (Figure	   5.5).	   This	   was	   surprising	   because	   around	   30%	   of	   cells	  incorporated	  EdU	  in	  the	  anti-­‐IgM+14h	  LPS	  cells.	  However,	  this	  figure	  might	  be	  an	  underestimation	  of	  the	  proportion	  of	  cells	  that	  are	  replicating	  their	  DNA.	  Due	  to	  their	  asynchronous	  behavior,	  we	  could	  have	  a	  representation	  of	  different	  points	  in	   S	   phase	   in	   these	   cells.	   EdU	   incorporation	   might	   also	   be	   not	   sufficiently	  sensitive	   to	   detect	   cells	   at	   very	   early	   and	   late	   stages	   of	   S	   phase.	   Based	   on	   the	  results	   obtained	   using	   the	   two	   methods,	   it	   is	   possible	   to	   conclude	   that	   Cnot3	  binding	  to	  promoters	  of	  active	  genes	  is	  strongly	  reduced	  during	  S	  phase	  and	  that	  this	  phenomenon	  is	  not	  caused	  by	  synchronization	  with	  aphidicolin.	  	  	  
	  
Figure	  5.5:	  Binding	  of	  Cnot3	  to	  gene	  promoters	  in	  resting	  B,	  mid-­late	  S	  phase	  
and	  anti-­IgM+LPS	  14	  hours.	  
	  qRT-­‐PCR	  ChIP	  with	  anti-­‐Cnot3	  antibody	  was	  carried	  out	  as	  described	  in	  the	  legend	  to	  Figure	  5.3.	   The	   experiment	  was	  performed	  using	   chromatin	   from	   resting,	   anti-­‐IgM+14h	   LPS	   and	   aphidicolin-­‐treated	   B	   cells	   analysed	   2	   hours	   after	   aphidicolin	  washout.	  Error	  bars	  represent	   the	  standard	  deviation	  of	   the	  mean	  (n=3	  biological	  replicates).	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5.5.1 Pcna	  binds	  to	  gene	  promoters	  during	  S	  phase	  To	  determine	  whether	  the	  loss	  of	  binding	  of	  Cnot3	  during	  S-­‐phase	  might	  be	  a	  ChIP	  artifact	  arising	  from	  global	  changes	  in	  chromatin	  structure	  during	  S-­‐phase,	  ChIP	  was	  used	  to	  analyse	  the	  binding	  of	  Pcna	  at	  promoters	  of	  active	  and	  inactive	  genes	  in	  S-­‐phase	  cells.	  Pcna	  is	  a	  DNA	  polymerase	  delta	  co-­‐factor	  that	  participates	  in	   the	   process	   of	   elongation	   during	   DNA	   replication	   and	   promotes	   DNA	  polymerase	   activity	   (Prelich	   et	   al.,	   1987).	   ChIP	   experiments	   with	   an	   anti-­‐Pcna	  antibody	  were	  performed	  using	  chromatin	  extracted	  from,	  early	  and	  mid	  to	  late	  S	  phase	  cells	  generated	  by	  aphidicolin	  block	  and	  washout.	  Resting	  B	  cells	  were	  also	  included	  in	  the	  analysis.	  Low	  levels	  of	  PCNA	  binding	  were	  observed	  in	  resting	  B	  cells	   and	   the	   level	   of	   binding	   was	   strongly	   increased	   at	   all	   stages	   of	   S-­‐phase	  examined	  (Figure	  5.6).	  The	  highest	  level	  of	  binding	  was	  observed	  in	  early	  S-­‐phase	  30	  minutes	  hours	  after	  aphidicolin	  washout	  and	  binding	  decreased	  in	  mid	  to	  late	  S-­‐phase.	  The	  level	  of	  binding	  of	  Pcna	  to	  gene	  promoters	  was	  similar	  at	  active	  and	  inactive	  genes.	  	  
Figure	  5.6:	  Pcna	  binds	  gene	  promoters	  in	  S	  phase.	  qRT-­‐PCR	  ChIP	  analysis	  of	  PCNA	  binding	  to	  gene	  promoters	  in	  resting	  and	  S-­‐phase	  B	  cells.	  The	  experiment	  was	  performed	  using	  chromatin	  from	  resting	  and	  aphidicolin	  blocked	  B	  cells	  and	  30	  minutes	  (early	  S)	  or	  2	  hours	  (mid	  to	  late	  S)	  after	  aphidicolin	  washout.	   Error	   bars	   represent	   standard	   deviation	   of	   the	   mean	   (n=3	   biological	  replicates).	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5.6 Analysis	   of	   transcription	   levels	   during	   cell	   cycle	  
progression	  
	   To	   correlate	   the	   binding	   of	   Cnot3	   to	   promoters	  with	   transcription	   status	   at	  different	   stages	   of	   the	   cell	   cycle,	   nuclear	   RNA	   was	   isolated	   from	   cells	   and	  analysed	   by	   qRT-­‐PCR	   using	   primers	   that	   were	   designed	   to	   amplify	   sequences	  containing	   intron-­‐exon	   junctions.	  This	   approach	  made	   it	  possible	   to	   selectively	  analyse	   the	   levels	   of	   primary	   transcripts.	   Due	   to	   the	   difficulty	   of	   having	   a	  housekeeping	  gene	  that	  does	  not	  fluctuate	  during	  the	  cell	  cycle,	  a	  spike	  RNA	  was	  added	   to	   the	   nuclear	   lysate	   before	   RNA	   purification.	   The	   spike	   RNA	   was	  generated	  by	  the	  transcription	  of	  a	  unique	  random	  sequence	  (see	  Materials	  and	  Methods,	  section	  2.10.1).	  The	  Ct	  values	  obtained	  for	  each	  gene	  were	  normalized	  to	  the	  spike	  RNA.	  	  All	   of	   the	   genes	   analysed	   had	   similar	   primary	   transcript	   profiles,	  with	   little	  change	  in	  transcript	  level	  observed	  during	  progression	  from	  resting	  to	  early	  and	  late	  G1	  stages	  (Figure	  5.7).	  A	  sharp	  increase	  in	  primary	  transcripts	  was	  seen	  in	  early	  S	  phase	  and	  these	  levels	  were	  maintained	  in	  G2	  and	  G2/M	  cells.	  The	  B	  cell-­‐specific	   genes	   had	   significantly	   higher	   transcript	   levels	   at	   all	   cell	   cycle	   stages	  compared	  with	  the	  housekeeping	  genes.	  No	  transcripts	  were	  detected	  for	  Nestin	  which	  is	  repressed	  in	  B	  cells	  (Figure	  5.7).	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Figure	   5.7:	   Analysis	   of	   primary	   transcripts	   during	   cell	   cycle	   progression	   of	  
activated	  B	  cells	  Nuclear	  RNA	  was	  extracted	  from	  cells	  collected	  in	  resting,	  early	  G1,	  late	  G1,	  early	  S	  phase,	   G2	   and	   G2/M	   B	   cells	   and	   analysed	   by	   qRT-­‐PCR.	   Gene	   expression	   was	  calculated	   relative	   to	   a	   spike-­‐in	   RNA	   that	   was	   added	   to	   the	   nuclear	   lysate	  immediately	  after	   lysis	   (see	  Material	  and	  methods	  section	  2.10.2).	   	  To	  detect	  only	  primary	   transcripts,	   primers	   that	   amplify	   sequences	   containing	   intron-­‐exon	  junctions	  were	  used	   for	   the	  analysis.	  Levels	   for	  B	  cell	  genes	  are	  shown	  separately	  due	  to	  their	  higher	  transcript	  levels.	  A)	  B	  cell	  genes	  primary	  transcripts.	  B)	  Primary	  transcripts	  of	  genes	  covering	  different	  cellular	  processes.	  n=4	  biological	  replicates	  for	  A	  and	  B.	  	   The	  same	  nuclear	  RNA	  was	  also	  analysed	  using	  primers	  with	  complementary	  sequences	  located	  within	  exons	  in	  order	  to	  quantify	  mRNA	  levels	  in	  the	  nucleus.	  Similar	  to	  the	  primary	  transcripts,	  RNA	  levels	  were	  lower	  in	  quiescent,	  early	  and	  late	  G1	  cells	  and	  then	  increased	  in	  early	  S,	  G2	  and	  G2/M.	  Some	  differences	  were	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observed	   between	   the	   relative	   levels	   of	   primary	   transcripts	   and	   mRNA	   for	  individual	  genes	  (see	   for	  example	  Prcc	  and	  Mtx1	  transcript	   levels	   in	  Figure	  5.7	  and	   5.8).	   	   Overall,	   the	   results	   of	   the	   primary	   transcript	   analysis	   indicate	   that	  there	  is	  a	  large	  increase	  in	  transcription	  and	  mRNA	  production	  from	  the	  onset	  of	  S-­‐phase	  through	  G2.	  
	  
Figure	   5.8:	   Analysis	   of	   nuclear	   mRNA	   during	   cell	   cycle	   progression	   of	  
activated	  B	  cells.	  Nuclear	  RNA	  was	  extracted	  from	  cells	  collected	  in	  resting,	  early	  G1,	  late	  G1,	  early	  S	  phase,	  G2	  and	  G2/M	  B	  cells.	  Gene	  expression	  was	  calculated	  relative	   to	  a	  spike-­‐in	  RNA	  that	  was	  added	  to	  the	  nuclear	  lysate	  immediately	  after	  lysis	  (see	  Material	  and	  methods	  section	  2.10.2).	  Primers	   that	  recognize	  complementary	  sequences	  within	  the	  exon	  were	  used.	  B	  cell	  genes	  are	  shown	  separately	  due	  to	  their	  higher	  transcript	  levels.	  A)	  B	  cell	  genes	  primary	  transcripts.	  B)	  Primary	  transcripts	  of	  genes	  covering	  different	  cellular	  processes.	  n=4	  biological	  replicates	  for	  A	  and	  B.	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5.7 Xrn2	  binds	   to	  promoters	  of	   active	  genes	   in	   resting	  and	  G2	  
cells	  	  	   	  Data	  obtained	  from	  co-­‐IP	  and	  mass	  spectrometry	  and	  subsequent	  validation	  by	   western	   blotting	   showed	   interaction	   between	   Xrn2,	   Cnot3	   and	   Aurora	   B	  (Section	   4.6).	   After	   having	   shown	   binding	   of	   Cnot3	   and	   Aurora	   B	   to	   the	   same	  active	  gene	  promoters	  in	  resting	  B	  cells,	  I	  wanted	  to	  test	  whether	  Xrn2	  binds	  to	  these	  promoters.	  Xrn2	  is	  not	  only	  found	  at	  the	  3’	  end	  of	  the	  gene	  but	  also	  binds	  to	  the	  region	  around	  the	  transcription	  start	  site	  where	  it	  has	  been	  shown	  to	  have	  a	   role	   in	   premature	   termination	   of	   RNA	   Pol	   II	   transcription	   (Brannan	   et	   al.,	  2012).	  ChIP	   experiments	  were	   performed	  using	   an	   anti-­‐Xrn2	   antibody	   in	   resting	  B	  cells	  and	  in	  G2	  cells.	  Xrn2	  binding	  was	  observed	  on	  active	  promoters	  in	  resting	  and	  G2	  B	  cells	   (Figure	  5.9),	  but	   the	  binding	  showed	  some	  differences	   from	   the	  profile	   for	   Cnot3.	   The	   level	   of	   binding	   of	   Xrn2	   in	   resting	   and	   G2	   B	   cells	   was	  comparable	  whereas	  binding	  of	  Cnot3	  was	   lower	   in	  G2	  (Figure	  5.3).	  A	  possible	  explanation	   for	   this	  might	  be	   that	   the	   region	   that	   is	  bound	  by	  Cnot3	   is	   located	  more	   within	   the	   body	   of	   the	   gene	   in	   G2	   cells,	   while	   Xrn2	   binding	   might	   be	  localized	  to	  the	  promoter	  in	  both	  phases.	  If	  this	  is	  correct,	  it	  would	  suggest	  that	  Cnot3	   is	   associated	   with	   transcription	   elongation	   in	   G2	   cells	   while	   Xrn2	  continues	  to	  associate	  with	  the	  initiation	  pausing	  regions	  at	  the	  5’	  ends	  of	  genes	  (Figure	  5.9).	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Figure	  5.9:	  Xrn2	  binding	  to	  gene	  promoters	  in	  resting	  and	  G2	  B	  cells.	  ChIP	  with	  anti-­‐Cnot3	  antibody	  was	  carried	  out	  on	  chromatin	  from	  resting	  and	  G2	  B	  cells.	   The	   immunoprecipitated	  DNA	  was	   analysed	  by	  qRT-­‐PCR	  using	  primer	  pairs	  that	  amplify	  in	  the	  promoter	  region.	  Error	  bars	  represent	  standard	  deviation	  of	  the	  mean	  (n=3	  biological	  replicates).	  	  
5.8 Summary	  The	  data	  presented	  in	  this	  chapter	  demonstrates	  that	  binding	  of	  Cnot3	  to	  gene	  promoters	  is	  subject	  to	  cell	  cycle	  regulation.	  Cnot3	  co-­‐localises	  with	  Aurora	  B	  at	  some	  active	  gene	  promoters	   in	  resting	  B	  cells,	  but	  Cnot3	   is	  still	  able	   to	  bind	   to	  these	  promoters	   in	  the	  absence	  of	   the	  kinase.	  Binding	  of	  Cnot3	  to	  promoters	   is	  high	  in	  resting	  and	  G1	  B	  cells	  drops	  sharply	  during	  S-­‐phase	  and	  increases	  again	  in	  G2,	  although	   it	  does	  not	   reach	   the	  same	   levels	  as	   in	   resting	  cells.	  This	  effect	  might	  be	  due	  to	  a	  shift	  of	  Cnot3	  binding	  towards	  the	  body	  of	  the	  gene.	   	  Pcna	  is	  bound	   to	   active	   and	   inactive	   gene	   promoters	   in	   S-­‐phase	   cells,	   with	   binding	  reaching	   a	   maximum	   during	   early	   S	   phase.	   Analysis	   of	   primary	   unspliced	  transcripts	  and	  spliced	  nuclear	  mRNA	  showed	   that	   the	   level	  of	   transcription	   is	  similar	   in	   resting	   B	   cells	   and	   in	   early	   and	   late	   G1	   cells.	   Transcription	   rises	  sharply	   at	   the	   onset	   of	   S	   phase	   and	   is	   maintained	   through	   G2.	   Finally,	   it	   was	  shown	  that	  the	  5’-­‐3’	  RNA	  exonuclease,	  Xrn2,	  binds	  at	  similar	  levels	  to	  promoters	  of	   active	   genes	   in	   resting	   and	   G2	   B	   cells.
Active genes Silent genes
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Chapter	  6 -­	  Genome	  wide	  binding	  profiles	  of	  Cnot3	  
during	  cell	  cycle	  progression	  	  
	  
6.1 Introduction	  The	   ChIP	   experiments	   described	   in	   Chapter	   5	   revealed	   binding	   of	   Cnot3	   to	  gene	   promoters	   that	   is	   regulated	   during	   the	   cell	   cycle.	   However,	   conventional	  qRT-­‐PCR	   ChIP	   has	   limitations	   because	   it	   is	   only	   possible	   to	   analyse	   protein	  binding	   at	   few	   genes	   or	   specific	   genomic	   regions.	   Therefore,	   the	   analysis	   of	  binding	  to	  chromatin	  was	  extended	  genome	  wide	  using	  ChIP-­‐sequencing	  (ChIP-­‐seq).	   The	   technology	   for	   ChIP-­‐seq	   has	   developed	   significantly	   over	   the	   last	  decade	  and	  has	  replaced	   the	  ChIP	  on	  ChIP	  approach	  as	  a	  method	   for	  analysing	  factor	  binding	  across	  large	  genomic	  regions.	  In	  this	  chapter,	  I	  will	  describe	  ChIP-­‐seq	  analysis	  of	  Cnot3	  binding	  at	  several	  different	  stages	  of	  the	  cell	  cycle.	  	  	  
6.2 Genome	   wide	   binding	   of	   Cnot3	   to	   chromatin	   is	   cell	   cycle	  
regulated	  
	   ChIP-­‐seq	   analysis	   was	   performed	   on	   DNA	   samples	   recovered	   from	   resting,	  early	  and	  late	  G1,	  early	  S,	  G2	  and	  G2/M	  cells.	  ChIP	  experiments	  for	  Cnot3	  were	  carried	  out	  on	  these	  cell	  cycle	  stages	  and	  the	  recovered	  DNA	  was	  then	  sequenced	  on	   a	   next	   generation	   high	   throughput	   sequencer.	   The	   cells	   from	   different	   cell	  cycle	  stages	  were	  prepared	  using	  the	  methods	  described	  in	  Chapter	  3.	  Early	  G1	  cells	  were	  obtained	  by	  treating	  cells	  with	  anti-­‐IgM	  for	  20	  hours	  and	  late	  G1	  cells	  by	  treating	  these	  cells	  for	  a	  further	  6	  hours	  with	  LPS.	  Early	  S,	  G2	  and	  G2/M	  cells	  were	  generated	  by	  blocking	  the	  cells	  with	  apihidicolin	  and	  then	  harvesting	  them	  at	  30	  minutes,	  4	  hours	  and	  6	  hours	  respectively	  after	  washout	  of	  the	  drug	  (see	  Section	  3.2)	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Preparation	   of	   libraries	   for	   sequencing	   of	   ChIP	   DNA	   requires	   a	   starting	  material	  of	  10ng	  of	  ChIP	  DNA	  (see	  Section	  2.9.1).	  For	  most	  of	  the	  phases	  of	  the	  cell	   cycle,	   it	   was	   possible	   to	   obtain	   this	   amount	   of	   DNA.	   However,	   it	   was	   not	  possible	  to	  recover	  enough	  DNA	  for	  the	  mid-­‐late	  S	  phase.	  The	  results	  in	  Chapter	  5	  showed	  that	  the	  lowest	  binding	  of	  Cnot3	  to	  chromatin	  was	  during	  this	  stage	  of	  the	  cell	  cycle.	  	  The	   bioinformatic	   analysis	   of	   the	   ChIP-­‐seq	   data	   was	   carried	   out	   in	  collaboration	   with	   Dr.	   Gopuraja	   Dharmalingam	   and	   Dr.	   Thomas	   Carroll	   (CSC	  Core	   Bioinformatics	   Facility).	   ChIP-­‐seq	   tracks	   for	   each	   cell	   cycle	   phase	   were	  normalized	   to	   the	   total	   sequencing	   depth	   of	   the	   sample.	   Figure	   6.1	   shows	   the	  ChIP-­‐seq	  tracks	  for	  four	  active	  genes	  (Pmf1	  and	  Mtx1,	  Cd83	  and	  Cd37).	  Additional	  tracks	  are	  shown	  in	  the	  Appendix	  (Figure	  B).	  Binding	  of	  Cnot3	  to	  active	  genes	  is	  detected	  mainly	  at	  the	  promoters.	  However,	  the	  protein	  was	  also	  detected	  at	  the	  3’end	  of	  Pmf1	  and	  Cd37	  (Figure	  6.1).	  This	  observation	  suggests	  that	  Cnot3	  might	  participate	   in	   mRNA	   3’end	   formation	   and	   transcriptional	   termination.	  Comparison	   of	   the	   results	   obtained	   from	   the	   ChIP-­‐seq	   analysis	   for	   Pmf1	   and	  
Mtx1	  with	   the	   results	   from	   the	   qRT-­‐PCR	   ChIP	   of	   the	   same	   genes	   (Section	   5.4,	  Figure	   5.3)	   shows	   a	   strong	   similarity	   in	   the	   relative	   levels	   of	   bound	   Cnot3	  measured	   at	   each	   the	   different	   cell	   cycle	   stages	   using	   the	   two	   methods.	   The	  binding	  of	  Cnot3	  was	  high	   in	  resting	  B	  cells,	  decreased	  gradually	   through	  early	  and	  late	  G1	  to	  a	  low	  level	  in	  early	  S	  phase	  and	  increased	  again	  in	  G2	  and	  G2/M.	  Broadly	  similar	  binding	  profiles	  were	  observed	  for	  the	  B	  cell-­‐specific	  genes	  Cd83	  and	  Cd37	   (Figure	  6.1),	  although	   the	  decrease	   in	  binding	  was	  more	  pronounced	  during	  activation	  in	  early	  and	  late	  G1.	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Figure	   6.1:	   ChIP-­seq	   analysis	   of	   Cnot3	   binding	   at	   different	   stages	   of	   the	   cell	  
cycle	  during	  B	  cell	  activation.	  Snapshots	  are	  shown	  of	  Cnot3	  binding	  across	  four	  genes.	  The	  tracks	  show	  binding	  profiles	  in	  resting,	  early	  and	  late	  G1,	  early	  S,	  G2	  and	  G2/M	  B	  cells.	  In	  A	  are	  reported	  
Pmf1	  and	  Mtx1.	   In	  B	  are	  reported	  Cd37	  and	  Cd83.	  The	  FPKM	  values	  in	  resting	  and	  G1	   elutriated	   LPS	   activated	   B	   cells	   are	   shown.	   FPKM	   values	   report	   the	   gene	  expression	  levels.	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6.3 The	  binding	  profile	  of	  Cnot3	  at	  the	  TSS	  changes	  during	  cell	  
cycle	  To	   gain	   additional	   information	   on	   the	   role	   of	   Cnot3	   in	   gene	   regulation,	   the	  area	   around	   the	   TSS	   was	   analysed	   in	   more	   detail.	   Heat	   maps	   showing	   Cnot3	  binding	  were	  generated	  for	  all	  of	  the	  cell	  cycle	  stages	  covering	  the	  area	  upstream	  and	  downstream	  from	  the	  TSS	  of	  14,788	  genes	  that	  are	  transcribed	  in	  resting	  B	  cells.	   The	   list	   of	   genes	  was	   generated	   based	   on	   RNA-­‐seq	   data	   generated	   by	   A.	  Frangini.	   Genes	   were	   judged	   to	   be	   transcribed	   if	   their	   expression	   exceeded	   a	  threshold	   FPKM	   of	   0.118.	   Genes	   were	   ranked	   in	   the	   heat	   map	   according	   to	  decreasing	   Cnot3	   binding.	   Initally,	   the	   area	   of	   the	   TSS	   from	   +3kb	   to	   -­‐3kb	  was	  plotted.	  The	  overall	  binding	  pattern	  is	  generally	  similar	  to	  the	  patterns	  observed	  at	   individual	   genes	   with	   high	   levels	   of	   binding	   detected	   in	   resting	   B	   cells,	  decreased	  binding	  through	  early	  and	  late	  G1,	  low	  levels	  in	  early	  S	  phase	  and	  then	  increased	  binding	  in	  G2	  and	  G2/M	  (Figure	  6.2-­‐A).	  	  To	  analyse	  Cnot3	  binding	  in	  more	  detail,	  the	  area	  that	  was	  studied	  around	  the	  TSS	  was	  reduced	  to	  +1kb	  to	  -­‐1kb.	  In	  order	  to	  have	  a	  quantitative	  chart	  of	  binding,	  line	   plots	   of	   the	   average	   Cnot3	   binding	   across	   the	   TSS	   regions	   of	   the	   14,788	  genes	   were	   generated.	   The	   line	   plots	   revealed	   a	   change	   in	   both	   intensity	   and	  shape	   of	   average	   Cnot3	   binding	   profiles	   during	   cell	   cycle	   progression	   (Figure	  6.2B).	  In	  resting	  early	  and	  late	  G1	  B	  cells,	  there	  was	  a	  peak	  of	  Cnot3	  binding	  was	  centred	   upstream	   the	   TSS.	   The	   peaks	   have	   the	   same	   shape	   at	   all	   three	   stages,	  albeit	  with	   reduced	   binding	   levels	   in	   early	   and	   late	   G1.	   The	  minimum	  binding	  was	   detected	   in	   early	   S	   phase,	   but	   the	   shape	   of	   the	   peak	   was	   similar	   to	   the	  previous	  phases.	  Plotting	  Cnot3	  average	  binding	  in	  resting	  and	  G2	  B	  cells	  in	  the	  same	  chart,	  the	  shape	  of	  the	  curve	  was	  different	  in	  the	  two	  stages	  (Figure	  6.2B).	  The	   binding	   of	   Cnot3	   in	   resting	   cells	   was	   a	   sharp	   peak	   with	   a	   maximum	  upstream	  the	  TSS.	  In	  G2	  the	  peak	  was	  not	  as	  sharp	  as	  in	  resting	  B	  cells	  and	  was	  more	  spread	  along	  the	  body	  of	  the	  gene.	  The	  height	  of	  the	  peak	  was	  slightly	  less	  in	   G2.	   This	   could	   be	   due	   to	   the	   fact	   that	   the	   gene	   cohort	   that	   was	   analysed	  represented	  genes	  that	  are	  expressed	  in	  resting	  B	  cells	  and	  some	  of	  these	  genes	  might	  be	  switched	  off	  in	  G2	  cells.	  G2/M	  cells	  had	  a	  very	  similar	  average	  profile	  to	  the	  one	  that	  was	  observed	  in	  G2.	  (Figure	  6.2B).	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Figure	  6.2:	  Cnot3	  binding	  around	  the	  TSS	  during	  cell	  cycle	  progression.	  A)	   Heat	   maps	   showing	   the	   area	   of	   the	   TSS	   from	   +3kb	   to	   -­‐3kb	   for	   14,788	   genes	  during	   cell	   cycle	   progression.	   The	   genes	   were	   shown	   by	   RNAseq	   analysis	   to	   be	  expressed	  in	  resting	  B	  cells	  and	  were	  ranked	  based	  on	  decreasing	  binding	  of	  Cnot3	  to	  the	  region	  analysed	  (see	  Materials	  and	  Methods,	  Section	  2.9.3).	  The	  colour	  scale	  settings	  used	  to	  generate	  the	  heat	  maps	  were	  kept	  at	  the	  same	  settings	  for	  each	  cell	  cycle	  phase.	  B)	  Line	  plots	  were	  generated	  by	  calculating	  the	  average	  binding	  of	  Cnot3	  to	  the	  set	  of	  genes	  as	  in	  A,	  using	  a	  window	  of	  2kb	  around	  the	  TSS.	  The	  resting	  B	  cell	  plot	  was	  compared	  to	  the	  other	  phases.	  The	  bottom	  right	  panel	  shows	  the	  plots	  for	  all	  of	  the	  cell	  cycle	  stages	  that	  were	  analysed.	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6.4 Comparison	   of	   peaks	   of	   Cnot3	   binding	   during	   cell	   cycle	  
progression	  
	   In	   order	   to	   compare	   the	   overall	   distribution	   of	   Cnot3	   binding	   at	   different	  stages	   of	   the	   cell	   cycle,	   peak	   calling	   was	   carried	   out	   for	   each	   cell	   cycle	   phase	  using	   the	   Model-­‐based	   Analysis	   for	   ChIP-­‐seq	   (MACS2)	   programme,	   (see	  Materials	  and	  Methods	  section	  2.9.2).	  The	  highest	  number	  of	  peaks	  (51,964)	  was	  found	  in	  resting	  B	  cells.	  Approximately	  half	  of	  that	  number	  was	  present	  early	  and	  late	  G1	   (25,591	   and	  23,636	   respectively).	   In	   early	   S	   phase,	   13,223	  peaks	  were	  detected.	   The	   number	   increased	   again	   in	   G2	   with	   33,208	   and	   in	   G2/M	   with	  32,452	  peaks	  identified	  (Table	  6.3).	  	  	  	  
	  	  
Number	  of	  peaks	  
Resting	   51,964	  
Early	  G1	   25,591	  
Late	  G1	   23,636	  
Early	  S	  	   13,223	  
G2	   33,208	  
G2/M	   32,452	  	  
Table	  6.3:	  Number	  of	  peaks	  of	  Cnot3	  binding	  called	  for	  each	  cell	  cycle	  phase.	  The	  peak	  calling	  analysis	  was	  carried	  out	  using	  Model-­‐based	  Analysis	  for	  ChIP-­‐seq	  (MACS2).	  	  	  Analaysis	  of	  the	  distribution	  of	  the	  peaks	  was	  performed	  using	  the	  Chipseeker	  Bioconductor	  package.	  Figure	  6.4	  shows	  the	  proportion	  of	   the	   total	  peak	  count	  that	  was	  located	  in	  different	  regions	  of	  the	  genome	  during	  cell	  cycle	  progression.	  	  In	   resting	  B	   cells	   around	  23%	  of	   the	   total	  Cnot3	  peaks	  were	   in	   the	  area	  of	   the	  promoter	  less	  than	  1	  kb	  upstream	  from	  the	  TSS.	  The	  distal	  part	  of	  the	  promoter	  from	   -­‐1	   to	   -­‐3kb	   is	   not	   particularly	   enriched	   in	  peaks.	   The	   introns	   (1st	   intron	  +	  other	  introns)	  and	  the	  distal	  intergenic	  regions	  together	  constitute	  around	  60%	  of	  the	  total	  (Figure	  6.4).	  In	  early	  and	  late	  G1	  and	  early	  S,	  as	  the	  overall	  number	  of	  Cnot3	  drops,	  the	  proportion	  that	  are	  present	  in	  the	  area	  of	  the	  promoter	  near	  the	  TSS	   increases.	   In	   these	   cell	   cycle	   phases	   Cnot3	   peaks	   located	   within	   the	   -­‐1kb	  region	  upstream	  from	  the	  TSS	  represent	  around	  40%	  of	  total	  peaks	  in	  early	  and	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late	  G1.	  The	  percentage	  of	  peaks	  within	  -­‐1	  kb	  of	  the	  TSS	  is	  around	  50%	  of	  total	  peaks	  in	  early	  S.	  From	  resting	  to	  early	  S	  the	  proportion	  of	  peaks	  that	  are	  located	  whithin	   introns	   shows	   a	   sharp	   decrease.	   The	   percentage	   goes	   from	   32%	   in	  resting	  to	  17%	  in	  early	  S.	  In	  the	  distal	  intergenic	  regions	  there	  is	  slight	  drop,	  the	  percentage	  of	  28%	  of	  total	  peaks	  decreases	  to	  22%	  in	  early	  S	  phase	  (Figure	  6.4).	  In	  G2	  this	  trend	  is	  reversed	  with	  around	  50%	  of	  Cnot3	  peaks	  residing	  in	  introns	  and	   distal	   intergenic	   regions,	   while	   around	   35%	   are	   present	   within	   -­‐1kb	  upstream	  from	  the	  promoter	  (Figure	  6.4).	  	  	  
	  	  
Figure	  6.4.	  Distribution	  of	  Cnot3	  binding	  peaks	  during	  cell	  cycle	  progression.	  A)	  The	  chart	  shows	  the	  distribution	  of	  called	  Cnot3	  peaks	  in	  six	  different	  cell	  cycle	  phases.	  The	  colour	  key	  for	  the	  segments	  of	  each	  bar	  is	  shown	  on	  the	  right.	  The	  area	  of	  each	  segment	   is	  proportional	   to	  the	  number	  of	  peaks	  detected	   in	  that	  region	  of	  the	  genome.	  B)	  The	  table	  shows	  the	  number	  of	  peaks	  that	  were	  called	  in	  each	  cell	  cycle	  phase	  for	  the	  region	  within	  -­‐1kb	  upstream	  from	  the	  TSS,	  in	  the	  introns	  and	  in	  the	  distal	  intergenic	  regions.	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It	  is	  important	  to	  note	  that	  Figure	  6.4	  represents	  the	  relative	  abundance	  of	  peaks	  in	   different	   regions	   of	   the	   genomes.	   Since	   the	   overall	   number	   of	   peaks	   drops	  sharply	   in	   G1	   and	   S-­‐phase,	   the	   percentage	   between	   40%	   and	   50%	   of	   peaks	  within	  -­‐1kb	  region	  upstream	  from	  the	  TSS	  in	  early	  and	  late	  G1	  and	  early	  S	  phase	  is	   not	   due	   to	   gain	   of	   peaks	   on	   promoters,	   but	   is	   instead	   caused	   by	   a	   more	  pronounced	  loss	  of	  peaks	  in	  distal	   intergenic	  regions	  and	  introns	  (see	  numbers	  in	   Figure	   6.4B	   and	   ChIP-­‐seq	   snapshots	   in	   Figure	   6.5).	   During	   G2	   and	   G2/M	   a	  higher	  percentage	  of	  peaks	  are	  observed	  at	   the	  region	   -­‐1kb	  upstream	  from	  the	  TSS	  compared	  to	  resting.	  However,	  the	  absolute	  number	  of	  peaks	  is	  very	  similar	  (Figure	  6.4	  B).	  The	  percentage	   is	   higher	   in	  G2	   and	  G2/M	  because	   the	   absolute	  number	   of	   peaks	   decreases	   in	   distal	   enhancer	   elements	   and	   within	   introns	  (Figure	  6.4	  B).	  Therefore,	   the	  proportion	  of	  peaks	   in	   the	  region	   -­‐1kb	  upstream	  from	   the	   TSS	   in	   G2	   and	  G2/M	   is	   higher	   because	   there	   is	   a	   loss	   in	   introns	   and	  distal	  regions.	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Figure	   6.5.	   ChIP-­seq	   analysis	   of	   Cnot3	   binding	   at	   different	   stages	   of	   the	   cell	  
cycle	  during	  B	  cell	  activation	  on	  enhancer	  regions.	  Snapshots	   show	  ChIP-­‐seq	   tracks	  of	  Cnot3	  binding	  on	  enhancer	   regions	   in	   resting,	  early	   and	   late	  G1,	   early	  S,	  G2	  and	  G2/M.	  The	   top	  panel	   shows	   the	  enhancer	  30kb	  upstream	  from	  Jak1.	  The	  bottom	  panel	  shows	  the	  enhancer	  region	  in	  the	  intron	  2	  of	  the	   Ppp1r16b	   gene.	   FPKM	   values	   shown	   in	   each	   panel	   represent	   the	   expression	  levels	   of	   the	   genes	   in	   resting	  B	   cells	   and	  G1	  B	   cells	  purified	  by	   elutriation	  3	  days	  after	   activation	   with	   LPS.	   The	   RNA-­‐seq	   data	   was	   generated	   by	   A.	   Frangini.	  Enhancers	  coordinates	  were	  taken	  from	  (Kieffer-­‐Kwon	  et	  al.,	  2013).	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6.5 Summary	  	  In	   this	   chapter,	   I	   have	   described	   the	   genome	   wide	   binding	   of	   Cnot3	   to	  chromatin	  during	   cell	   cycle	  progression.	  The	  genome	  wide	  binding	  of	  Cnot3	  at	  gene	  promoters	  varies	  during	  the	  cell	  cycle.	  The	  analysis	  of	   the	  region	  -­‐	  1kb	  to	  +1kb	   from	   the	   TSS	   has	   revealed	   differences	   during	   cell	   cycle	   progression.	   The	  average	   binding	   of	   Cnot3	   on	   expressed	   genes	   shows	   a	   peak	   that	   decreases	   in	  intensity	   from	  resting	   to	   early	   S	  phase.	   In	  G2	   the	  peak	   is	   similar	   to	   resting	   for	  intensity	  but	   the	  shape	  of	   the	  curve	   is	  different,	  meaning	   that	  Cnot3	  binding	   is	  shifted	  towards	  the	  body	  of	  the	  gene.	  The	  peaks	  are	  enriched	  in	  the	  region	  of	  the	  TSS	  and	  distal	  regions	   in	  resting	  B	  cells.	   In	  early	  and	  late	  G1	  and	  early	  S,	  when	  the	  overall	  number	  of	  Cnot3	  peaks	  is	  reduced	  compared	  to	  resting	  B	  cells,	  peaks	  are	   retained	   at	   promoters	   but	   the	   number	   of	   peaks	   in	   intronic	   and	   distal	  intergenic	  regions	  is	  sharply	  reduced.	  During	  G2	  and	  G2/M	  a	  higher	  proportion	  of	   peaks	   are	   found	   in	   introns	   and	  distal	   intergenic	   regions	   than	  on	  promoters.	  	  Overall	   the	   results	   suggest	   that	   significant	   changes	   in	   the	   location	   of	   Cnot3	  binding	   take	   place	   during	   cell	   cycle	   progression.	   	   These	   results	   could	   reflect	  global	  changes	  in	  the	  functioning	  of	  distal	  enhancers	  at	  different	  stages	  of	  the	  cell	  cycle.	  
	   132	  
Chapter	  7 -­	  Design	  and	  generation	  of	  Cnot3	  conditional	  
knock	  out	  mouse	  
	  
7.1 Introduction	  The	   results	   presented	   in	   the	   previous	   chapters	   described	   the	   behaviour	   of	  Cnot3	   during	   the	   cell	   cycle	   in	   B	   cells.	   However,	   it	  was	   not	   possible	   to	   directly	  probe	   the	   functional	   role	   of	   Cnot3	   in	   gene	   regulation	   using	   siRNA	   or	   shRNA	  approaches	   to	   deplete	   the	   protein.	   Primary	   B	   cells	   have	   many	   advantages	  because	  they	  are	  non-­‐transformed	  cells	  that	  can	  be	  readily	  isolated	  and	  cultured.	  However	   genetic	   studies	   are	   difficult	   to	   perform	   in	   these	   cells	   because	   they	  cannot	   be	   easily	   transfected	   or	   infected	  with	   retroviruses.	   The	   solution	   to	   this	  problem	   was	   to	   generate	   a	   conditional	   Cnot3	   knockout	   mouse	   to	   study	   the	  effects	  of	  knocking	  down	  the	  protein.	  Germline	  Cnot3	  knockout	  mice	  have	  been	  described	   in	   literature,	   but	   the	   homozygous	   knockout	   animals	   are	   embryonic	  lethal	  at	  the	  implantation	  stage	  (Neely	  et	  al.,	  2010).	  The	  design	  and	  production	  of	  a	  conditional	  Cnot3	  knockout	  mouse	  using	  TALEN	  targeting	  will	  be	  described	  in	  this	  chapter.	  	  	  	  
7.2 TALEN	  targeting	  of	  the	  Cnot3	  gene	  	  TALEN	   targeting	   is	   based	  on	   the	  principle	   that	   the	   introduction	   of	   a	   double	  strand	   (DS)	  break	   leads	   to	   repair	  of	   the	  break,	  either	  by	  non-­‐homologous	  end-­‐joining	  (NHEJ)	  or,	  alternatively,	  by	  homologous	  recombination	  (HR)	  if	  a	  suitable	  target	  sequence	  is	  available.	  Efficient	  introduction	  of	  a	  DS	  break	  results	  in	  HR	  at	  an	  efficiency	  that	  is	  much	  higher	  than	  the	  levels	  achieved	  by	  conventional	  gene	  targeting	  methods	   in	   ES	   cells.	   One	   of	   the	   systems	   that	   has	   been	  developed	   for	  efficient	   introduction	   of	   DS	   breaks	   at	   specific	   sites	   uses	   the	   transcription	  activator	  like	  effector	  nucleases	  (TALENs).	  TALENs	  consist	  of	  synthetic	  arrays	  of	  TAL	   effectors,	   which	   were	   discovered	   in	   plants	   as	   products	   of	   the	   pathogenic	  bacteria	   Xanthomonas.	   They	   are	   DNA	   binding	   proteins	   able	   to	   promote	  transcription	  in	  host	  organisms	  (Bogdanove	  et	  al.,	  2010).	  TAL	  effectors	  contain	  a	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DNA	  binding	  domain	  that	  is	  formed	  by	  repeat-­‐variable	  di-­‐residue	  (RVD)	  repeats.	  Each	  RVD	  is	  able	  to	  bind	  to	  a	  specific	  nucleotide	  in	  the	  DNA	  sequence.	  In	  TALEN	  targeting	   the	  RVD	  repeats	   are	  arranged	   in	  a	   specific	  order	   that	   allows	   them	   to	  target	   the	  desired	  sequence.	  The	  TAL	  effectors	  have	  been	  modified	  by	   fusing	  a	  FokI	  endonuclease	  at	   the	  C-­‐terminal	  of	   the	  TAL	  sequence.	   In	  order	  to	  be	  active	  and	  generate	  a	  cut,	  FokI	  needs	  to	  dimerize.	  Two	  TAL	  effectors	  recognize	  opposite	  strands	   on	   DNA	   target	   sequences	   to	   promote	   FokI	   dimerization.	   The	   active	  nuclease	   is	   therefore	   able	   to	   cause	   a	   double	   strand	   break	   that	   can	   be	   used	   to	  promote	  efficient	  homologous	  recombination	  (Figure	  7.1).	  	  	  
	  	  
Figure	  7.1:	  TALEN	  targeting.	  A)	  TAL	  effector	  composed	  of	  N	  terminal	  domain,	  a	  central	  DNA	  binding	  domain	  and	  a	  C	  terminal	  domain	  with	  the	  NLS	  signal.	  The	  DNA	  binding	  domain	  is	  composed	  by	  RVDs.	   Each	   RVD	   recognizes	   a	   nucleotide.	   B)	   TALEN	   dimer	   of	   single	   TAL	   effectors	  fused	  to	  FokI	  monomers	  (adapted	  from	  (Cermak	  et	  al.,	  2011)).	  	  	  	  	   We	  have	  developed	  a	  strategy	  to	  generate	  a	  mouse	  conditional	  knockout	   for	  Cnot3.	   The	   design	   of	   the	  TALEN	  plasmids	   and	   the	   experimental	   procedures	   to	  generate	  them	  were	  carried	  out	  in	  collaboration	  with	  Dr.	  Mónica	  Román	  Trufero.	  The	  TALEN	   targeting	  was	  used	   to	   insert	   two	  LoxP	   sequences	  within	   the	  Cnot3	  gene.	  In	  order	  to	  insert	  LoxP	  sequences	  into	  the	  genome	  with	  as	  little	  disruption	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ofthe	  gene	  as	  possible,	  promoters	  and	  5’UTR	  regions	  should	  be	  avoided	  and	  the	  distance	   from	   intron-­‐exon	   junctions	  must	  be	  at	   least	  200	  bp.	  For	   the	  design	  of	  the	   DNA	   binding	   domain	   of	   the	   TALEN	   sequence,	   we	   took	   advantage	   of	   free	  software	  designed	  by	  Cermak	  et	  al.	  (TAL	  Effector	  Nucleotide	  Targeter	  2.0;	  TALE-­‐NT)	  (Cermak	  et	  al.,	  2011).	  The	  software	  predicts	  the	  sequence	  of	  the	  TALEN	  that	  is	  needed	  to	  generate	  a	  double	  strand	  break	  in	  a	  desired	  position.	  Two	  pairs	  of	  TALEN	  were	  designed	  to	  induce	  double	  strand	  breaks	  in	  intron	  1	  and	  7.	  The	  first	  LoxP	  sequence	  was	  inserted	  into	  intron	  1	  of	  the	  Cnot3	  gene	  and	  the	  second	  one	  in	   intron	   7	   (see	   Materials	   and	   Methods	   section	   2.11.1).	   The	   two	   targeting	  constructs	  that	  contained	  300bp	  of	  homology	  on	  each	  side	  of	  the	  cut	  site.	  After	  Cre	  recombination,	  this	  strategy	  will	  allow	  the	  deletion	  of	  6	  exons	  (Figure	  7.2).	  	  	  
	  	  
Figure	  7.2:	  Strategy	  to	  flox	  Cnot3	  gene.	  TALENs	   were	   designed	   to	   generate	   cuts	   in	   introns	   1	   and	   7	   of	   Cnot3	   gene.	   Targeting	  constructs	  containing	  the	  LoxP	  sequences	  carried	  300	  bp	  of	  homology	  arms	  on	  each	  side	  of	  the	  cut	  site.	  	  	  	  
7.3 Testing	  of	  the	  TALEN	  constructs	  in	  ES	  cells	  	  	   The	  aim	  of	  the	  TALEN	  targeting	  was	  to	  edit	  the	  genome	  in	  the	  zygote	  in	  order	  to	   transmit	   the	   floxed	   gene	   to	   the	   whole	  mouse.	   To	   test	   the	   efficiency	   of	   this	  approach,	   we	   decided	   to	   apply	   this	   genome	   editing	   technique	   to	   ES	   cells.	   To	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perform	   the	   test,	   the	   editing	   of	   the	   exon	   1	   was	   carried	   out.	   The	   targeting	  construct	  contained	  300	  bp	  of	  homology	  with	  the	  endogenous	  sequence	  on	  both	  sides	  of	   the	   cut	   site.	  The	   construct	   also	   contained	  a	  Neomycin	   resistance	  gene,	  under	   the	   control	   of	   the	   Pgk	   promoter,	  which	  was	   used	   to	   perform	   a	   positive	  selection	  on	  the	  cells.	  To	  carry	  out	  this	  experiment,	  ES	  cells	  were	  electroporated	  with	   two	   circular	   plasmids	   expressing	   TALENs	   and	   a	   linearized	   targeting	  construct	   to	   replace	   the	   genomic	   sequence.	   A	   separate	   ES	   cell	   plate	   was	  electroporated	   with	   only	   the	   targeting	   construct.	   After	   the	   electroporation,	   a	  selection	  was	  performed	  by	  culturing	  cells	  in	  medium	  containing	  neomycin.	  Only	  cells	  with	  the	  targeting	  construct	   integrated	   in	  the	  genome	  would	  survive	  after	  this	   selection.	   Cells	  were	   stained	  with	   crystal	   violet	   to	   visualize	   the	  number	  of	  neomycin	   resistant	   colonies.	  Figure	  7.3	   shows	   that	   the	  number	  of	   cells	  alive	   in	  the	  plate	  electroporated	  with	  TALENs	  and	  the	  targeting	  construct	  is	  much	  higher	  than	   the	  one	   for	   the	  plate	   that	  was	  electroporated	  with	   the	   targeting	  construct	  only	   (Figure	   7.3).	   The	   much	   higher	   frequency	   obtained	   when	   the	   TALEN	   is	  included	  indicated	  that	  it	  was	  promoting	  a	  specific	  integration	  event,	  which	  was	  presumed	  to	  be	  homologous	  recombination	  at	  the	  DS	  break.	  The	  small	  number	  of	  colonies	  obtained	  without	  the	  TALEN	  would	  be	  the	  result	  of	  random	  integration	  of	   the	   construct,	   which	  would	   be	  much	   less	   efficient.	   Successful	   targeting	  was	  also	  achieved	  in	  ES	  cells	  with	  the	  other	  TALEN	  pair	  (data	  not	  shown).	  	  	  
	  
Figure	  7.3:	  Crystal	  violet	  staining	  of	  ES	  cells	  after	  neomycin	  selection.	  ES	  cells	  were	  electroporated	  either	  with	  TALEN	  and	  targeting	  construct	  for	  intron	  1	  or	  with	  the	  targeting	  construct	  only.	  Neomycin	  selection	  was	  carried	  out	  for	  one	  week	  and	  crystal	  violet	  staining	  was	  used	   to	  compare	   the	  number	  of	   live	  cells	  on	  the	  two	  plates.	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7.4 Generation	  of	  Cnot3	  conditional	  knockout	  mouse	  The	  positive	  result	  obtained	  in	  ES	  cells	  demonstrated	  the	  high	  efficiency	  of	  the	  TALEN	   targeting.	   We	   applied	   this	   technology	   to	   generate	   a	   Cnot3	   conditional	  knockout	   mouse.	   To	   achieve	   this	   purpose,	   fertilized	   eggs	   were	   micro-­‐injected	  with	   RNA	   molecules	   coding	   for	   TALEN	   proteins	   and	   the	   DNA	   targeting	  constructs.	  The	  zygote	  would	  have	  a	  transient	  expression	  of	  TALENs	  in	  order	  to	  promote	  the	  recombination	  with	  the	  targeting	  constructs.	  The	  editing	  generated	  in	   the	   one	   cell	   stage	   would	   be	   propagated	   to	   every	   cell	   in	   the	   mouse.	   The	  fertilised	   eggs	   were	   generated	   in	   a	   background	   of	   CRE-­‐ERT2	   under	   the	  constitutive	   expression	   of	   the	  Rosa	  26	  promoter.	   The	   oocyte	   injections	   and	   all	  accompanying	   manipulations	   were	   carried	   out	   by	   the	   MRC	   CSC	   Transgenic	  Facility.	  A	   total	   of	   21	  mice	  were	   generated	   from	   the	   oocyte	   injections	   of	  which	   two	  were	  heterozygous	  for	  the	  two	  LoxP	  sites	  (Figure	  7.4A).	  	  One	  of	  these	  mice	  was	  bred	  successfully	  and	  gave	  the	  expected	  Mendellian	  level	  of	  transmission	  of	  the	  floxed	   allele	   (Figure	   7.4B).	  Work	   is	   currently	   in	   progress	   to	   breed	   the	   line	   to	  homozygosity	   and	   to	   generate	   enough	   mice	   to	   carry	   out	   experiments.	   The	  TALEN	   RNAs	   and	   targeting	   constructs	   are	   also	   being	   re-­‐injected	   to	   obtain	   a	  second	  mouse	  line,	  which	  will	  be	  used	  to	  verify	  important	  results	  obtained	  with	  the	  first	  targeted	  line	  and	  exclude	  any	  contribution	  from	  off-­‐target	  mutations.	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Figure	  7.4:	  Genotyping	  of	  the	  Cnot3	  gene.	  





	   This	  chapter	  describes	  the	  strategy	  for	  the	  production	  of	  a	  Cnot3	  conditional	  knockout	   mouse.	   TALEN	   targeting	   was	   used	   to	   generate	   two	   cuts	   in	   specific	  positions	   in	   the	   intron	   1	   and	   7.	   This	   allowed	   a	   homologous	   recombination	  process	  for	  the	  insertion	  of	  two	  LoxP	  sites	  at	  these	  positions.	  The	  intron	  1	  TALEN	  was	  tested	  in	  ES	  cells	  showing	  a	  high	  efficiency	  of	  targeting	  construct	  integration	  in	  the	  genome.	  TALEN	  RNAs	  with	  two	  targeting	  constructs	  were	  micro-­‐injected	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to	   fertilised	   mouse	   eggs.	   The	   micro-­‐injection	   experiment	   gave	   rise	   to	   of	   2	  targeted	  mice	  out	  of	  21	  animals	  generated.	  The	  progeny	  of	  one	  of	  these	  two	  mice	  has	  been	  bred	  successfully	   to	  generate	  heterozygous	  offspring.	  Work	   is	  now	   in	  progress	  to	  breed	  these	  mice	  to	  generate	  homozygous	  floxed	  Cnot3	  mice.	  	  	  	  	  	  	  	  Note:	   The	   design	   and	   generation	   of	   TALEN	   plasmids	   has	   been	   carried	   out	   in	  collaboration	   with	   Dr.	   Mónica	   Román	   Trufero.	   The	   ES	   cell	   transfections	   and	  mouse	  breeding	  were	   carried	  out	  by	  Dr.	  Román	  Trufero.	  The	  oocyte	   injections	  and	   all	   associated	  manipulations	  were	   performed	   by	   the	  MRC	   CSC	   Transgenic	  Facility.	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Chapter	  8 -­	  Discussion	  	  
8.1 Overview	  The	   overall	   theme	   of	   this	   thesis	   has	   been	   the	   behaviour	   of	   nuclear	   Cnot3	  during	  cell	  cycle	  progression.	  Although	  the	  protein	  is	  present	  in	  the	  nucleus	  and	  in	   the	   cytoplasm,	   my	   analysis	   of	   Cnot3	   has	   been	   focused	   on	   the	   nuclear	  compartment.	   The	   importance	   of	   studying	   the	   role	   of	   Cnot3	   in	   transcriptional	  and	  post-­‐transcriptional	  regulation	  has	  been	  highlighted	  by	  recent	  studies.	  Cnot3	  was	  shown	  to	  be	  a	  tumor	  suppressor	  in	  T-­‐cell	  acute	  lymphoblastic	  leukaemia	  (De	  Keersmaecker	   et	   al.,	   2013).	   It	   has	   also	   been	   implicated	   in	   a	   number	   of	   other	  human	   pathologies,	   including	   osteoporosis	   (Watanabe	   et	   al.,	   2014),	   obesity	  (Morita	   et	   al.,	   2011),	   impaired	   heart	   function	   (Neely	   et	   al.,	   2010)	   and	   retinitis	  pigmentosa	  (Venturini	  et	  al.,	  2012).	  	  Cnot3	   is	   part	   of	   the	   CCR4-­‐NOT	   complex	   and	   is	   required	   for	   stability	   of	   the	  complex	   (Boland	   et	   al.,	   2013).	   This	  means	   that	   Cnot3	  has	   a	  major	   role	   in	  RNA	  degradation	   (Watanabe	   et	   al.,	   2014)	   (Morita	   et	   al.,	   2011).	   The	   co-­‐IP	   and	  mass	  spectrometry	  data	  described	   in	   this	   thesis	  have	  confirmed	   that	  Cnot3	   interacts	  with	   other	   Cnot	   proteins	   (Cnot1,	   Cnot2,	   Cnot6,	   Cnot6L,	   Cnot7,	   Cnot8,	   Cnot10,	  Cnot11)	  in	  B	  cells.	  Although	  CCR4-­‐NOT	  is	   involved	  in	  RNA	  metabolism,	  none	  of	  the	   subunits	  of	   the	   complex	  has	   an	  RNA	  binding	  motif.	  This	   could	  be	  part	  of	   a	  mechanism	  to	  target	   the	  deadenylase	  activity	  to	  specific	  mRNA	  targets.	   Instead	  of	  binding	  RNA	  directly,	  the	  complex	  requires	  RNA	  binding	  proteins,	  such	  as	  TTP	  (Lykke-­‐Andersen	  and	  Wagner,	  2005),	  to	  be	  recruited	  to	  the	  3’	  end	  of	  mRNAs.	  	  Cnot3	  contains	  a	  NOT-­‐box	  domain	  in	  the	  C-­‐terminal	  region	  which	  is	  involved	  in	  interactions	  with	  other	  proteins	  (Figure	  8.1).	  The	  NOT-­‐box	  has	  been	  shown	  to	  be	  responsible	  for	  the	  interactions	  with	  different	  proteins,	  such	  as	  Cnot2	  (Boland	  et	  al.,	  2013),	  TBP-­‐interacting	  protein	  B	  (TIP120B)	  (Aoki	  et	  al.,	  2002),	  Aurora	  B.	  NOT-­‐box	   proteins	   were	   first	   described	   in	   yeast	   as	   negative	   regulators	   of	  transcription	   (Collart	   and	   Struhl,	   1994).	   Furthermore,	   a	   study	   in	   human	   cells	  reported	   that	   the	   NOT-­‐box	   domain	   of	   CNOT2	   and	   CNOT3	   negatively	   affected	  transcription	   in	   a	   luciferase	   reporter	   assay.	   However,	   the	   same	   study	   also	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showed	   that	   the	   full	   length	   CNOT3	   protein	   did	   not	   have	   any	   repressive	   effect	  (Zwartjes	  et	  al.,	  2004).	  	  	  
	  	  
Figure	   8.1:	   Schematic	   representation	   of	   the	   domain	   structure	   of	   human	  
CNOT3.	  The	  Figure	  shows	  the	  domains	  in	  the	  human	  CNOT3	  protein.	  The	  protein	  consists	  of	  a	  coiled	  coil	  domain	  at	  the	  N	  terminal,	  an	  unstructured	  domain	  in	  the	  middle	  part	  and	   a	   C	   terminal	   domain.	   The	  C	   terminal	   domain	   contains	   a	  NOT1	   anchor	   region	  (NAR),	  a	  Connector	  Sequence	  (CS)	  and	  the	  NOT-­‐box	  domain.	  	  	   In	  this	  thesis	  Cnot3	  has	  also	  been	  shown	  to	  interact	  with	  Aurora	  B	  through	  the	  NOT-­‐box	  domain,	  creating	  a	  connection	  between	  the	  CCR4-­‐NOT	  complex	  and	  the	  CPC.	  The	  interactions	  with	  histones,	  chromatin	  remodelers,	  nucleolar	  factors	  and	  the	  presence	  of	  Cnot3	  on	  active	  gene	  promoters	  suggest	  that	  Cnot3	  play	  a	  role	  in	  transcriptional	  regulation.	  However,	  the	  data	  obtained	  to	  date	  cannot	  answer	  the	  question	  whether	  Cnot3	  is	  an	  activator	  or	  a	  repressor.	  Characterization	  of	  Cnot3	  depleted	  B	  cells	  using	  the	  conditional	  knockout	  mouse	  will	  allow	  this	  point	  to	  be	  investigated.	  Many	   interactions	   were	   detected	   between	   Cnot3	   and	   proteins	   involved	   in	  splicing.	  These	  data	  suggest	   that	  Cnot3	  plays	  a	   role	   in	  RNA	  processing,	  but	   the	  precise	   task	   that	   the	   protein	   has	   in	   this	   co-­‐transcriptional	   process	   is	   still	  unknown.	  	  Again,	  the	  analysis	  of	  the	  knockout	  mouse	  should	  allow	  this	  question	  to	   be	   addressed.	   From	   the	   analysis	   of	   our	   data	   and	   the	   studies	   published	   in	  literature,	   it	   seems	   reasonable	   to	   hypothesise	   that	   Cnot3	   acts	   as	   an	   adaptor	  protein	  by	  interacting	  with	  a	  number	  different	  classes	  of	  proteins	  in	  the	  nucleus.	  The	   role	   of	   Cnot3	  might	   be	   to	   recruit	   or	  mediate	   interactions	   among	   proteins	  that	  are	  involved	  in	  transcriptional	  and	  post-­‐transcriptional	  regulation.	  A	   recent	   paper	   reported	   that	   Cnot3	   is	   important	   for	   maintaining	   the	   self-­‐renewal	   program	   in	   ES	   cells	   (Hu	   et	   al.,	   2009).	   ChIP-­‐seq	   analysis	   revealed	  extensive	  binding	  to	  promoters	  in	  ES	  cells	  and	  knockdown	  of	  Cnot3	  resulted	  in	  upregulation	  of	  trophectoderm	  genes	  and	  differentiation	  into	  the	  trophectoderm	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lineage.	   Based	   on	  motif	   analysis	   of	   ChIP-­‐seq	   data,	   Hu	   et	   al.	   also	   reported	   that	  Cnot3	   is	   a	   sequence-­‐specific	   transcription	   factor	   that	   binds	   to	   a	   specific	  consensus	   sequence	   (Hu	   et	   al.,	   2009).	   Our	   efforts	   to	   verify	   this	   conclusion	   by	  analysing	  binding	  of	  Cnot3	  to	  the	  sequence	  described	  by	  Hu	  et	  al.	  in	  EMSA	  assays	  were	  unsuccessful.	   Instead	  our	   results	   suggested	   that	  Cnot3	  binds	   to	  DNA	  as	  a	  co-­‐factor	  that	  interacts	  with	  DNA-­‐binding	  factors	  (data	  not	  shown).	  	  To	   gain	   further	   insights	   into	   the	   role	   of	   Cnot3	   in	   gene	   regulation,	   a	   B	   cell	  system	  was	  developed	  that	  uses	  a	  controlled	  activation	  of	  resting	  B	  cells.	  This	  is	  a	  powerful	   tool	   to	   study	   the	  behaviour	   of	   Cnot3	  during	   cell	   cycle	   progression	   in	  primary	  B	  cells.	  Activation	  of	  resting	  B	  cells	  by	  the	  stimulation	  of	  BCR	  and	  TLR4	  receptors	  and	  the	  use	  of	  the	  DNA	  polymerase	  inhibitor	  aphidicolin	  allowed	  us	  to	  isolate	  cell	  populations	  that	  were	  highly	  enriched	  for	  different	  phases	  of	  the	  cell	  cycle.	   Using	   this	   system,	   I	   have	   analysed	   several	   different	   aspects	   of	   the	  behaviour	  of	  Cnot3	  during	  the	  cell	  cycle.	  	  	  
8.2 Cnot3	  interacts	  with	  the	  cell	  cycle	  regulator	  Aurora	  B	  Data	   obtained	   by	   our	   lab	   showed	   that	   Aurora	   B	   is	   involved	   in	   regulating	  transcription	   in	   resting	   B	   cells	   (Frangini	   et	   al.,	   2013).	   The	   strong	   interaction	  between	   Cnot3	   and	   Aurora	   B	   that	   was	   revealed	   by	   co-­‐IP	   and	   the	   presence	   of	  Cnot3	   on	   active	   gene	   promoters	   led	   us	   to	   investigate	   the	   role	   of	   Cnot3	   in	  transcriptional	   regulation	   in	   B	   cells.	   In	   this	   thesis	   I	   have	   shown	   that	   Cnot3	  interacts	  with	  Aurora	  B	   in	  a	   cell	   cycle	  dependent	  manner.	  A	   strong	   interaction	  was	  observed	   in	   resting	  B	  cells.	  The	   interaction	  decreased	   in	  early	  and	   late	  G1	  and	   reached	   its	   lowest	   level	   in	   S-­‐phase	   before	   increasing	   again	   in	   G2.	   The	  reduced	   interaction	  coincided	  with	   loss	  of	  binding	  of	  Cnot3	  to	  gene	  promoters.	  However,	   experiments	   performed	   in	   Aurora	   B	   knockout	   mice	   showed	   that	  depletion	  of	  Aurora	  B	  does	  not	  affect	  binding	  of	  Cnot3	  to	  promoters,	   indicating	  that	   loss	   of	   Cnot3	   binding	   in	   S-­‐phase	   is	   not	   directly	   linked	   to	   loss	   of	   the	  interaction	  with	  Aurora	  B.	  Another	  possibility	  is	  that	  binding	  of	  both	  proteins	  to	  the	  same	  region	  of	  chromatin	  promotes	  the	  interaction	  between	  them.	  Detection	  of	  the	  Cnot3-­‐Aurora	  B	  interaction	  in	  resting	  B	  cells	  requires	  intensive	  digestion	  of	   the	  compact	  chromatin	  to	  release	  the	  bound	  proteins.	  This	  suggests	   that	   the	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interacting	   Cnot3-­‐Aurora	   B	   are	   bound	   to	   chromatin	   in	   the	   nucleus.	   However,	  digestion	  of	  resting	  B	  cell	  chromatin	  with	  Benzonase,	  which	  completely	  degrades	  DNA	  in	  the	  preparation,	  does	  not	  affect	  the	  interaction,	  indicating	  that	  it	  is	  a	  bona	  fide	   interaction	   and	   is	   not	   simply	   a	   consequence	   of	   co-­‐localisation	   of	   the	   two	  proteins	  to	  the	  same	  region	  of	  DNA.	  	  	  Aurora	  B	  and	  Cnot3	  have	  both	  been	  shown	  to	  have	  a	  role	  in	  G1/S	  transition	  in	  other	  cell	  types	  (Song	  et	  al.,	  2007)	  (Mittal	  et	  al.,	  2011).	  The	  interaction	  that	  was	  observed	  between	   the	   two	  proteins	   in	   late	  G1	  and	   in	  aphidicolin	  blocked	  cells,	  which	  are	  at	   the	  G1/S	  boundary,	   raises	   the	  possibility	   that	   the	  Cnot3-­‐Aurora	  B	  interaction	  plays	  a	  role	  in	  the	  G1/S	  transition	  in	  B	  cells.	  A	  strong	  interaction	  between	  Aurora	  B	  and	  Cnot3	  proteins	  was	  detected	  in	  G2	  cells.	   Cnot3	   was	   also	   shown	   to	   interact	   with	   the	   CPC	   members	   INCENP	   and	  Borealin	   in	  G2.	   	   Interaction	  of	  Cnot3	  with	   several	  other	  members	  of	   the	  CCR4-­‐Not	   complex	   including	   Cnot1	   and	   Cnot2	   was	   also	   detected	   at	   this	   stage.	   This	  suggests	   that	   the	   CPC	   performs	   some	   of	   its	   functions	   in	   concert	   with	   sub-­‐complexes	   of	   the	   CCR4-­‐Not	   complex.	   The	   CPC	   controls	   the	   activity	   of	   many	  proteins	   through	   phosphorylation	   during	   mitosis	   and	   is	   directly	   involved	   in	  regulating	  the	  spindle	  assembly	  checkpoint	  (Sampath	  et	  al.,	  2004).	  A	  target	  of	  the	  CPC	  is	  MAD1,	  which	  is	  involved	  in	  spindle	  assembly.	  Localization	  of	  MAD1	  to	  the	  spindle	  during	  mitosis	  is	  controlled	  by	  Aurora	  B	  (Matson	  and	  Stukenberg,	  2014).	  A	  recent	  study	  has	  shown	  that	  Cnot3	   is	   involved	   in	  correct	  mitotic	  progression	  by	  controlling	  the	  stability	  of	  MAD1	  mRNA	  and	  the	  level	  of	  MAD1	  protein.	  This	  result,	  together	  with	  our	  data,	  suggests	  that	  Cnot3	  and	  the	  CPC	  could	  act	  together	  to	   ensure	   a	   proper	   mitotic	   division.	   Furthermore,	   during	   this	   phase	   Cnot3	   is	  phosphorylated	  by	  CDK1,	  which	  promotes	  the	  G2	  to	  M	  transition	  (Takahashi	  et	  al.,	   2012).	   Our	   Co-­‐IP	   and	  MS	   analysis	   has	   confirmed	   that	   Cnot3	   interacts	  with	  CDK1	  in	  G2	  (Appendix	  Table	  A).	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8.3 The	   interaction	   of	   Cnot3	   with	   histones	   suggests	   a	   role	   in	  
transcriptional	  regulation	  The	   co-­‐IP	   and	   MS	   analysis	   revealed	   the	   presence	   of	   many	   histones	   among	  Cnot3	  interactors.	  The	  absence	  of	  any	  enzymatic	  activity	  for	  Cnot3,	  suggests	  that	  the	  interaction	  with	  histones	  could	  be	  a	  mechanism	  to	  recruit	  other	  proteins	  to	  chromatin.	   Cnot3	   interacts	   with	   core	   histones	   and	   many	   variants	   of	   these	  proteins,	  such	  as	  H2A,	  H2A.Z,	  H2B,	  H2A.V,	  H3.3,	  H3.3C,	  H4	  (Appendix	  Table	  A).	  This	  indicates	  that	  Cnot3	  is	  in	  contact	  with	  chromatin	  and	  suggests	  that	  it	  could	  be	  involved	  in	  recruiting	  modifications	  enzymes	  to	  chromatin.	  	  In	  addition	  to	  the	  interactions	  with	  core	  histones,	  it	  is	  particularly	  interesting	  that	   Cnot3	   interacts	  with	  many	   isoforms	   of	   the	   linker	   histone	   histone	   H1	   and	  that	   this	   interaction	   is	   detected	  mainly	   in	   G1.	   The	   presence	   of	   histone	  H1	   has	  been	  connected	  mainly	  with	  repression	  because	  it	  has	  been	  shown	  to	  promote	  a	  more	   closed	   chromatin	   structure	   (Robinson	   and	   Rhodes,	   2006).	   However,	   a	  recent	  study	  has	  reported	  that	  histone	  H1.4	  that	  is	  acetylated	  at	  lysine	  34	  is	  also	  found	   around	   the	   TSS	   of	   active	   genes.	   The	   presence	   of	   histone	   H1.4K34ac	   is	  correlated	  to	  the	  expression	  levels	  of	  the	  genes	  in	  MCF-­‐7	  cells	  (Kamieniarz	  et	  al.,	  2012).	  	  In	  a	  peptide	  binding	  assay,	  we	  did	  not	   find	  any	  preference	  for	  Cnot3	  to	  bind	  the	  acetylated	  form	  of	  the	  histone.	  A	  possible	  explanation	  for	  this	  could	  be	  that	  Cnot3	  binds	  to	  unmodified	  H1	  to	  promote	  the	  recruitment	  of	  chromatin	  factors.	  	  Furthermore,	  Cnot3	   interacts	  with	  Nucleolin,	  which	  also	   interacts	  with	  histone	  H1	  to	  promote	  decondensation	  of	  chromatin	  (Erard	  et	  al.,	  1988).	  Nucleolin	  has	  been	   described	   to	   have	   an	   activity	   that	   resembles	   the	   FACT	   complex	   and	   to	  enhance	   the	   activity	   of	   the	   remodelers	   SWI/SNF	   (Angelov	   et	   al.,	   2006).	   The	  interaction	  of	  Cnot3	  with	  Nucleolin,	  histone	  H1,	  and	  also	  with	  the	  FACT	  complex	  subunits	   (Appendix	  Table	  A),	   could	  be	  explained	  by	   function	  of	  Cnot3	  being	   to	  promote	  the	  passage	  of	  the	  elongation	  complex	  through	  the	  first	  nucleosome.	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8.4 Cnot3	  binds	  chromatin	  in	  a	  cell	  cycle	  dependent	  manner	  	   The	   role	   of	   Cnot3	   in	   transcriptional	   regulation	   has	   been	   studied	   in	   ES	   cells,	  where	  it	  has	  been	  proposed	  to	  form	  a	  self-­‐renewal	  module	  with	  Trim28,	  c-­‐myc	  and	  Zfx.	  In	  these	  cells	  Cnot3	  has	  been	  shown	  to	  be	  an	  activator	  of	  a	  distinct	  class	  of	  genes.	  At	  the	  moment	  it	  is	  not	  possible	  to	  say	  whether	  Cnot3	  is	  an	  activator	  or	  repressor	  in	  B	  cells.	  The	  genome	  wide	  analysis	  showed	  that	  Cnot3	  binds	  to	  gene	  promoters	  in	  a	  cell	  cycle	  dependent	  manner.	  Cnot3	  binding	  is	  particularly	  high	  in	  resting	   B	   cells	   and	   in	   G2	   activated	   B	   cells.	   A	   generalised	   drop	   of	   binding	   is	  detected	  during	  S	  phase.	  The	  result	  obtained	  in	  S	  phase	  was	  also	  validated	  in	  a	  drug-­‐free	   system.	   Binding	   of	   Pcna	   was	   detected	   at	   gene	   promoters	   indicating	  that	   the	   apparent	   loss	   of	   Cnot3	   binding	  was	   not	   a	   ChIP	   artefact	   generated	   by	  differences	  in	  the	  properties	  of	  the	  chromatin	  at	  different	  stages	  of	  the	  cell	  cycle.	  	  S-­‐phase	  is	  a	  period	  of	  transition	  when	  chromatin	  undergoes	  changes	  because	  of	  DNA	  replication.	  Histones	  are	  subject	  to	  disruption	  and	  remodelling	  due	  to	  the	  passage	  of	  the	  replication	  fork.	  During	  B	  cell	  activation	  chromatin	  also	  becomes	  more	  generally	  sensitive	  to	  nuclease	  digestion	  compared	  to	  the	  other	  stages	  (our	  unpublished	  observations).	  These	   changes	   could	   lead	   to	  Cnot3	  being	  displaced	  but	  we	  do	  not	  have	  any	  information	  about	  the	  detailed	  mechanism	  behind	  this	  at	  present.	  My	  analysis	  of	   the	   levels	  of	  primary	  transcripts	  revealed	  high	   levels	  of	  transcription	  during	   this	  phase,	  but	  also	   in	  G2	  when	  significant	   levels	  of	  Cnot3	  bindinga	  are	  detected	  at	  gene	  promoters.	  This	  makes	  it	  difficult	  to	  establish	  any	  clear	   correlation	  between	  binding	   of	   Cnot3	   and	   transcription	   levels	   in	   S	   phase	  and	  G2.	   It	  should	  be	  noted,	  however,	   that	  the	  analysis	  of	  Cnot3	  binding	  around	  the	  TSS	  in	  G2	  showed	  a	  shift	  in	  binding	  towards	  the	  body	  of	  the	  gene	  compared	  to	  other	  phases	  of	  the	  cell	  cycle.	  This	  shift	  in	  binding	  could	  indicate	  a	  change	  in	  the	   functions	   of	   Cnot3	   between	   the	   resting	   and	   G2	   stages	   and	   might	   be	  connected	   to	   the	   hypothesis	   that	   Cnot3	  works	   in	   concert	  with	   Xrn2	   to	   control	  proximal	  promoter	  pausing	  and	  termination.	  Involvement	  of	  Cnot3	  could	  also	  act	  in	  promoting	  Pol	  II	  passage	  through	  the	  first	  nucleosome	  would	  also	  explain	  the	  shift	  in	  binding	  when	  transcription	  is	  high	  in	  G2	  cells.	  	  Cnot3	  is	  not	  only	  bound	  to	  promoter	  regions,	  but	  is	  present	  in	  distal	  regions	  where	   it	   binds	   to	   established	   and	   putative	   enhancer	   elements	   in	   a	   cell	   cycle	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regulated	  manner.	   High	   levels	   of	   binding	   to	   enhancers	   are	   detected	   in	   resting	  and	  G2	  cells.	  During	  early	  and	  late	  G1	  and	  early	  S,	  Cnot3	  the	  number	  of	  peaks	  in	  these	  regions	  is	  reduced	  whereas	  binding	  is	  retained	  to	  a	  greater	  degree	  on	  the	  promoter	   regions.	   Cnot3	   binding	   is	   also	   found	   in	   the	   body	   of	   the	   gene,	  particularly	   within	   introns.	   It	   is	   possible	   that	   this	   binding	   is	   important	   for	  recruitment	   of	   SR	   or	   hnRNP	   proteins	   to	   exon/intron	   junctions	   and	   a	   role	   in	  splicing.	  	  
8.5 Involvement	  of	  Cnot3	  with	  the	  RNA	  processing	  machinery	  The	   co-­‐IP	   and	   MS	   analysis	   detected	   many	   interactions	   of	   Cnot3	   with	   SR	  proteins,	   hnRNPs,	   RNA	   helicases	   and	   small	   RNA	   associated	   proteins.	   SR	   and	  hnRNP	  proteins	   are	   known	   to	  have	  opposite	   roles	  during	   splicing.	   SR	  proteins	  promote	  the	   inclusion	  of	  exons	  (Long	  and	  Caceres,	  2009),	  whereas	  the	  hnRNPs	  are	  usually	  inhibitors	  of	  exon	  inclusion	  (Han	  et	  al.,	  2010).	  Therefore,	  Cnot3	  could	  be	   important	   in	   the	   decision	   between	   exon	   inclusion	   or	   exclusion	   and	   in	  alternative	  splicing.	  However,	  hnRNPs	  are	  also	  implicated	  in	  mRNA	  export	  to	  the	  cytoplasm.	  Cnot3	   could	  direct	   the	  binding	  of	  hnRNPs	   to	  mediate	  mRNA	  export	  out	  of	  the	  nucleus.	  The	  MS	  analysis	  also	  highlighted	  the	   interaction	  with	  proteins	  such	  as	  Cpsf1	  and	  Fip1	  that	  are	  involved	  in	  the	  process	  of	  pre-­‐mRNA	  cleavage	  and	  stimulation	  (Kaufmann	   et	   al.,	   2004).	   It	   is	   also	   possible	   that	   the	   interaction	   of	   Cnot3	   with	  these	  proteins	  facilitates	  the	  3’	  end	  formation	  RNA.	  Moreover,	  the	  interaction	  of	  Cnot3	  with	  Poly-­‐A	  binding	  proteins	  (Pabps)	  could	  support	  this	  hypothesis	  due	  to	  the	   fact	   that	   Pabps	   stabilize	   the	   3’	   end	   of	   the	   RNA	   after	   the	   cleavage	   to	   avoid	  degradation.	  Another	  component	  of	  RNA	  termination	  that	  has	  been	  found	  among	  the	   Cnot3	   interactors	   in	   G2	   is	   the	   exoribonuclease	   Xrn2.	   According	   to	   the	  Torpedo	  model,	  Xrn2	  promotes	  termination	  by	  digesting	  the	  nascent	  transcript	  after	  cleavage	  at	  the	  Poly-­‐A	  site,	  resulting	  in	  displacement	  of	  Pol	  II	  from	  the	  DNA	  (West	  et	  al.,	  2004).	  The	   interaction	  between	  Cnot3	  and	  Xrn2	  could	  also	  exert	  a	  role	  in	  the	  promoter	  region,	  as	  Xrn2	  has	  been	  found	  at	  promoters	  of	  active	  genes,	  where	   it	   has	   been	   suggest	   that	   it	   controls	   promoter-­‐proximal	   transcription.	   It	  has	  been	  hypothesised	  that	  Xrn2	  ensures	  directionality	  of	  Pol	  II	  at	  the	  beginning	  of	  transcription	  by	  terminating	  transcription	  that	  is	  directed	  upstream	  (Brannan	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et	   al.,	   2012).	   The	   possibility	   that	   Cnot3	   is	   involved	   in	   this	   process	   will	   be	  investigated	  using	  the	  	  	  conditional	  Cnot3	  knockout	  mouse.	  	  	  
8.6 Future	   directions:	   characterization	   of	   Cnot3	   knockout	  
mouse	  The	   TALEN	   targeting	   approach	   has	   been	   a	   useful	   tool	   for	   generating	   a	  conditional	   Cnot3	   knockout	  mouse.	   These	  mice	  will	   be	   used	   to	   investigate	   the	  functional	  role	  of	  Cnot3	  in	  B	  cells.	  The	  hypotheses	  that	  have	  been	  formulated	  in	  this	  thesis	  can	  be	  tested	  in	  Cnot3	  depleted	  ex	  vivo	  cultured	  B	  cells.	  Experiments	  using	   this	  system	  can	  be	  expected	   to	  clarify	  whether	  Cnot3	   is	  an	  activator	  or	  a	  repressor	  in	  B	  cells.	  	  
Ex	  vivo	  experiments	  will	  make	  it	  possible	  to	  study	  Cnot3	  ablation	  in	  the	  B	  cell	  system	   that	   I	   have	   set	   up.	   Cnot3	   knockout	   in	   resting	   B	   cells	   will	   address	   the	  question	  of	  whether	  Cnot3	  affects	  the	  quiescence	  program.	  The	  absence	  of	  Cnot3	  in	   resting	   B	   cells	   will	   also	   be	   used	   to	   determine	   whether	   it	   affects	   Aurora	   B	  binding	  on	  active	  gene	  promoters.	  The	  data	  presented	  in	  this	  thesis	  suggests	  that	  Cnot3	   could	   participate	   in	   the	   G1/S	   transition.	   This	   idea	   is	   supported	   by	   the	  study	  of	  Mittal	  et	  al.,	  2011	  and	  the	  strong	  interaction	  between	  Cnot3	  and	  Aurora	  B	   that	   I	   have	   observed	   in	   aphidicolin	   blocked	   cells.	   Cell	   cycle	   profiles	   will	   be	  compared	  between	  wild-­‐type	  and	  knockout	  B	  cells	  to	  analyse	  progression	  from	  G1	   to	   S	   phase.	   Depletion	   of	   Cnot3	   by	   addition	   of	   tamoxifen	   at	   different	   time-­‐points	   after	   B	   cell	   activation	   can	   also	   be	   used	   to	   examine	   whether	   Cnot3	   is	  involved	  in	  the	  later	  stages	  of	  the	  cell	  cycle,	  including	  mitosis.	  	  It	   will	   also	   be	   possible	   to	   study	   the	   role	   in	   transcriptional	   and	   post-­‐transcriptional	  regulation	  by	  analysis	  of	  primary	  and	  fully	  processed	  transcripts	  at	  different	  stages	  of	  the	  cell	  cycle.	  Analysis	  of	  different	  classes	  of	  transcripts	  can	  used	  to	  determine	  whether	  Cnot3	  affects	  transcription	  globally	  or,	  alternatively,	  whether	  it	  targets	  specific	  categories	  of	  genes.	  Additional	  questions	  that	  can	  be	  addressed	  using	  the	  Cnot3-­‐/-­‐	  B	  cells	  include	  whether	  Pol	  II	  activity	  is	  affected	  and	  whether	   Cnot3	   affects	   directionality	   of	   Pol	   II	   transcription	   via	   the	   interaction	  with	   Xrn2.	   Analysis	   of	   active	   and	   repressive	   histone	  marks	   at	   gene	   promoters	  will	  provide	  information	  on	  whether	  Cnot3	  affects	  the	  recruitment	  of	  chromatin	  modifiers.	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Appendix	  	  
Table	  A:	  Cnot3	  interactors	  in	  early	  G1	  and	  G2.	  591	  proteins	  were	  detected	  by	  MS	  analysis	  after	  Cnot3	  IPs	  carried	  out	  in	  early	  G1	  and	  G2.	  The	   table	   reports	   the	  protein	  name,	   the	  protein	   score	   and	  Normalised	  MS	   intensities	   (fold	   over	   max).	   See	   Materials	   and	   Methods	   section	   2.7.6	   for	  details.	  	  	  
	  
Protein name Protein score Control  G1 G2 
CNOT1_MOUSE 3528.449744 #REF!	   #VALUE!	   #REF!	  
DDX21_MOUSE 1393.945489 #REF!	   #VALUE!	   #REF!	  
TOP2A_MOUSE 1289.480389 #REF!	   #VALUE!	   #REF!	  
NUCL_MOUSE 1228.040559 #REF!	   #VALUE!	   #REF!	  
RRP5_MOUSE 1163.337728 #REF!	   #VALUE!	   #REF!	  
NPAT_MOUSE 1107.526525 #REF!	   #VALUE!	   #REF!	  
RL3_MOUSE 1093.419356 #REF!	   #VALUE!	   #REF!	  
PABP1_MOUSE 992.6687118 #REF!	   #VALUE!	   #REF!	  
TB182_MOUSE 988.8592707 #REF!	   #VALUE!	   #REF!	  
H12_MOUSE 922.245237 #REF!	   #VALUE!	   #REF!	  
U520_MOUSE 882.3503041 #REF!	   #VALUE!	   #REF!	  
H4_MOUSE 869.47 #REF!	   #VALUE!	   #REF!	  
CROCC_MOUSE 866.5340332 #REF!	   #VALUE!	   #REF!	  
PRP8_MOUSE 857.4147619 #REF!	   #VALUE!	   #REF!	  
RL4_MOUSE 841.2299151 #REF!	   #VALUE!	   #REF!	  
H2AY_MOUSE 827.2599151 #REF!	   #VALUE!	   #REF!	  
H14_MOUSE 824.4873388 #REF!	   #VALUE!	   #REF!	  
NOP56_MOUSE 795.9828795 #REF!	   #VALUE!	   #REF!	  
H13_MOUSE 787.573305 #REF!	   #VALUE!	   #REF!	  
NOP2_MOUSE 778.011932 #REF!	   #VALUE!	   #REF!	  
YBOX1_MOUSE 772.4920169 #REF!	   #VALUE!	   #REF!	  
MBB1A_MOUSE 732.608542 #REF!	   #VALUE!	   #REF!	  
MTMR5_MOUSE 731.7853219 #REF!	   #VALUE!	   #REF!	  
DHX9_MOUSE 717.1753219 #REF!	   #VALUE!	   #REF!	  
ACTH_MOUSE 708.2053219 #REF!	   #VALUE!	   #REF!	  
SON_MOUSE 675.4480675 #REF!	   #VALUE!	   #REF!	  
HNRPC_MOUSE 674.5953219 #REF!	   #VALUE!	   #REF!	  
H15_MOUSE 666.033305 #REF!	   #VALUE!	   #REF!	  
ROA3_MOUSE 658.563305 #REF!	   #VALUE!	   #REF!	  
H11_MOUSE 654.6265251 #REF!	   #VALUE!	   #REF!	  
RL6_MOUSE 646.7066101 #REF!	   #VALUE!	   #REF!	  
QCR2_MOUSE 644.63 #REF!	   #VALUE!	   #REF!	  
HNRPU_MOUSE 631.1532201 #REF!	   #VALUE!	   #REF!	  
TPR_MOUSE 628.8886264 #REF!	   #VALUE!	   #REF!	  
CNO10_MOUSE 612.8521862 #REF!	   #VALUE!	   #REF!	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IQGA1_MOUSE 612.5225758 #REF!	   #VALUE!	   #REF!	  
RL7A_MOUSE 596.8166101 #REF!	   #VALUE!	   #REF!	  
TOP2B_MOUSE 577.7766095 #REF!	   #VALUE!	   #REF!	  
ROA2_MOUSE 576.3 #REF!	   #VALUE!	   #REF!	  
RLA0_MOUSE 567.8166101 #REF!	   #VALUE!	   #REF!	  
RS3A_MOUSE 566.2373388 #REF!	   #VALUE!	   #REF!	  
RL5_MOUSE 556.8166101 #REF!	   #VALUE!	   #REF!	  
RMXL1_MOUSE 552.5598302 #REF!	   #VALUE!	   #REF!	  
H2B1H_MOUSE 550.163305 #REF!	   #VALUE!	   #REF!	  
RBMX_MOUSE 545.1432201 #REF!	   #VALUE!	   #REF!	  
SRRM2_MOUSE 507.1702521 #REF!	   #VALUE!	   #REF!	  
RL7_MOUSE 503.9760506 #REF!	   #VALUE!	   #REF!	  
ANR17_MOUSE 490.6826607 #REF!	   #VALUE!	   #REF!	  
H33_MOUSE 489.8753219 #REF!	   #VALUE!	   #REF!	  
RS18_MOUSE 466.9266101 #REF!	   #VALUE!	   #REF!	  
WDR62_MOUSE 465.7066101 #REF!	   #VALUE!	   #REF!	  
NOP58_MOUSE 463.443305 #REF!	   #VALUE!	   #REF!	  
SMCA5_MOUSE 458.4164402 #REF!	   #VALUE!	   #REF!	  
RRBP1_MOUSE 456.4061305 #REF!	   #VALUE!	   #REF!	  
ROA1_MOUSE 454.3286269 #REF!	   #VALUE!	   #REF!	  
DDX3L_MOUSE 444.943305 #REF!	   #VALUE!	   #REF!	  
H2A2C_MOUSE 439.1966101 #REF!	   #VALUE!	   #REF!	  
UBF1_MOUSE 435.2599151 #REF!	   #VALUE!	   #REF!	  
IF4A3_MOUSE 434.5366101 #REF!	   #VALUE!	   #REF!	  
RL8_MOUSE 422.7 #REF!	   #VALUE!	   #REF!	  
RENT1_MOUSE 417.17 #REF!	   #VALUE!	   #REF!	  
H1T_MOUSE 413.903305 #REF!	   #VALUE!	   #REF!	  
FBRL_MOUSE 413.583305 #REF!	   #VALUE!	   #REF!	  
CAPR1_MOUSE 408.6299151 #REF!	   #VALUE!	   #REF!	  
H2B3B_MOUSE 407.483305 #REF!	   #VALUE!	   #REF!	  
RS6_MOUSE 400.723305 #REF!	   #VALUE!	   #REF!	  
RL30_MOUSE 398.41 #REF!	   #VALUE!	   #REF!	  
NPM_MOUSE 398.243305 #REF!	   #VALUE!	   #REF!	  
LYAR_MOUSE 389.7287118 #REF!	   #VALUE!	   #REF!	  
H3C_MOUSE 388.793305 #REF!	   #VALUE!	   #REF!	  
MDC1_MOUSE 388.2588811 #REF!	   #VALUE!	   #REF!	  
IMA1_MOUSE 386.903305 #REF!	   #VALUE!	   #REF!	  
ARP3_MOUSE 384.7099151 #REF!	   #VALUE!	   #REF!	  
RLA2_MOUSE 380.99 #REF!	   #VALUE!	   #REF!	  
HELZ2_MOUSE 376.2132201 #REF!	   #VALUE!	   #REF!	  
AZI1_MOUSE 370.2232201 #REF!	   #VALUE!	   #REF!	  
RN219_MOUSE 367.5686269 #REF!	   #VALUE!	   #REF!	  
RS14_MOUSE 363.6553219 #REF!	   #VALUE!	   #REF!	  
EF2_MOUSE 362.3820169 #REF!	   #VALUE!	   #REF!	  
H2AX_MOUSE 361.4 #REF!	   #VALUE!	   #REF!	  
NAT10_MOUSE 361.041932 #REF!	   #VALUE!	   #REF!	  
RL26_MOUSE 359.353305 #REF!	   #VALUE!	   #REF!	  
DDX3Y_MOUSE 359.1 #REF!	   #VALUE!	   #REF!	  
TOP1_MOUSE 357.1614574 #REF!	   #VALUE!	   #REF!	  
HNRPQ_MOUSE 354.1820169 #REF!	   #VALUE!	   #REF!	  
TBA1C_MOUSE 351.63 #REF!	   #VALUE!	   #REF!	  
CNO11_MOUSE 350.58 #REF!	   #VALUE!	   #REF!	  
	   173	  
TR150_MOUSE 348.983305 #REF!	   #VALUE!	   #REF!	  
NPA1P_MOUSE 347.6286269 #REF!	   #VALUE!	   #REF!	  
RBM14_MOUSE 346.123305 #REF!	   #VALUE!	   #REF!	  
RL9_MOUSE 340.163305 #REF!	   #VALUE!	   #REF!	  
COR1A_MOUSE 340.11 #REF!	   #VALUE!	   #REF!	  
RL14_MOUSE 339.903305 #REF!	   #VALUE!	   #REF!	  
DDX24_MOUSE 337.3653219 #REF!	   #VALUE!	   #REF!	  
ALDH2_MOUSE 335.97 #REF!	   #VALUE!	   #REF!	  
MYO1G_MOUSE 334.9953219 #REF!	   #VALUE!	   #REF!	  
BCLF1_MOUSE 332.3920169 #REF!	   #VALUE!	   #REF!	  
H2B1A_MOUSE 327.45 #REF!	   #VALUE!	   #REF!	  
PRP19_MOUSE 327.19 #REF!	   #VALUE!	   #REF!	  
H2B2E_MOUSE 326.87 #REF!	   #VALUE!	   #REF!	  
HNRL2_MOUSE 325.64 #REF!	   #VALUE!	   #REF!	  
HP1B3_MOUSE 324.3687118 #REF!	   #VALUE!	   #REF!	  
CPSF1_MOUSE 324.2 #REF!	   #VALUE!	   #REF!	  
G3BP1_MOUSE 322.9166101 #REF!	   #VALUE!	   #REF!	  
RS9_MOUSE 320.2853219 #REF!	   #VALUE!	   #REF!	  
RUVB1_MOUSE 315.453305 #REF!	   #VALUE!	   #REF!	  
RS2_MOUSE 308.96 #REF!	   #VALUE!	   #REF!	  
RAVR1_MOUSE 308.173305 #REF!	   #VALUE!	   #REF!	  
PARP1_MOUSE 305.2366101 #REF!	   #VALUE!	   #REF!	  
RS8_MOUSE 304.4 #REF!	   #VALUE!	   #REF!	  
ACINU_MOUSE 303.6687118 #REF!	   #VALUE!	   #REF!	  
YBOX3_MOUSE 299.223305 #REF!	   #VALUE!	   #REF!	  
FLNA_MOUSE 296.8186269 #REF!	   #VALUE!	   #REF!	  
RL24_MOUSE 296.2866101 #REF!	   #VALUE!	   #REF!	  
RCD1_MOUSE 295.183305 #REF!	   #VALUE!	   #REF!	  
CNOT6_MOUSE 293.48 #REF!	   #VALUE!	   #REF!	  
RSSA_MOUSE 292.233305 #REF!	   #VALUE!	   #REF!	  
DKC1_MOUSE 289.263305 #REF!	   #VALUE!	   #REF!	  
RRP1B_MOUSE 288.463305 #REF!	   #VALUE!	   #REF!	  
RL23A_MOUSE 284.3787118 #REF!	   #VALUE!	   #REF!	  
GEMI5_MOUSE 283.7153219 #REF!	   #VALUE!	   #REF!	  
ARHG6_MOUSE 283.563305 #REF!	   #VALUE!	   #REF!	  
RL19_MOUSE 282.5587118 #REF!	   #VALUE!	   #REF!	  
RL18_MOUSE 281.883305 #REF!	   #VALUE!	   #REF!	  
RL28_MOUSE 280.0374237 #REF!	   #VALUE!	   #REF!	  
CNOT2_MOUSE 278.8120169 #REF!	   #VALUE!	   #REF!	  
MYO1C_MOUSE 276.9486269 #REF!	   #VALUE!	   #REF!	  
SRSF7_MOUSE 276.43 #REF!	   #VALUE!	   #REF!	  
GBLP_MOUSE 275.813305 #REF!	   #VALUE!	   #REF!	  
RL12_MOUSE 275.223305 #REF!	   #VALUE!	   #REF!	  
RL10A_MOUSE 275.0386269 #REF!	   #VALUE!	   #REF!	  
SRSF1_MOUSE 274.8932201 #REF!	   #VALUE!	   #REF!	  
EBP2_MOUSE 272.3786269 #REF!	   #VALUE!	   #REF!	  
PAIRB_MOUSE 269.7420169 #REF!	   #VALUE!	   #REF!	  
SYF1_MOUSE 267.46 #REF!	   #VALUE!	   #REF!	  
U5S1_MOUSE 267.16 #REF!	   #VALUE!	   #REF!	  
LBR_MOUSE 266.1787118 #REF!	   #VALUE!	   #REF!	  
TRA2B_MOUSE 265.2366101 #REF!	   #VALUE!	   #REF!	  
RS17_MOUSE 263.393305 #REF!	   #VALUE!	   #REF!	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RL17_MOUSE 261.9 #REF!	   #VALUE!	   #REF!	  
SAFB1_MOUSE 260.3840337 #REF!	   #VALUE!	   #REF!	  
RS27A_MOUSE 260.073305 #REF!	   #VALUE!	   #REF!	  
LARP1_MOUSE 258.5 #REF!	   #VALUE!	   #REF!	  
HNRPK_MOUSE 258.4787118 #REF!	   #VALUE!	   #REF!	  
NOL6_MOUSE 256.79 #REF!	   #VALUE!	   #REF!	  
SCRIB_MOUSE 256.223305 #REF!	   #VALUE!	   #REF!	  
DDX17_MOUSE 252.9166101 #REF!	   #VALUE!	   #REF!	  
RL10_MOUSE 252.89 #REF!	   #VALUE!	   #REF!	  
PCBP1_MOUSE 249.426695 #REF!	   #VALUE!	   #REF!	  
TBB2B_MOUSE 245.39 #REF!	   #VALUE!	   #REF!	  
TBB4A_MOUSE 244.58 #REF!	   #VALUE!	   #REF!	  
DHX15_MOUSE 241.3765251 #REF!	   #VALUE!	   #REF!	  
CHD4_MOUSE 241.3239488 #REF!	   #VALUE!	   #REF!	  
K2C6A_MOUSE 240.493305 #REF!	   #VALUE!	   #REF!	  
DDX18_MOUSE 240.153305 #REF!	   #VALUE!	   #REF!	  
RL31_MOUSE 239.82 #REF!	   #VALUE!	   #REF!	  
PININ_MOUSE 237.9066101 #REF!	   #VALUE!	   #REF!	  
SF3B3_MOUSE 237.863305 #REF!	   #VALUE!	   #REF!	  
CLH1_MOUSE 237.8487118 #REF!	   #VALUE!	   #REF!	  
RL37A_MOUSE 236.42 #REF!	   #VALUE!	   #REF!	  
RS7_MOUSE 234.43 #REF!	   #VALUE!	   #REF!	  
ROAA_MOUSE 233.73 #REF!	   #VALUE!	   #REF!	  
HNRPD_MOUSE 233.15 #REF!	   #VALUE!	   #REF!	  
AURKB_MOUSE	   233.0321846	   #REF!	   #VALUE!	   #REF!	  
HNRPL_MOUSE 232.9666101 #REF!	   #VALUE!	   #REF!	  
RL35_MOUSE 232.6366101 #REF!	   #VALUE!	   #REF!	  
RL36A_MOUSE 230.6131352 #REF!	   #VALUE!	   #REF!	  
SRSF3_MOUSE 230.603305 #REF!	   #VALUE!	   #REF!	  
RL34_MOUSE 230.113305 #REF!	   #VALUE!	   #REF!	  
PRC2A_MOUSE 226.9873388 #REF!	   #VALUE!	   #REF!	  
RL21_MOUSE 226.52 #REF!	   #VALUE!	   #REF!	  
PTBP1_MOUSE 225.26 #REF!	   #VALUE!	   #REF!	  
HDGR2_MOUSE 223.8587118 #REF!	   #VALUE!	   #REF!	  
UTP20_MOUSE 222.7994406 #REF!	   #VALUE!	   #REF!	  
DDX47_MOUSE 222.79 #REF!	   #VALUE!	   #REF!	  
RS5_MOUSE 222.753305 #REF!	   #VALUE!	   #REF!	  
CBX3_MOUSE 218.93 #REF!	   #VALUE!	   #REF!	  
MOV10_MOUSE 218.93 #REF!	   #VALUE!	   #REF!	  
ROA0_MOUSE 215.06 #REF!	   #VALUE!	   #REF!	  
CAZA1_MOUSE 213.94 #REF!	   #VALUE!	   #REF!	  
DDX51_MOUSE 213.666695 #REF!	   #VALUE!	   #REF!	  
RS13_MOUSE 211.3087118 #REF!	   #VALUE!	   #REF!	  
SMCA1_MOUSE 211.2066101 #REF!	   #VALUE!	   #REF!	  
ECHA_MOUSE 209.933305 #REF!	   #VALUE!	   #REF!	  
MTA2_MOUSE 207.9127456 #REF!	   #VALUE!	   #REF!	  
CNOT8_MOUSE 206.993305 #REF!	   #VALUE!	   #REF!	  
UHRF1_MOUSE 205.9166101 #REF!	   #VALUE!	   #REF!	  
H2AV_MOUSE 203.933305 #REF!	   #VALUE!	   #REF!	  
UBP2L_MOUSE 203.18 #REF!	   #VALUE!	   #REF!	  
DNJC9_MOUSE 202.2166101 #REF!	   #VALUE!	   #REF!	  
WDR46_MOUSE 202.083305 #REF!	   #VALUE!	   #REF!	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CG050_MOUSE 201.8 #REF!	   #VALUE!	   #REF!	  
MK67I_MOUSE 201.563305 #REF!	   #VALUE!	   #REF!	  
UBB_MOUSE 200.5866929 #REF!	   #VALUE!	   #REF!	  
HNRPF_MOUSE 200.4901678 #REF!	   #VALUE!	   #REF!	  
CDC5L_MOUSE 200.3987118 #REF!	   #VALUE!	   #REF!	  
TCPD_MOUSE 199.433305 #REF!	   #VALUE!	   #REF!	  
RL27_MOUSE 198.633305 #REF!	   #VALUE!	   #REF!	  
TCPE_MOUSE 197.493305 #REF!	   #VALUE!	   #REF!	  
CNO6L_MOUSE 194.893305 #REF!	   #VALUE!	   #REF!	  
GNL3_MOUSE 194.7487118 #REF!	   #VALUE!	   #REF!	  
HNRH2_MOUSE 194.6 #REF!	   #VALUE!	   #REF!	  
C8AP2_MOUSE 193.7873388 #REF!	   #VALUE!	   #REF!	  
RL10L_MOUSE 193.7 #REF!	   #VALUE!	   #REF!	  
RN213_MOUSE 192.3865251 #REF!	   #VALUE!	   #REF!	  
PR40A_MOUSE 192.1420169 #REF!	   #VALUE!	   #REF!	  
SP16H_MOUSE 191.7987118 #REF!	   #VALUE!	   #REF!	  
AQR_MOUSE 191.6420169 #REF!	   #VALUE!	   #REF!	  
SAFB2_MOUSE 191.6366101 #REF!	   #VALUE!	   #REF!	  
RL35A_MOUSE 191.42 #REF!	   #VALUE!	   #REF!	  
YBOX2_MOUSE 191.32 #REF!	   #VALUE!	   #REF!	  
H2AZ_MOUSE 189.56 #REF!	   #VALUE!	   #REF!	  
LARP4_MOUSE 188.08 #REF!	   #VALUE!	   #REF!	  
ARP3B_MOUSE 187.97 #REF!	   #VALUE!	   #REF!	  
PP1A_MOUSE 187.0187118 #REF!	   #VALUE!	   #REF!	  
FXR1_MOUSE 185.4353219 #REF!	   #VALUE!	   #REF!	  
GLYR1_MOUSE 184.0766101 #REF!	   #VALUE!	   #REF!	  
ABEC3_MOUSE 182.353305 #REF!	   #VALUE!	   #REF!	  
RL18A_MOUSE 181.18 #REF!	   #VALUE!	   #REF!	  
IF4G1_MOUSE 180.6174237 #REF!	   #VALUE!	   #REF!	  
NHP2_MOUSE 178.68 #REF!	   #VALUE!	   #REF!	  
LA_MOUSE 178.3966101 #REF!	   #VALUE!	   #REF!	  
FMR1_MOUSE 178.0387118 #REF!	   #VALUE!	   #REF!	  
ARP2_MOUSE 177.68 #REF!	   #VALUE!	   #REF!	  
WDR3_MOUSE 176.43 #REF!	   #VALUE!	   #REF!	  
HNRDL_MOUSE 176.403305 #REF!	   #VALUE!	   #REF!	  
PTN6_MOUSE 176.33 #REF!	   #VALUE!	   #REF!	  
KAP2_MOUSE 176.3 #REF!	   #VALUE!	   #REF!	  
PP1G_MOUSE 174.64 #REF!	   #VALUE!	   #REF!	  
ELYS_MOUSE 173.7 #REF!	   #VALUE!	   #REF!	  
KI20A_MOUSE 172.94 #REF!	   #VALUE!	   #REF!	  
EDC4_MOUSE 171.4387118 #REF!	   #VALUE!	   #REF!	  
CI114_MOUSE 169.5687118 #REF!	   #VALUE!	   #REF!	  
CHTOP_MOUSE 169.445237 #REF!	   #VALUE!	   #REF!	  
PYR1_MOUSE 169.3720169 #REF!	   #VALUE!	   #REF!	  
RL22_MOUSE 168.27 #REF!	   #VALUE!	   #REF!	  
K1C15_MOUSE 168 #REF!	   #VALUE!	   #REF!	  
SFPQ_MOUSE 167.673305 #REF!	   #VALUE!	   #REF!	  
RL27A_MOUSE 167.15 #REF!	   #VALUE!	   #REF!	  
LSP1_MOUSE 166.7687118 #REF!	   #VALUE!	   #REF!	  
MATR3_MOUSE 165.94 #REF!	   #VALUE!	   #REF!	  
XRN2_MOUSE 164.9920169 #REF!	   #VALUE!	   #REF!	  
RUVB2_MOUSE 161.4587118 #REF!	   #VALUE!	   #REF!	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OASL1_MOUSE 161.14 #REF!	   #VALUE!	   #REF!	  
SSRP1_MOUSE 160.9887118 #REF!	   #VALUE!	   #REF!	  
BAZ1B_MOUSE 160.7166101 #REF!	   #VALUE!	   #REF!	  
THOC2_MOUSE 159.92 #REF!	   #VALUE!	   #REF!	  
PCNT_MOUSE 157.3873388 #REF!	   #VALUE!	   #REF!	  
SYNE1_MOUSE 156.7648453 #REF!	   #VALUE!	   #REF!	  
ILF2_MOUSE 155.78 #REF!	   #VALUE!	   #REF!	  
RS25_MOUSE 155.71 #REF!	   #VALUE!	   #REF!	  
DDX1_MOUSE 155.563305 #REF!	   #VALUE!	   #REF!	  
RBBP4_MOUSE 155.243305 #REF!	   #VALUE!	   #REF!	  
ISY1_MOUSE 155.16 #REF!	   #VALUE!	   #REF!	  
DDX6_MOUSE 154.803305 #REF!	   #VALUE!	   #REF!	  
C1TM_MOUSE 153.853305 #REF!	   #VALUE!	   #REF!	  
RBM25_MOUSE 152.33 #REF!	   #VALUE!	   #REF!	  
RL13A_MOUSE 151.353305 #REF!	   #VALUE!	   #REF!	  
BAZ1A_MOUSE 151.2566101 #REF!	   #VALUE!	   #REF!	  
RS15A_MOUSE 150.1 #REF!	   #VALUE!	   #REF!	  
U3IP2_MOUSE 149.183305 #REF!	   #VALUE!	   #REF!	  
SPB1_MOUSE 148.54 #REF!	   #VALUE!	   #REF!	  
SRSF5_MOUSE 147.38 #REF!	   #VALUE!	   #REF!	  
RS12_MOUSE 146.84 #REF!	   #VALUE!	   #REF!	  
RL36_MOUSE 146.09 #REF!	   #VALUE!	   #REF!	  
K0020_MOUSE 145.6299151 #REF!	   #VALUE!	   #REF!	  
IMB1_MOUSE 144.29 #REF!	   #VALUE!	   #REF!	  
MTMR1_MOUSE 143.043305 #REF!	   #VALUE!	   #REF!	  
NH2L1_MOUSE 142.91 #REF!	   #VALUE!	   #REF!	  
NOG1_MOUSE 142.503305 #REF!	   #VALUE!	   #REF!	  
DHX8_MOUSE 140.7040337 #REF!	   #VALUE!	   #REF!	  
TRIPC_MOUSE 138.1721018 #REF!	   #VALUE!	   #REF!	  
CNOT7_MOUSE 138.08 #REF!	   #VALUE!	   #REF!	  
KAPCA_MOUSE 137.55 #REF!	   #VALUE!	   #REF!	  
GIT2_MOUSE 137.24 #REF!	   #VALUE!	   #REF!	  
PRDX1_MOUSE 135.24 #REF!	   #VALUE!	   #REF!	  
HNRH1_MOUSE 134.25 #REF!	   #VALUE!	   #REF!	  
CEP85_MOUSE 134.1199151 #REF!	   #VALUE!	   #REF!	  
CRNL1_MOUSE 134.1066101 #REF!	   #VALUE!	   #REF!	  
MRT4_MOUSE 134.0720169 #REF!	   #VALUE!	   #REF!	  
PGAM5_MOUSE 133.45 #REF!	   #VALUE!	   #REF!	  
CDC73_MOUSE 133.2432201 #REF!	   #VALUE!	   #REF!	  
SRSF4_MOUSE 132.5520169 #REF!	   #VALUE!	   #REF!	  
ZC11A_MOUSE 132.283305 #REF!	   #VALUE!	   #REF!	  
CTR9_MOUSE 132.063305 #REF!	   #VALUE!	   #REF!	  
NCOR1_MOUSE 131.9532201 #REF!	   #VALUE!	   #REF!	  
H2A3_MOUSE 131.143305 #REF!	   #VALUE!	   #REF!	  
RL29_MOUSE 130.063305 #REF!	   #VALUE!	   #REF!	  
SF3B1_MOUSE 129.7266101 #REF!	   #VALUE!	   #REF!	  
AGO2_MOUSE 129.59 #REF!	   #VALUE!	   #REF!	  
EIF3A_MOUSE 128.8265251 #REF!	   #VALUE!	   #REF!	  
CN166_MOUSE 128.11 #REF!	   #VALUE!	   #REF!	  
TCPA_MOUSE 126.9453219 #REF!	   #VALUE!	   #REF!	  
RU2A_MOUSE 126.6720169 #REF!	   #VALUE!	   #REF!	  
RS10_MOUSE 126.6 #REF!	   #VALUE!	   #REF!	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H2B2B_MOUSE 126.1820169 #REF!	   #VALUE!	   #REF!	  
GFAP_MOUSE 125.71 #REF!	   #VALUE!	   #REF!	  
CH60_MOUSE 125.483305 #REF!	   #VALUE!	   #REF!	  
IF6_MOUSE 125.2 #REF!	   #VALUE!	   #REF!	  
EIF3F_MOUSE 124.96 #REF!	   #VALUE!	   #REF!	  
SNW1_MOUSE 124.7799151 #REF!	   #VALUE!	   #REF!	  
TNR6A_MOUSE 123.933305 #REF!	   #VALUE!	   #REF!	  
DOCK2_MOUSE 123.9234728 #REF!	   #VALUE!	   #REF!	  
PP1B_MOUSE 122.71 #REF!	   #VALUE!	   #REF!	  
SYNE2_MOUSE 122.1528641 #REF!	   #VALUE!	   #REF!	  
DNLI3_MOUSE 121.9221846 #REF!	   #VALUE!	   #REF!	  
PLRG1_MOUSE 121.7766101 #REF!	   #VALUE!	   #REF!	  
UIF_MOUSE 121.42 #REF!	   #VALUE!	   #REF!	  
KAPCB_MOUSE 120.4174237 #REF!	   #VALUE!	   #REF!	  
RL15_MOUSE 120.16 #REF!	   #VALUE!	   #REF!	  
RALY_MOUSE 119.7666101 #REF!	   #VALUE!	   #REF!	  
EVPL_MOUSE 119.2632201 #REF!	   #VALUE!	   #REF!	  
HYOU1_MOUSE 119.12 #REF!	   #VALUE!	   #REF!	  
SMC1B_MOUSE 118.9499151 #REF!	   #VALUE!	   #REF!	  
SAMH1_MOUSE 118.78 #REF!	   #VALUE!	   #REF!	  
LPPRC_MOUSE 118.673305 #REF!	   #VALUE!	   #REF!	  
RBM28_MOUSE 118.67 #REF!	   #VALUE!	   #REF!	  
LACTB_MOUSE 118.033305 #REF!	   #VALUE!	   #REF!	  
RCC2_MOUSE 117.523305 #REF!	   #VALUE!	   #REF!	  
SAP18_MOUSE 116.943305 #REF!	   #VALUE!	   #REF!	  
RS26_MOUSE 116.48 #REF!	   #VALUE!	   #REF!	  
ELAV1_MOUSE 115.07 #REF!	   #VALUE!	   #REF!	  
ARC1B_MOUSE 115.0687118 #REF!	   #VALUE!	   #REF!	  
GAR1_MOUSE 114.78 #REF!	   #VALUE!	   #REF!	  
WDR43_MOUSE 114.55 #REF!	   #VALUE!	   #REF!	  
CN37_MOUSE 113.143305 #REF!	   #VALUE!	   #REF!	  
CD11B_MOUSE 113.0466101 #REF!	   #VALUE!	   #REF!	  
LAR4B_MOUSE 112.8866101 #REF!	   #VALUE!	   #REF!	  
CAPZB_MOUSE 112.81 #REF!	   #VALUE!	   #REF!	  
PCBP2_MOUSE 112.04 #REF!	   #VALUE!	   #REF!	  
NUFP2_MOUSE 111.91 #REF!	   #VALUE!	   #REF!	  
DHX30_MOUSE 111.62 #REF!	   #VALUE!	   #REF!	  
CK5P2_MOUSE 110.603305 #REF!	   #VALUE!	   #REF!	  
DYH17_MOUSE 109.9607407 #REF!	   #VALUE!	   #REF!	  
SAHH_MOUSE 109.1266101 #REF!	   #VALUE!	   #REF!	  
FXR2_MOUSE 109 #REF!	   #VALUE!	   #REF!	  
ATX2L_MOUSE 108.77 #REF!	   #VALUE!	   #REF!	  
PRKDC_MOUSE 108.5366101 #REF!	   #VALUE!	   #REF!	  
RL32_MOUSE 108.51 #REF!	   #VALUE!	   #REF!	  
DDX49_MOUSE 107.99 #REF!	   #VALUE!	   #REF!	  
MCM5_MOUSE 106.473305 #REF!	   #VALUE!	   #REF!	  
DDX27_MOUSE 106.31 #REF!	   #VALUE!	   #REF!	  
M4K4_MOUSE 106.0486269 #REF!	   #VALUE!	   #REF!	  
CBX1_MOUSE 105.99 #REF!	   #VALUE!	   #REF!	  
KV3A7_MOUSE 105.773305 #REF!	   #VALUE!	   #REF!	  
RBM39_MOUSE 104.5 #REF!	   #VALUE!	   #REF!	  
MED12_MOUSE 104.103305 #REF!	   #VALUE!	   #REF!	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VIGLN_MOUSE 102.953305 #REF!	   #VALUE!	   #REF!	  
INCE_MOUSE 102.483305 #REF!	   #VALUE!	   #REF!	  
LAMA2_MOUSE 102.1287118 #REF!	   #VALUE!	   #REF!	  
SRP14_MOUSE 101.86 #REF!	   #VALUE!	   #REF!	  
DDX54_MOUSE 101.62 #REF!	   #VALUE!	   #REF!	  
DYH2_MOUSE 101.2927456 #REF!	   #VALUE!	   #REF!	  
PR38A_MOUSE 101.0820169 #REF!	   #VALUE!	   #REF!	  
GON4L_MOUSE 100.7299151 #REF!	   #VALUE!	   #REF!	  
GOGA4_MOUSE 100.6708965 #REF!	   #VALUE!	   #REF!	  
RLA1_MOUSE 100.6 #REF!	   #VALUE!	   #REF!	  
RALYL_MOUSE 100.493305 #REF!	   #VALUE!	   #REF!	  
PIWL1_MOUSE 100.4866101 #REF!	   #VALUE!	   #REF!	  
LMNA_MOUSE 100.46 #REF!	   #VALUE!	   #REF!	  
SURF6_MOUSE 99.97661006 #REF!	   #VALUE!	   #REF!	  
ASPM_MOUSE 99.62240498 #REF!	   #VALUE!	   #REF!	  
ABCAD_MOUSE 99.52523699 #REF!	   #VALUE!	   #REF!	  
SRS10_MOUSE 99.1853219 #REF!	   #VALUE!	   #REF!	  
RS28_MOUSE 98.81 #REF!	   #VALUE!	   #REF!	  
RPGF2_MOUSE 98.68201687 #REF!	   #VALUE!	   #REF!	  
RNPS1_MOUSE 97.7 #REF!	   #VALUE!	   #REF!	  
TBL3_MOUSE 97.42742369 #REF!	   #VALUE!	   #REF!	  
UTP15_MOUSE 97.39 #REF!	   #VALUE!	   #REF!	  
VPS53_MOUSE 97.37991508 #REF!	   #VALUE!	   #REF!	  
ALDR_MOUSE 97.04 #REF!	   #VALUE!	   #REF!	  
LORF2_MOUSE 96.59862693 #REF!	   #VALUE!	   #REF!	  
CHD2_MOUSE 96.32540682 #REF!	   #VALUE!	   #REF!	  
DX39A_MOUSE 96.2 #REF!	   #VALUE!	   #REF!	  
LAMA1_MOUSE 96.14 #REF!	   #VALUE!	   #REF!	  
EPIPL_MOUSE 95.94519895 #REF!	   #VALUE!	   #REF!	  
PSMD3_MOUSE 95.72330503 #REF!	   #VALUE!	   #REF!	  
TCPZ_MOUSE 95.37 #REF!	   #VALUE!	   #REF!	  
1433T_MOUSE 94.95 #REF!	   #VALUE!	   #REF!	  
PESC_MOUSE 94.76330503 #REF!	   #VALUE!	   #REF!	  
LARP7_MOUSE 94.43 #REF!	   #VALUE!	   #REF!	  
EIF3C_MOUSE 94.34330503 #REF!	   #VALUE!	   #REF!	  
ACSF2_MOUSE 94.1 #REF!	   #VALUE!	   #REF!	  
DX39B_MOUSE 94.03 #REF!	   #VALUE!	   #REF!	  
HYDIN_MOUSE 93.7853219 #REF!	   #VALUE!	   #REF!	  
SSA27_MOUSE 93.51 #REF!	   #VALUE!	   #REF!	  
RAC2_MOUSE 92.76 #REF!	   #VALUE!	   #REF!	  
NOL9_MOUSE 92.66330503 #REF!	   #VALUE!	   #REF!	  
TLN1_MOUSE 92.43 #REF!	   #VALUE!	   #REF!	  
BAG6_MOUSE 92.28 #REF!	   #VALUE!	   #REF!	  
IF4A1_MOUSE 92.14 #REF!	   #VALUE!	   #REF!	  
NUSAP_MOUSE 91.03 #REF!	   #VALUE!	   #REF!	  
ROCK2_MOUSE 90.80540682 #REF!	   #VALUE!	   #REF!	  
SYDC_MOUSE 90.58 #REF!	   #VALUE!	   #REF!	  
GCC2_MOUSE 90.51661006 #REF!	   #VALUE!	   #REF!	  
PLEC_MOUSE 90.39832017 #REF!	   #VALUE!	   #REF!	  
DDB1_MOUSE 90.32330503 #REF!	   #VALUE!	   #REF!	  
TT23L_MOUSE 90.11862693 #REF!	   #VALUE!	   #REF!	  
CMC1_MOUSE 90.01330503 #REF!	   #VALUE!	   #REF!	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DDX52_MOUSE 89.90661006 #REF!	   #VALUE!	   #REF!	  
GNAL_MOUSE 89.46661006 #REF!	   #VALUE!	   #REF!	  
RS24_MOUSE 89.39330503 #REF!	   #VALUE!	   #REF!	  
LYST_MOUSE 88.86 #REF!	   #VALUE!	   #REF!	  
CHM4B_MOUSE 87.50330503 #REF!	   #VALUE!	   #REF!	  
MICA3_MOUSE 87.3953219 #REF!	   #VALUE!	   #REF!	  
HDAC2_MOUSE 87.34072872 #REF!	   #VALUE!	   #REF!	  
DDX56_MOUSE 87.30330503 #REF!	   #VALUE!	   #REF!	  
SLTM_MOUSE 87.18661006 #REF!	   #VALUE!	   #REF!	  
TBB1_MOUSE 87.06 #REF!	   #VALUE!	   #REF!	  
NONO_MOUSE 86.98 #REF!	   #VALUE!	   #REF!	  
SYVC_MOUSE 86.89201687 #REF!	   #VALUE!	   #REF!	  
FHAD1_MOUSE 86.65862693 #REF!	   #VALUE!	   #REF!	  
NACC1_MOUSE 86.61 #REF!	   #VALUE!	   #REF!	  
RBBP7_MOUSE 86.53330503 #REF!	   #VALUE!	   #REF!	  
ZN512_MOUSE 86.53 #REF!	   #VALUE!	   #REF!	  
CKP2L_MOUSE 86.44862693 #REF!	   #VALUE!	   #REF!	  
CTRO_MOUSE 86.43733877 #REF!	   #VALUE!	   #REF!	  
PELP1_MOUSE 86.35 #REF!	   #VALUE!	   #REF!	  
CE290_MOUSE 86.06862693 #REF!	   #VALUE!	   #REF!	  
CMYA5_MOUSE 85.68338788 #REF!	   #VALUE!	   #REF!	  
CAZA2_MOUSE 85.61 #REF!	   #VALUE!	   #REF!	  
SYNEM_MOUSE 85.44 #REF!	   #VALUE!	   #REF!	  
DYH12_MOUSE 85.37055889 #REF!	   #VALUE!	   #REF!	  
LDHA_MOUSE 85.24 #REF!	   #VALUE!	   #REF!	  
SMC2_MOUSE 85.06201687 #REF!	   #VALUE!	   #REF!	  
ITPR2_MOUSE 84.78201687 #REF!	   #VALUE!	   #REF!	  
MAST4_MOUSE 84.76072872 #REF!	   #VALUE!	   #REF!	  
UCKL1_MOUSE 84.62330503 #REF!	   #VALUE!	   #REF!	  
ATX7_MOUSE 84.52322011 #REF!	   #VALUE!	   #REF!	  
RRS1_MOUSE 84.5 #REF!	   #VALUE!	   #REF!	  
THOC5_MOUSE 84.28330503 #REF!	   #VALUE!	   #REF!	  
SNUT1_MOUSE 84.06661006 #REF!	   #VALUE!	   #REF!	  
CCNL2_MOUSE 83.74 #REF!	   #VALUE!	   #REF!	  
DHX36_MOUSE 83.35330503 #REF!	   #VALUE!	   #REF!	  
AURKA_MOUSE 82.83661006 #REF!	   #VALUE!	   #REF!	  
SAS10_MOUSE 82.78 #REF!	   #VALUE!	   #REF!	  
RP1_MOUSE 82.75733877 #REF!	   #VALUE!	   #REF!	  
ERC2_MOUSE 82.65991508 #REF!	   #VALUE!	   #REF!	  
EXOS5_MOUSE 82.6 #REF!	   #VALUE!	   #REF!	  
MGT4A_MOUSE 82.42 #REF!	   #VALUE!	   #REF!	  
CDAN1_MOUSE 82.39330503 #REF!	   #VALUE!	   #REF!	  
U2AF1_MOUSE 82.38 #REF!	   #VALUE!	   #REF!	  
ESF1_MOUSE 82.36201687 #REF!	   #VALUE!	   #REF!	  
KI21B_MOUSE 82.28862693 #REF!	   #VALUE!	   #REF!	  
GVIN1_MOUSE 82.18484738 #REF!	   #VALUE!	   #REF!	  
KIF27_MOUSE 82.11742369 #REF!	   #VALUE!	   #REF!	  
CTTB2_MOUSE 82.09 #REF!	   #VALUE!	   #REF!	  
CLK1_MOUSE 82.03661006 #REF!	   #VALUE!	   #REF!	  
GNAI2_MOUSE 81.94871184 #REF!	   #VALUE!	   #REF!	  
DYHC2_MOUSE 81.76652514 #REF!	   #VALUE!	   #REF!	  
MRCKA_MOUSE 81.75201687 #REF!	   #VALUE!	   #REF!	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THOC4_MOUSE 81.67 #REF!	   #VALUE!	   #REF!	  
ZN292_MOUSE 80.99193196 #REF!	   #VALUE!	   #REF!	  
SPTN1_MOUSE 80.82944056 #REF!	   #VALUE!	   #REF!	  
GPR98_MOUSE 80.56661006 #REF!	   #VALUE!	   #REF!	  
CSDE1_MOUSE 80.56330503 #REF!	   #VALUE!	   #REF!	  
MAP11_MOUSE 80.54 #REF!	   #VALUE!	   #REF!	  
EIF3D_MOUSE 80.37 #REF!	   #VALUE!	   #REF!	  
S12A2_MOUSE 80.26201687 #REF!	   #VALUE!	   #REF!	  
TEFM_MOUSE 80.20330503 #REF!	   #VALUE!	   #REF!	  
HIP1_MOUSE 80 #REF!	   #VALUE!	   #REF!	  
PRP6_MOUSE 79.68330503 #REF!	   #VALUE!	   #REF!	  
CUL1_MOUSE 79.33330503 #REF!	   #VALUE!	   #REF!	  
TLN2_MOUSE 78.89733877 #REF!	   #VALUE!	   #REF!	  
DSRAD_MOUSE 78.78330503 #REF!	   #VALUE!	   #REF!	  
RRP12_MOUSE 78.76330503 #REF!	   #VALUE!	   #REF!	  
SSF1_MOUSE 78.71 #REF!	   #VALUE!	   #REF!	  
RTN4_MOUSE 78.68 #REF!	   #VALUE!	   #REF!	  
FCRLA_MOUSE 78.63330503 #REF!	   #VALUE!	   #REF!	  
CCD38_MOUSE 78.30871184 #REF!	   #VALUE!	   #REF!	  
GIT1_MOUSE 78.26 #REF!	   #VALUE!	   #REF!	  
CENPJ_MOUSE 78.21201687 #REF!	   #VALUE!	   #REF!	  
TNIK_MOUSE 77.91991508 #REF!	   #VALUE!	   #REF!	  
FIP1_MOUSE 77.84 #REF!	   #VALUE!	   #REF!	  
RPF2_MOUSE 77.77330503 #REF!	   #VALUE!	   #REF!	  
SPKAP_MOUSE 77.74330503 #REF!	   #VALUE!	   #REF!	  
SCLT1_MOUSE 77.43523699 #REF!	   #VALUE!	   #REF!	  
MYOM1_MOUSE 77.29201687 #REF!	   #VALUE!	   #REF!	  
RBM33_MOUSE 77.11 #REF!	   #VALUE!	   #REF!	  
ETAA1_MOUSE 76.99193196 #REF!	   #VALUE!	   #REF!	  
APC_MOUSE 76.43114917 #REF!	   #VALUE!	   #REF!	  
H2AW_MOUSE 76.3 #REF!	   #VALUE!	   #REF!	  
HDAC1_MOUSE 76.13 #REF!	   #VALUE!	   #REF!	  
4ET_MOUSE 75.98669497 #REF!	   #VALUE!	   #REF!	  
CCD86_MOUSE 75.83 #REF!	   #VALUE!	   #REF!	  
KRT86_MOUSE 75.81 #REF!	   #VALUE!	   #REF!	  
ADA12_MOUSE 75.61661006 #REF!	   #VALUE!	   #REF!	  
EP300_MOUSE 75.49661006 #REF!	   #VALUE!	   #REF!	  
PCBP3_MOUSE 75.36094755 #REF!	   #VALUE!	   #REF!	  
PERQ2_MOUSE 75.35 #REF!	   #VALUE!	   #REF!	  
LRIF1_MOUSE 75.32944056 #REF!	   #VALUE!	   #REF!	  
NOC2L_MOUSE 75.22 #REF!	   #VALUE!	   #REF!	  
NUCB2_MOUSE 75.15 #REF!	   #VALUE!	   #REF!	  
FBF1_MOUSE 75.12330503 #REF!	   #VALUE!	   #REF!	  
TIF1B_MOUSE 74.99661006 #REF!	   #VALUE!	   #REF!	  
WWC2_MOUSE 74.86330503 #REF!	   #VALUE!	   #REF!	  
FR1OP_MOUSE 74.8 #REF!	   #VALUE!	   #REF!	  
DNJA1_MOUSE 74.68 #REF!	   #VALUE!	   #REF!	  
MY18A_MOUSE 74.64201687 #REF!	   #VALUE!	   #REF!	  
HS105_MOUSE 74.63661006 #REF!	   #VALUE!	   #REF!	  
CBX5_MOUSE 74.47330503 #REF!	   #VALUE!	   #REF!	  
CKAP5_MOUSE 74.34983017 #REF!	   #VALUE!	   #REF!	  
K2022_MOUSE 74.26871184 #REF!	   #VALUE!	   #REF!	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SMD1_MOUSE 74.2 #REF!	   #VALUE!	   #REF!	  
TCPQ_MOUSE 74.2 #REF!	   #VALUE!	   #REF!	  
SR140_MOUSE 73.71862693 #REF!	   #VALUE!	   #REF!	  
COCA1_MOUSE 73.71201687 #REF!	   #VALUE!	   #REF!	  
BLM_MOUSE 73.68016777 #REF!	   #VALUE!	   #REF!	  
FAT3_MOUSE 73.43201687 #REF!	   #VALUE!	   #REF!	  
DOCK8_MOUSE 73.3053219 #REF!	   #VALUE!	   #REF!	  
UT14A_MOUSE 73.08 #REF!	   #VALUE!	   #REF!	  
ZCCHV_MOUSE 72.62 #REF!	   #VALUE!	   #REF!	  
RS30_MOUSE 72.58 #REF!	   #VALUE!	   #REF!	  
RRP8_MOUSE 72.47 #REF!	   #VALUE!	   #REF!	  
CDK1_MOUSE 72.45 #REF!	   #VALUE!	   #REF!	  
RFC1_MOUSE 72.40871184 #REF!	   #VALUE!	   #REF!	  
SRRM1_MOUSE 72.39871184 #REF!	   #VALUE!	   #REF!	  
FBLL1_MOUSE 72.27 #REF!	   #VALUE!	   #REF!	  
IGSF2_MOUSE 72.24330503 #REF!	   #VALUE!	   #REF!	  
CBP_MOUSE 72.18661006 #REF!	   #VALUE!	   #REF!	  
LRWD1_MOUSE 72.07 #REF!	   #VALUE!	   #REF!	  
RIMB3_MOUSE 72.05330503 #REF!	   #VALUE!	   #REF!	  
TPX2_MOUSE 71.67661006 #REF!	   #VALUE!	   #REF!	  
CIP2A_MOUSE 71.63991508 #REF!	   #VALUE!	   #REF!	  
UBN1_MOUSE 71.60330503 #REF!	   #VALUE!	   #REF!	  
RTCB_MOUSE 71.59 #REF!	   #VALUE!	   #REF!	  
ANFY1_MOUSE 71.44 #REF!	   #VALUE!	   #REF!	  
FLNB_MOUSE 71.35 #REF!	   #VALUE!	   #REF!	  
TCF20_MOUSE 71.33 #REF!	   #VALUE!	   #REF!	  
BIG3_MOUSE 71.25661006 #REF!	   #VALUE!	   #REF!	  
MAP7_MOUSE 71.19733877 #REF!	   #VALUE!	   #REF!	  
TTLL7_MOUSE 71.11991508 #REF!	   #VALUE!	   #REF!	  
PTRF_MOUSE 71.09871184 #REF!	   #VALUE!	   #REF!	  
TRRAP_MOUSE 71.08330503 #REF!	   #VALUE!	   #REF!	  
IGFN1_MOUSE 70.97733877 #REF!	   #VALUE!	   #REF!	  
ODF2L_MOUSE 70.97661006 #REF!	   #VALUE!	   #REF!	  
LAMC1_MOUSE 70.91201687 #REF!	   #VALUE!	   #REF!	  
M3K6_MOUSE 70.88330503 #REF!	   #VALUE!	   #REF!	  
DPOLB_MOUSE 70.73661006 #REF!	   #VALUE!	   #REF!	  
GOGA5_MOUSE 70.7 #REF!	   #VALUE!	   #REF!	  
RS29_MOUSE 70.7 #REF!	   #VALUE!	   #REF!	  
RCL1_MOUSE 70.58 #REF!	   #VALUE!	   #REF!	  
ZEP1_MOUSE 70.50661006 #REF!	   #VALUE!	   #REF!	  
ZN638_MOUSE 70.5053219 #REF!	   #VALUE!	   #REF!	  
IQGA2_MOUSE 70.45 #REF!	   #VALUE!	   #REF!	  
GRWD1_MOUSE 70.42330503 #REF!	   #VALUE!	   #REF!	  
DMD_MOUSE 70.36854201 #REF!	   #VALUE!	   #REF!	  
F178A_MOUSE 70.36661006 #REF!	   #VALUE!	   #REF!	  
OBSCN_MOUSE 70.30089648 #REF!	   #VALUE!	   #REF!	  
NOG2_MOUSE 70.25871184 #REF!	   #VALUE!	   #REF!	  
EME1_MOUSE 70.23330503 #REF!	   #VALUE!	   #REF!	  
NEST_MOUSE 69.97330503 #REF!	   #VALUE!	   #REF!	  
RFIP1_MOUSE 69.71201687 #REF!	   #VALUE!	   #REF!	  
DDX50_MOUSE 69.69871184 #REF!	   #VALUE!	   #REF!	  
ALMS1_MOUSE 69.69072872 #REF!	   #VALUE!	   #REF!	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CLK4_MOUSE 69.46 #REF!	   #VALUE!	   #REF!	  
EIF3H_MOUSE 69.12 #REF!	   #VALUE!	   #REF!	  
DESP_MOUSE 68.97355922 #REF!	   #VALUE!	   #REF!	  
DDX20_MOUSE 68.72 #REF!	   #VALUE!	   #REF!	  
RGRF1_MOUSE 68.45330503 #REF!	   #VALUE!	   #REF!	  
KMT2D_MOUSE 68.34338788 #REF!	   #VALUE!	   #REF!	  
TIAM2_MOUSE 68.33330503 #REF!	   #VALUE!	   #REF!	  
DPOE1_MOUSE 68.14661006 #REF!	   #VALUE!	   #REF!	  
EEA1_MOUSE 67.99871184 #REF!	   #VALUE!	   #REF!	  
CTND2_MOUSE 67.96330503 #REF!	   #VALUE!	   #REF!	  
RAI14_MOUSE 67.94991508 #REF!	   #VALUE!	   #REF!	  
THADA_MOUSE 67.83330503 #REF!	   #VALUE!	   #REF!	  
SDHA_MOUSE 67.81 #REF!	   #VALUE!	   #REF!	  
RB6I2_MOUSE 67.80330503 #REF!	   #VALUE!	   #REF!	  
K1109_MOUSE 67.64322011 #REF!	   #VALUE!	   #REF!	  
RYR1_MOUSE 67.63330503 #REF!	   #VALUE!	   #REF!	  
CNTRL_MOUSE 67.62887961 #REF!	   #VALUE!	   #REF!	  
GNAS2_MOUSE 67.42330503 #REF!	   #VALUE!	   #REF!	  
KI26B_MOUSE 67.25733877 #REF!	   #VALUE!	   #REF!	  
TNR6B_MOUSE 67.25 #REF!	   #VALUE!	   #REF!	  
TTC3_MOUSE 67.2353219 #REF!	   #VALUE!	   #REF!	  
APC2_MOUSE 67.1853219 #REF!	   #VALUE!	   #REF!	  
G3BP2_MOUSE 67.16 #REF!	   #VALUE!	   #REF!	  
UTP18_MOUSE 67.15 #REF!	   #VALUE!	   #REF!	  
HAUS1_MOUSE 66.9053219 #REF!	   #VALUE!	   #REF!	  
RBP2_MOUSE 66.80742369 #REF!	   #VALUE!	   #REF!	  
NINL_MOUSE 66.65661006 #REF!	   #VALUE!	   #REF!	  
TCPH_MOUSE 66.64661006 #REF!	   #VALUE!	   #REF!	  
IPYR2_MOUSE 66.57 #REF!	   #VALUE!	   #REF!	  
SP110_MOUSE 66.51330503 #REF!	   #VALUE!	   #REF!	  
TDIF2_MOUSE 66.41330503 #REF!	   #VALUE!	   #REF!	  
PLSL_MOUSE 66.39 #REF!	   #VALUE!	   #REF!	  
ARPC3_MOUSE 66.30330503 #REF!	   #VALUE!	   #REF!	  
K1731_MOUSE 66.27201687 #REF!	   #VALUE!	   #REF!	  
VP13C_MOUSE 66.18742369 #REF!	   #VALUE!	   #REF!	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Figure	  B:	   Snapshots	   of	   ChIP-­seq	   tracks	   of	   Cnot3	  binding	  during	   cell	   cycle	  
progression.	  The	  figures	  show	  snapshots	  of	  ChIP-­‐seq	  tracks	  for	  Cnot3	  binding	  in	  resting,	  early	  and	  late	  G1,	  early	  S,	  G2	  and	  G2/M.	  FPKM	  values	  are	  reported	  in	  each	  chart.	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